U.S. patent application number 14/911225 was filed with the patent office on 2016-06-30 for compounds and methods for inhibiting phosphate transport.
The applicant listed for this patent is Dominique CHARMOT, Jeffrey W. JACOBS, Ingrid LANGSETMO, Jason G. LEWIS, Christopher RERAS. Invention is credited to Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Ingrid Langsetmo, Jason G. Lewis.
Application Number | 20160184387 14/911225 |
Document ID | / |
Family ID | 51392426 |
Filed Date | 2016-06-30 |
United States Patent
Application |
20160184387 |
Kind Code |
A1 |
Charmot; Dominique ; et
al. |
June 30, 2016 |
COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
Abstract
Provided are non-NHE3-binding agents having activity as
phosphate transport/uptake inhibitors in the gastrointestinal
tract, including in the small intestine, methods for their use as
therapeutic or prophylactic agents, and related methods of drug
discovery.
Inventors: |
Charmot; Dominique;
(Campbell, CA) ; Lewis; Jason G.; (Castro Valley,
CA) ; Jacobs; Jeffrey W.; (San Mateo, CA) ;
Langsetmo; Ingrid; (Fremont, CA) ; Carreras;
Christopher; (Belmont, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CHARMOT; Dominique
LEWIS; Jason G.
JACOBS; Jeffrey W.
LANGSETMO; Ingrid
RERAS; Christopher |
Campbell
Castro Valley
San Mateo
Fremont
Belmont |
CA
CA
CA
CA
CA |
US
US
US
US
US |
|
|
Family ID: |
51392426 |
Appl. No.: |
14/911225 |
Filed: |
August 8, 2014 |
PCT Filed: |
August 8, 2014 |
PCT NO: |
PCT/US2014/050290 |
371 Date: |
February 9, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61936715 |
Feb 6, 2014 |
|
|
|
61864215 |
Aug 9, 2013 |
|
|
|
Current U.S.
Class: |
424/78.1 ;
424/617; 424/646; 424/686; 424/690; 435/29; 514/167; 514/21.1;
514/269; 514/283; 514/320; 514/342; 514/344; 514/354; 514/356;
514/377; 514/415; 514/432; 514/455; 514/456; 514/478; 514/51;
514/567 |
Current CPC
Class: |
A61K 31/195 20130101;
A61P 9/00 20180101; A61P 43/00 20180101; A61K 31/506 20130101; A61P
1/00 20180101; A61K 31/352 20130101; A61K 31/353 20130101; A61K
31/421 20130101; A61P 7/00 20180101; A61P 13/12 20180101; G01N
33/84 20130101; A61P 3/12 20180101; A61P 13/02 20180101; A61K
31/382 20130101; A61K 38/10 20130101; A61K 31/00 20130101; A61K
33/26 20130101; A61K 31/4439 20130101; A61P 5/20 20180101; A61K
31/7072 20130101; A61K 38/16 20130101; A61K 31/27 20130101; G01N
33/5038 20130101; A61K 31/4525 20130101; A61K 31/475 20130101; A61K
31/4045 20130101; A61K 31/4418 20130101; G01N 33/5044 20130101;
A61K 45/06 20130101; A61K 31/00 20130101; A61K 2300/00 20130101;
A61K 38/10 20130101; A61K 2300/00 20130101; A61K 38/16 20130101;
A61K 2300/00 20130101 |
International
Class: |
A61K 38/10 20060101
A61K038/10; A61K 31/4418 20060101 A61K031/4418; A61K 31/7072
20060101 A61K031/7072; A61K 31/4525 20060101 A61K031/4525; A61K
31/382 20060101 A61K031/382; A61K 31/27 20060101 A61K031/27; A61K
31/421 20060101 A61K031/421; A61K 31/353 20060101 A61K031/353; A61K
31/4439 20060101 A61K031/4439; A61K 31/4045 20060101 A61K031/4045;
A61K 33/26 20060101 A61K033/26; A61K 31/475 20060101 A61K031/475;
A61K 31/352 20060101 A61K031/352; A61K 31/195 20060101 A61K031/195;
A61K 45/06 20060101 A61K045/06; G01N 33/50 20060101 G01N033/50;
G01N 33/84 20060101 G01N033/84; A61K 31/506 20060101
A61K031/506 |
Claims
1. A method for inhibiting phosphate uptake in the gastrointestinal
tract of a patient in need of phosphate lowering, comprising
administering to the patient a guanylate cyclase C receptor (GC-C)
agonist compound, where the GC-C agonist compound is substantially
active in the gastrointestinal tract to inhibit transport of
phosphate ions (Pi) therein upon administration to the patient in
need thereof.
2. A method for inhibiting phosphate uptake in the gastrointestinal
tract of a patient in need of phosphate lowering, comprising
administering to the patient a compound that does not bind NHE3,
where the compound is substantially active in the gastrointestinal
tract to inhibit transport of phosphate ions (Pi) therein upon
administration to the patient in need thereof.
3. The method of claim 2, where the compound decreases the
cross-epithelial pH gradient (CEPG) in the small intestine, where
the CEPG is defined as the difference in pH between (i) the
cytoplasm of the epithelial cells of the surface of the small
intestine, optionally at the subapical surface of the epithelial
cell, and (ii) the unstirred layer at the apical surface of the
small intestine, where the compound is substantially active in the
gastrointestinal tract to inhibit transport of phosphate ions (Pi)
therein upon administration to the patient in need thereof.
4. The method of claim 2, where the compound decreases water
absorption in the small intestine, optionally the jejunum, and
where the compound is substantially active in the gastrointestinal
tract to inhibit transport of phosphate ions (Pi) therein upon
administration to the patient in need thereof.
5. The method of claim 2, where the compound decreases the CEPG and
decreases water absorption in the small intestine.
6. The method of claim 2, where the compound decreases the CEPG in
the small intestine without significantly decreasing water
absorption in the small intestine.
7. The method of claim 2, where the compound decreases water
absorption in the small intestine without significantly decreasing
the CEPG in the small intestine, optionally without significantly
stimulating bicarbonate secretion and/or inhibiting acid secretion
in the small intestine.
8. The method of claim 2, where the method results in a method
selected from one or more of: (a) a method for treating
hyperphosphatemia, optionally postprandial hyperphosphatemia; (b) a
method for treating a renal disease, optionally chronic kidney
disease (CKD) or end-stage renal disease (ESRD); (c) a method for
reducing serum creatinine levels; (d) a method for treating
proteinuria; (e) a method for delaying time to renal replacement
therapy (RRT), optionally dialysis; (f) a method for reducing FGF23
levels; (g) a method for reducing the hyperphosphatemic effect of
active vitamin D; (h) a method for attenuating hyperparathyroidism,
optionally secondary hyperparathyroidism; (i) a method for reducing
serum parathyroid hormone (PTH) a method for improving endothelial
dysfunction, optionally induced by postprandial serum phosphorus;
(k) a method for reducing vascular calcification, optionally
intima-localized vascular calcification; (l) a method for reducing
urinary phosphorous; (m) a method for normalizing serum phosphorus
levels; (n) a method for reducing phosphate burden in an elderly
patient; (o) a method for decreasing dietary phosphate uptake; (p)
a method for reducing renal hypertrophy; and (q) a method for
reducing heart hypertrophy.
9. The method of claim 2, where the compound decreases the
intracellular pH of the epithelial cells of the surface of the
small intestine, optionally at the subapical surface of the
epithelial cell.
10. The method of claim 2, where the compound increases the pH of
the unstirred layer at the apical surface of the small
intestine.
11. The method of claim 2, where the compound (a) stimulates
bicarbonate secretion in the small intestine, or (b) inhibits acid
secretion in the small intestine, or (c) stimulates bicarbonate
secretion and inhibits acid secretion in the small intestine.
12. The method of claim 2, where the compound increases one or more
intracellular secondary messengers of epithelial cells of the
surface of the small intestine.
13. The method of claim 12, where the one or more intracellular
secondary messengers are selected from Ca.sup.++, cyclic adenosine
monophosphate (cAMP), and cyclic guanosine monophosphate
(cGMP).
14. The method of claim 2, where the compound is substantially
systemically non-bioavailable upon enteral administration to the
patient.
15. The method of claim 14, where the compound is substantially
impermeable to the epithelium of the gastrointestinal tract.
16. The method of claim 14, where the compound is substantially
permeable to the epithelium of the gastrointestinal tract.
17. The method of claim 2, where administration to the patient in
need thereof (a) reduces serum phosphorus concentrations or levels
to about 150% or less of normal serum phosphorus levels, and/or (b)
reduces uptake of dietary phosphorous by at least about 10%
relative to an untreated state.
18. The method of claim 2, where administration to the patient in
need thereof increases phosphate levels in fecal excretion by at
least about 10% relative to an untreated state.
19. The method of claim 2, where administration to the patient in
need thereof reduces urinary phosphate concentrations or levels by
at least about 10% relative to an untreated state.
20. The method of claim 2, where the patient in need thereof has
ESRD, and where administration to the patient reduces serum
phosphorus concentrations or levels by at least about 10% relative
to an untreated state.
21. The method of claim 2, where the patient in need thereof has
CKD, and where administration to the patient reduces FGF23 levels
and serum intact parathyroid hormone (iPTH) levels by at least
about 10% relative to an untreated state.
22. The method of claim 2, where the compound is selected from one
or more of a guanylate cyclase C receptor (GC-C) agonist, a P2Y
agonist, an adenosine A2b receptor agonist, a soluble guanylate
cyclase agonist, an adenylate cyclase receptor agonist, an
imidazoline-1 receptor agonist, a cholinergic agonist, a
prostaglandin EP4 receptor agonist, a dopamine D1 agonist, a
melatonin receptor agonist, a 5HT4 agonist, an atrial natriuretic
peptide receptor agonist, a carbonic anhydrase inhibitor, a
phosphodiesterase inhibitor, and a Down-Regulated in Adenoma (DRA
or SLC26A3) agonist.
23. The method of claim 1 or 22, where the GC-C agonist is a
peptide, optionally a bacterial heat stable enterotoxin, guanylin,
proguanylin, uroguanylin, prouroguanylin, lymphoguanylin, or a
variant or analog of any of the foregoing.
24. The method of claim 23, where the GC-C agonist peptide
comprises the amino acid sequence (I): Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8
Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14
Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20
Xaa.sub.21 (SEQ ID NO:1) where: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Xaa.sub.4 Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ ID NO:2) or is
missing or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing.
25. The method of claim 24, where Xaa.sub.5 is Asn, Trp, Tyr, Asp,
or Phe.
26. The method of claim 24, where Xaa.sub.5 is Thr or Ile.
27. The method of claim 24, where Xaa.sub.5 is Tyr, Asp, or
Trp.
28. The method of claim 24, where Xaa.sub.8 is Glu, Asp, Gln, Gly,
or Pro.
29. The method of claim 24, where Xaa.sub.9 is Leu, Ile, Val, Ala,
Lys, Arg, Trp, Tyr, or Phe.
30. The method of claim 24, where Xaa.sub.9 is Leu, Ile, Val, Lys,
Arg, Trp, Tyr, or Phe.
31. The method of claim 24, where Xaa.sub.12 is Asn, Tyr, Asp, or
Ala.
32. The method of claim 24, where Xaa.sub.13 is Ala, Pro, or
Gly.
33. The method of claim 24, where Xaa.sub.14 is Ala, Leu, Ser, Gly,
Val, Glu, Gln, Ile, Leu, Lys, Arg, or Asp.
34. The method of claim 24, where Xaa.sub.16 is Thr, Ala, Asn, Lys,
Arg, or Trp.
35. The method of claim 24, where Xaa.sub.17 is Gly, Pro, or
Ala.
36. The method of claim 24, where Xaa.sub.19 is Trp, Tyr, Phe, Asn,
or Leu.
37. The method of claim 24, where Xaa.sub.19 is Lys or Arg.
38. The method of claim 24, where Xaa.sub.20 Xaa.sub.21 is AspPhe
or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing.
39. The method of claim 24, where Xaa.sub.19 Xaa.sub.20 Xaa.sub.21
is missing.
40. The method of claim 24, where the GC-C agonist peptide
comprises the amino acid sequence: Asn Ser Ser Asn Tyr Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:3), or a
variant thereof having 1, 2, 3, 4, or 5 deletions, insertions,
and/or substitutions.
41. The method of claim 24, where the peptide comprises the amino
acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr (SEQ ID NO:4), or a variant thereof having 1, 2, 3, 4, or 5
deletions, insertions, and/or substitutions.
42. The method of claim 23, where the GC-C agonist peptide
comprises the amino acid sequence (III): Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Cys.sub.4 Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8
Xaa.sub.9 Xaa.sub.10 Xaa.sub.11 Cys.sub.12 Xaa.sub.13 Xaa.sub.14
Xaa.sub.15 Xaa.sub.16 (SEQ ID NO:5), where Xaa.sub.1 is: Ser, Asn,
Tyr, Ala, Gln, Pro, Lys, Gly, or Thr, or is missing; Xaa.sub.2 is
His, Asp, Glu, Ala, Ser, Asn, Gly, or is missing; Xaa.sub.3 is Thr,
Asp, Ser, Glu, Pro, Val or Leu; Xaa.sub.5 is Asp, Ile or Glu;
Xaa.sub.6 is Ile, Trp or Leu; Xaa.sub.7 is Cys, Ser, or Tyr;
Xaa.sub.8 is Ala, Val, Thr, Ile, Met or is missing; Xaa.sub.9 is
Phe, Tyr, Asn, or Trp; Xaa.sub.10 is Ala, Val, Met, Thr or Ile;
Xaa.sub.11 is Ala or Val; Xaa.sub.13 is Thr or Ala; Xaa.sub.14 is
Gly, Ala or Ser; Xaa.sub.15 is Cys, Tyr or is missing; and
Xaa.sub.16 is His, Leu or Ser.
43. The method of claim 42, where the peptide comprises the amino
acid sequence: Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr
Gly Cys Leu (SEQ ID NO:6), or a variant thereof having 1, 2, 3, 4,
or 5 deletions, insertions, and/or substitutions.
44. The method of claim 22, where the P2Y agonist is selected from
a compound in FIG. 4 or FIGS. 5A-5C.
45. The method of claim 22, where the adenosine A2b receptor
agonist is selected from a compound in FIGS. 6A-6C.
46. The method of claim 22, where the soluble guanylate cyclase
agonist is selected from a compound in FIGS. 9A-9L.
47. The method of claim 22, where the adenylate cyclase receptor
agonist is selected from a compound in FIG. 10.
48. The method of claim 22, where the imidazoline-1 receptor
agonist is selected from moxonidine and a compound in FIG. 11.
49. The method of claim 22, where the cholinergic agonist is
selected from a compound in FIG. 12.
50. The method of claim 22, where the prostaglandin EP4 receptor
agonist is selected from PGE.sub.2 or its analogs/derivatives and a
compound in FIG. 7 or FIG. 13.
51. The method of claim 22, where the dopamine D1 agonist is
selected from a compound in FIG. 14.
52. The method of claim 22, where the melatonin receptor agonist is
selected from melatonin and a compound in FIG. 15.
53. The method of claim 22, where the 5HT4 agonist is selected from
serotonin and its analogs, prucalopride, metoclopramide,
cleobopride, mosapride, prucalopride, renzapride, tegaserod,
zacopride, norcisapride, naronopride, and velusetrag.
54. The method of claim 22, where the atrial natriuretic peptide
receptor agonist comprises or consists of an amino acid sequence
selected from: Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp
Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr (SEQ ID
NO:7), Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly Leu
Gly Cys (SEQ ID NO:8) and Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg
Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg (SEQ ID NO:9),
including variants thereof having 1, 2, 3, 4, or 5 deletions,
insertions, and/or substitutions.
55. The method of claim 22, where the carbonic anhydrase inhibitor
is selected from a compound in FIG. 17.
56. The method of claim 22, where the phosphodiesterase inhibitor
is selected from a compound in FIG. 18.
57. The method of claim 22, where the DRA agonist is selected from
FIGS. 21A-B.
58. The method of claim 2, where the compound is substantially
systemically non-bioavailable upon enteral administration to the
patient and has (i) a tPSA of at least about 200 .ANG..sup.2.
59. The method of claim 58, where the compound has a tPSA of at
least about 250 .ANG..sup.2.
60. The method of claim 58, where the compound has a tPSA of at
least about 270 .ANG..sup.2.
61. The method of claim 58, where the compound has a tPSA of at
least about 300 .ANG..sup.2.
62. The method of claim 58, where the compound has a tPSA of at
least about 350 .ANG..sup.2.
63. The method of claim 58, where the compound has a tPSA of at
least about 400 .ANG..sup.2.
64. The method of claim 58, where the compound has a tPSA of at
least about 500 .ANG..sup.2.
65. The method of claim 58, where the compound has a molecular
weight of at least about 500 Da.
66. The method of claim 58, where the compound has a molecular
weight of at least about 1000 Da.
67. The method of claim 58, where the compound has a molecular
weight of at least about 2500 Da.
68. The method of claim 58, where the compound has a molecular
weight of at least about 5000 Da.
69. The method of claim 58, where the compound has (i) a total
number of NH and/or OH and/or other potential hydrogen bond donor
moieties greater than about 5; (ii) a total number of O atoms
and/or N atoms and/or other potential hydrogen bond acceptors
greater than about 10; and/or (iii) a Moriguchi partition
coefficient greater than about 10.sup.5 or less than about 10.
70. The method of claim 58, where the compound has a permeability
coefficient, P.sub.app, of less than about 100.times.10.sup.-6
cm/s, or less than about 10.times.10.sup.-6 cm/s, or less than
about 1.times.10.sup.-6 cm/s, or less than about
0.1.times.10.sup.-6 cm/s.
71. The method of claim 2, further comprising administering one or
more additional biologically active agents.
72. The method of claim 71, where the compound and the one or more
additional biologically active agents are administered as part of a
single pharmaceutical composition.
73. The method of claim 71, where the compound and the one or more
additional biologically active agents are administered as
individual pharmaceutical compositions.
74. The method of claim 73, where the individual pharmaceutical
compositions are administered sequentially.
75. The method of claim 73, where the individual pharmaceutical
compositions are administered simultaneously.
76. The method of claim 71, where the additional biologically
active agent is selected from vitamin D.sub.2 (ergocalciferol),
vitamin D.sub.3 (cholecalciferol), active vitamin D (calcitriol)
and active vitamin D analogs (e.g. doxercalciferol,
paricalcitol).
77. The method of claim 71, where the additional biologically
active agent is a phosphate binder.
78. The method of claim 77, where the phosphate binder is selected
from the group consisting of sevelamer (e.g., Renvela.RTM.
(sevelamer carbonate), Renagel.RTM. (sevelamer hydrochloride)),
lanthanum carbonate (e.g., Fosrenol.RTM.), calcium carbonate (e.g.,
Calcichew.RTM., Titralac.RTM.), calcium acetate (e.g. PhosLo.RTM.,
Phosex.RTM.), calcium acetate/magnesium carbonate (e.g.,
Renepho.RTM., OsvaRen.RTM.), MCI-196, ferric citrate (e.g.,
Zerenex.TM.), magnesium iron hydroxycarbonate (e.g.,
Fermagate.TM.), aluminum hydroxide (e.g., Alucaps.RTM.,
Basaljel.RTM.), APS1585, SBR-759, and PA-21.
79. The method of claim 71, where the additional biologically
active agent is a NaPi2b inhibitor.
80. The method of claim 71, where the additional biologically
active agent is niacin or nicotinamide.
81. The method of claim 71, where the subject has CKD and the
additionally active biological agent is selected from one or more
of ACE inhibitors, antiogensin II receptor blockers, beta-blockers,
calcium channel blockers, direct renin inhibitors, diuretics,
vasodilators, erythropoietin therapy, iron replacement therapy,
inhibitors of advanced glycation end products, vitamin D, and
statins.
82. The method of claim 2, where the compound is administered
orally.
83. The method of claim 82, where the compound is administered
orally once-a-day.
84. A method of screening for an inhibitor of phosphate uptake,
comprising (a) culturing intestinal cells, (b) contacting the
cultured intestinal cells with a test compound, and (c) measuring
(i) the pH at the apical surface of the intestinal cells, (ii) the
intracellular pH of the intestinal cells, and/or (iii) phosphate
uptake by the intestinal cells, and (d) identifying the test
compound as an inhibitor of phosphate uptake where the pH from
(c)(i) increases relative to a control, the intracellular pH from
(c)(ii) decreases relative to a control, and/or phosphate uptake
from (c)(iii) decreases relative to a control.
85. The method of claim 84, where step (a) comprise culturing
intestinal cells to monolayers.
86. The method of claim 84, where step (a) comprises isolating the
cells from intestinal crypts and culturing under conditions
sufficient to form enteroids.
87. The method of claim 84, where step (a) comprises culturing
isolated embryonic stem cells, endoderm cells, or pluripotent stem
cells under conditions sufficient to form organoids.
88. The method of claim 84, where step (a) comprises culturing
intestinal section(s) in a Ussing chamber.
89. The method of claim 84, where step (c)(i) comprises contacting
the cells with a pH-sensitive fluorescent dye and measuring
fluorescence of the dye.
90. The method of claim 84, where step (c)(ii) comprises contacting
the cells with .sup.33P-labeled phosphate ions and measuring uptake
of the labeled phosphate ions.
91. The method of claim 84, where the increase and/or decrease of
(d) is statistically significant.
92. The method of claim 84, where the test compound is a small
molecule or peptide that is known or suspected to stimulate
bicarbonate secretion and/or inhibit acid secretion in the small
intestine.
93. The method of claim 92, where the test compound is selected
from one or more of a P2Y agonist, an adenosine A2b receptor
agonist, a guanylate cyclase C receptor agonist, a soluble
guanylate cyclase agonist, an adenylate cyclase receptor agonist,
an imidazoline-1 receptor agonist, a cholinergic agonist, a
prostaglandin EP4 receptor agonist, a dopamine D1 agonist, a
melatonin receptor agonist, a 5HT4 agonist, an atrial natriuretic
peptide receptor agonist, a carbonic anhydrase inhibitor, a
phosphodiesterase inhibitor, and a Down-Regulated in Adenoma (DRA
or SLC26A3) agonist.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C.
.sctn.119(e) to U.S. Application No. 61/864,215, filed Aug. 9,
2013; and U.S. Application No. 61/936,715, filed on Feb. 6, 2014;
each of which is incorporated by reference in its entirety.
STATEMENT REGARDING SEQUENCE LISTING
[0002] The Sequence Listing associated with this application is
provided in text format in lieu of a paper copy, and is hereby
incorporated by reference into the specification. The name of the
text file containing the Sequence Listing is
ARDE_017_01WO_ST25.txt. The text file is 193 KB, was created on
Aug. 8, 2014, and is being submitted electronically via
EFS-Web.
BACKGROUND
[0003] 1. Technical Field
[0004] The present invention relates to non-NHE3-binding agents
having activity as phosphate transport inhibitors in the
gastrointestinal tract, including in the small intestine, methods
for their use as therapeutic or prophylactic agents, and related
methods of drug discovery.
[0005] 2. Description of the Related Art
[0006] Patients with inadequate renal function, hypoparathyroidism,
or certain other medical conditions (such as hereditary
hyperphosphatemia, Albright hereditary osteodystrophy, amyloidosis,
etc.) often have hyperphosphatemia, or elevated serum phosphorus
levels (where the level, for example, is more than about 6 mg/dL).
Hyperphosphatemia, especially if present over extended periods of
time, leads to severe abnormalities in calcium and phosphorus
metabolism, often manifested by secondary hyperparathyroidism, bone
disease and ectopic calcification in the cardiovascular system,
joints, lungs, eyes and other soft tissues. Higher serum phosphorus
levels are strongly associated with the progression of renal
failure, cardiovascular calcification and mortality in end-stage
renal disease (ESRD) patients. High-normal serum phosphorus levels
have been associated with cardiovascular events and mortality among
individuals who have chronic kidney disease (CKD) and among those
who have normal kidney function (see, e.g., Joy et al., J. Manag.
Care Pharm., 13:397-411, 2007) The progression of kidney disease
can be slowed by reducing phosphate retention. Thus, for renal
failure patients who are hyperphosphatemic and for chronic kidney
disease patients who have serum phosphorus levels within the normal
range or only slightly elevated, therapy to reduce phosphate
retention is beneficial.
[0007] For patients who experience hyperphosphatemia, calcium salts
have been widely used to bind intestinal phosphate and prevent its
absorption. Different types of calcium salts, including calcium
carbonate, acetate, citrate, alginate, and ketoacid salts have been
utilized for phosphate binding. However, these therapies often
cause hypercalcemia, a condition which results from absorption of
high amounts of ingested calcium. Hypercalcemia causes serious side
effects such as cardiac arrhythmias, renal failure, and skin and
vascular calcification. Frequent monitoring of serum calcium levels
is required during therapy with calcium-based phosphate binders.
Other calcium and aluminum-free phosphate binders, such as
sevelamer, a crosslinked polyamine polymer, have drawbacks that
include the amount and frequency of dosing required to be
therapeutically active. The relatively modest phosphate binding
capacity of those drugs in vivo obliges patients to escalate the
dose (up to 7 grams per day or more). Such quantities have been
shown to produce gastrointestinal discomfort, such as dyspepsia,
abdominal pain and, in some extreme cases, bowel perforation.
[0008] An alternative approach to the prevention of phosphate
absorption from the intestine in patients with elevated phosphate
serum levels is through inhibition of the intestinal transport
system which mediates phosphate uptake in the intestine. It is
understood that phosphate absorption in the upper intestine is
mediated at least in part by a carrier-mediated mechanism which
couples the absorption of phosphate to that of sodium Inhibition of
intestinal phosphate transport will reduce body phosphorus
overload. In patients with advanced kidney disease (e.g. stage 4
and 5), the body phosphorus overload manifests itself by serum
phosphorus concentration above normal levels, i.e.,
hyperphosphatemia. Hyperphosphatemia is directly related to
mortality and morbidity Inhibition of intestinal phosphate
transport will reduce serum phosphorus concentration and therefore
improve outcome in those patients. In chronic kidney disease
patients at stage 2 or 3, the body phosphorus overload does not
necessarily lead to hyperphosphatemia, i.e., some patients remain
normophosphatemic, but there is a need to reduce or prevent body
phosphorus overload even at those early stages to avoid associated
bone and vascular disorders, and ultimately improve mortality rate.
Similarly, inhibition of intestinal phosphate transport would be
particularly advantageous in patients that have a disease that is
treatable by inhibiting the uptake of phosphate from the
intestines. Furthermore, inhibition of phosphate transport may slow
the progression of renal failure and reduce risk of cardiovascular
events.
[0009] The luminal pole of the intestinal epithelia comprises a
so-called unstirred water layer (UWL) where transport is
essentially of diffusive nature because of the viscosity of the
mucus layer. This unstirred layer is defined as a stagnant layer
adjacent to the membrane on the apical side acting as a diffusion
barrier so that rapidly permeating substances could actually be
rate-limited by diffusion. This limited diffusion applies to
H.sup.+ and therefore the UWL contributes to establishing a pH
microclimate due to the outward flux of proton and the diffusion
limit imposed by the mucus layer. The acidic environment at the
vicinity of the cell surface maintains a relatively large
electrochemical gradient across the epithelial membrane--a cross
epithelial pH gradient, or CEPG.
[0010] Strong evidence exists for the involvement of this CEPG in
the transport of nutrients via proton co-transporters and --OH--
antiporters, such as PEPT1, folate/OH-- antiporter, and
.beta.-alanine/H+ cotransporter. See, e.g., Ikuma, J Med Chem.
50:1166-1176, 1996. The disturbance of the pH microclimate, for
example, a decrease of the CEPG, can alter the absorption of
nutrients. This has been shown in the case of proton-mediated
absorption of peptide via PEPT1. See, e.g., Thwaites et al.,
Gastroenterology. 122:1322-1333, 2002; and Thwaites and Anderson,
Exp. Physiol. 92:603-619, 2007. However, no role for the CEPG has
been established in the absorption of phosphate ions across the
intestinal membrane.
[0011] Evidence also exists for the involvement of water absorption
in the transport of ions across the epithelia of the small
intestine particularly the jejenum. Juan et al., J Clin Endocrinol
Metab. 43:517-22, 1976. But such mechanisms have been
little-explored in the area of phosphate-lowering therapeutics.
BRIEF SUMMARY
[0012] The present invention relates generally to non-NHE3-binding
compounds having activity as phosphate transport inhibitors in the
gastrointestinal tract, especially in the small intestine,
including stereoisomers, pharmaceutically acceptable salts and
prodrugs thereof, and the use of such compounds to inhibit
phosphate uptake and to thereby treat any of a variety of
conditions or diseases in which modulation of phosphate uptake
provides a therapeutic benefit.
[0013] Embodiments of the present invention thus include methods
for inhibiting phosphate uptake in the gastrointestinal tract of a
patient in need of phosphate lowering, comprising administering to
the patient a compound that does not bind NHE3, where the compound
is substantially active in the gastrointestinal tract to inhibit
transport of phosphate ions (Pi) therein upon administration to the
patient in need thereof.
[0014] In specific embodiments, the compound is a guanylate cyclase
C receptor (GC-C) agonist compound.
[0015] In certain embodiments, the compounds are pH-modulatory
agents. These and related embodiments include methods for
inhibiting phosphate uptake in the gastrointestinal tract of a
patient in need of phosphate lowering, comprising administering to
the patient a compound that decreases the cross-epithelial pH
gradient (CEPG) in the small intestine, where the CEPG is defined
as the difference in pH between (i) the cytoplasm of the epithelial
cells of the surface of the small intestine, optionally at the
subapical surface of the epithelial cell, and (ii) the unstirred
layer at the apical surface of the small intestine, where the
compound is substantially active in the gastrointestinal tract to
inhibit transport of phosphate ions (Pi) therein upon
administration to the patient in need thereof, and where the
compound does not bind NHE3.
[0016] In some embodiments, the compounds reduce water absorption
in the small intestine, optionally the jejunum. These and related
embodiments include methods for inhibiting phosphate uptake in the
gastrointestinal tract of a patient in need of phosphate lowering,
comprising administering to the patient a compound that decreases
water absorption in the small intestine, optionally the jejunum,
where the compound does not bind NHE3, and where the compound is
substantially active in the gastrointestinal tract to inhibit
transport of phosphate ions (Pi) therein upon administration to the
patient in need thereof.
[0017] In some embodiments, the compound decreases the CEPG in the
small intestine and also decreases water absorption in the small
intestine. In some embodiments, the compound decreases the CEPG in
the small intestine without significantly decreasing water
absorption in the small intestine. In other embodiments, the
compound decreases water absorption in the small intestine without
significantly decreasing the CEPG in the small intestine (e.g.,
without significantly stimulating bicarbonate secretion and/or
inhibiting acid secretion).
[0018] In some embodiments, the method results in a method selected
from one or more of:
[0019] (a) a method for treating hyperphosphatemia, optionally
postprandial hyperphosphatemia;
[0020] (b) a method for treating a renal disease, optionally
chronic kidney disease (CKD) or end-stage renal disease (ESRD);
[0021] (c) a method for reducing serum creatinine levels;
[0022] (d) a method for treating proteinuria;
[0023] (e) a method for delaying time to renal replacement therapy
(RRT), optionally dialysis;
[0024] (f) a method for reducing FGF23 levels;
[0025] (g) a method for reducing the hyperphosphatemic effect of
active vitamin D;
[0026] (h) a method for attenuating hyperparathyroidism, optionally
secondary hyperparathyroidism;
[0027] (i) a method for reducing serum parathyroid hormone
(PTH)
[0028] (i) a method for improving endothelial dysfunction,
optionally induced by postprandial serum phosphorus;
[0029] (k) a method for reducing vascular calcification, optionally
intima-localized vascular calcification;
[0030] (l) a method for reducing urinary phosphorous;
[0031] (m) a method for normalizing serum phosphorus levels;
[0032] (n) a method for reducing phosphate burden in an elderly
patient;
[0033] (o) a method for decreasing dietary phosphate uptake;
[0034] (p) a method for reducing renal hypertrophy; and
[0035] (q) a method for reducing heart hypertrophy.
[0036] In certain embodiments, the compound decreases the
intracellular pH of the epithelial cells of the surface of the
small intestine, optionally at the subapical surface of the
epithelial cell. In certain embodiments, the compound increases the
pH of the unstirred layer at the apical surface of the small
intestine. In some embodiments, the compound (a) stimulates
bicarbonate secretion in the small intestine, or (b) inhibits acid
secretion in the small intestine, or (c) stimulates bicarbonate
secretion and inhibits acid secretion in the small intestine.
[0037] In certain embodiments, the compound increases one or more
intracellular secondary messengers of epithelial cells of the
surface of the small intestine. In some embodiments, the one or
more intracellular secondary messengers are selected from
Ca.sup.++, cyclic adenosine monophosphate (cAMP), and cyclic
guanosine monophosphate (cGMP).
[0038] In certain embodiments, the compound is substantially
systemically non-bioavailable upon enteral administration to the
patient. In particular embodiments, the compound is substantially
impermeable to the epithelium of the gastrointestinal tract. In
some embodiments, the compound is substantially permeable to the
epithelium of the gastrointestinal tract.
[0039] In certain embodiments, administration to the patient in
need thereof (a) reduces serum phosphorus concentrations or levels
to about 150% or less of normal serum phosphorus levels, and/or (b)
reduces uptake of dietary phosphorous by at least about 10%
relative to an untreated state. In some embodiments, administration
to the patient in need thereof increases phosphate levels in fecal
excretion by at least about 10% relative to an untreated state. In
some embodiments, administration to the patient in need thereof
reduces urinary phosphate concentrations or levels by at least
about 10% relative to an untreated state.
[0040] In some embodiments, the patient in need thereof has ESRD,
and administration to the patient reduces serum phosphorus
concentrations or levels by at least about 10% relative to an
untreated state.
[0041] In some embodiments, the patient in need thereof has CKD,
and administration to the patient reduces FGF23 levels and serum
intact parathyroid hormone (iPTH) levels by at least about 10%
relative to an untreated state.
[0042] In certain embodiments, the compound is selected from one or
more of a guanylate cyclase C receptor (GC-C) agonist, a P2Y
agonist, an adenosine A2b receptor agonist, a soluble guanylate
cyclase agonist, an adenylate cyclase receptor agonist, an
imidazoline-1 receptor agonist, a cholinergic agonist, a
prostaglandin EP4 receptor agonist, a dopamine D1 agonist, a
melatonin receptor agonist, a 5HT4 agonist, an atrial natriuretic
peptide receptor agonist, a carbonic anhydrase inhibitor, a
phosphodiesterase inhibitor, and a Down-Regulated in Adenoma (DRA
or SLC26A3) agonist.
[0043] In some embodiments, the GC-C agonist is a peptide,
optionally a bacterial heat stable enterotoxin, guanylin,
proguanylin, uroguanylin, prouroguanylin, lymphoguanylin, or a
variant or analog of any of the foregoing.
[0044] In some embodiments, the GC-C agonist peptide comprises the
amino acid sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10
Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16
Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID
NO:1) where: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
Asn Ser Ser Asn Tyr (SEQ ID NO:2) or is missing or Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing.
[0045] In certain embodiments, Xaa.sub.5 is Asn, Trp, Tyr, Asp, or
Phe.
[0046] In certain embodiments, Xaa.sub.5 is Thr or Ile.
[0047] In certain embodiments, Xaa.sub.5 is Tyr, Asp, or Trp.
[0048] In certain embodiments, Xaa.sub.8 is Glu, Asp, Gln, Gly, or
Pro.
[0049] In certain embodiments, Xaa.sub.9 is Leu, Ile, Val, Ala,
Lys, Arg, Trp, Tyr, or Phe.
[0050] In certain embodiments, Xaa.sub.9 is Leu, Ile, Val, Lys,
Arg, Trp, Tyr, or Phe.
[0051] In certain embodiments, Xaa.sub.12 is Asn, Tyr, Asp, or
Ala.
[0052] In certain embodiments, Xaa.sub.13 is Ala, Pro, or Gly.
[0053] In certain embodiments, Xaa.sub.14 is Ala, Leu, Ser, Gly,
Val, Glu, Gln, Ile, Leu, Lys, Arg, or Asp.
[0054] In certain embodiments, Xaa.sub.16 is Thr, Ala, Asn, Lys,
Arg, or Trp.
[0055] In certain embodiments, Xaa.sub.17 is Gly, Pro, or Ala.
[0056] In certain embodiments, Xaa.sub.19 is Trp, Tyr, Phe, Asn, or
Leu.
[0057] In certain embodiments, Xaa.sub.19 is Lys or Arg.
[0058] In certain embodiments, Xaa.sub.20 Xaa.sub.21 is AspPhe or
Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing. In certain
embodiments, Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0059] In specific embodiments, the GC-C agonist peptide comprises
the amino acid sequence: Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:3), or a variant
thereof having 1, 2, 3, 4, or 5 deletions, insertions, and/or
substitutions. In particular embodiments, the peptide comprises the
amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO:4), or a variant thereof having 1, 2, 3, 4,
or 5 deletions, insertions, and/or substitutions.
[0060] In certain embodiments, the GC-C agonist peptide comprises
the amino acid sequence (III): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Cys.sub.4 Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 Xaa.sub.9
Xaa.sub.10 Xaa.sub.11 Cys.sub.12 Xaa.sub.13 Xaa.sub.14 Xaa.sub.15
Xaa.sub.16 (SEQ ID NO:5), where Xaa.sub.1 is: Ser, Asn, Tyr, Ala,
Gln, Pro, Lys, Gly, or Thr, or is missing; Xaa.sub.2 is His, Asp,
Glu, Ala, Ser, Asn, Gly, or is missing; Xaa.sub.3 is Thr, Asp, Ser,
Glu, Pro, Val or Leu; Xaa.sub.5 is Asp, Ile or Glu; Xaa.sub.6 is
Ile, Trp or Leu; Xaa.sub.7 is Cys, Ser, or Tyr; Xaa.sub.8 is Ala,
Val, Thr, Ile, Met or is missing; Xaa.sub.9 is Phe, Tyr, Asn, or
Trp; Xaa.sub.10 is Ala, Val, Met, Thr or Ile; Xaa.sub.11 is Ala or
Val; Xaa.sub.13 is Thr or Ala; Xaa.sub.14 is Gly, Ala or Ser;
Xaa.sub.15 is Cys, Tyr or is missing; and Xaa.sub.16 is His, Leu or
Ser.
[0061] In some embodiments, the peptide comprises the amino acid
sequence: Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly
Cys Leu (SEQ ID NO:6), or a variant thereof having 1, 2, 3, 4, or 5
deletions, insertions, and/or substitutions.
[0062] In certain embodiments, the P2Y agonist is selected from a
compound in FIG. 4 or FIGS. 5A-5C. In certain embodiments, the
adenosine A2b receptor agonist is selected from a compound in FIGS.
6A-6C. In some embodiments, the soluble guanylate cyclase agonist
is selected from a compound in FIGS. 9A-9L. In certain embodiments,
the adenylate cyclase receptor agonist is selected from a compound
in FIG. 10. In some embodiments, the imidazoline-1 receptor agonist
is selected from moxonidine and a compound in FIG. 11. In certain
embodiments, the cholinergic agonist is selected from a compound in
FIG. 12. In particular embodiments, the prostaglandin EP4 receptor
agonist is selected from PGE.sub.2 or its analogs/derivatives and a
compound in FIG. 7 or FIG. 13. In certain embodiments, the dopamine
D1 agonist is selected from a compound in FIG. 14. In some
embodiments, the melatonin receptor agonist is selected from
melatonin and a compound in FIG. 15. In some embodiments, the 5HT4
agonist is selected from serotonin and its analogs, prucalopride,
metoclopramide, cleobopride, mosapride, prucalopride, renzapride,
tegaserod, zacopride, norcisapride, naronopride, and
velusetrag.
[0063] In some embodiments, the atrial natriuretic peptide receptor
agonist comprises or consists of an amino acid sequence selected
from: Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile
Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr (SEQ ID NO:7),
Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys
(SEQ ID NO:8) and Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly
Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg (SEQ ID NO:9),
including variants thereof having 1, 2, 3, 4, or 5 deletions,
insertions, and/or substitutions.
[0064] In certain embodiments, the carbonic anhydrase inhibitor is
selected from a compound in FIG. 17. In certain embodiments, the
phosphodiesterase inhibitor is selected from a compound in FIG. 18.
In some embodiments, the DRA agonist is selected from FIGS.
21A-B.
[0065] In some embodiments, the compound is substantially
systemically non-bioavailable upon enteral administration to the
patient and has (i) a tPSA of at least about 200 .ANG..sup.2. In
certain embodiments, the compound has a tPSA of at least about 250
.ANG..sup.2, a tPSA of at least about 270 .ANG..sup.2, a tPSA of at
least about 300 .ANG..sup.2, a tPSA of at least about 350
.ANG..sup.2, a tPSA of at least about 400 .ANG..sup.2, or a tPSA of
at least about 500 .ANG..sup.2. In particular embodiments, the
compound has a molecular weight of at least about 500 Da, at least
about 1000 Da, at least about 2500 Da, or at least about 5000 Da or
more. In some embodiments, the compound has (i) a total number of
NH and/or OH and/or other potential hydrogen bond donor moieties
greater than about 5; (ii) a total number of O atoms and/or N atoms
and/or other potential hydrogen bond acceptors greater than about
10; and/or (iii) a Moriguchi partition coefficient greater than
about 10.sup.5 or less than about 10. In some embodiments, the
compound has a permeability coefficient, P.sub.app, of less than
about 100.times.10.sup.-6 cm/s, or less than about
10.times.10.sup.-6 cm/s, or less than about 1.times.10.sup.-6 cm/s,
or less than about 0.1.times.10.sup.-6 cm/s.
[0066] Certain methods further comprise administering one or more
additional biologically active agents. In some embodiments, the
compound and the one or more additional biologically active agents
are administered as part of a single pharmaceutical composition. In
certain embodiments, the compound and the one or more additional
biologically active agents are administered as individual
pharmaceutical compositions. In some embodiments, the individual
pharmaceutical compositions are administered sequentially. In some
embodiments, the individual pharmaceutical compositions are
administered simultaneously.
[0067] In certain embodiments, the additional biologically active
agent is selected from vitamin D.sub.2 (ergocalciferol), vitamin
D.sub.3 (cholecalciferol), active vitamin D (calcitriol) and active
vitamin D analogs (e.g. doxercalciferol, paricalcitol).
[0068] In certain embodiments, the additional biologically active
agent is a phosphate binder. In some embodiments, the phosphate
binder is selected from the group consisting of sevelamer (e.g.,
Renvela.RTM. (sevelamer carbonate), Renagel.RTM. (sevelamer
hydrochloride)), lanthanum carbonate (e.g., Fosrenol.RTM.), calcium
carbonate (e.g., Calcichew.RTM., Titralac.RTM.), calcium acetate
(e.g. PhosLo.RTM., Phosex.RTM.), calcium acetate/magnesium
carbonate (e.g., Renepho.RTM., OsvaRen.RTM.), MCI-196, ferric
citrate (e.g., Zerenex.TM.) magnesium iron hydroxycarbonate (e.g.,
Fermagate.TM.), aluminum hydroxide (e.g., Alucaps.RTM.,
Basaljel.RTM.), APS1585, SBR-759, and PA-21.
[0069] In certain embodiments, the additional biologically active
agent is a NaPi2b inhibitor. In some embodiments, the additional
biologically active agent is niacin or nicotinamide
[0070] In certain embodiments, the subject has CKD and the
additionally active biological agent is selected from one or more
of ACE inhibitors, antiogensin II receptor blockers, beta-blockers,
calcium channel blockers, direct renin inhibitors, diuretics,
vasodilators, erythropoietin therapy, iron replacement therapy,
inhibitors of advanced glycation end products, vitamin D, and
statins.
[0071] In certain embodiments, the compound or composition is
administered orally, optionally where the compound or composition
is administered orally once-a-day.
[0072] Also included are methods of screening for an inhibitor of
phosphate uptake, comprising (a) culturing intestinal cells, (b)
contacting the cultured intestinal cells with a test compound, and
(c) measuring (i) the pH at the apical surface of the intestinal
cells, (ii) the intracellular pH of the intestinal cells, and/or
(iii) phosphate uptake by the intestinal cells, and (d) identifying
the test compound as an inhibitor of phosphate uptake where the pH
from (c)(i) increases relative to a control, the intracellular pH
from (c)(ii) decreases relative to a control, and/or phosphate
uptake from (c)(iii) decreases relative to a control.
[0073] In some embodiments, step (a) comprise culturing intestinal
cells to monolayers. In certain embodiments, step (a) comprises
isolating the cells from intestinal crypts and culturing under
conditions sufficient to form enteroids. In certain embodiments,
step (a) comprises culturing isolated embryonic stem cells,
endoderm cells, or pluripotent stem cells under conditions
sufficient to form organoids. In some embodiments, step (a)
comprises culturing intestinal section(s) in a Ussing chamber.
[0074] In certain embodiments, step (c)(i) comprises contacting the
cells with a pH-sensitive fluorescent dye and measuring
fluorescence of the dye. In some embodiments, step (c)(ii)
comprises contacting the cells with .sup.33P-labeled phosphate ions
and measuring uptake of the labeled phosphate ions.
[0075] In some embodiments, the increase and/or decrease of (d) is
statistically significant.
[0076] In certain embodiments, the test compound is a small
molecule or peptide that is known or suspected to stimulate
bicarbonate secretion and/or inhibit acid secretion in the small
intestine.
[0077] In certain embodiments, the test compound is selected from
one or more of a P2Y agonist, an adenosine A2b receptor agonist, a
guanylate cyclase C receptor agonist, a soluble guanylate cyclase
agonist, an adenylate cyclase receptor agonist, an imidazoline-1
receptor agonist, a cholinergic agonist, a prostaglandin EP4
receptor agonist, a dopamine D1 agonist, a melatonin receptor
agonist, a 5HT4 agonist, an atrial natriuretic peptide receptor
agonist, a carbonic anhydrase inhibitor, a phosphodiesterase
inhibitor, and a Down-Regulated in Adenoma (DRA or SLC26A3)
agonist, as described herein and/or known in the art.
[0078] These and other aspects of the invention will be apparent
upon reference to the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0079] FIGS. 1A-1B shows that linaclotide (a GC-C receptor agonist)
reduces the uptake of phosphate uptake in the gastrointestinal
tract of rats.
[0080] FIGS. 2A-2B show that moxonidine (an imidazoline subtype 1
(I.sub.1) receptor agonist) and the water soluble-forskolin analog
colforsin (an adenylate cyclase agonist) reduce the uptake of
phosphate uptake in the gastrointestinal tract of rats.
[0081] FIG. 3 shows that the P2Y2 receptor agonist Up.sub.4U
reduces the uptake of phosphate uptake in the gastrointestinal
tract of rats.
[0082] FIG. 4 shows exemplary small molecule P2Y receptor
agonists.
[0083] FIGS. 5A-5C show exemplary small molecule P2Y receptor
agonists.
[0084] FIGS. 6A-6C show exemplary small molecule adenosine A2b
receptor agonist, including representative adenosine-like A2b
agonists (6B) and representative dicyanopyridine A2b agonists
(6C).
[0085] FIG. 7 shows a list of exemplary prostaglandin EP4 receptor
agonists.
[0086] FIGS. 8A-8B show the photophysical properties of exemplary
near-neutral pH indicators (8A) and acidic pH indicators (8B).
[0087] FIGS. 9A-9L show exemplary soluble guanylate cyclase (sGC)
agonists, including heme-dependent and heme-independent agonists
(9A).
[0088] FIG. 10 shows exemplary adenylate cyclase receptor
agonists.
[0089] FIG. 11 shows exemplary imidazoline receptor agonists.
[0090] FIG. 12 shows exemplary cholinergic agonists and the
antagonists atropine and (-)-hyosine.
[0091] FIG. 13 shows exemplary EP4 receptor agonists.
[0092] FIG. 14 shows exemplary dopamine D1 receptor agonists.
[0093] FIG. 15 shows exemplary melatonin (MT2) receptor
agonists.
[0094] FIG. 16 shows the structures of exemplary peptide agonists
(SEQ ID Nos. 7, 8 and 9) of the NP receptor(s).
[0095] FIG. 17 shows exemplary carbonic anhydrase inhibitors.
[0096] FIG. 18 shows exemplary phosphodiesterase inhibitors.
[0097] FIG. 19 illustrates the pH gradients found in the intestine,
including the pH gradient across the cell membrane, and the pH
gradient at the immediate vicinity of the epithelial membrane and
the gut lumen.
[0098] FIG. 20 shows a phase diagram of the solubility calcium and
phosphate ions in an aqueous environment (at RT) over a range of pH
values.
[0099] FIGS. 21A-21B depict representative examples of subtype
selective PKC inhibitors.
[0100] FIGS. 22A-22C show that acidification of the interior of
HEK-293 cells led to a significant reduction in phosphate uptake,
as measured by uptake of .sup.33P labeled Pi.
DETAILED DESCRIPTION
[0101] In the following description, certain specific details are
set forth in order to provide a thorough understanding of various
embodiments of the invention. However, one skilled in the art will
understand that the invention may be practiced without these
details.
[0102] Unless the context requires otherwise, throughout the
present specification and claims, the word "comprise" and
variations thereof, such as, "comprises" and "comprising" are to be
construed in an open, inclusive sense, that is, as "including, but
not limited to".
[0103] Reference throughout this specification to "one embodiment"
or "an embodiment" means that a particular feature, structure or
characteristic described in connection with the embodiment is
included in at least one embodiment of the present invention. Thus,
the appearances of the phrases "in one embodiment" or "in an
embodiment" in various places throughout this specification are not
necessarily all referring to the same embodiment. Furthermore, the
particular features, structures, or characteristics may be combined
in any suitable manner in one or more embodiments.
[0104] Embodiments of the present invention relate generally to the
discovery that non-NHE3-binding compounds, such as guanylate
cyclase agonist compounds, are able to inhibit phosphate uptake in
the gastrointestinal tract, for example, in the small
intestine.
[0105] According to one non-limiting theory, the cellular uptake of
phosphate ions (Pi) can be influenced by changes to intracellular
pH and/or the pH of the adjacent extracellular environment. For
instance, as shown in the accompanying Examples, acidification of
the cell interior of Human Embryonic Kidney (HEK-293) cells (while
maintaining the extracellular pH at about 7.4) led to a significant
reduction in phosphate uptake, as measured by uptake of .sup.33P
labeled Pi.
[0106] In related experiments, where the phosphate transporter
NaPi2b (SLC34A2) was transiently expressed in HEK-293 cells, the
same phenomenon was observed. Because the endogenous Pi
transporters, Pit-1 and/or Pit-2 (SLC20A2) are responsible for Pi
uptake in non-transformed HEK-293 cells (to satisfy cell metabolic
demands), it was concluded that the effect of a decrease in
intracellular pH on Pi uptake is a general phenomenon not
necessarily linked to a specific phosphate transporter. Pit-1 and
Pit-2 transport the monobasic form of phosphate
NaH.sub.2PO.sub.3.sup.- whereas NaPi2b transports the dibasic form
NaHPO.sub.3.sup.2-. The observation that the cell acidification
affects phosphate uptake with both transporters is inconsistent
with a mechanism based on a change in the H.sup.+ electrochemical
gradient alone.
[0107] These observations are counterintuitive in the least because
an increase in Pi uptake could have been expected. For example, a
decrease in intracellular pH (e.g., without any corresponding
change in the extracellular pH) could have been expected to create
a driving force for the uptake of basic anions such as the dibasic
form of phosphate (NaPO.sub.3.sup.2-).
[0108] Nonetheless, a reduction in phosphate uptake was observed,
presenting the potential of using direct or indirect pH-modulatory
agents, particularly those having activity as pH-modulatory agents
in the gastrointestinal tract (e.g., small intestine), to reduce
phosphate uptake in a patient in need of phosphate lowering. This
potential is supported by the observation that a variety of
pH-modulatory agents are capable of reducing phosphate uptake in
the mammalian gastrointestinal tract (see the accompanying
Examples). The term "pH-modulatory" agents, as used herein,
includes agents or compounds that are capable of directly or
indirectly increasing bicarbonate (HCO.sub.3.sup.-) secretion
and/or decreasing acid/proton (e.g., H.sup.+) secretion into the
lumen of the gastrointestinal tract, for example, the small
intestine or duodenum. Some pH-modulatory compounds may act, for
example, by modulating (e.g., increasing) certain intracellular
secondary messengers of epithelial cells of the gastrointestinal
tract, such as Ca.sup.++, cAMP, cGMP, and others. Some exemplary
compounds thus either directly or indirectly stimulate bicarbonate
secretion into the lumen of the small intestine, inhibit acid
secretion into the lumen of the small intestine, or stimulate
bicarbonate secretion and inhibit acid secretion into the lumen of
the small intestine. In some aspects, the compound decreases the
cytoplasmic or intracellular pH of the epithelial cells of the
surface of the small intestine, optionally at the subapical surface
of the epithelial cell, without or without modulating the pH of the
adjacent extracellular environment. In certain embodiments, the
compound does not bind to and inhibit the sodium-hydrogen
antiporter 3 (NHE3).
[0109] In some aspects, the compound decreases the pH of the
"unstirred layer" at the apical surface of the small intestine. The
"unstirred layer" refers to a stagnant layer adjacent to the
membrane on the apical side (e.g., about 600 .mu.m deep) which acts
as a diffusion barrier so that rapidly permeating substances (e.g.,
.sup.1H.sup.+) can be rate-limited by diffusion. Without wishing to
be bound to theory, such an approach would elicit a flux of
bicarbonate across the epithelial cells of the gastrointestinal
tract, increase the pH in immediate vicinity of the cell exterior
(UWL), and therefore decrease the pH gradient at the mucosal
surface. Because of the continuous exchange of proton and
bicarbonate ions at the apical surface of the intestinal cells via
co-transporters, antiporters and channels, a pH gradient is
maintained across the cell membrane. As a result of the unstirred
layer, another pH gradient is established between the immediate
vicinity of the epithelial membrane and the gut lumen. The two pH
gradients are represented schematically in FIG. 19.
[0110] Accordingly, in some aspects, a compound decreases the
cross-epithelial pH gradient (CEPG) in the gastrointestinal tract.
The term "CEPG" includes the difference in pH between (i) the
cytoplasm of the epithelial cells of the surface of the small
intestine (i.e., the intracellular pH), optionally at the subapical
surface of the epithelial cell, and (ii) the unstirred layer at the
apical surface of the small intestine. Certain embodiments exclude
compounds (e.g., antacids) that merely increase the luminal pH of
the gastrointestinal tract without modulating bicarbonate and/or
acid secretion or without altering the pH in the unstirred layer or
UWL.
[0111] In some embodiments, and without wishing to be bound by any
one theory, intraluminal free calcium ions may contribute to the
inhibition of Pi uptake induced by a decrease, in the CEPG. A phase
diagram of calcium and phosphate ions in an aqueous environment at
room temperature shows that the solubility of calcium (and
therefore phosphate) is pH dependent, that is, phosphate solubility
decreases as pH increases. See FIG. 20. This phenomenon would
suggest that, all things being equal, a drug-induced pH increase in
the microenvironment of the mucosal surface would minimize free Pi
availability, thus reducing its cellular uptake in the
gastrointestinal tract.
[0112] According to another non-limiting theory, the uptake of
phosphate ions can be influenced by the absorption of water in the
small intestine, primarily in the jejunum. Specifically, increased
water absorption in the small intestine associates with increased
phosphate uptake, and vice versa. In such instances,
non-NHE3-binding compounds that reduce water absorption in the
small intestine can be used to inhibit phosphate uptake. Certain
embodiments thus relate to methods for inhibiting phosphate uptake
in the gastrointestinal tract of a patient in need of phosphate
lowering, comprising administering to the patient a compound that
decreases water absorption in the small intestine, where the
compound does not bind NHE3, and where the compound is
substantially active in the gastrointestinal tract to inhibit
transport of phosphate ions (Pi) therein upon administration to the
patient in need thereof. In certain embodiments, the compound
decreases "net" water absorption, for instance, by modulating the
balance between secretion and absorption, e.g., by decreasing
absorption, increasing secretion, or both. In some embodiments, the
compound decreases water absorption in the jejunum.
[0113] In some aspects, inhibition of phosphate uptake in the
gastrointestinal tract may be achieved by the administration of
certain compounds, and/or pharmaceutical compositions comprising
them, which may advantageously be designed such that little, or
substantially none, of the compound is absorbed into the blood
stream (that is, it is designed to be non-systemic or substantially
non-systemic). In this regard, the compounds have features that
give rise to little or substantially no systemic availability upon
enteral administration, including oral administration. In other
words, the compounds are not absorbed into the bloodstream at
meaningful levels and therefore have no activity there, but instead
have their activity localized substantially within the GI
tract.
[0114] Therefore, in certain illustrative embodiments as further
described herein, the compounds of the invention generally require
a combination of structural and/or functional features relating or
contributing to their activity in the GI tract and/or their
substantial non-systemic bioavailability. Such features may
include, for example, one or more of (i) specific tPSA and/or MW
values (e.g., at least about 190 .ANG..sup.2 and/or at least about
736 Daltons, respectively), (ii) specific levels of fecal recovery
of the compound and/or its metabolites after administration (e.g.,
greater than 50% at 72 hours); (iii) specific numbers of NH and/or
OH and/or potentially hydrogen bond donor moieties (e.g., greater
than about five); (iv) specific numbers of rotatable bonds (e.g.,
greater than about five); (iv) specific permeability features
(e.g., P.sub.app less than about 100.times.10.sup.-6 cm/s); and/or
any of a number of other features and characteristics as described
herein.
[0115] In patients with advanced kidney disease (e.g. stage 4 and
5), the body phosphorus overload manifests itself by serum
phosphorus concentration above normal levels, i.e.,
hyperphosphatemia. Hyperphosphatemia is directly related to
mortality and morbidity Inhibition of intestinal phosphate
transport will reduce serum phosphorus concentration and therefore
improve outcome in those patients. In stage 2 and 3 chronic kidney
disease patients, the body phosphorus overload does not necessarily
lead to hyperphosphatemia, i.e., patients remain normophosphatemic,
but it does trigger an increase in FGF-23, a risk factor in
mortality and morbidity in those patients. Therefore, there is a
need to reduce body phosphorus overload even at those early stages
to avoid associated bone and vascular disorders, and ultimately
improve mortality rate.
[0116] Inhibition of intestinal phosphate transport will be
particularly advantageous in patients that have a disease that is
treatable by inhibiting the uptake of phosphate from the
intestines. Furthermore, inhibition of phosphate transport may slow
the progression of renal failure and reduce the risk of
cardiovascular events, among other diseases or conditions
associated with the need for phosphate lowering.
I. Compounds that Inhibit Phosphate Transport
[0117] Embodiments of the present invention relate to compounds
that are able to inhibit or reduce phosphate transport/uptake in
the gastrointestinal tract, for instance, by modulating the pH
within or adjacent to the epithelial membrane of the
gastrointestinal lumen, by decreasing water absorption in the small
intestine, or both. Examples of pH-modulatory compounds include
those that stimulate bicarbonate secretion in the small intestine
(i.e., duodenal bicarbonate secretion or DBS), inhibit acid/proton
secretion in the small intestine, or both.
[0118] The compounds provided herein can include small molecules of
synthetic or biologic origin and peptides or polypeptides. The
terms "peptide" and "polypeptide" are used interchangeably herein;
however, in certain instances, the term "peptide" can refer to
shorter polypeptides, for example, polypeptides that consist of
about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 25, 30, 35, 40, 45, or 50 amino acids, including all
integers and ranges (e.g., 5-10, 8-12, 10-15) in between.
Polypeptides and peptides can be composed of naturally-occurring
amino acids and/or non-naturally occurring amino acids. Antibodies
are also included as polypeptides.
[0119] In some embodiments, the compound is selected from one or
more of a P2Y receptor agonist, an adenosine A2b receptor agonist,
a guanylate cyclase C receptor agonist, a soluble guanylate cyclase
agonist, an adenylate cyclase receptor agonist, an imidazoline-1
receptor agonist, a cholinergic agonist, a prostaglandin EP4
receptor agonist, a dopamine D1 agonist, a melatonin receptor
agonist, a 5HT4 agonist, an atrial natriuretic peptide receptor
agonist, a carbonic anhydrase inhibitor, a phosphodiesterase
inhibitor, or a Down-Regulated in Adenoma (DRA or SLC26A3) agonist.
In some aspects, as noted above, such agonist compounds induce
bicarbonate secretion and/or inhibit acid secretion in the upper
gastrointestinal tract, including the duodenum and the proximal
jejunum. In some aspects, the mechanism of action directly or
indirectly modulates apical proton and bicarbonate transporters to
produce a decrease in CEPG or a relatively basic microenvironment
at the mucosal surface, which thereby reduces phosphate
uptake/absorption.
[0120] In specific aspects, the compound directly or indirectly
stimulates duodenal bicarbonate secretion (DBS). DBS is a natural
defense of the mucosa which operates in the duodenal and proximal
jejunum segments of the gut to neutralize acidic gastric fluid. DBS
can be stimulated by a number of biological pathways, including
those which regulate the activity of chloride/bicarbonate
antiporters such as SLC26A3 (DRA) and SLC26A3 (PAT-1), chloride and
bicarbonate channels via CFTR, and calcium-activated chloride
channels, among others. In some aspects, these pathways are
stimulated by an increase in one or more secondary messengers, such
as intracellular Ca.sup.++, cAMP, and/or cGMP.
[0121] In some aspects, the compound directly or indirectly
decreases water absorption in the small intestine. In particular
aspects, the compound decreases water absorption in the jejunum.
The specific aspects, the compound decreases water absorption in
the small intestine by about or at least about 10%, 20%, 30%, 40%,
50%, 60%, 70%, 80%, 90%, or 100% relative to a control compound or
no compound.
[0122] The term "agonist" includes a compound that binds to a
target molecule such as a receptor and triggers or stimulates a
cellular response by that target molecule. Included are super
agonists, full agonists, partial agonists, and selective agonists.
Super agonists produce a greater maximal response than the
endogenous agonist(s) for the target molecule, full agonists
produce a comparable response relative to the endogenous agonist(s)
for the target molecule, and partial agonists produce a
significantly lesser (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%)
maximal response than the endogenous agonist(s) for the target
molecule.
[0123] Further to its activity as an agonist, in certain
embodiments a compound can also be characterized by its "specific
binding" to a target. For instance, in some embodiments a compound
(e.g., a direct-acting compound) can specifically bind to a target
described herein with a binding affinity (K.sub.d) of at least
about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, or 50 nM. In particular
embodiments, the target is selected from one or more of a P2Y
receptor, an adenosine A2b receptor, a guanylate cyclase C
receptor, an adenylate cyclase receptor, an imidazoline-1 receptor,
an acetylcholine receptor, a prostaglandin EP4 receptor, a dopamine
D1 receptor, a melatonin receptor, 5HT4, an atrial natriuretic
peptide receptor, a carbonic anhydrase, a phosphodiesterase, and
Down-Regulated in Adenoma (DRA or SLC26A3), as described
herein.
[0124] A. P2Y Agonists
[0125] In certain embodiments, the compound is a P2Y agonist (or
P2Y receptor agonist). P2Y receptors refer to a family of
purinergic G protein-coupled receptors. Examples of human P2Y
receptors include P2Y.sub.1, P2Y.sub.2, P2Y.sub.4, P2Y.sub.5,
P2Y.sub.6, P2Y.sub.8, P2Y.sub.9, P2Y.sub.10, P2Y.sub.11,
P2Y.sub.12, P2Y.sub.13, and P2Y.sub.14. The main native or
endogenous ligands of the P2Y receptors are adenosine
5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP), uridine
5'-triphosphate (UTP), uridine 5'-diphosphate (UDP), and
UDP-glucose (or other UDP sugars). Dinucleotides such as Ap.sub.4U
are also naturally-occurring P2Y agonists.
[0126] P2Y receptors have been shown to mediate Ca.sup.++ signaling
in duodenocytes and contribute to duodenal mucosal bicarbonate
secretion. See, e.g., Dong et al., Am J Physiol Gastrointest Liver
Physiol 296:G424-G432, 2009. Without being bound by any one
mechanism, in certain aspects a P2Y receptor agonist inhibits or
reduces phosphate uptake in the gastrointestinal tract by
stimulating bicarbonate secretion into the small intestine (also
referred to as duodenal bicarbonate secretion; DBS).
[0127] In some embodiments, and without being bound by any one
mechanism, a P2Y receptor agonist inhibits or reduces phosphate
uptake in the gastrointestinal tract by decreasing water absorption
in the small intestine.
[0128] Some P2Y receptors are selectively activated, for example,
by adenine nucleotides such as ATP and ADP, and others are by
uracil nucleotides or UDP-glucose. The P2Y.sub.1 receptor accounts
for the functionality of the defined P2Y-purinoreceptor. It
operates in a variety of tissues including smooth muscle,
endothelium and neuronal tissues as well as in blood platelets. The
P2Y.sub.1 receptor is selective for adenine nucleotides. ADP is the
most potent physiological agonist. In some embodiments, the
compound is a P2Y.sub.1 receptor agonist, optionally a selective
P2Y.sub.1 receptor agonist relative to other P2Y receptors. One
example of a P2Y.sub.1 receptor agonist is 2-methylthio-ADP.
[0129] In particular embodiments, the compound is a P2Y.sub.2
and/or P2Y.sub.4 receptor agonist, optionally a selective P2Y.sub.2
receptor agonist relative to other P2Y receptors. These two
receptors display the highest identity in the sequences of their TM
domains (66.8%) of all the P2Y receptor subtypes. The P2Y.sub.2
receptor can be activated, for instance, by uracil nucleotides,
UDP-sugar derivatives, and adenine nucleotides such as ATP.
P2Y.sub.2 receptors are expressed in many tissues including lung,
heart, skeletal muscle, spleen, kidney, liver and epithelia. These
receptors play an important role in regulating ion transport in
epithelial cells. Triphosphate nucleotides including UTP, ATP,
UTP.gamma.S and ATP.gamma.S act as full agonists of the P2Y.sub.2
receptor. In addition to the above-mentioned agonists, the
P2Y.sub.2 receptor also responds to diadenosine-tetraphosphate
(AP4A) and Up4U (diquafosol, INS365, used for the treatment for dry
eye disease). The analogue P-(uridine 5')-P4-(2'-deoxycytidine 5')
tetraphosphate (INS37217 is a potent agonist at the P2Y.sub.2
receptor with some agonist effects on the P2Y.sub.4 receptor.
Denufosol
((3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hyd-
roxyphosphoryl]
[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]met-
hoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate;
including its tetrasodium salt) is also an exemplary P2Y.sub.2
receptor agonist. Also included is PSB1114.
[0130] For ribose and uracil modifications, both
2'-deoxy-2'-amino-UTP and 2-thio-UTP preserve the agonist potency
of UTP at the P2Y.sub.2 receptor. The combination of these two
modifications yields 2'-amino-2-thio-UTP, which synergizes to
enhance both potency (8 nM EC.sub.50) and selectivity (300-fold
P2Y.sub.2-selective versus P2Y.sub.4). Modifications at position 5,
such as 5-bromo-UTP (EC.sub.50=0.75 .mu.M) and 5-iodo-UTP
(EC.sub.50=0.83 .mu.M), suggest that introducing a small
hydrophobic group might be beneficial at the P2Y.sub.2
receptor.
[0131] The P2Y receptor agonists provided herein include
mononucleotides, dinucleotides, and nucleotide-sugars, among other
agonists known in the art. See, e.g., U.S. Pat. No. 6,624,150; EP
1196396; WO 2008/060632; Cosyn et al., Bioorg Med Chem Lett.
19:3002-5, 2009 (describing uridine 5'-(phospho)phosphonate and a
5'-methylenephosphonate equivalent of UMP); Ko et al., Bioorg Med
Chem. 16:6319-32, 2008 (describing, for example,
alpha,beta-methylene-UDP, a P2Y.sub.6 receptor agonist;
Up(4)-phenyl ester and Up(4)-[1]glucose, selective P2Y.sub.2
receptor agonists; dihalomethylene phosphonate analogues, selective
P2Y.sub.2 receptor agonists; a 2-thio analogue of INS37217
(P(1)-(uridine-5')-P(4)-(2'-deoxycytidine-5')tetraphosphate), a
potent and selective P2Y.sub.2 receptor agonist; Ivanov et al., J
Med Chem. 50:1166-76, 2007; Brookings et al., Bioorg Med Chem Lett.
17:562-5, 2007 (describing the synthesis and P2Y.sub.2 agonist
activities of a series of nucleoside triphosphates); and Jacobson
et al., Purinergic Signal. 5:75-89, 2009; each of which is
incorporated by reference in its entirety.
[0132] Additional examples of P2Y receptor agonists include those
described in WO 1999/09998 and U.S. Application Nos. 2002/0052336
and 2003/0027785, including
P.sub.1,P.sub.4-diadenosinetetraphosphate (A.sub.2P.sub.4);
uridine-5'-diphosphate (UDP); uridine-5'-O-(2-thiodiphosphate)
(UDP.beta.S); 5-bromouridine-5'-triphosphate (5-BrUTP);
5-(1-phenylethynyl)-uridine-5'-triphosphate
(5-(1-phenylethynyl)UTP); 5-methyluridine-5'-diphosphate
(5-methylUDP); 4-hexylthiouridine-5'-triphosphate (4-hexylthioUTP);
4-thiouridine-5'-triphosphate (4-thioUTP);
2-methoxyuridine-5'-triphosphate (2-methoxyUTP);
4-(1-morpholino)uridine-5'-tetraphosphate
(4-(1-morpholino))UP.sub.4; 4-hexyloxyuridine-5'-diphosphate
(4-hexyloxyUDP); 4-(N, N-dimethyl)cytidine-5'-triphosphate (N,
N-dimethylCTP); 4-(N-hexyl)cytidine-5'-triphosphate (N-hexylCTP);
P.sup.1-(cytidine-5')-P.sup.4-(uridine-5'-)tetraphosphate
(CP.sub.4U); P.sup.1-O-(methyl)-P.sup.4-(uridine-5'-)tetraphosphate
(MeP.sub.4U) and 4-(N-cyclopentyl)thymidine-5'-triphosphate
(N-cyclopentylCTP).
[0133] Also included are 5'-adenosine-triphosphate (ATP),
5'-uridine-triphosphate (UTP), uridine-5'-O-(3-thiotriphosphate)
(UTP.gamma.S),
P.sup.1-(uridine-5')-P.sup.4-(uridine-5'-)tetraphosphate
(U.sub.2P.sub.4), 5'-[4-(thiouridine)]-triphosphate (4-thioUTP),
and P.sub.1-(cytidine-5')-P.sub.4-(uridine-5'-) tetraphosphate
(CP.sub.4U). The identification and preparation of certain
thiophosphate analogues of nucleoside diphosphates (such as
UDP-.beta.-S) are described in U.S. Pat. No. 3,846,402 and Goody
and Eckstein (J. Am. Chem. Soc. 93: 6252-6257. 1971).
Alternatively, UTP and other analogs thereof are also commercially
available from vendors such as Sigma (St. Louis, Mo.) and Pharmacia
(Uppsala, Sweden). Exemplary methods of identifying P2Y receptor
agonists are described, for example, in U.S. Application No.
2003/0175810.
[0134] In some embodiments, the P2Y receptor agonist is a
non-endogenous small molecule agonist. Additional examples of P2Y
receptor agonists are shown in FIGS. 4 and 5A-5C.
[0135] B. Adenosine A2b Receptor Agonists
[0136] In certain embodiments, the compound is an adenosine A2b
receptor agonist, optionally a selective agonist. Adenosine exerts
most of its physiological functions by acting as a local modulator
at four receptor subtypes named A1, A2A, A2B and A3 adenosine
receptors (ARs). The adenosine A2b receptor (or ADORA2B) is a
G-protein coupled adenosine receptor integral membrane protein that
stimulates adenylate cyclase activity in the presence of
adenosine.
[0137] The A2b receptor is expressed in a variety of tissues, and
high concentrations have been suggested in the caecum and large
intestine on both the mucosal and basolateral aspect of colonic
epithelial cells. See Baraldi et al., Purinergic Signal. 5:3-19,
2009. Activation at either site results in Cl- secretion via direct
activation of the cAMP-activated Cl-- channel cystic fibrosis
transmembrane conductance regulator (CFTR). CFTR modulates the
secretion of both chloride and bicarbonate. For example, in rats
the A2B receptor has been immuno-localized to the brush border
membrane of duodenal villi, where luminal adenosine has been shown
to stimulate bicarbonate secretion via A2B receptors and CFTR. See,
e.g., Ham et al., J Pharmacol Exp Ther. 335:607-13, 2010. Without
being bound by any one mechanism, in certain aspects an adenosine
A2b receptor agonist inhibits or reduces phosphate uptake in the
gastrointestinal tract by stimulating bicarbonate secretion into
the small intestine, e.g., by decreasing the CEPG.
[0138] In some embodiments, and without being bound by any one
mechanism, an adenosine A2b receptor agonist inhibits or reduces
phosphate uptake in the gastrointestinal tract by decreasing water
absorption in the small intestine.
[0139] General examples of adenosine A2b receptor agonists include
adenosine, adenosine-like compounds, and non-adenosine compounds.
In some embodiments, nucleoside-based adenosine A2b receptor
agonists include modified adenosine compounds, such as adenosine
compounds substituted at the N (6)-position of the purine
heterocycle, the C(2)-position of the purine heterocycle, the
5'-position of the ribose moiety, and any combination of the
foregoing. Also included are non-ribose ligands such as substituted
dicarbonitrilepyridines, among which
2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-ylsulfan-
yl]acetamide is an example. See, e.g., Baraldi et al., Purinergic
Signal. 4:287-303, 2008; and Baraldi et al., Purinergic Signal.
5:3-19, 2009; each of which is incorporated by reference in its
entirety.
[0140] Additional non-limiting examples of adenosine A2b receptor
agonists include BAY 60-6583, CV 1808, AMP579, NECA
(N-ethylcarboxamidoadenosine), (S)-PHPNECA, LUF-5835, 6-guanyl
NECA, and LUF-584. See also Beukers et al., J. Med. Chem.
47:3707-3709, 2004 (describing, for example, non-adenosine agonists
such as LUF5834
(2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-2-ylmethylsulfanyl)pyridine-3-
,5-dicarbonitrile) and LUF5835 (a 3-hydroxyphenyl analogue));
Beukers et al., Med Res Rev. 26:667-98, 2006 (describing, for
example, (S)PHPNECA and certain non-ribose ligands as adenosine A2b
receptor agonists); and Liu et al., Basic Res Cardiol. 105:129-37,
2010. Also included are the A2b receptor agonists described in U.S.
Application No. 2002/0156076. These references are incorporated by
reference in their entireties.
[0141] Examples of adenosine A2b receptor agonists are shown in
FIGS. 6A-6C, and further disclosed, together with methods for their
synthesis, in U.S. Application No. 2009/0221649 and PCT Publication
Nos. WO 2006/027142, WO 2007/101531, and WO 2003/008384, each of
which is incorporated by reference in its entirety.
[0142] C. Guanylate Cyclase C Receptor Agonists
[0143] In certain embodiments, the compound is a guanylyl cyclase C
(GC-C) agonist, optionally a selective agonist. GC-C is an isoform
of the guanylate cyclase family that is highly concentrated at the
apical membrane of intestinal epithelial cells. It is also the
target receptor for bacterially-secreted heat stable-enterotoxins,
which are responsible for acute secretory diarrhea. GC-C is also
known as guanylate cyclase 2C, intestinal guanylate cyclase,
guanylate cyclase C receptor, and heat-stable enterotoxin receptor
(hSTAR).
[0144] GC-C has an extracellular ligand-binding domain, a single
transmembrane region, a region similar to protein kinases, and a
C-terminal guanylate cyclase domain. Tyrosine kinase activity
mediates the GC-C signaling pathway within the cell. Guanylin and
uroguanylin are endogenous peptide ligands for GC-C. Activation of
GC-C leads, for example, to intracellular cGMP elevation,
PKGII-dependent phosphorylation of the cystic fibrosis
transmembrane regulator (CFTR), and other downstream signals which
trigger increased chloride and bicarbonate intraluminal secretion
(via CFTR, and possibly DRA or PAT-1).
[0145] GC-C agonists such as linaclotide, guanylin, and E. coli
heat stable enterotoxins (STa) have been shown to stimulate
duodenal bicarbonate secretion. See, e.g., Rao et al., Am J Physiol
Gastrointest Liver Physiol 286:G95-G101, 2004; Busby et al., Eur J
Pharmacol. 649:328-35, 2010; Bryant et al., Life Sci. 86:760-5,
2010. Without being bound by any one mechanism, in certain aspects
a GC-C agonist inhibits or reduces phosphate uptake in the
gastrointestinal tract by stimulating bicarbonate secretion into
the small intestine.
[0146] In some embodiments, and without being bound by any one
mechanism, a GC-C agonist inhibits or reduces phosphate uptake in
the gastrointestinal tract by decreasing water absorption in the
small intestine.
[0147] General examples of GC-C agonists include peptide agonists
and analogs thereof, including synthetic analogs of endogenous GC-C
peptide agonists. Particular examples of GC-C agonists include,
without limitation, heat stable enterotoxins (ST or STa peptides)
including those from E. coli, guanylin, proguanylin, uroguanylin,
prouroguanylin, lymphoguanylin, linaclotide (Linzess), SP-333, and
plecanatide. See, e.g., Drug Des Devel Ther. 7:351-60, 2013.
Linaclotide is a STa synthetic analog marketed for the treatment of
irritable bowel syndrome--constipation dominant (IBS-C). See, e.g.,
Bryant et al., Life Sci. 86:760-5, 2010. Plecanatide is a synthetic
analog of uroguanylin developed for the treatment of IBS-C. See,
e.g., Pitari, supra; and Shailubhai et al., Dig Dis Sci. 2013 Apr.
27. [Epub ahead of print]. Additional examples of GC-C agonists are
described in U.S. Application Nos. 2012/0064039, 2004/0258687,
2005/0287067, 2006/0281682, 2006/0258593, 2006/0094658,
2008/0025966, 2003/0073628, 2004/0121961 and 2004/0152868 and in
U.S. Pat. Nos. 5,140,102, 7,041,786, and 7,304,036. These
references are incorporated by reference in their entireties.
[0148] In some embodiments, the GC-C agonist is a bacterial ST (or
STa) peptide, or a variant or analog or derivative thereof. In
bacteria, ST or STa peptides are derived from a preproprotein that
generally has at least 70 amino acids. The pre and pro regions are
cleaved as part of the secretion process, and the resulting mature
protein, which generally includes fewer than about 20 amino acids,
is biologically active.
[0149] Exemplary bacterial ST peptides include: E. coli ST Ib
(Moseley et al., Infect. Immun. 39:1167, 1983) having the mature
amino acid sequence Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:10); E. coli ST Ia (So and
McCarthy, PNAS USA. 77:4011, 1980) having the mature amino acid
sequence Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys
Ala Gly Cys Tyr (SEQ ID NO:11); E. coli ST I (Chan and Giannella,
J. Biol. Chem. 256:7744, 1981) having the mature amino acid
sequence Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys Tyr Pro Ala Cys
Ala Gly Cys Asn (SEQ ID NO:12); C. freundii ST peptide (Guarino et
al., Infect. Immun. 57:649, 1989) having the mature amino acid
sequence Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys
Ala Gly Cys Tyr (SEQ ID NO:13); Y. enterocolitica ST peptides,
Y-ST(Y-STa), Y-STh, and Y-STc (reviewed in Huang et al., Microb.
Pathog. 22:89, 1997) having the following pro-form amino acid
sequences: Gln Ala Cys Asp Pro Pro Ser Pro Pro Ala Glu Val Ser Ser
Asp Trp Asp Cys Cys Asp Val Cys Cys Asn Pro Ala Cys Ala Gly Cys
(SEQ ID NO:14) (as well as a Ser-7 to Leu-7 variant of Y-STa (SEQ
ID NO:15), (Takao et al., Eur. J. Biochem. 152:199, 1985); Lys Ala
Cys Asp Thr Gln Thr Pro Ser Pro Ser Glu Glu Asn Asp Asp Trp Cys Cys
Glu Val Cys Cys Asn Pro Ala Cys Ala Gly Cys (SEQ ID NO:16); Gln Glu
Thr Ala Ser Gly Gln Val Gly Asp Val Ser Ser Ser Thr Ile Ala Thr Glu
Val Ser Glu Ala Glu Cys Gly Thr Gln Ser Ala Thr Thr Gln Gly Glu Asn
Asp Trp Asp Tip Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Phe Gly Cys
(SEQ ID NO:17), respectively; Y. kristensenii ST peptide having the
mature amino acid sequence Ser Asp Trp Cys Cys Glu Val Cys Cys Asn
Pro Ala Cys Ala Gly Cys (SEQ ID NO:18); V. cholerae non-01 ST
peptide (Takao et al., FEBS Lett. 193:250, 1985) having the mature
amino acid sequence Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys
Phe Gly Cys Leu Asn (SEQ ID NO:19); and V. mimicus ST peptide
(Arita et al., FEMS Microbiol. Lett. 79:105, 1991) having the
mature amino acid sequence Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro
Ala Cys Phe Gly Cys Leu Asn (SEQ ID NO:20). Table A1 below shows
the sequences of exemplary mature ST peptides.
TABLE-US-00001 TABLE A1 SEQ Mature ST Peptides ID NO:
NSSNYCCELCCNPACTGCY 10 NTFYCCELCCNPACAGCY 11 NTFYCCELCCNPACAPCY 21
NTFYCCELCCYPACAGCN 12 IDCCEICCNPACFGCLN 19 IDCCEICCNPACFGCLN 19
IDCCEICCNPACF 22 IDCCEICCNPACFG 23 IDCCEICCNPACFGCLN 19
IDRCEICCNPACFGCLN 24 DWDCCDVCCNPACAGC 25 DWDCCDVCCNPACAGC 26
NDDWCCEVCCNPACAGC 27 WDWCCELCCNPACFGC 28 SDWCCEVCCNPACAGC 18
QACDPPSPPAEVSSDWDCCDVCCDPACAGC 29 QACDPPSPPAEVSSDWDCCDVCCNPACAGC 14
KACDTQTPSPSEENDDTCCEVCCNPACAGC 16 QETASGQVGDVSSSTIATEVSEAECGTQSAT
30 TQGENDWDWCCELCCNPACFGC 31 MKKLMLAIFISVLSFPSFSQSTESLDS 32
SKEKITLETKKCDVVKNNSEKKSEN 33 MNNTFYCCELCCNPACAGCY 34
MKKSILFIFLSVLSFSPFAQDAKPVES 35 SKEKITLESKKCNIAKKSNKSGPESM 36
NSSNYCCELCCNPACTGCY 37 MKKIVFVLVLMLSSFGAFGQETVSG 38
QFSDALSTPITAEVYKQACDPPLPPA 39 EVSSDWDCCDVCCNPACAGC 40
[0150] The immature (including pre and pro regions) form of E. coli
ST-IA (ST-P) protein has the sequence:
mkklmlaifisvlsfpsfsqstesldsskekitletkkcdvvknnsekksenmnntfyccelccnpacagcy
(SEQ ID NO:41); see GenBank.RTM. Accession No. P01559 (gi:123711).
The pre sequence extends from residues 1-19. The pro sequence
extends from residues 20-54. The mature protein extends from
residues 55-72. The immature (including pre and pro regions) form
of E. coli ST-1B (ST-H) protein has the sequence:
mkksilfiflsvlsfspfaqdakpvesskekitleskkcniakksnksgpesmnssnyccelccnpactgcy
(SEQ ID NO:42); see GenBank.RTM. Accession No. P07965
(gi:3915589)). The immature (including pre and pro regions) form of
Y. enterocolitica ST protein has the sequence:
mkkivfvlylmlssfgafgqetvsgqfsdalstpitaevykqacdpplppaevssdwdccdvccnpacagc
(SEQ ID NO:43); see GenBank.RTM. Accession No. 525659 (gi:282047)).
Accordingly, a GC-C agonist peptide may comprise or consist of any
one or more of the bacterial ST peptide sequences described herein,
including variants thereof.
[0151] The bacterial ST peptides typically have six Cys residues.
These six Cys residues form three disulfide bonds in the mature and
active form of the peptide. If the six Cys residues are identified,
from the amino to carboxy terminus of the peptide, as A, B, C, D,
E, and F, then the disulfide bonds usually form as follows: A-D,
B-E, and C-F. The formation of these bonds is believed to
contribute GC-C receptor binding. Hence, in certain embodiments, a
GC-C agonist peptide has at least one, two, or three disulfide
bonds selected from any combination of A-D, B-E, and C-F, as shown
above. In some embodiments, however, one or more cysteines of the
GC-C peptide agonists described herein are deleted or replaced with
a different amino acid. In some embodiments, 1, 2, 3, 4, 5, or 6
cysteines are deleted or replaced with a different amino acid. In
particular aspects, the most N-terminal cysteine residues (e.g., A,
B, or A and B) and/or the most C-terminal cysteine residue or
residues (e.g., E, F, or E and F) are deleted or replaced with a
different amino acid. In certain embodiments, the different amino
acid is alanine or serine.
[0152] Certain of the GC-C agonist peptides include a potentially
functional chymotrypsin cleavage site, e.g., a Trp, Tyr or Phe
located between either Cys B/Cys D or between Cys E/Cys F. Cleavage
at either chymotrypsin cleavage site may reduce the ability of the
peptide to bind to the GC-C receptor. In the human body an inactive
form of chymotrypsin, chymotrypsinogen is produced in the pancreas.
When this inactive enzyme reaches the small intestine it is
converted to active chymotrypsin by the excision of two
di-peptides. Active chymotrypsin can cleave peptides at the peptide
bond on the carboxy-terminal side of Trp, Tyr, or Phe. The presence
of active chymotrypsin in the intestinal tract can lead to cleavage
of certain of the GC-C peptide agonists having an appropriately
positioned functional chymotrypsin cleavage site. In some
instances, it is expected that chymotrypsin cleavage will moderate
the action of a GC-C peptide agonist having an appropriately
positioned chymotrypsin cleavage site as the peptide passes through
the intestinal tract.
[0153] Certain of the GC-C agonist peptides include a potentially
functional trypsin cleavage site, e.g., Lys or Arg. Trypsinogen,
like chymotrypsin, is a serine protease that is produced in the
pancreas and is present in the digestive tract. The active form,
trypsin, will cleave peptides having a Lys or Arg. The presence of
active trypsin in the intestinal tract can lead to cleavage of
certain of the GC-C agonist peptides having an appropriately
positioned functional trypsin cleavage site. In certain instances,
it is expected that trypsin cleavage will moderate the action of a
GC-C peptide agonist having an appropriately positioned trypsin
cleavage site as the peptide passes through the intestinal
tract.
[0154] In certain embodiments, the peptide comprises at least six
cysteines that can form three disulfide bonds. In certain
embodiments, the disulfide bonds are replaced by other covalent
cross-links and in some cases the cysteines are substituted by
other residues to provide for alternative covalent cross-links
(described elsewhere herein). Certain peptides include a functional
chymotrypsin or trypsin cleavage site located so as to allow
inactivation of the peptide upon cleavage. Certain peptides having
a functional cleavage site undergo cleavage and gradual
inactivation in the digestive tract, and this is desirable in some
circumstances. In certain peptides, a functional chymotrypsin site
is altered, increasing the stability of the peptide in vivo.
[0155] In certain embodiments, the peptides include either one or
two or more contiguous negatively charged amino acids (e.g., Asp or
Glu) or one or two or more contiguous positively charged residues
(e.g., Lys or Arg) or one or two or more contiguous positively or
negatively charged amino acids at the carboxy terminus. In these
and related embodiments, all of the flanking amino acids at the
carboxy terminus are either positively or negatively charged. In
some embodiments, the carboxy terminal charged amino acids are
preceded by a Leu. For example, the following amino acid sequences
can be added to the carboxy terminus of the peptide: Asp; Asp Lys;
Lys Lys Lys Lys Lys Lys (SEQ ID NO:44); Asp Lys Lys Lys Lys Lys Lys
(SEQ ID NO:45); Leu Lys Lys; and Leu Asp. In particular
embodiments, a Leu is added to the carboxy terminus.
[0156] In some aspects, the (bacterial ST analog) GC-C agonist
peptide comprises, consists, or consists essentially of the amino
acid sequence shown below (I):
TABLE-US-00002 (SEQ ID NO: 46) Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9
Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15
Xaa.sub.16 Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20
Xaa.sub.21
[0157] In some embodiments, Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ ID NO:2) or is missing or
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing. In certain
embodiments, Xaa.sub.8, Xaa.sub.9, Xaa.sub.12, Xaa.sub.14,
Xaa.sub.16, Xaa.sub.17, and Xaa.sub.15 are any amino acid. In
certain embodiments, Xaa.sub.8, Xaa.sub.9, Xaa.sub.12, Xaa.sub.14,
Xaa.sub.16, Xaa.sub.17, and Xaa.sub.19 are any natural or
non-natural amino acid or amino acid analog.
[0158] In certain embodiments, Xaa.sub.5 is Asn, Trp, Tyr, Asp, or
Phe. In other embodiments, Xaa.sub.5 is Thr or Ile. In some
embodiments, Xaa.sub.5 is Tyr, Asp or Trp. In certain embodiments,
Xaa.sub.5 is Asn, Trp, Tyr, Asp, Ile, Thr or Phe. In specific
embodiments Xaa.sub.5 is Asn.
[0159] In certain embodiments, Xaa.sub.8 is any natural or
non-natural amino acid or amino acid analog. In some embodiments,
Xaa.sub.8 is Glu, Asp, Gln, Gly or Pro. In other embodiments,
Xaa.sub.8 is Glu. In some embodiments, Xaa.sub.9 is Glu or Asp. In
some embodiments, Xaa.sub.8 is Asn, Glu, or Asp. In some
embodiments, Xaa.sub.8 is Glu, His, Lys, Gln, Asn, or Asp. In some
embodiments, Xaa.sub.8 is Glu, His, Gln, Asn, or Asp. In some
embodiments, Xaa.sub.8 is Glu, Asn, His, Gln, Lys, Asp or Ser. In
specific embodiments, Xaa.sub.8 is Pro.
[0160] In certain embodiments, Xaa.sub.9 is any natural or
non-natural amino acid or amino acid analog. In some embodiments,
Xaa.sub.9 is any natural or non-natural aromatic amino acid or
amino acid analog. In some embodiments, Xaa.sub.9 is Leu, Ile, Val,
Ala, Lys, Arg, Trp, Tyr or Phe. In some embodiments, Xaa.sub.9 is
Leu, Ile, Val, Lys, Arg, Trp, Tyr or Phe. In some embodiments,
Xaa.sub.9 is Leu, Ile, Val, Trp, Tyr or Phe. In some embodiments,
Xaa.sub.9 is Leu, Ile or Val. In some embodiments, Xaa.sub.9 is
Trp, Tyr or Phe. In some embodiments, Xaa.sub.9 is Leu, Ile, Lys,
Arg, Trp, Tyr, or Phe. In some embodiments, Xaa.sub.9 is Leu, Val,
Ile, or Met. In some embodiments, Xaa.sub.9 is Leu or Phe. In some
embodiments, Xaa.sub.9 is Leu, Phe, or Tyr. In some embodiments,
Xaa.sub.9 is Tyr, Phe or His. In some embodiments, Xaa.sub.9 is
Phe, His, Trp, or Tyr. In certain embodiments, Xaa.sub.9 is not
Leu. In specific embodiments, Xaa.sub.9 is Tyr.
[0161] In certain embodiments, Xaa.sub.12 is any natural or
non-natural amino acid or amino acid analog. In certain
embodiments, Xaa.sub.12 is Asn, Tyr, Asp or Ala. In specific
embodiments, Xaa.sub.12 Asn. In certain embodiments, Xaa.sub.12 is
Asn, Met, Arg, Lys, His, or Gln. In certain embodiments, Xaa.sub.12
is Asn, Lys, His, or Gln. In certain embodiments, Xaa.sub.12 is
Asn, Asp, Glu or Gln. In certain embodiments, Xaa.sub.12 is Asn,
Thr, Ser, Arg, Lys, Gln, or His. In some embodiments, Xaa.sub.12 is
Asn, Ser, or His.
[0162] In certain embodiments, Xaa.sub.13 is Ala, Pro or Gly. In
certain embodiments, Xaa.sub.13 is Pro or Gly. In specific
embodiments, Xaa.sub.13 is Pro. In particular embodiments,
Xaa.sub.13 is Gly.
[0163] In certain embodiments, Xaa.sub.14 is any natural or
non-natural amino acid or amino acid analog. In certain
embodiments, Xaa.sub.14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile,
Leu, Thr, Lys, Arg, or Asp. In certain embodiments, Xaa.sub.14 is
Ala or Gly. In some embodiments, Xaa.sub.14 is Val or Ala. In
certain embodiments, Xaa.sub.14 is Ala or Thr. In specific
embodiments, Xaa.sub.14 is Ala. In certain embodiments, Xaa.sub.14
is Val, Gln, Asn, Glu, Asp, Thr, or Ala. In certain embodiments,
Xaa.sub.14 is Gly, Cys or Ser.
[0164] In certain embodiments, Xaa.sub.16 is any natural or
non-natural amino acid or amino acid analog. In some embodiments,
Xaa.sub.16 is any natural or non-natural non-aromatic amino acid or
amino acid analog. In certain embodiments, Xaa.sub.16 Thr, Ala,
Asn, Lys, Arg, Trp, Gly or Val. In certain embodiments, Xaa.sub.16
is Thr, Ala, Asn, Lys, Arg or Trp. In certain embodiments,
Xaa.sub.16 is Thr, Ala, Lys, Arg or Trp. In some embodiments,
Xaa.sub.16 is Thr, Ala or Trp. In some embodiments, Xaa.sub.16 is
Thr. In some embodiments, Xaa.sub.16 is Trp, Tyr or Phe. In some
embodiments, Xaa.sub.16 is Thr or Ala. In specific embodiments,
Xaa.sub.16 it is Val. In particular embodiments, Xaa.sub.16 is Gly.
In some embodiments, Xaa.sub.16 is Thr, Ser, Met or Val. In some
embodiments, Xaa.sub.16 is Val, Ala, or Thr. In some embodiments,
Xaa.sub.16 is Ile, Val, Lys, Asn, Glu, Asp, or Thr.
[0165] In certain embodiments, Xaa.sub.17 is any natural or
non-natural amino acid or amino acid analog. In some embodiments,
Xaa.sub.17 is Gly, Pro or Ala. In specific embodiments, Xaa.sub.17
is Gly. In particular embodiments, Xaa.sub.17 is Ala. In some
embodiments, Xaa.sub.17 is Gly or Ala. In some embodiments,
Xaa.sub.17 is Gly, Asn, Ser or Ala. In some embodiments, Xaa.sub.17
is Asn, Glu, Asp, Thr, Ala, Ser, or Gly. In some embodiments,
Xaa.sub.17 is Asp, Ala, Ser, or Gly.
[0166] In certain embodiments, Xaa.sub.19 is any natural or
non-natural amino acid or amino acid analog. In some embodiments,
Xaa.sub.19 is Trp, Tyr, Phe, Asn, Ile, Val, His, Leu, or Arg. In
some embodiments, Xaa.sub.19 is Trp, Tyr, Asn or Leu. In some
embodiments, Xaa.sub.19 is Trp, Tyr or Phe. In some embodiments,
Xaa.sub.19 is Tyr, Phe or His. In some embodiments, Xaa.sub.19 is
Tyr or Trp. In specific embodiments, Xaa.sub.19 is Tyr. In some
embodiments, Xaa.sub.19 is Leu, Ile or Val. In particular
embodiments, Xaa.sub.19 is His. In some embodiments, Xaa.sub.19 is
Trp, Tyr, Phe, Asn, Ile, Val, His or Leu. In some embodiments,
Xaa.sub.19 is Trp, Tyr, Phe or Leu. In some embodiments, Xaa.sub.19
is Tyr or Leu. In some embodiments, Xaa.sub.19 is Lys or Arg. In
some embodiments, Xaa.sub.19 is any amino acid other than Pro, Arg,
Lys, Asp or Glu. In some embodiments, Xaa.sub.19 is any amino acid
other than Pro. In some embodiments, Xaa.sub.19 is missing.
[0167] In certain embodiments Xaa.sub.20 is Asp or Asn. In certain
embodiments Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing. In some
embodiments, Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing. In
some embodiments, Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0168] In some aspects, the GC-C agonist peptide comprises,
consists, or consists essentially of the amino acid sequence shown
below (II):
TABLE-US-00003 (SEQ ID NO: 47) Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9
Cys.sub.10 Cys.sub.11 Asn.sub.12 Pro.sub.13 Ala.sub.14 Cys.sub.15
Xaa.sub.16 Gly.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20
Xaa.sub.21
[0169] where Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
Asn Ser Ser Asn Tyr (SEQ ID NO:2) or is missing or Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is Asn;
[0170] Xaa.sub.8 is Glu or Asp;
[0171] Xaa.sub.9 is Leu, Ile, Val, Trp, Tyr or Phe;
[0172] Xaa.sub.16 is Thr, Ala, Trp;
[0173] Xaa.sub.19 is Trp, Tyr, Phe or Leu or is missing; and
Xaa.sub.20Xaa.sub.21 is AspPhe.
[0174] In some aspects, the GC-C agonist peptide comprises,
consists, or consists essentially of the amino acid sequence (II):
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3Xaa.sub.4 Xaa.sub.5 Cys.sub.6
Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Asn.sub.12
Pro.sub.13 Ala.sub.14 Cys.sub.15 Xaa.sub.16 Gly.sub.17 Cys.sub.18
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:48) where, Xaa.sub.9 is
Leu, Ile or Val and Xaa.sub.16 is Trp, Tyr or Phe; Xaa.sub.9 is
Trp, Tyr or Phe, and Xaa.sub.16 is Thr or Ala; Xaa.sub.19 is Trp,
Tyr, Phe and Xaa.sub.20Xaa.sub.21 is AspPhe; and Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is Asn; the
peptide comprises fewer than 50, 40, 30 or 25 amino acids; or fewer
than five amino acids precede Cys.sub.6.
[0175] In some aspects, the GC-C agonist peptide comprises,
consists, or consists essentially of the amino acid sequence
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys Cys Glu
Xaa.sub.9 Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Xaa.sub.20
Xaa.sub.21 (II) (SEQ ID NO:49) where Xaa.sub.9 is any amino acid:
where Xaa.sub.9 is any amino acid other than Leu; where Xaa.sub.9
is selected from Phe, Trp and Tyr; where Xaa.sub.9 is selected from
any other natural or non-natural aromatic amino acid; where
Xaa.sub.9 is Tyr; where Xaa.sub.9 is Phe; where Xaa.sub.9 is Trp;
where Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn Ser
Ser Asn Tyr; where Xaa.sub.1, Xaa.sub.2, Xaa.sub.3, Xaa.sub.4, and
Xaa.sub.5 are missing; where Xaa.sub.1, Xaa.sub.2, Xaa.sub.3 and
Xaa.sub.4 are missing; where Xaa.sub.1, Xaa.sub.2 and Xaa.sub.3 are
missing; where Xaa.sub.1 and Xaa.sub.2 are missing; where Xaa.sub.1
is missing; where Xaa.sub.20Xaa.sub.21 is AspPhe or is missing or
Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing or
Xaa.sub.19Xaa.sub.20Xaa.sub.21 is missing; where Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 and Tyr Xaa.sub.20
Xaa.sub.21 are missing. In some aspects, the GC-C agonist peptide
comprises, consists, or consists essentially of the amino acid
sequence Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (I) (SEQ ID NO:50)
where: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is missing
and/or the sequence Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing,
where the peptide optionally comprises additional carboxy-terminal
and/or amino-terminal amino acids. In instances where the peptide
is missing one or more terminal amino acids such as Xaa.sub.1 or
Xaa.sub.21, the peptide can optionally comprise additional
carboxy-terminal and/or amino-terminal amino acids.
[0176] In certain embodiments, the peptide includes disulfide bonds
between Cys.sub.6 and Cys.sub.11, between Cys.sub.7 and Cys.sub.15
and between Cys.sub.10 and Cys.sub.16. In some embodiments, the
peptide is a reduced peptide having no disulfide bonds. In still
other embodiments, the peptide has one or two disulfide bonds
selected from: a disulfide bond between Cys.sub.6 and Cys.sub.11, a
disulfide bond between Cys.sub.7 and Cys.sub.15 and a disulfide
bond between Cys.sub.10 and Cys.sub.16.
[0177] In certain embodiments, one or more amino acids are replaced
by a non-naturally occurring amino acid, or a naturally or
non-naturally occurring amino acid analog. There are many amino
acids beyond the standard 20 amino acids. Some are
naturally-occurring others non-naturally-occurring (see, e.g.,
Hunt, The Non-Protein Amino Acids: In Chemistry and Biochemistry of
the Amino Acids, Barrett, Chapman and Hall, 1985). For example, an
aromatic amino acid can be replaced by
3,4-dihydroxy-L-phenylalanine, 3-iodo-L-tyrosine, triiodothyronine,
L-thyroxine, phenylglycine (Phg) or nor-tyrosine (norTyr). Phg and
norTyr and other amino acids including Phe and Tyr can be
substituted by, for example, a halogen, --CH.sub.3, --OH,
--CH.sub.2NH.sub.3, --C(O)H, --CH.sub.2CH.sub.3, --CN,
--CH.sub.2CH.sub.2CH.sub.3, --SH, or another group. Any amino acid
can be substituted by the D-form of the amino acid.
[0178] With regard to non-naturally occurring amino acids or
naturally and non-naturally occurring amino acid analogs, a number
of substitutions in the peptide of formula I or the peptide of
formula II are possible. For example, in some aspects Xaa.sub.8 can
be replaced by gamma-Hydroxy-Glu or gamma-Carboxy-Glu. In some
aspects, Xaa.sub.9 can be replaced by an alpha substituted amino
acid such as L-alpha-methylphenylalanine or by analogues such as:
3-Amino-Tyr; Tyr(CH.sub.3); Tyr(PO.sub.3(CH.sub.3).sub.2);
Tyr(SO.sub.3H); beta-Cyclohexyl-Ala; beta-(1-Cyclopentenyl)-Ala;
beta-Cyclopentyl-Ala; beta-Cyclopropyl-Ala; beta-Quinolyl-Ala;
beta-2-Thiazolyl)-Ala; beta-(Triazole-1-yl)-Ala;
beta-(2-Pyridyl)-Ala; beta-(3-Pyridyl)-Ala; Amino-Phe; Fluoro-Phe;
Cyclohexyl-Gly; tBu-Gly; beta-(3-benzothienyl)-Ala;
beta-2-thienyl)-Ala; 5-Methyl-Trp; and 4-Methyl-Trp.
[0179] In some embodiments, Xaa.sub.13 can be an N(alpha)-C(alpha)
cyclized amino acid analogues with the structure:
##STR00001##
[0180] Xaa.sub.13 can also be homopro (L-pipecolic acid);
hydroxy-Pro; 3,4-Dehydro-Pro; 4-fluoro-Pro; or
alpha-methyl-Pro.
[0181] In aspects where Xaa.sub.13 is Gly, Ala, Leu or Val,
Xaa.sub.14 can be:
##STR00002##
[0182] In certain aspects, Xaa.sub.14 can be an alpha-substituted
or N-methylated amino acid such as alpha-amino isobutyric acid
(aib), L/D-alpha-ethylalanine (L/D-isovaline), L/D-methylvaline, or
L/D-alpha-methylleucine or a non-natural amino acid such as
beta-fluoro-Ala.
[0183] In some aspects, Xaa.sub.17 can be alpha-amino isobutyric
acid (aib) or L/D-alpha-ethylalanine (LID-isovaline).
[0184] Additional examples of non-natural amino acids and amino
acid analogs are known in the art and described elsewhere
herein.
[0185] In some instances, for example, where Xaa.sub.9 is Trp, Tyr,
or Phe or where Xaa.sub.16 is Trp, the peptide has a potentially
functional chymotrypsin cleavage site that is located at a position
where cleavage may alter GC-C receptor binding by the peptide. When
Xaa.sub.9 is Lys or Arg or when Xaa.sub.16 is Lys or Arg, the
peptide has a potentially functional trypsin cleavage site that is
located at a position where cleavage may alter GC-C receptor
binding by the peptide.
[0186] In certain instances, for example, where Xaa.sub.19 is Trp,
Tyr, or Phe, the peptide has a chymotrypsin cleavage site that is
located at a position where cleavage will liberate the portion of
the peptide carboxy-terminal to Xaa.sub.19. When Xaa.sub.19 is Leu,
Ile or Val, the peptide can have a chymotrypsin cleavage site that
is located at a position where cleavage will liberate the portion
of the peptide amino-terminal to Xaa.sub.19. At relatively high pH
the same effect can be seen if Xaa.sub.19 is His. Where Xaa.sub.19
is Lys or Arg, the peptide has a trypsin cleavage site that is
located at a position where cleavage will liberate portion of the
peptide carboxy-terminal to Xaa.sub.19.
[0187] In some instances, for example, where Xaa.sub.1 or the
amino-terminal amino acid of the peptide (e.g., Xaa.sub.2 or
Xaa.sub.3) is Trp, Tyr, or Phe, the peptide has a chymotrypsin
cleavage site that is located at a position where cleavage will
liberate the portion of the peptide amino-terminal to Xaa.sub.1 (or
Xaa.sub.2 or Xaa.sub.3) along with Xaa.sub.1, Xaa.sub.2 or
Xaa.sub.3. If Xaa.sub.1 or the amino-terminal amino acid of the
peptide of the invention (e.g., Xaa.sub.2 or Xaa.sub.3) is Lys or
Arg, the peptide has a trypsin cleavage site that is located at a
position where cleavage will liberate portion of the peptide
amino-terminal to Xaa.sub.1 along with Xaa.sub.1, Xaa.sub.2 or
Xaa.sub.3). If Xaa.sub.1 or the amino-terminal amino acid of the
peptide of the invention is Leu, Ile or Val, the peptide can have a
chymotrypsin cleavage site that is located at a position where
cleavage will liberate the portion of the peptide amino-terminal to
Xaa.sub.1. At relatively high pH the same effect is seen when
Xaa.sub.1 is His.
[0188] If fully-folded, disulfide bonds may be present between:
Cys.sub.6 and Cys.sub.11; Cys.sub.7 and Cys.sub.15; and Cys.sub.10
and Cys.sub.15. In some aspects, the GC-C agonist peptides are
identical to or have sequence similarity to ST peptides. However,
in some aspects the GC-C agonist peptides comprise amino acid
changes and/or additions that improve functionality. These changes
can, for example, increase or decrease activity (e.g., increase or
decrease the ability of the peptide to reduce phosphate uptake),
alter the ability of the peptide to fold correctly, alter the
stability of the peptide, alter the ability of the peptide to bind
the GC-C receptor, and/or decrease toxicity. In some instances, the
peptides may function more desirably than a wild-type ST peptide.
For example, in certain instances, undesirable side effects such as
diarrhea and dehydration are reduced.
[0189] In the case of a peptide comprising or consisting of the
sequence (I) Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:50) or
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys Cys Glu
Xaa.sub.9 Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Xaa.sub.20
Xaa.sub.21 (II) (SEQ ID NO:49) where: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Xaa.sub.4 Xaa.sub.5 is missing and/or the sequence Xaa.sub.19
Xaa.sub.20 Xaa.sub.21 is missing, the peptide can optionally
comprise additional carboxy-terminal and/or amino-terminal amino
acids. For example, the peptide can include an amino terminal
sequence that facilitates recombinant production of the peptide and
is cleaved prior to administration of the peptide to a patient. The
peptide can also include other amino-terminal or carboxy-terminal
amino acids. In some instances, the additional amino acids protect
the peptide, stabilize the peptide, and/or alter the activity of
the peptide. In instances, some or all of the additional amino
acids are removed prior to administration of the peptide to a
patient. The peptide can include 1, 2, 3, 4, 5, 10, 15, 20, 25, 30,
40, 50, 60, 70 80, 90, 100 or more amino acids at its
amino-terminus and/or carboxy-terminus. The number of flanking
amino acids need not be the same. For example, there can be 10
additional amino acids at the amino-terminus of the peptide and
none at the carboxy-terminus.
[0190] In some embodiments, the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6Cys.sub.7Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15
Xaa.sub.16Xaa.sub.17Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21
(SEQ ID NO:50) where: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 is missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys,
Arg, Trp, Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro;
Xaa.sub.14 is Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp;
Xaa.sub.17 is Gly; Xaa.sub.19 is Tyr or Leu; and Xaa.sub.20
Xaa.sub.21 is Asp Phe or is missing. In instances where Xaa.sub.20
Xaa.sub.21 and/or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
are missing, the peptide may optionally comprise additional
flanking amino acids.
[0191] Examples of GC-C agonist peptides which comprise, consist,
or consist essentially of the amino acid sequence Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys Cys Glu Xaa.sub.9 Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Xaa.sub.20Xaa.sub.21 (II) (SEQ
ID NO:49) are shown in Table A2 below.
TABLE-US-00004 TABLE A2 Gln Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 51) Asn Leu Ser Asn Tyr
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
52) Asn Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO: 53) Gln Ser Ser Gln Tyr Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 54) Asn Ser Ser Asn
Tyr Cys Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID
NO: 55) Asn Ser Ser Asn Tyr Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 56) Asn Ser Ser Asn Tyr Cys Cys Glu Cys
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 57) Asn Ser Ser
Asn Tyr Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 58) Asn Ser Ser Asn Tyr Cys Cys Glu His Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 59) Asn Ser Ser Asn Tyr Cys Cys
Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 60) Asn
Ser Ser Asn Tyr Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr (SEQ ID NO: 61) Asn Ser Ser Asn Tyr Cys Cys Glu Ser Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 62) Asn Ser Ser Asn Tyr Cys
Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 63)
Cys Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
64) Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID
NO: 65) Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 66) Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr (SEQ ID NO: 67) Cys Cys Glu His Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 68) Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO: 69) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 70) Cys Cys Glu Ser Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr (SEQ ID NO: 71) Cys Cys Glu Trp Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 72) Cys Cys Glu Tyr Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 73) Cys Cys Glu Arg Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 74) Cys Cys Glu Asp Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 75) Cys Cys Glu Gln Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 76) Cys Cys Glu Gly Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 77) Cys Cys Glu Ile Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 78) Cys Cys Glu Met Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 79) Cys Cys Glu Pro Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 80) Cys Cys Glu Thr Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 81) Cys Cys Glu Val Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 82) Asn Thr Ser Asn Tyr Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 83) Asn
Ile Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr (SEQ ID NO: 84) Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 85) Ser Ser Gln Tyr Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr. (SEQ ID NO: 86) Asn
Ser Ser Asn Tyr Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr (SEQ ID NO: 87) Asn Ser Ser Asn Tyr Cys Cys Glu Asp Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 88) Asn Ser Ser Asn Tyr Cys
Cys Glu Gln Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 89)
Asn Ser Ser Asn Tyr Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 90) Asn Ser Ser Asn Tyr Cys Cys Glu Ile Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 91) Asn Ser Ser Asn Tyr
Cys Cys Glu Met Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
92) Asn Ser Ser Asn Tyr Cys Cys Glu Pro Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO: 93) Asn Ser Ser Asn Tyr Cys Cys Glu Thr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 94) Asn Ser Ser Asn
Tyr Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID
NO: 95) Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 96) Cys Cys Glu Asp Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr (SEQ ID NO: 97) Cys Cys Glu Gln Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 98) Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO: 99) Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 100) Cys Cys Glu Met Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 101) Cys Cys Glu Pro Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 102) Cys Cys Glu Thr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 103) Cys Cys
Glu Val Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 104)
Cys Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:
105) Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 106) Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 107) Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 108) Cys Cys Gln His Cys Cys Asn Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 109) Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 110) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 111) Cys Cys Glu Ser Cys Cys Asn Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 112) Cys Cys Glu Trp Cys Cys Asn Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 113)
Additional examples of GC-C agonist peptides are shown in Table A3
below.
TABLE-US-00005 TABLE A3 Cys Cys Glu Leu Cys Cys Ala Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO: 114) Cys Cys Glu Leu Cys Cys Leu Pro Ala
Cys Thr Gly Cys Tyr (SEQ ID NO: 115) Cys Cys Glu Leu Cys Cys Pro
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 116) Cys Cys Glu Leu Cys
Cys Phe Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 117) Cys Cys Glu
Leu Cys Cys Gly Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 118) Cys
Cys Glu Leu Cys Cys Thr Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
119) Cys Cys Glu Leu Cys Cys Gln Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 120) Cys Cys Glu Leu Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 121) Cys Cys Glu Leu Cys Cys Lys Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 122) Cys Cys Glu Leu Cys Cys His Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 123) Cys Cys Glu Tyr Cys Cys Val Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 124) Cys Cys Glu Tyr Cys Cys
Ile Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 125) Cys Cys Glu Tyr
Cys Cys Met Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 126) Cys Cys
Glu Tyr Cys Cys Trp Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 127)
Cys Cys Glu Tyr Cys Cys Ser Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
128) Cys Cys Glu Tyr Cys Cys Cys Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 129) Cys Cys Glu Tyr Cys Cys Tyr Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 130) Cys Cys Glu Tyr Cys Cys Glu Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 131) Cys Cys Glu Tyr Cys Cys Arg Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 132) Cys Cys Glu Leu Cys Cys Ala Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 133) Cys Cys Glu Leu Cys Cys Leu
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 134) Cys Cys Glu Leu Cys Cys
Pro Pro Ala Cys Thr Gly Cys (SEQ ID NO: 135) Cys Cys Glu Leu Cys
Cys Phe Pro Ala Cys Thr Gly Cys (SEQ ID NO: 136) Cys Cys Glu Leu
Cys Cys Gly Pro Ala Cys Thr Gly Cys (SEQ ID NO: 137) Cys Cys Glu
Leu Cys Cys Thr Pro Ala Cys Thr Gly Cys (SEQ ID NO: 138) Cys Cys
Glu Leu Cys Cys Gln Pro Ala Cys Thr Gly Cys (SEQ ID NO: 139) Cys
Cys Glu Leu Cys Cys Asp Pro Ala Cys Thr Gly Cys (SEQ ID NO: 140)
Cys Cys Glu Leu Cys Cys Lys Pro Ala Cys Thr Gly Cys (SEQ ID NO:
141) Cys Cys Glu Leu Cys Cys His Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 142) Cys Cys Glu Tyr Cys Cys Val Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 143) Cys Cys Glu Tyr Cys Cys Ile Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 144) Cys Cys Glu Tyr Cys Cys Met Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 145) Cys Cys Glu Tyr Cys Cys Trp Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 146) Cys Cys Glu Tyr Cys Cys Ser Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 147) Cys Cys Glu Tyr Cys Cys Cys Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 148) Cys Cys Glu Tyr Cys Cys Tyr Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 149) Cys Cys Glu Tyr Cys Cys Glu
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 150) Cys Cys Glu Tyr Cys Cys
Arg Pro Ala Cys Thr Gly Cys (SEQ ID NO: 151) Cys Cys Glu Leu Cys
Cys Asn Pro Thr Cys Thr Gly Cys Tyr (SEQ ID NO: 152) Cys Cys Glu
Leu Cys Cys Asn Pro Thr Cys Thr Gly Cys (SEQ ID NO: 153) Cys Cys
Glu Phe Cys Cys Asn Pro Thr Cys Thr Gly Cys Tyr (SEQ ID NO: 154)
Cys Cys Glu Trp Cys Cys Asn Pro Thr Cys Thr Gly Cys Tyr (SEQ ID NO:
155) Cys Cys Glu Leu Cys Cys Asn Gly Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 156) Cys Cys Glu Leu Cys Cys Asn Gly Ala Cys Thr Gly Cys
(SEQ ID NO: 157) Cys Cys Glu Phe Cys Cys Asn Gly Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 158) Cys Cys Glu Trp Cys Cys Asn Gly Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 159) Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Val Gly Cys Tyr (SEQ ID NO: 160) Cys Cys Glu Leu Cys Cys
Asn Pro Ala Cys Val Gly Cys (SEQ ID NO: 161) Cys Cys Glu Phe Cys
Cys Asn Pro Ala Cys Val Gly Cys Tyr (SEQ ID NO: 162) Cys Cys Glu
Trp Cys Cys Asn Pro Ala Cys Val Gly Cys Tyr (SEQ ID NO: 163) Cys
Cys Glu Leu Cys Cys Asn Pro Ala Cys Gly Gly Cys Tyr (SEQ ID NO:
164) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Gly Gly Cys (SEQ ID
NO: 165) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Gly Gly Cys Tyr
(SEQ ID NO: 166) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Gly Gly
Cys Tyr (SEQ ID NO: 167) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys
Thr Ala Cys Tyr (SEQ ID NO: 168) Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Thr Ala Cys (SEQ ID NO: 169) Cys Cys Glu Trp Cys Cys Asn
Pro Ala Cys Thr Ala Cys Tyr (SEQ ID NO: 170) Cys Cys Glu Phe Cys
Cys Asn Pro Ala Cys Thr Ala Cys Tyr (SEQ ID NO: 171) Cys Cys Glu
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala (SEQ ID NO: 172) Cys
Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu (SEQ ID NO:
173) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Pro (SEQ
ID NO: 174) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe
(SEQ ID NO: 175) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys Gly (SEQ ID NO: 176) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys
Thr Gly Cys Thr (SEQ ID NO: 177) Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Thr Gly Cys Asn (SEQ ID NO: 178) Cys Cys Glu Leu Cys Cys
Asn Pro Ala Cys Thr Gly Cys Asp (SEQ ID NO: 179) Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys (SEQ ID NO: 180) Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys His (SEQ ID NO: 181)
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Val (SEQ ID NO:
182) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Ile (SEQ
ID NO: 183) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Met
(SEQ ID NO: 184) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys Trp (SEQ ID NO: 185) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys
Thr Gly Cys Ser (SEQ ID NO: 186) Cys Cys Glu Tyr Cys Cys Asn Pro
Ala Cys Thr Gly Cys Cys (SEQ ID NO: 187) Cys Cys Glu Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Gln (SEQ ID NO: 188) Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Glu (SEQ ID NO: 189) Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Arg (SEQ ID NO: 190)
Cys Cys Ala Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
191) Cys Cys Leu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 192) Cys Cys Met Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 193) Cys Cys Trp Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 194) Cys Cys Ser Leu Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 195) Cys Cys Cys Leu Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 196)
Cys Cys Gln Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
197) Cys Cys Asp Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 198) Cys Cys Arg Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 199) Cys Cys Ala Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 200) Cys Cys Leu Leu Cys Cys Asn Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 201) Cys Cys Met Leu Cys Cys Asn Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 202) Cys Cys Trp Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 203) Cys Cys Ser Leu Cys Cys Asn Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 204) Cys Cys Cys Leu Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 205) Cys Cys Gln Leu Cys Cys
Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 206) Cys Cys Asp Leu Cys
Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 207) Cys Cys Arg Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 208) Cys Cys Ala
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 209) Cys
Cys Leu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
210) Cys Cys Met Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 211) Cys Cys Trp Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 212) Cys Cys Ser Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 213) Cys Cys Cys Tyr Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 214) Cys Cys Gln Tyr Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 215) Cys Cys Asp Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 216) Cys Cys Arg Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 217) Cys Cys
Ala Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 218) Cys
Cys Leu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 219)
Cys Cys Met Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:
220) Cys Cys Trp Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 221) Cys Cys Ser Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 222) Cys Cys Cys Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 223) Cys Cys Gln Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 224) Cys Cys Asp Tyr Cys Cys Asn Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 225) Cys Cys Arg Tyr Cys Cys Asn Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 226) Cys Cys Glu Phe Cys Cys Ala Pro Ala
Cys Thr Gly Cys Tyr (SEQ ID NO: 227) Cys Cys Glu Phe Cys Cys Leu
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 228) Cys Cys Glu Phe Cys
Cys Pro Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 229) Cys Cys Glu
Phe Cys Cys Phe Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 230) Cys
Cys Glu Phe Cys Cys Gly Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
231) Cys Cys Glu Phe Cys Cys Thr Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 232) Cys Cys Glu Phe Cys Cys Gln Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 233) Cys Cys Glu Phe Cys Cys Asp Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 234) Cys Cys Glu Phe Cys Cys Lys Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 235) Cys Cys Glu Phe Cys Cys His Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 236) Cys Cys Glu Phe Cys Cys
Val Pro Ala Cys Thr Gly Cys (SEQ ID NO: 237) Cys Cys Glu Phe Cys
Cys Ile Pro Ala Cys Thr Gly Cys (SEQ ID NO: 238) Cys Cys Glu Phe
Cys Cys Met Pro Ala Cys Thr Gly Cys (SEQ ID NO: 239) Cys Cys Glu
Phe Cys Cys Trp Pro Ala Cys Thr Gly Cys (SEQ ID NO: 240) Cys Cys
Glu Phe Cys Cys Ser Pro Ala Cys Thr Gly Cys (SEQ ID NO: 241) Cys
Cys Glu Phe Cys Cys Cys Pro Ala Cys Thr Gly Cys (SEQ ID NO: 242)
Cys Cys Glu Phe Cys Cys Tyr Pro Ala Cys Thr Gly Cys (SEQ ID NO:
243) Cys Cys Glu Phe Cys Cys Glu Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 244) Cys Cys Glu Phe Cys Cys Arg Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 245) Cys Cys Glu Trp Cys Cys Ala Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 246) Cys Cys Glu Trp Cys Cys Leu Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 247) Cys Cys Glu Trp Cys Cys Pro Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 248) Cys Cys Glu Trp Cys Cys Phe Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 249) Cys Cys Glu Trp Cys Cys
Gly Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 250) Cys Cys Glu Trp
Cys Cys Thr Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 251) Cys Cys
Glu Trp Cys Cys Gln Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 252)
Cys Cys Glu Trp Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
253) Cys Cys Glu Trp Cys Cys Lys Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 254) Cys Cys Glu Trp Cys Cys His Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 255) Cys Cys Glu Trp Cys Cys Val Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 256) Cys Cys Glu Trp Cys Cys Ile Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 257) Cys Cys Glu Trp Cys Cys Met Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 258) Cys Cys Glu Trp Cys Cys Trp Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 259) Cys Cys Glu Trp Cys Cys Ser Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 260) Cys Cys Glu Trp Cys Cys Cys
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 261) Cys Cys Glu Trp Cys Cys
Tyr Pro Ala Cys Thr Gly Cys (SEQ ID NO: 262) Cys Cys Glu Trp Cys
Cys Glu Pro Ala Cys Thr Gly Cys (SEQ ID NO: 263) Cys Cys Glu Trp
Cys Cys Arg Pro Ala Cys Thr Gly Cys (SEQ ID NO: 264) Cys Cys Glu
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala (SEQ ID NO: 265) Cys
Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu (SEQ ID NO:
266) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Pro (SEQ
ID NO: 267) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe
(SEQ ID NO: 268) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly
Cys Gly (SEQ ID NO: 269) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys
Thr Gly Cys Thr (SEQ ID NO: 270) Cys Cys Glu Trp Cys Cys Asn Pro
Ala Cys Thr Gly Cys Asn (SEQ ID NO: 271) Cys Cys Glu Trp Cys Cys
Asn Pro Ala Cys Thr Gly Cys Asp (SEQ ID NO: 272) Cys Cys Glu Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys (SEQ ID NO: 273) Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys His (SEQ ID NO: 274)
Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Val (SEQ ID NO:
275) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Ile (SEQ
ID NO: 276) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Met
(SEQ ID NO: 277) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly
Cys Trp (SEQ ID NO: 278) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys Ser (SEQ ID NO: 279) Cys Cys Glu Phe Cys Cys Asn Pro
Ala Cys Thr Gly
Cys Cys (SEQ ID NO: 280) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys Gln (SEQ ID NO: 281) Cys Cys Glu Phe Cys Cys Asn Pro
Ala Cys Thr Gly Cys Glu (SEQ ID NO: 282) Cys Cys Glu Phe Cys Cys
Asn Pro Ala Cys Thr Gly Cys Arg (SEQ ID NO: 283) Cys Cys Ala Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 284) Cys Cys
Leu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 285)
Cys Cys Met Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
286) Cys Cys Trp Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 287) Cys Cys Ser Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 288) Cys Cys Cys Phe Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 289) Cys Cys Gln Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 290) Cys Cys Asp Phe Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 291) Cys Cys Arg Phe Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 292) Cys Cys Ala Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 293) Cys Cys Leu
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 294) Cys Cys
Met Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 295) Cys
Cys Trp Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 296)
Cys Cys Ser Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:
297) Cys Cys Cys Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 298) Cys Cys Gln Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 299) Cys Cys Asp Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 300) Cys Cys Arg Phe Cys Cys Asn Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 301) Cys Cys Ala Trp Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO: 302) Cys Cys Leu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr (SEQ ID NO: 303) Cys Cys Met Trp Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 304) Cys Cys Trp Trp Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 305) Cys Cys Ser
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 306) Cys
Cys Cys Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
307) Cys Cys Gln Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 308) Cys Cys Asp Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 309) Cys Cys Arg Trp Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 310) Cys Cys Ala Trp Cys Cys Asn Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 311) Cys Cys Leu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 312) Cys Cys Met Trp Cys Cys Asn Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 313) Cys Cys Trp Trp Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 314) Cys Cys Ser Trp Cys Cys
Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 315) Cys Cys Cys Trp Cys
Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 316) Cys Cys Gln Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 317) Cys Cys Asp
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 318) Cys Cys
Arg Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 319) Cys
Cys Glu Leu Cys Cys Val Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
320) Cys Cys Glu Leu Cys Cys Ile Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 321) Cys Cys Glu Leu Cys Cys Met Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 322) Cys Cys Glu Leu Cys Cys Trp Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 323) Cys Cys Glu Leu Cys Cys Ser Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 324) Cys Cys Glu Leu Cys Cys Cys Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 325) Cys Cys Glu Leu Cys Cys
Tyr Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 326) Cys Cys Glu Leu
Cys Cys Glu Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 327) Cys Cys
Glu Leu Cys Cys Arg Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 328)
Cys Cys Glu Tyr Cys Cys Ala Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
329) Cys Cys Glu Tyr Cys Cys Leu Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 330) Cys Cys Glu Tyr Cys Cys Pro Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 331) Cys Cys Glu Tyr Cys Cys Phe Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 332) Cys Cys Glu Tyr Cys Cys Gly Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 333) Cys Cys Glu Tyr Cys Cys Thr Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 334) Cys Cys Glu Tyr Cys Cys
Gln Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 335) Cys Cys Glu Tyr
Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 336) Cys Cys
Glu Tyr Cys Cys Lys Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 337)
Cys Cys Glu Tyr Cys Cys His Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
338) Cys Cys Glu Leu Cys Cys Val Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 339) Cys Cys Glu Leu Cys Cys Ile Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 340) Cys Cys Glu Leu Cys Cys Met Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 341) Cys Cys Glu Leu Cys Cys Trp Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 342) Cys Cys Glu Leu Cys Cys Ser Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 343) Cys Cys Glu Leu Cys Cys Cys Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 344) Cys Cys Glu Leu Cys Cys Tyr Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 345) Cys Cys Glu Leu Cys Cys Glu Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 346) Cys Cys Glu Leu Cys Cys Arg
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 347) Cys Cys Glu Tyr Cys Cys
Ala Pro Ala Cys Thr Gly Cys (SEQ ID NO: 348) Cys Cys Glu Tyr Cys
Cys Leu Pro Ala Cys Thr Gly Cys (SEQ ID NO: 349) Cys Cys Glu Tyr
Cys Cys Pro Pro Ala Cys Thr Gly Cys (SEQ ID NO: 350) Cys Cys Glu
Tyr Cys Cys Phe Pro Ala Cys Thr Gly Cys (SEQ ID NO: 351) Cys Cys
Glu Tyr Cys Cys Gly Pro Ala Cys Thr Gly Cys (SEQ ID NO: 352) Cys
Cys Glu Tyr Cys Cys Thr Pro Ala Cys Thr Gly Cys (SEQ ID NO: 353)
Cys Cys Glu Tyr Cys Cys Gln Pro Ala Cys Thr Gly Cys (SEQ ID NO:
354) Cys Cys Glu Tyr Cys Cys Asp Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 355) Cys Cys Glu Tyr Cys Cys Lys Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 356) Cys Cys Glu Tyr Cys Cys His Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 357) Cys Cys Glu Tyr Cys Cys Asn Pro Thr Cys Thr Gly
Cys Tyr (SEQ ID NO: 358) Cys Cys Glu Tyr Cys Cys Asn Pro Thr Cys
Thr Gly Cys (SEQ ID NO: 359) Cys Cys Glu Phe Cys Cys Asn Pro Thr
Cys Thr Gly Cys (SEQ ID NO: 360) Cys Cys Glu Trp Cys Cys Asn Pro
Thr Cys Thr Gly Cys (SEQ ID NO: 361) Cys Cys Glu Tyr Cys Cys Asn
Gly Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 362) Cys Cys Glu Tyr Cys
Cys Asn Gly Ala Cys Thr Gly Cys (SEQ ID NO: 363)
Cys Cys Glu Phe Cys Cys Asn Gly Ala Cys Thr Gly Cys (SEQ ID NO:
364) Cys Cys Glu Trp Cys Cys Asn Gly Ala Cys Thr Gly Cys (SEQ ID
NO: 365) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Val Gly Cys Tyr
(SEQ ID NO: 366) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Val Gly
Cys (SEQ ID NO: 367) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Val
Gly Cys (SEQ ID NO: 368) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys
Val Gly Cys (SEQ ID NO: 369) Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Gly Gly Cys Tyr (SEQ ID NO: 370) Cys Cys Glu Tyr Cys Cys Asn
Pro Ala Cys Gly Gly Cys (SEQ ID NO: 371) Cys Cys Glu Phe Cys Cys
Asn Pro Ala Cys Gly Gly Cys (SEQ ID NO: 372) Cys Cys Glu Trp Cys
Cys Asn Pro Ala Cys Gly Gly Cys (SEQ ID NO: 373) Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Ala Cys Tyr (SEQ ID NO: 374) Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Ala Cys (SEQ ID NO: 375) Cys
Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Ala Cys (SEQ ID NO: 376)
Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Ala Cys (SEQ ID NO:
377) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Val (SEQ
ID NO: 378) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Ile
(SEQ ID NO: 379) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys Met (SEQ ID NO: 380) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys
Thr Gly Cys Trp (SEQ ID NO: 381) Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Thr Gly Cys Ser (SEQ ID NO: 382) Cys Cys Glu Leu Cys Cys
Asn Pro Ala Cys Thr Gly Cys Cys (SEQ ID NO: 383) Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Gln (SEQ ID NO: 384) Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Glu (SEQ ID NO: 385)
Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Arg (SEQ ID NO:
386) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala (SEQ
ID NO: 387) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu
(SEQ ID NO: 388) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys Pro (SEQ ID NO: 389) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys
Thr Gly Cys Phe (SEQ ID NO: 390) Cys Cys Glu Tyr Cys Cys Asn Pro
Ala Cys Thr Gly Cys Gly (SEQ ID NO: 391) Cys Cys Glu Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Thr (SEQ ID NO: 392) Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Asn (SEQ ID NO: 393) Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Asp (SEQ ID NO: 394)
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys (SEQ ID NO:
395) Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys His (SEQ
ID NO: 396) Cys Cys Val Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 397) Cys Cys Ile Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 398) Cys Cys Phe Leu Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 399) Cys Cys Gly Leu Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 400) Cys Cys Thr Leu Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 401) Cys Cys Asn Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 402) Cys Cys
Tyr Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 403)
Cys Cys Lys Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
404) Cys Cys His Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 405) Cys Cys Val Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 406) Cys Cys Ile Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 407) Cys Cys Phe Leu Cys Cys Asn Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 408) Cys Cys Gly Leu Cys Cys Asn Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 409) Cys Cys Thr Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 410) Cys Cys Asn Leu Cys Cys Asn Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 411) Cys Cys Tyr Leu Cys Cys Asn
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 412) Cys Cys Lys Leu Cys Cys
Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 413) Cys Cys His Leu Cys
Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 414) Cys Cys Val Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 415) Cys Cys
Ile Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 416)
Cys Cys Phe Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
417) Cys Cys Gly Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 418) Cys Cys Thr Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 419) Cys Cys Asn Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 420) Cys Cys Tyr Tyr Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 421) Cys Cys Lys Tyr Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 422) Cys Cys His Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 423) Cys Cys Val Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 424) Cys Cys Ile
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 425) Cys Cys
Phe Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 426) Cys
Cys Gly Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 427)
Cys Cys Thr Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:
428) Cys Cys Asn Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 429) Cys Cys Tyr Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 430) Cys Cys Lys Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 431) Cys Cys His Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 432) Cys Cys Glu Phe Cys Cys Val Pro Ala Cys Thr
Gly Cys Tyr (SEQ ID NO: 433) Cys Cys Glu Phe Cys Cys Ile Pro Ala
Cys Thr Gly Cys Tyr (SEQ ID NO: 434) Cys Cys Glu Phe Cys Cys Met
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 435) Cys Cys Glu Phe Cys
Cys Trp Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 436) Cys Cys Glu
Phe Cys Cys Ser Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 437) Cys
Cys Glu Phe Cys Cys Cys Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
438) Cys Cys Glu Phe Cys Cys Tyr Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 439) Cys Cys Glu Phe Cys Cys Glu Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 440) Cys Cys Glu Phe Cys Cys Arg Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 441) Cys Cys Glu Phe Cys Cys Ala Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 442) Cys Cys Glu Phe Cys Cys Leu Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 443) Cys Cys Glu Phe Cys Cys Pro Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 444) Cys Cys Glu Phe Cys Cys Phe
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 445) Cys Cys Glu Phe Cys Cys
Gly Pro Ala Cys Thr Gly Cys (SEQ ID NO: 446) Cys Cys Glu Phe Cys
Cys Thr Pro Ala Cys Thr Gly Cys (SEQ ID NO: 447)
Cys Cys Glu Phe Cys Cys Gln Pro Ala Cys Thr Gly Cys (SEQ ID NO:
448) Cys Cys Glu Phe Cys Cys Asp Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 449) Cys Cys Glu Phe Cys Cys Lys Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 450) Cys Cys Glu Phe Cys Cys His Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 451) Cys Cys Glu Trp Cys Cys Val Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 452) Cys Cys Glu Trp Cys Cys Ile Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 453) Cys Cys Glu Trp Cys Cys Met Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 454) Cys Cys Glu Trp Cys Cys
Trp Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 455) Cys Cys Glu Trp
Cys Cys Ser Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 456) Cys Cys
Glu Trp Cys Cys Cys Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 457)
Cys Cys Glu Trp Cys Cys Tyr Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
458) Cys Cys Glu Trp Cys Cys Glu Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 459) Cys Cys Glu Trp Cys Cys Arg Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 460) Cys Cys Glu Trp Cys Cys Ala Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 461) Cys Cys Glu Trp Cys Cys Leu Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 462) Cys Cys Glu Trp Cys Cys Pro Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 463) Cys Cys Glu Trp Cys Cys Phe Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 464) Cys Cys Glu Trp Cys Cys Gly Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 465) Cys Cys Glu Trp Cys Cys Thr
Pro Ala Cys Thr Gly Cys (SEQ ID NO: 466) Cys Cys Glu Trp Cys Cys
Gln Pro Ala Cys Thr Gly Cys (SEQ ID NO: 467) Cys Cys Glu Trp Cys
Cys Asp Pro Ala Cys Thr Gly Cys (SEQ ID NO: 468) Cys Cys Glu Trp
Cys Cys Lys Pro Ala Cys Thr Gly Cys (SEQ ID NO: 469) Cys Cys Glu
Trp Cys Cys His Pro Ala Cys Thr Gly Cys (SEQ ID NO: 470) Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Val (SEQ ID NO: 471)
Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Ile (SEQ ID NO:
472) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Met (SEQ
ID NO: 473) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Trp
(SEQ ID NO: 474) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly
Cys Ser (SEQ ID NO: 475) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys
Thr Gly Cys Cys (SEQ ID NO: 476) Cys Cys Glu Trp Cys Cys Asn Pro
Ala Cys Thr Gly Cys Gln (SEQ ID NO: 477) Cys Cys Glu Trp Cys Cys
Asn Pro Ala Cys Thr Gly Cys Glu (SEQ ID NO: 478) Cys Cys Glu Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Arg (SEQ ID NO: 479) Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala (SEQ ID NO: 480)
Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu (SEQ ID NO:
481) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Pro (SEQ
ID NO: 482) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe
(SEQ ID NO: 483) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly
Cys Gly (SEQ ID NO: 484) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys Thr (SEQ ID NO: 485) Cys Cys Glu Phe Cys Cys Asn Pro
Ala Cys Thr Gly Cys Asn (SEQ ID NO: 486) Cys Cys Glu Phe Cys Cys
Asn Pro Ala Cys Thr Gly Cys Asp (SEQ ID NO: 487) Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys (SEQ ID NO: 488) Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys His (SEQ ID NO: 489)
Cys Cys Val Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
490) Cys Cys Ile Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 491) Cys Cys Phe Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 492) Cys Cys Gly Phe Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 493) Cys Cys Thr Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 494) Cys Cys Asn Phe Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 495) Cys Cys Tyr Phe Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 496) Cys Cys Lys Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 497) Cys Cys
His Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 498)
Cys Cys Val Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:
499) Cys Cys Ile Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 500) Cys Cys Phe Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 501) Cys Cys Gly Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys
(SEQ ID NO: 502) Cys Cys Thr Phe Cys Cys Asn Pro Ala Cys Thr Gly
Cys (SEQ ID NO: 503) Cys Cys Asn Phe Cys Cys Asn Pro Ala Cys Thr
Gly Cys (SEQ ID NO: 504) Cys Cys Tyr Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys (SEQ ID NO: 505) Cys Cys Lys Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys (SEQ ID NO: 506) Cys Cys His Phe Cys Cys Asn Pro
Ala Cys Thr Gly Cys (SEQ ID NO: 507) Cys Cys Val Trp Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 508) Cys Cys Ile Trp Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 509) Cys Cys Phe
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 510) Cys
Cys Gly Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:
511) Cys Cys Thr Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO: 512) Cys Cys Asn Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO: 513) Cys Cys Tyr Trp Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO: 514) Cys Cys Lys Trp Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr (SEQ ID NO: 515) Cys Cys His Trp Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 516) Cys Cys Val Trp Cys Cys
Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 517) Cys Cys Ile Trp Cys
Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 518) Cys Cys Phe Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 519) Cys Cys Gly
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 520) Cys Cys
Thr Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 521) Cys
Cys Asn Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO: 522)
Cys Cys Tyr Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID NO:
523) Cys Cys Lys Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ ID
NO: 524) Cys Cys His Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys (SEQ
ID NO: 525)
[0192] In specific embodiments, the GC-C agonist peptide comprises,
consists, or consists essentially of the amino acid sequence Cys
Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID
NO:4).
[0193] Also included are deletion variants of any of the GC-C
agonist peptides described herein. Examples include deletion
variants where one, two, three or four amino acids (or non-natural
amino acids or natural or non-natural amino acid analogs), other
than a Cys (or an amino acid substituted for Cys, e.g., an amino
acid capable of forming a covalent bond to another amino acid), are
deleted. Specific examples include where two (or more) amino acids
are deleted and the peptide comprises the sequence: Cys.sub.a
Cys.sub.b Xaa Xaa Cys.sub.c Cys.sub.d Xaa Xaa Xaa Cys.sub.e Xaa Xaa
Cys.sub.f (SEQ ID NO:526). In some of these and related
embodiments, two or more deletions can be located between Cys.sub.b
and Cys.sub.c and/or between Cys.sub.d and Cys.sub.e and/or between
Cys.sub.e and Cys.sub.f. However, in other embodiments there is at
most one deletion between each of Cys.sub.b and Cys.sub.c or
between Cys.sub.d and Cys.sub.e or between Cys.sub.e and Cys.sub.f.
Thus, included are any of the GC-C agonist peptides described
herein comprising the sequence Cys.sub.a Cys.sub.b Xaa Xaa
Cys.sub.c Cys.sub.d Xaa Xaa Xaa Cys.sub.e Xaa Xaa Cys.sub.f (SEQ ID
NO:526) where: a) one amino acid between Cys.sub.b and Cys.sub.c is
deleted; b) one amino acid between Cys.sub.d and Cys.sub.e is
deleted; c) one amino acid between Cys.sub.e and Cys.sub.f is
deleted; d) one amino acid between Cys.sub.b and Cys.sub.c is
deleted and one amino acid between Cys.sub.d and Cys.sub.e is
deleted; e) one amino acid between Cys.sub.d and Cys.sub.e is
deleted and one amino acid between Cys.sub.e and Cys.sub.f is
deleted; f) one amino acid between Cys.sub.b and Cys.sub.c is
deleted and one amino acid between Cys.sub.e and Cys.sub.f is
deleted or g) one amino acid between Cys.sub.b and Cys.sub.c is
deleted, one amino acid between Cys.sub.d and Cys.sub.e is deleted
and one amino acid between Cys.sub.e and Cys.sub.f is deleted. In
certain embodiments, the deletion variants are peptides that bind
to and/or agonize the GC-C receptor.
[0194] Also included are insertion variants of any of the GC-C
agonist peptides described herein. Examples include insertion
variants where one, two, three or four amino acids (e.g., Gly or
Ala) are inserted before or after any amino acid in the peptide. In
some embodiments, no more than one amino acid is inserted between
two Cys residues. Particular examples include where two or more
amino acids are inserted and the peptide comprises the sequence
Cys.sub.a Cys.sub.b Xaa Xaa Cys.sub.c Cys.sub.d Xaa Xaa Xaa
Cys.sub.e Xaa Xaa Cys.sub.f (SEQ ID NO:526). In some of these and
related embodiments, two or more insertions can be located between
Cys.sub.b and Cys.sub.c or between Cys.sub.d and Cys.sub.e or
between Cys.sub.e and Cys.sub.f. However, in other embodiments, no
more than one insertion is located between Cys.sub.b and Cys.sub.c
or between Cys.sub.d and Cys.sub.e or between Cys.sub.e and
Cys.sub.f. Thus, included are any of the GC-C agonist peptides
described herein comprising the sequence Cys.sub.a Cys.sub.b Xaa
Xaa Cys.sub.c Cys.sub.d Xaa Xaa Xaa Cys.sub.e Xaa Xaa Cys.sub.f
(SEQ ID NO:526) where: a) one amino acid is inserted between
Cys.sub.b and Cys.sub.c; b) one amino acid is inserted between
Cys.sub.d and Cys.sub.e; c) one amino acid is inserted between
Cys.sub.e and Cys.sub.f; d) one amino acid is inserted between
Cys.sub.b and Cys.sub.c and one amino acid is inserted between
Cys.sub.d and Cys.sub.e; e) one amino acid is inserted between
Cys.sub.d and Cys.sub.e and one amino acid is inserted between
Cys.sub.e and Cys.sub.f; f) one amino acid is inserted between
Cys.sub.b and Cys.sub.c and one amino acid is inserted between
Cys.sub.e and Cys.sub.f, or g) one amino acid is inserted between
Cys.sub.b and Cys.sub.c, one amino acid is inserted between
Cys.sub.d and Cys.sub.e and one amino acid is inserted between
Cys.sub.e and Cys.sub.f. In addition, one or more amino acids can
be inserted preceding Cys.sub.a and/or one or more amino acids can
be inserted following Cys.sub.f. In some embodiments, the insertion
variants are peptides that bind to and/or agonize the GC-C
receptor.
[0195] Examples of insertion variants of Cys Cys Glu Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:4) include those in
which up to four amino acids (i.e., 0, 1, 2, 3 or 4) are inserted
after each amino acid. Thus, included are peptides having the
sequence: Cys Xaa.sub.(0-4) Cys Xaa.sub.(0-4) Glu Xaa.sub.(0-4) Tyr
Xaa.sub.(0-4) Cys Xaa.sub.(0-4) Cys Xaa.sub.(0-4) Asn Xaa.sub.(0-4)
Pro Xaa.sub.(0-4) Ala Xaa.sub.(0-4)Cys Xaa.sub.(0-4) Thr
Xaa.sub.(0-4) Gly Xaa.sub.(0-4) Cys Xaa.sub.(0-4) Tyr
Xaa.sub.(0-4)(SEQ ID NO:527). The inserted amino acids can be any
amino acid or amino acid analog (natural or non-natural) and can be
the same or different. In certain embodiments, the inserted amino
acids are all Gly or all Ala or a combination of Gly and Ala.
[0196] Also included are GC-C agonist peptides comprising or
consisting of the sequence Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10
Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16
Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID
NO:46), and including, for example, variants of Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:4), in which up to
four amino acids are deleted and/or up to four amino acids are
inserted. In some instances, the insertions and/or deletions can be
between Cys.sub.6 and Cys.sub.18 or they can be amino terminal to
Cys.sub.6 and/or carboxy terminal to Cys.sub.18.
[0197] In certain embodiments, a GC-C agonist peptide is based on
the core sequence: Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr (SEQ ID NO:528). To create a variant having a potentially
functional chymotrypsin cleavage site capable of inactivating the
peptide, either the Leu (underlined) or the Thr (underlined) can be
replaced by Trp, Phe or Tyr; or both the Leu and the Thr can be
replaced by (independently) Trp, Phe, or Tyr. The core sequence can
be optionally be preceded by Asn Ser Ser Asn Tyr or Asn. Specific
examples of GC-C agonist peptides based on the core sequence
include those in Table A4 below.
TABLE-US-00006 TABLE A4 SEQ ID NO: Asn Ser Ser Asn Tyr Cys Cys Glu
Leu Cys 529 Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr
Cys Cys Glu Leu Cys 530 Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asn Ser
Ser Asn Tyr Cys Cys Glu Tyr Cys 531 Cys Asn Pro Ala Cys Thr Gly Cys
Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys 528 Thr Gly Cys Tyr Cys
Cys Glu Leu Cys Cys Asn Pro Ala Cys 532 Thr Gly Cys Tyr Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys 532 Thr Gly Cys Tyr Asn Cys Cys Glu Leu
Cys Cys Asn Pro Ala 533 Cys Thr Gly Cys Tyr Asn Cys Cys Glu Leu Cys
Cys Asn Pro Ala 534 Cys Thr Gly Cys Tyr Asn Cys Cys Glu Phe Cys Cys
Asn Pro Ala 535 Cys Thr Gly Cys Tyr Asn Cys Cys Glu Tyr Cys Cys Asn
Pro Ala 536 Cys Thr Gly Cys Tyr Asn Cys Cys Glu Trp Cys Cys Asn Pro
Ala 537 Cys Thr Gly Cys Tyr Asn Cys Cys Glu Arg Cys Cys Asn Pro Ala
538 Cys Thr Gly Cys Tyr Asn Cys Cys Glu Lys Cys Cys Asn Pro Ala 539
Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys 540 Cys
Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe Asn Ser Ser Asn Tyr Cys Cys
Glu Leu Cys 541 Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asp Phe Asn Ser
Ser Asn Tyr Cys Cys Glu Phe Cys 542 Cys Asn Pro Ala Cys Thr Gly Cys
Tyr Asp Phe Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys 543 Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asp Phe Asn Ser Ser Asn Tyr Cys Cys Glu Trp
Cys 544 Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe Asn Ser Ser Asn
Tyr Cys Cys Glu Arg Cys 545 Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
Phe Asn Ser Ser Asn Tyr Cys Cys Glu Lys Cys 546 Cys Asn Pro Ala Cys
Thr Gly Cys Tyr Asp Phe Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys 547
Thr Gly Cys Tyr Asp Phe Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys 548
Thr Gly Cys Tyr Asp Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys 549
Thr Gly Cys Tyr Asp Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys 550
Thr Gly Cys Tyr Asp Phe Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys 551
Thr Gly Cys Tyr Asp Phe Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys 552
Thr Gly Cys Tyr Asp Phe Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys 553
Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala 554
Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala
555 Cys Trp Gly Cys Tyr Asp Phe Asn Cys Cys Glu Phe Cys Cys Asn Pro
Ala 556 Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Tyr Cys Cys Asn
Pro Ala 557 Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Trp Cys Cys
Asn Pro Ala 558 Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Arg Cys
Cys Asn Pro Ala 559 Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Lys
Cys Cys Asn Pro Ala 560 Cys Thr Gly Cys Tyr Asp Phe
[0198] In certain embodiments, the GC-agonist peptide is a
guanylin, lymphoguanylin, uroguanylin, or a renoguanylin peptide,
optionally a human peptide, or a variant or derivative or analog
thereof. The amino acid sequence of human guanylin is Pro Gly Thr
Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Gly Cys (SEQ ID NO:562).
Exemplary analogs of the human guanylin sequence are shown in Table
A5 below.
TABLE-US-00007 TABLE A5 SEQ Human Guanylin Analogs ID NO:
Pro-Gly-Thr-Cys-Glu-Gly-Ile-Cys-Ala- 563
Tyr-Ala-Ala-Cys-Thr-Gly-Cys Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala-
564 Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Gly- 565
Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 566
Gly-Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 567
Tyr-Gly-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 568
Tyr-Ala-Gly-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 569
Tyr-Ala-Ala-Gly-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 570
Tyr-Ala-Ala-Cys-Gly-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 571
Tyr-Ala-Ala-Cys-Thr-Gly-Gly-Cys
Pro-Gly-Thr-Cys-Ala-Glu-Ile-Cys-Ala- 572
Tyr-Ala-Ala-Cys-Thr-Gly-Cys Pro-Gly-Thr-Cys-Glu-Ala-Ile-Cys-Ala-
573 Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Ala-Cys-Ala- 574
Tyr-Ala-Ala-Cys-Thr-Gly-Cys Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala-
575 Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 576
Tyr-Ala-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 577
Tyr-Ala-Ala-Cys-Ala-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 578
Tyr-Ala-Ala-Cys-Thr-Ala-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Gly-Cys-Ala- 579
Tyr-Ala-Ala-Cys-Thr-Gly-Ala-Cys
Pro-Gly-Thr-Cys-Ala-Glu-Ile-Cys-Ala- 580
Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ala-Ile-Cys-Ala- 581
Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Pro-Gly-Thr-Cys-Glu-Ile-Ala-Cys-Ala- 582
Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 583
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 584
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 585
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 586
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 587
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 588
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 589
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 590
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 591
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 592
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 593
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 594
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 595
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 596
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 597
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Ser.sup.1-His.sup.2-Thr.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 598
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 599
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 600
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 601
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 602
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 603
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 604
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 605
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 606
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 607
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 608
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 609
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 610
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ala.-
sup.8- 611
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ala.-
sup.8- 612
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Val.sup.6-Cys.sup.7-Ala.-
sup.8- 613
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ala.-
sup.8- 614
Asn.sup.9-Ala.sup.10-Ala.sup.11-Cys.sup.12-Ala.sup.13-Gly.sup.14-Cys.sup.1-
5
[0199] Hence, in some embodiments, the GC-C agonist peptide
comprises, consists, or consists essentially of the human guanylin
sequence or a variant or derivative or analog thereof.
[0200] The amino acid sequence of lymphoguanylin is:
Gln-Glu-Glu-Cys-Glu-Leu-Cys-Ile-Asn-Met-Ala-Cys-Thr-Gly-Tyr. (SEQ
ID NO:615). Exemplary analogs of the human lymphoguanylin sequence
are shown in Table A6 below.
TABLE-US-00008 TABLE A6 SEQ Human Lymphoguanylin Analogs ID NO:
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 616
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 617
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 618
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 619
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 620
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 621
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 622
Met.sup.10-A1a.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 623
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 624
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 625
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 626
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 627
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 628
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 629
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 630
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 631
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Tyr.sup.15
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 632
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 633
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 634
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Thr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 635
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 636
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 637
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 638
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Glu.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 639
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 640
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 641
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 642
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 643
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
G1n.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 644
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 645
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 646
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Ile.sup.6-Cys.sup.7-Ile.-
sup.8-Asn.sup.9- 647
Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.15-Ser.sup.-
16
[0201] Hence, in some embodiments, the GC-C agonist peptide
comprises, consists, or consists essentially of the human
lymphoguanylin sequence or a variant or derivative or analog
thereof.
[0202] The amino acid sequence of human uroguanylin is Asn Asp Asp
Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID
NO:648). In some embodiments, the GC-C agonist peptide comprises,
consists, or consists essentially of the human uroguanylin sequence
or an analog thereof. In specific embodiments, the human
uroguanylin analog has the amino acid sequence Asn Asp Glu Cys Glu
Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:6;
Plecanatide), or Gln Asp Asp Cys Glu Thr Cys Ile Asn Met Ala Cys
Thr Gly Tyr (SEQ ID NO:649). In particular embodiments, the
N-terminal Asn of the peptide (e.g., plecanatide) is a pyroglutamic
acid. In some embodiments, the C-terminal Leu of the peptide (e.g.,
plecanatide) is a D-amino acid (d-Leu).
[0203] In certain embodiments, the human uroguanylin peptide or
analog comprise, consists, or consists essentially of the amino
acid sequence shown below (III):
TABLE-US-00009 (SEQ ID NO: 650) Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Cys.sub.4 Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 Xaa.sub.9
Xaa.sub.10 Xaa.sub.11 Cys.sub.12 Xaa.sub.13 Xaa.sub.14 Xaa.sub.15
Xaa.sub.16
[0204] In some embodiments, the GC-C agonist peptide of formula III
is defined as follows:
[0205] Xaa.sub.1 is any any natural or non-natural amino acid or
amino acid analog or is missing;
[0206] Xaa.sub.2 is any natural or non-natural amino acid or amino
acid analog or is missing;
[0207] Xaa.sub.3 is any natural or non-natural amino acid or amino
acid analog or is missing;
[0208] Xaa.sub.5 is Glu;
[0209] Xaa.sub.6 is Tyr, Trp, Phe or Leu;
[0210] Xaa.sub.7 is Cys;
[0211] Xaa.sub.8 is any natural or non-natural amino acid or amino
acid analog (optionally any of the 20 naturally-occurring amino
acids) other than Cys or is missing;
[0212] Xaa.sub.9 is any natural or non-natural amino acid or amino
acid analog (optionally any of the 20 naturally-occurring amino
acids) other than Cys;
[0213] Xaa.sub.10 is Pro or Gly;
[0214] Xaa.sub.11 is any natural or non-natural amino acid or amino
acid analog (optionally any of the 20 naturally-occurring amino
acids);
[0215] Xaa.sub.13 is Thr, Val or Gly;
[0216] Xaa.sub.14 is Gly or Ala;
[0217] Xaa.sub.15 is Cys; and
[0218] Xaa.sub.16 is any natural or non-natural amino acid or amino
acid analog (optionally any of the 20 naturally-occurring amino
acids) or is missing.
[0219] In certain embodiments: Xaa.sub.9 is Asn; Xaa.sub.11 is Ala
or Thr; Xaa.sub.8 is missing; and Xaa.sub.16 is Tyr.
[0220] In some embodiments Xaa.sub.4 is immediately preceded by an
amino acid sequence selected from:
TABLE-US-00010 Ser His Thr; Pro Ser Thr; Thr; Pro Asp Pro; (SEQ ID
NO: 651) Ile Ala Glu Asp Ser His Thr; (SEQ ID NO: 652) Ile Ala Gln
Asp Pro Ser Thr; Ala Asn Thr; Asn Thr; (SEQ ID NO: 653) Asp Pro Asn
Thr; Lys Asn Thr; Pro Asn Thr; (SEQ ID NO: 654) Ile Ala Gln Asp Pro
Asn Thr; (SEQ ID NO: 655) Lys Pro Asn Thr; (SEQ ID NO: 656) Asp Pro
Gly Thr; (SEQ ID NO: 657) Glu Asp Pro Gly Thr; Pro Gly Thr; Pro Ala
Thr; (SEQ ID NO: 658) Val Ala Ala Arg Ala Asp Leu; Gly Asp Asp; Asn
Asp Glu; Gln Glu Asp; Asn Asp Asp; (SEQ ID NO: 659) Arg Thr Ile Ala
Asn Asp Asp; (SEQ ID NO: 660) Thr Ile Ala Asn Asp Asp; Asp Asp;
(SEQ ID NO: 661) Arg Thr Met Asp Asn Asp Glu; (SEQ ID NO: 662) Arg
Thr Ile Ala Gly Asp Asp; (SEQ ID NO: 663) Arg Thr Ile Ala Asn Asp;
Asp; Glu Asp; (SEQ ID NO: 664) Arg Ser Ile Ser Gln Glu Asp; Thr Asp
Glu; (SEQ ID NO: 665) Arg Thr Ile Ala Thr Asp Glu; Glu; (SEQ ID NO:
666) Ile Ile Thr Pro Pro Asp Pro; Gln Glu Leu; Lys Asp Asp; Gln Glu
Glu; (SEQ ID NO: 667) Arg Tyr Ile Asn Gln Glu Glu; (SEQ ID NO: 668)
Ala Ser Ser Tyr Ala Ser; and (SEQ ID NO: 669) Thr Ser Ser Tyr Ala
Ser.
[0221] In particular embodiments, the GC-C agonist peptide of
formula III is defined as follows:
[0222] Xaa.sub.1 is: a) Ser, Asn, Tyr, Ala, Gln, Pro, Lys, Gly, or
Thr, or is missing; b) preceded by Lys or Tyr; c) any amino acid;
d) missing; e) any amino acid other than Cys; or f) Lys or Arg;
[0223] Xaa.sub.2 is: a) His, Asp, Glu, Ala, Ser, Asn, Gly, or is
missing; b) His, Asp, Glu, Ala, Ser, Asn, Gly, Pro or is missing;
c) Asp, Glu, any amino acid or is missing; d) Asp or Glu; e) any
amino acid other than Cys; e) Glu; f) missing; g) Trp, Tyr or Phe;
or h) Lys or Arg;
[0224] Xaa.sub.3 is: a) Thr, Asp, Ser, Glu, Pro, Val or Leu; Asp or
Glu; b) any amino acid other than Cys; c) Glu; d) Thr; e) Thr, Asp,
Ser, Glu, Pro, Val or Leu or is missing; f) Trp, Tyr or Phe; or g)
Lys or Arg;
[0225] Cys.sub.4 is optionally Xaa.sub.4 and is Cys, Mpt
(mercaptoproline), Pen (penicillamine), Dpr (diaminopropionic
acid), Asp, or Glu;
[0226] Xaa.sub.5 is: a) any amino acid; b) Glu, Asp, Gln, Gly or
Pro; c) Glu; d) Glu or Asp; e) Asp, Ile or Glu; f) any amino acid;
or g) any amino acid other than Cys;
[0227] Xaa.sub.6 is: a) Leu, Ile, Val, Ala, Lys, Arg, Trp, Tyr or
Phe; b) Leu, Ile, Val, Lys, Arg, Trp, Tyr or Phe; Leu, Ile, Lys,
Arg, Trp, Tyr or Phe; c) Leu, Ile, Val, Trp, Tyr or Phe; d) Trp,
Tyr, Phe or Leu; e) Leu, Ile or Val; f) Ile, Trp or Leu; g) Trp,
Tyr or Phe; h) Ile or Leu; i) Tyr; j) any amino acid; k) any amino
acid except Leu; 1) any natural or non-natural aromatic amino acid;
or m) any amino acid other than Cys;
[0228] Xaa.sub.7 is: a) Cys, Ser, or Tyr; Cys; b) Cys, Mpt
(mercaptoproline), Pen (penicillamine), Dpr (diaminopropionic
acid), Asp or Glu; c) Ser; or d) an amino acid other than Cys;
[0229] Xaa.sub.8 is: a) Ala, Val, or Ile; b) Ala, Val, Thr, Ile,
Met or is missing; c) any amino acid; d) Val; e) any amino acid
other than Cys; or f) missing;
[0230] Xaa.sub.9 is: a) any amino acid; b) any amino acid other
than Phe and Tyr; c) any amino acid other than Phe, Tyr, and Trp;
d) any amino acid other than Phe, Tyr, Trp, Ile, Leu and Val; e)
any amino acid other than Phe, Tyr, Trp, Ile, Leu, Val, and His; i)
any amino acid other than Gln; g) any amino acid other than Lys,
Arg, Phe, Tyr, and Trp; h) any amino acid other than Lys, Arg, Phe,
Tyr, Trp, Ile, Leu and Val; i) any amino acid other than Lys, Arg,
Phe, Tyr, Trp, Ile, Leu, Val, and His; j) any non-aromatic amino
acid; k) missing; 1) Phe, Tyr, Asn, or Trp; m) Asn, Tyr, Asp or
Ala; n) Asn, Gln, or Tyr; o) Phe or Tyr; p) Asn; or q) any amino
acid other than Cys;
[0231] Xaa.sub.10 is: a) Ala, Pro or Gly; b) Pro or Gly; c) Pro; d)
Ala, Val, Met, Thr or Ile; e) any amino acid; f) Val; g) Val or
Pro; h) Ala or Val; i) any amino acid other than Cys; j) Pro; or k)
Gly;
[0232] Xaa.sub.11 is: a) any amino acid; b) Ala, Leu, Ser, Gly,
Val, Glu, Gln, Ile, Leu, Lys, Arg, or Asp; c) Ala or Gly; d) Ala;
e) Ala or Val; f) any amino acid; g) Ala or Aib
(alpha-aminoisobutyric acid); h) any amino acid other than Cys; i)
Ala or Thr; or j) Thr;
[0233] Cys.sub.12 is optionally Xaa.sub.12 and is a) Cys, Mpt
(mercaptoproline), Pen (penicillamine), Dpr (diaminopropionic
acid), Asp, or Glu; or b) any amino acid other than Cys;
[0234] Xaa.sub.13 is: a) Thr, Ala, Asn, Lys, Arg, or Trp; b) Thr,
Ala, Lys, Arg, or Trp; c) any amino acid; d) any non-aromatic amino
acid; e) Thr, Ala, or Trp; f) Trp, Tyr or Phe; g) Thr or Ala; h)
any amino acid; i) Thr; j) any amino acid other than Cys; k) Thr,
Val, or Gly; 1) Thr or Val, m) Thr or Gly, n) Val or Thr; o) Val;
p) Thr; or q) Gly;
[0235] Xaa.sub.14 is: a) Gly, Pro or Ala; b) Gly; c) any amino
acid; d) Gly, Ala or Ser; e) Gly or Ala; f) any amino acid other
than Cys; or g) Ala;
[0236] Xaa.sub.15 is: a) Cys, Tyr or is missing; b) Cys; c) Cys,
Mpt (mercaptoproline), Pen (penicillamine), Dpr (diaminopropionic
acid), Asp, Glu; or d) any amino acid other than Cys or is missing;
and
[0237] Xaa.sub.16 is: a) Trp, Tyr, Phe, Asn, lie, Val, His or Leu;
b) Trp, Tyr, Phe, Asn or Leu; c) Tip, Tyr, Phe or Leu; d) Trp, Tyr,
or Phe; e) Leu, Ile or Val; f) His, Leu or Ser; g) Tyr or Leu; Lys
or Arg; h) His; i) any amino acid, j) Leu, or missing; k) Trp, Tyr,
Phe, Lys, Arg or is missing; 1) missing; m) any amino acid other
than Cys; or n) Tyr.
[0238] In some embodiments, the GC-C agonist peptide of formula III
is defined as follows:
[0239] Xaa.sub.1 is any natural or non-natural amino acid or amino
acid analog or is missing;
[0240] Xaa.sub.2 is any natural or non-natural amino acid or amino
acid analog or is missing;
[0241] Xaa.sub.3 is any natural or non-natural amino acid or amino
acid analog or is missing;
[0242] Xaa.sub.4 is Cys, Mpt (mercaptoproline), Pen
(penicillamine), Dpr (diaminopropionic acid), Asp or Glu;
[0243] Xaa.sub.5 is Glu;
[0244] Xaa.sub.6 is Tyr, Trp, Phe or Leu;
[0245] Xaa.sub.7 is Cys, Mpt (mercaptoproline), Pen
(penicillamine), Dpr (diaminopropionic acid), Asp or Glu;
[0246] Xaa.sub.8 is any natural or non-natural amino acid or amino
acid analog other than Cys or is missing;
[0247] Xaa.sub.9 is any amino acid;
[0248] Xaa.sub.10 is Pro or Gly;
[0249] Xaa.sub.11 is any amino acid;
[0250] Xaa.sub.12 is Cys, Mpt (mercaptoproline), Pen
(penicillamine), Dpr (diaminopropionic acid), Asp or Glu;
[0251] Xaa.sub.13 is Thr, Val or Gly;
[0252] Xaa.sub.14 is Gly or Ala;
[0253] Xaa.sub.15 is Cys, Mpt (mercaptoproline), Pen
(penicillamine), Dpr (diaminopropionic acid), Asp or Glu; and
[0254] Xaa.sub.16 is any amino acid or is missing.
[0255] In particular embodiments, the GC-C agonist peptide of
formula III is defined as follows:
[0256] Xaa.sub.1 is Asn, any amino acid or is missing;
[0257] Xaa.sub.2 is Asp, Glu, any amino acid or is missing;
[0258] Xaa.sub.3 is Asp or Glu;
[0259] Xaa.sub.5 is any amino acid or Glu;
[0260] Xaa.sub.6 is any amino acid or Leu;
[0261] Xaa.sub.7 is Cys;
[0262] Xaa.sub.8 is any amino acid or Val;
[0263] Xaa.sub.9 is Asn, Gln, or Tyr;
[0264] Xaa.sub.10 is any amino acid or Val;
[0265] Xaa.sub.11 is any amino acid or Ala;
[0266] Xaa.sub.13 is any amino acid or Thr;
[0267] Xaa.sub.14 is any amino acid or Gly;
[0268] Xaa.sub.15 is Cys;
[0269] Xaa.sub.16 is any amino acid, Leu or missing
[0270] In some embodiments, the GC-C agonist peptide of formula III
is not cleaved after Xaa.sub.9 by chymotrypsin, and is defined as
follows:
[0271] Xaa.sub.1 is Ser, Asn, Tyr, Ala, Gln, Pro, Lys, Gly or Thr,
or is missing;
[0272] Xaa.sub.2 is His, Asp, Glu, Ala, Ser, Asn, or Gly or is
missing;
[0273] Xaa.sub.3 is Thr, Asp, Ser, Glu, Pro, Val or Leu or is
missing;
[0274] Xaa.sub.5 is Asp, Ile or Glu;
[0275] Xaa.sub.6 is Ile, Trp or Leu;
[0276] Xaa.sub.7 is Cys, Ser, or Tyr;
[0277] Xaa.sub.8 is Ala, Val, Thr, Ile, or Met or is missing;
[0278] Xaa.sub.9 is either: a) any amino acid other than Phe and
Tyr, b) any amino acid other than Phe, Tyr, and Trp, c) any amino
acid other than Phe, Tyr, Trp, Ile, Leu and Val; d) any amino acid
other than Phe, Tyr, Trp, Ile, Leu, Val, and His; d) any
non-aromatic amino acid or e) is missing;
[0279] Xaa.sub.10 is Ala, Val, Met, Thr or Ile;
[0280] Xaa.sub.11 is Ala or Val;
[0281] Xaa.sub.13 is Ala or Thr;
[0282] Xaa.sub.14 is Gly, Ala or Ser;
[0283] Xaa.sub.15 is Cys, Tyr or is missing; and
[0284] Xaa.sub.16 is: a) Trp, Tyr or Phe to create a chymotrypsin
cleavage site; b) Lys or Arg to create a trypsin cleavage site; c)
is missing or d) His or Leu or Ser.
[0285] In specific embodiments, the human uroguanylin peptide or
analog comprises, consists, or consists essentially of the amino
acid sequence shown below (IV):
TABLE-US-00011 (SEQ ID NO: 670) Asn.sub.1 Xaa.sub.2 Xaa.sub.3
Xaa.sub.4 Glu.sub.5 Leu.sub.6 Xaa.sub.7 Val.sub.8 Asn.sub.9
Xaa.sub.10 Xaa.sub.11 Xaa.sub.12 Thr.sub.13 Xaa.sub.14 Xaa.sub.15
Leu.sub.16
[0286] Where, Xaa.sub.2 is Asp or Glu;
[0287] Xaa.sub.3 is Asp or Glu;
[0288] Xaa.sub.4 is Cys or Mpt (mercaptoproline) or Pen
(penicillamine) or Dpr (diaminopropionic acid) or Asp or Glu;
[0289] Xaa.sub.7 is Cys or Mpt (mercaptoproline) or Pen
(penicillamine) or Dpr (diaminopropionic acid) or Asp or Glu;
[0290] Xaa.sub.10 is Val or Pro;
[0291] Xaa.sub.11 is Ala or Aib (alpha-aminoisobutyric acid);
[0292] Xaa.sub.12 is Cys or Mpt (mercaptoproline) or Pen
(penicillamine) or Dpr (diaminopropionic acid) or Asp or Glu;
[0293] Xaa.sub.14 is Gly or Ala; and
[0294] Xaa.sub.15 is Cys or Mpt (mercaptoproline) or Pen
(penicillamine) or Dpr (diaminopropionic acid) or Asp or Glu.
[0295] In certain embodiments of Formula IV, Xaa.sub.15 is other
than Cys or is missing, Xaa.sub.7 is Ser or an amino acid other
than Cys.
[0296] In certain embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or
12 of Xaa.sub.1, Xaa.sub.2, Xaa.sub.3, Xaa.sub.5, Xaa.sub.6,
Xaa.sub.7, Xaa.sub.8, Xaa.sub.9, Xaa.sub.10, Xaa.sub.11,
Xaa.sub.13, Xaa.sub.14, and Xaa.sub.16 are any amino acid other
than Cys. In some embodiments, Xaa.sub.9 is any amino acid other
than Gln. In embodiments where Xaa.sub.2 and Xaa.sub.3 are Glu,
Xaa.sub.9 is any amino acid other than Gln. In certain embodiments,
Xaa.sub.1 and Xaa.sub.2 are missing; Xaa.sub.3 is Thr; Xaa.sub.5 is
Glu; Xaa.sub.6 is Ile or Leu; Xaa.sub.8 is Ala, Val, or Ile;
Xaa.sub.9 is Phe or Tyr; Xaa.sub.10 is Ala or Val; Xaa.sub.11 is
Ala; Xaa.sub.13 is Ala or Thr; Xaa.sub.14 is Gly; and Xaa.sub.16 is
Trp, Tyr, Phe, Lys, or Arg or is missing.
[0297] Specific examples of human uroguanylin analogs are provided
in Table A7 below.
TABLE-US-00012 TABLE A7 SEQ ID Exemplary Human Uroguanylin Analogs
NO:
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 672
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 673
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 674
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 675
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 676
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 677
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 678
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 679
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 680
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 681
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 682
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 683
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 684
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 685
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 686
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 687
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 688
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Glu.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 689
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Glu.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 690
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Glu.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 691
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 692
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 693
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 694
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 695
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 696
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 697
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 698
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 699
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 700
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 701
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 702
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 703
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Glu.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 704
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 705
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 706
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 707
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 708
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 709
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 710
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Asp.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 711
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 712
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 713
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 714
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 715
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 716
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 717
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 718
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Lys.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 719
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Leu.sup.16
Glu.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 720
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Glu.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 721
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Glu.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 722
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Glu.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 723
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 724
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 725
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 726
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asp.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 727
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 728
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 729
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 730
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Gln.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 731
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Asp.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 732
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 733
Asn.sup.9-Met.sup.10-Ala.sup.1l-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Glu.sup.2-Asp.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 734
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Lys.sup.1-Glu.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Ile.-
sup.8- 735
Asn.sup.9-Met.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- Ser.sup.16
Asn.sup.1-Glu.sup.2-Cys.sup.3-Glu.sup.4-Leu.sup.5-Cys.sup.6-Val.sup.7-Asn.-
sup.8- 736
Val.sup.9-Ala.sup.10-Cys.sup.11-Thr.sup.12-Gly.sup.13-Cys.sup.14-Leu.sup.1-
5
Asp.sup.1-Glu.sup.2-Cys.sup.3-Glu.sup.4-Leu.sup.5-Cys.sup.6-Val.sup.7-Asn.-
sup.8- 737
Val.sup.9-Ala.sup.10-Cys.sup.11-Thr.sup.12-Gly.sup.13-Cys.sup.14
Glu.sup.1-Cys.sup.2-Glu.sup.3-Leu.sup.4-Cys.sup.5-Val.sup.6-Asn.sup.7-Val.-
sup.8- 738
Ala.sup.9-Cys.sup.10-Thr.sup.11-Gly.sup.12-Cys.sup.13-Leu.sup.14
Glu.sup.1-Cys.sup.2-Glu.sup.3-Leu.sup.4-Cys.sup.5-Val.sup.6-Asn.sup.7-Val.-
sup.8- 739 Ala.sup.9-Cys.sup.10-Thr.sup.11-Gly.sup.12-Cys.sup.13
Cys.sup.1-Glu.sup.2-Leu.sup.3-Cys.sup.4-Val.sup.5-Asn.sup.6-Val.sup.7-Ala.-
sup.8- 740 Cys.sup.9-Thr.sup.10-Gly.sup.11-Cys.sup.12-Leu.sup.l3
Cys.sup.1-Glu.sup.2-Leu.sup.3-Cys.sup.4-Val.sup.5-Asn.sup.6-Val.sup.7-Ala.-
sup.8- 741 Cys.sup.9-Thr.sup.10-Gly.sup.11-Cys.sup.12
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-dAsp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Va-
l.sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-dAsp.sup.2-dGlu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-V-
al.sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-dLeu.sup.6-Cys.sup.7-Va-
l.sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
Asn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val.-
sup.8- 742
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 743
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dNal.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-AIB-
.sup.8- 744
Asn.sup.9-AIB.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6- 745
Asp[Lactam].sup.7-Val.sup.8-Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-
Thr.sup.13-Gly.sup.14-Orn.sup.15-dLeu.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Tyr.sup.6-Cys.sup.7-Val-
.sup.8- 746
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Ser.sup.6-Cys.sup.7-Val-
.sup.8- 747
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 671
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dLeu-AMIDE.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 748
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dSer.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 748
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dSer-AMIDE.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 749
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dTyr.sup.16
dAsn.sup.1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-Val-
.sup.8- 749
Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-Cys.sup.1-
5- dTyr-AMIDE.sup.16
Pyglu1-Asp.sup.2-Glu.sup.3-Cys.sup.4-Glu.sup.5-Leu.sup.6-Cys.sup.7-
750
Val.sup.8-Asn.sup.9-Val.sup.10-Ala.sup.11-Cys.sup.12-Thr.sup.13-Gly.sup.14-
- Cys.sup.15-dLeu-8AMIDE.sup.16
Cys.sup.1-Cys.sup.2-Glu.sup.3-Ser.sup.4-Cys.sup.5-Cys.sup.6-Asn.sup.7-Pro.-
sup.8- 751
Ala.sup.9-Cys.sup.10-Thr.sup.11-Gly.sup.12-Cys.sup.13-Tyr.sup.14
Cys.sup.1-Cys.sup.2-Glu.sup.3-Phe.sup.4-Cys.sup.5-Cys.sup.6-Asn.sup.7-Pro.-
sup.8- 752
Ala.sup.9-Cys.sup.10-Thr.sup.11-Gly.sup.12-Cys.sup.13-Tyr.sup.14
Cys.sup.1-Cys.sup.2-Glu.sup.3-Ser.sup.4-Cys.sup.5-Cys.sup.6-Asn.sup.7-Pro.-
sup.8- 753 Ala.sup.9-Cys.sup.10-Thr.sup.11-Gly.sup.12-Cys.sup.13
Cys.sup.1-Cys.sup.2-Glu.sup.3-Phe.sup.4-Cys.sup.5-Cys.sup.6-Asn.sup.7-Pro.-
sup.8- 754 Ala.sup.9-Cys.sup.10-Thr.sup.11-Gly.sup.12-Cys.sup.13
Pen.sup.1-Pen.sup.2-Glu.sup.3-Tyr.sup.4-Pen.sup.5-Pen.sup.6-Asn.sup.7-Pro.-
sup.8- 755
Ala.sup.9-Pen.sup.10-Thr.sup.11-Gly.sup.12-Pen.sup.13-Tyr.sup.14
Pen.sup.1-Pen.sup.2-Glu.sup.3-Tyr.sup.4-Pen.sup.5-Pen.sup.6-Asn.sup.7-Pro.-
sup.8- 756
Ala.sup.9-Pen.sup.10-Thr.sup.11-Gly.sup.12-Pen.sup.13
[0298] Also included are variants of the GC-C agonist peptides
described herein. Examples include variant peptides which comprise
about, at least about, or no more than about 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, or 12 amino acid substitutions, insertions, and/or
deletions relative to any of Formulas I, II, III, or IV, or SEQ ID
Nos. 1,5,46-50,650 and 670, or the sequences in any of Tables
A1-A7. The substitution(s) can be conservative or non-conservative.
One example of a conservative amino acid substitution is one in
which the amino acid residue is replaced with an amino acid residue
having a similar side chain. Families of amino acid residues having
similar side chains have been defined in the art. These families
include amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic
acid), uncharged polar side chains (e.g., glycine, asparagine,
glutamine, serine, threonine, tyrosine, cysteine), nonpolar side
chains (e.g., alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan), beta-branched side chains
(e.g., threonine, valine, isoleucine) and aromatic side chains
(e.g., tyrosine, phenylalanine, tryptophan, histidine). A
conservative substitution can substitute a naturally-occurring
amino acid for a non-naturally-occurring amino acid or an amino
acid analog. The insertions and/or deletions can be at the
N-terminus, C-terminus, and/or the internal regions of the peptide
(e.g., an insertion or deletion of about 1, 2, 3, 4, 5, 6, 7, 8, 9,
10 amino acids at the C-terminus, N-terminus, and/or within about
2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of the N-terminus and/or
C-terminus). In some instances it can be desirable to use a variant
peptide that binds to and agonizes the intestinal GC-C receptor,
but is less active than the non-variant form the peptide. This
reduced activity can arise from reduced affinity for the receptor
or a reduced ability to activate the receptor once bound or reduced
stability of the peptide.
[0299] The GC-C agonist peptides can be cyclic peptides or linear
peptides. In addition, multiple copies of the same peptide can be
incorporated into a single cyclic or linear peptide. Cyclic
peptides can be prepared by methods known in the art. For example,
macrocyclization is often accomplished by forming an amide bond
between the peptide N- and C-termini, between a side chain and the
N- or C-terminus [e.g., with K.sub.3Fe(CN).sub.6 at pH .about.8.5]
(Samson et al., Endocrinology, 137:5182-5185, 1996), or between two
amino acid side chains, such as cysteine (DeGrado, Adv Protein
Chem, 39:51-124, 1988).
[0300] The peptides can include the amino acid sequence of a
peptide that occurs naturally in a vertebrate (e.g., mammalian)
species or in a bacterial species. In addition, the peptides can be
partially or completely non-naturally occurring peptides.
[0301] Also included are peptide analogs corresponding to the GC-C
agonist peptides described herein. Peptide analogs are commonly
used in the pharmaceutical industry as non-peptide drugs with
properties analogous to those of the template peptide. These types
of non-peptide compound are termed "peptide mimetics" or
"peptidomimetics" (Luthman, et al., A Textbook of Drug Design and
Development, 14:386-406, 2nd Ed., Harwood Academic Publishers,
1996; Joachim Grante, Angew. Chem. Int. Ed. Engl., 33:1699-1720,
1994; Fauchere, J., Adv. Drug Res., 15:29 (1986); Veber and
Freidinger TINS, p. 392 (1985); and Evans et al., J. Med. Chem.
30:229, 1987). A peptidomimetic is a molecule that mimics the
biological activity of a peptide but is no longer peptidic in
chemical nature. Peptidomimetic compounds are known in the art and
are described, for example, in U.S. Pat. No. 6,245,886.
[0302] The present invention also includes peptoids. Peptoid
derivatives of peptides represent another form of modified peptides
that retain the important structural determinants for biological
activity, yet eliminate the peptide bonds, thereby conferring
resistance to proteolysis (see, e.g., Simon et al., PNAS USA.
89:9367-9371, 1992). Peptoids are oligomers of N-substituted
glycines. A number of N-alkyl groups have been described, each
corresponding to the side chain of a natural amino acid. The
peptoids of the present invention include compounds in which at
least one amino acid, a few amino acids, or all amino acid residues
are replaced by the corresponding N-substituted glycines. Peptoid
libraries are described, for example, in U.S. Pat. No.
5,811,387.
[0303] In some aspects, the GC-C agonist peptide comprises or
consists of about, at least about, or less than about 150, 140,
130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 29, 28, 27, 26, 25,
24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 8, 7,
6, or 5 amino acids. In some aspects, the peptide comprises no more
than 5 amino acids that are N-terminal of Cys.sub.6 (of Formula I
or II) In some aspects, the peptide comprises no more than 20, 15,
10, or 5 amino acids that are C-terminal of Cys.sub.18 (of Formula
I or II).
[0304] In some aspects, the peptides are purified. A purified
peptides is separated from other proteins, lipids, and nucleic
acids or from the compounds from which is it synthesized or
otherwise prepared. A purified peptide can constitute at least
about 50, 60, 70, 80, 85, 90, 95, 96, 97, or 98% by dry weight of
the purified preparation.
[0305] As noted above, certain peptides described herein can
include one or more or all non-natural amino acids or amino acid
analogs. Further to those described elsewhere herein (e.g., supra),
examples include: a non-natural analogue of tyrosine; a non-natural
analogue of glutamine; a non-natural analogue of phenylalanine; a
non-natural analogue of serine; a non-natural analogue of
threonine; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine,
hydrazide, hydroxyl, alkenyl, alkynl, ether, thiol, sulfonyl,
seleno, ester, thioacid, borate, boronate, phospho, phosphono,
phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine,
keto, or amino substituted amino acid, or any combination thereof;
an amino acid with a photoactivatable cross-linker; a spin-labeled
amino acid; a fluorescent amino acid; an amino acid with a novel
functional group; an amino acid that covalently or noncovalently
interacts with another molecule; a metal binding amino acid; a
metal-containing amino acid; a radioactive amino acid; a photocaged
and/or photoisomerizable amino acid; a biotin or biotin-analogue
containing amino acid; a glycosylated or carbohydrate modified
amino acid; a keto containing amino acid; amino acids comprising
polyethylene glycol or polyether; a heavy atom substituted amino
acid (e.g., an amino acid containing deuterium, tritium, .sup.13C,
.sup.15N, or .sup.18O); a chemically cleavable or photocleavable
amino acid; an amino acid with an elongated side chain; an amino
acid containing a toxic group; a sugar substituted amino acid,
e.g., a sugar substituted serine or the like; a carbon-linked
sugar-containing amino acid; a redox-active amino acid; an
.alpha..-hydroxy containing acid; an amino thio acid containing
amino acid; an .alpha.,.alpha. disubstituted amino acid; a
.beta.-amino acid; a cyclic amino acid other than proline; an
O-methyl-L-tyrosine; an L-3-(2-naphthyl)alanine; a
3-methyl-phenylalanine; a p-acetyl-L-phenylalanine; an
0-4-allyl-L-tyrosine; a 4-propyl-L-tyrosine; a
tri-O-acetyl-GlcNAc.beta.-serine; an L-Dopa; a fluorinated
phenylalanine; an isopropyl-L-phenylalanine; a
p-azido-L-phenylalanine; a p-acyl-L-phenylalanine; a
p-benzoyl-L-phenylalanine; an L-phosphoserine; a phosphonoserine; a
phosphonotyrosine; a p-iodo-phenylalanine; a 4-fluorophenylglycine;
a p-bromophenylalanine; a p-amino-L-phenylalanine; a
isopropyl-L-phenylalanine; L-3-(2-naphthyl)alanine; an amino-,
isopropyl-, or O-allyl-containing phenylalanine analogue; a dopa,
O-methyl-L-tyrosine; a glycosylated amino acid; a
p-(propargyloxy)phenylalanine; dimethyl-Lysine; hydroxy-proline;
mercaptopropionic acid; methyl-lysine; 3-nitro-tyrosine;
norleucine; pyro-glutamic acid; Z (Carbobenzoxyl);
.epsilon.-Acetyl-Lysine; .beta.-alanine; aminobenzoyl derivative;
aminobutyric acid (Abu); citrulline; aminohexanoic acid;
aminoisobutyric acid; cyclohexylalanine; d-cyclohexylalanine;
hydroxyproline; nitro-arginine; nitro-phenylalanine;
nitro-tyrosine; norvaline; octahydroindole carboxylate; ornithine;
penicillamine; tetrahydroisoquinoline; acetamidomethyl protected
amino acids and pegylated amino acids. Further examples of
non-natural amino acids and amino acid analogs can be found in U.S.
Application Nos. 2003/0108885 and 2003/0082575, and the references
cited therein.
[0306] In some embodiments, an amino acid can be replaced by a
naturally-occurring, non-essential amino acid, e.g., taurine.
[0307] In some embodiments, 1, 2, 3, 4, 5, or 6 cysteines are
deleted or replaced with a different amino acid. In particular
aspects, the most N-terminal and/or C-terminal cysteine residue or
residues are deleted or replaced with a different amino acid. In
certain embodiments, the different amino acid is alanine or
serine.
[0308] Peptides can be polymers of L-amino acids, D-amino acids, or
a combination thereof. For example, in certain embodiments, the
peptides are D retro-inverso peptides. The term "retro-inverso
isomer" refers to an isomer of a linear peptide in which the
direction of the sequence is reversed and the chirality of each
amino acid residue is inverted. See, e.g., Jameson et al., Nature.
368:744-746, 1994; Brady et al., Nature. 368:692-693, 1994. The net
result of combining D-enantiomers and reverse synthesis is that the
positions of carbonyl and amino groups in each amide bond are
exchanged, while the position of the side-chain groups at each
alpha carbon is preserved. Unless specifically stated otherwise,
any given L-amino acid sequence of the invention can be made into a
D retro-inverso peptide by synthesizing a reverse of the sequence
for the corresponding native L-amino acid sequence
[0309] Methods of manufacturing peptides containing non-natural
amino acids can be found, for example, in U.S. Application Nos.
2003/0108885 and 2003/0082575, Deiters et al., J Am Chem. Soc.
125:11782-3, 2003; Chin et al., Science. 301:964-7, 2003, and the
references cited therein.
[0310] In some aspects, the GC-C agonist peptides can have one or
more conventional peptide bonds replaced by an alternative bond.
Such replacements can increase the stability of the peptide. For
example, replacement of the peptide bond between Cys.sub.18 and
Xaa.sub.19 (of Formula I or II) with an alternative bond can reduce
cleavage by carboxy peptidases and may increase half-life in the
digestive tract. Bonds that can replace peptide bonds include
without limitation: a retro-inverso bonds (C(O)--NH instead of
NH--C(O); a reduced amide bond (NH--CH.sub.2); a thiomethylene bond
(S--CH.sub.2 or CH.sub.2--S); an oxomethylene bond (O--CH.sub.2 or
CH.sub.2--O); an ethylene bond (CH.sub.2--CH.sub.2); a thioamide
bond (C(S)--NH); a trans-olefine bond (CH.dbd.CH); an fluoro
substituted trans-olefine bond (CF.dbd.CH); a ketomethylene bond
(C(O)--CHR or CHR--C(O) where R is H or CH.sub.3; and a
fluoro-ketomethylene bond (C(O)--CFR or CFR--C(O) where R is H or F
or CH.sub.3.
[0311] In some GC-C agonist peptides, one or both members of one or
more pairs of Cys residues which normally form a disulfide bond are
replaced by homocysteine, penicillamine, 3-mercaptoproline (see,
e.g., Kolodziej et al., Int J Pept Protein Res. 48:274, 1996);
.beta.,.beta. dimethylcysteine (see, e.g., Hunt et al., Int J Pept
Protein Res. 42:249, 1993) or diaminopropionic acid (see, e.g.,
Smith et al., J Med Chem. 21:117, 1978), to form alternative
internal cross-links at the positions of the normal disulfide
bonds.
[0312] In some embodiments, one or more disulfide bonds can be
replaced by alternative covalent cross-linkages, e.g., an amide
linkage (--CH.sub.2CH(O)NHCH.sub.2-- or
--CH.sub.2NHCH(O)CH.sub.2--), an ester linkage, a thioester
linkage, a lactam bridge, a carbamoyl linkage, a urea linkage, a
thiourea linkage, a phosphonate ester linkage, an alkyl linkage
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--), an alkenyl
linkage(--CH.sub.2CH.dbd.CHCH.sub.2--), an ether linkage
(--CH.sub.2CH.sub.2OCH.sub.2-- or --CH.sub.2OCH.sub.2CH.sub.2--), a
thioether linkage (--CH.sub.2CH.sub.2SCH.sub.2-- or
--CH.sub.2SCH.sub.2CH.sub.2--), an amine linkage
(--CH.sub.2CH.sub.2NHCH.sub.2-- or --CH.sub.2NHCH.sub.2CH.sub.2--)
or a thioamide linkage (--CH.sub.2CH(S)HNHCH.sub.2-- or
--CH.sub.2NHCH(S)CH.sub.2--). For example, Ledu et al. (PNAS.
100:11263-78, 2003) describe methods for preparing lactam and amide
cross-links. Schafmeister et al. (J. Am. Chem. Soc. 122:5891, 2000)
describe stable, hydrocarbon cross-links. Hydrocarbon cross links
can be produced via metathesis (or methathesis followed by
hydrogenation in the case of saturated hydrocarbons cross-links)
using one or another of the Grubbs catalysts (available from
Materia, Inc. and Sigma-Aldrich and described, for example, in U.S.
Pat. Nos. 5,831,108 and 6,111,121). In some instances, the
generation of such alternative cross-links requires replacing the
Cys residues with other residues such as Lys or Glu or
non-naturally occurring amino acids. In addition, the lactam, amide
and hydrocarbon cross-linkages can be used to stabilize the peptide
even if they link amino acids at positions other than those
occupied by Cys. Such cross-linkages can occur, for example,
between two amino acids that are separated by two amino acids or
between two amino acids that are separated by six amino acids (see,
e.g., Schafmeister et al., J. Am. Chem. Soc. 122:5891, 2000).
[0313] The GC-C agonist peptides can be modified using standard
modifications. Modifications may occur at the amino (N--), carboxy
(C--) terminus, internally or a combination of any of the
foregoing. In some aspects, there may be more than one type of
modification of the peptide. Modifications include but are not
limited to: acetylation, amidation, biotinylation, cinnamoylation,
farnesylation, formylation, myristoylation, palmitoylation,
phosphorylation (Ser, Tyr or Thr), stearoylation, succinylation,
sulfurylation and cyclisation (via disulfide bridges or amide
cyclisation), and modification by Cy3 or Cy5. The peptides of the
invention may also be modified by 2,4-dinitrophenyl (DNP),
DNP-lysin, modification by 7-Amino-4-methyl-coumarin (AMC),
fluorescein, NBD (7-Nitrobenz-2-Oxa-1,3-Diazole), p-nitro-anilide,
rhodamine B, EDANS (5-((2-aminoethyl)amino)naphthalene-1-sulfonic
acid), dabcyl, dabsyl, dansyl, Texas red, FMOC, and Tamra
(Tetramethylrhodamine). The peptides of the invention may also be
conjugated to, for example, polyethylene glycol (PEG); alkyl groups
(e.g., C1-C20 straight or branched alkyl groups); fatty acid
radicals; combinations of PEG, alkyl groups and fatty acid radicals
(see U.S. Pat. No. 6,309,633; Soltero et al., Innovations in
Pharmaceutical Technology. 106-110, 2001); BSA and KLH (Keyhole
Limpet Hemocyanin). For instance, in certain embodiments, the
N-terminal amino acid, C-terminal amino acid, or both, is conjuated
to a PEG molecule.
[0314] In certain embodiments, the GC-C agonist peptides described
herein can be present with a counterion. Exemplary counterions
include salts of: acetate, benzenesulfonate, benzoate, calcium
edetate, camsylate, carbonate, citrate, edetate (EDTA), edisylate,
embonate, esylate, fumarate, gluceptate, gluconate, glutamate,
glycollylarsanilate, hexylresorcinate, iodide, bromide, chloride,
hydroxynaphthoate, isethionate, lactate, lactobionate, estolate,
maleate, malate, mandelate, mesylate, mucate, napsylate, nitrate,
pantothenate, phosphate, salicylate, stearate, succinate, sulfate,
tartarate, theoclate, acetamidobenzoate, adipate, alginate,
aminosalicylate, anhydromethylenecitrate, ascorbate, aspartate,
camphorate, caprate, caproate, caprylate, cinnamate, cyclamate,
dichloroacetate, formate, gentisate, glucuronate, glycerophosphate,
glycolate, hippurate, fluoride, malonate, napadisylate, nicotinate,
oleate, orotate, oxalate, oxoglutarate, palmitate, pectinate,
pectinate polymer, phenylethylbarbiturate, picrate, propionate,
pidolate, sebacate, rhodanide, tosylate, and tannate.
[0315] GC-C agonist peptides can be produced according to a variety
of techniques. For instance, peptides can be produced in bacteria
including, without limitation, E. coli, or in other systems for
peptide or protein production (e.g., Bacillus subtilis, baculovirus
expression systems using Drosophila Sf9 cells, yeast or filamentous
fungal expression systems, mammalian cell expression systems), or
they can be chemically synthesized. If the peptide or variant
peptide is to be produced in bacteria, e.g., E. coli, the nucleic
acid molecule encoding the peptide may optionally encode a leader
sequence that permits the secretion of the mature peptide from the
cell. Thus, the sequence encoding the peptide can include the pre
sequence and the pro sequence of, for example, a
naturally-occurring bacterial ST peptide. The secreted, mature
peptide can be purified from the culture medium.
[0316] In some instances, the sequence encoding a peptide of the
invention is inserted into a vector capable of delivering and
maintaining the nucleic acid molecule in a bacterial cell. The DNA
molecule may be inserted into an autonomously replicating vector
(suitable vectors include, for example, pGEM3Z and pcDNA3, and
derivatives thereof). The vector nucleic acid may be a bacterial or
bacteriophage DNA such as bacteriophage lambda or M13 and
derivatives thereof. Construction of a vector containing a nucleic
acid described herein can be followed by transformation of a host
cell such as a bacterium. Suitable bacterial hosts include but are
not limited to, E. coli B. subtilis, Pseudomonas, Salmonella. The
genetic construct may also include, in addition to the encoding
nucleic acid molecule, elements that allow expression, such as a
promoter and regulatory sequences. The expression vectors may
contain transcriptional control sequences that control
transcriptional initiation, such as promoter, enhancer, operator,
and repressor sequences. A variety of transcriptional control
sequences are well known to those in the art. The expression vector
can also include a translation regulatory sequence (e.g., an
untranslated 5' sequence, an untranslated 3' sequence, or an
internal ribosome entry site). The vector can be capable of
autonomous replication or it can integrate into host DNA to ensure
stability during peptide production. In some embodiments, the
vectors, expression systems and methods described in U.S. Pat. No.
5,395,490 can be used to produce the GC-C agonist peptides
described herein.
[0317] The protein coding sequence that includes a peptide of the
invention can also be fused to a nucleic acid encoding a
polypeptide affinity tag, e.g., glutathione S-transferase (GST),
maltose E binding protein, protein A, FLAG tag, hexa-histidine, myc
tag or the influenza HA tag, in order to facilitate purification.
The affinity tag or reporter fusion joins the reading frame of the
peptide of interest to the reading frame of the gene encoding the
affinity tag such that a translational fusion is generated.
Expression of the fusion gene results in translation of a single
polypeptide that includes both the peptide of interest and the
affinity tag. In some instances where affinity tags are utilized,
DNA sequence encoding a protease recognition site will be fused
between the reading frames for the affinity tag and the peptide of
interest.
[0318] Genetic constructs and methods suitable for production of
immature and mature forms of the peptides and variants of the
invention in protein expression systems other than bacteria, and
well known to those skilled in the art, can also be used to produce
peptides in a biological system.
[0319] Peptides and variants thereof can be synthesized by the
solid-phase chemical synthesis. For example, the peptide can be
synthesized on
Cyc(4-CH.sub.2Bxl)-OCH.sub.2-4-(oxymethyl)-phenylacetamidomethyl
resin using a double coupling program. Protecting groups must be
used appropriately to create the correct disulfide bond pattern.
For example, the following protecting groups can be used:
t-butyloxycarbonyl (alpha-amino groups); acetamidomethyl (thiol
groups of Cys residues B and E); 4-methylbenzyl (thiol groups of
Cys residues C and F); benzyl (.gamma.-carboxyl of glutamic acid
and the hydroxyl group of threonine, if present); and bromobenzyl
(phenolic group of tyrosine, if present). Coupling is effected with
symmetrical anhydride of t-butoxylcarbonylamino acids or
hydroxybenzotriazole ester (for asparagine or glutamine residues),
and the peptide is deprotected and cleaved from the solid support
in hydrogen fluoride, dimethyl sulfide, anisole, and p-thiocresol
using 8/1/1/0.5 ratio (v/v/v/w) at 0.degree. C. for 60 min. After
removal of hydrogen fluoride and dimethyl sulfide by reduced
pressure and anisole and p-thiocresol by extraction with ethyl
ether and ethyl acetate sequentially, crude peptides are extracted
with a mixture of 0.5M sodium phosphate buffer, pH 8.0 and
N,N-dimethylformamide using 1/1 ratio, v/v. The disulfide bond for
Cys residues B and E is the formed using dimethyl sulfoxide (Tam et
al., J. Am. Chem. Soc. 113:6657-62, 1991). The resulting peptide
can be purified by reverse-phase chromatography. The disulfide bond
between Cys residues C and F is formed by first dissolving the
peptide in 50% acetic acid in water. Saturated iodine solution in
glacial acetic acid is added (1 ml iodine solution per 100 ml
solution). After incubation at room temperature for 2 days in an
enclosed glass container, the solution is diluted five-fold with
deionized water and extracted with ethyl ether four times for
removal of unreacted iodine. After removal of the residual amount
of ethyl ether by rotary evaporation the solution of crude product
is lyophilized and purified by successive reverse-phase
chromatography.
[0320] Peptides can also be synthesized by many other methods
including solid phase synthesis using traditional FMOC protection
(i.e., coupling with DCC-HOBt and deprotection with piperidine in
DMF). Cys thiol groups can be trityl protected. Treatment with TFA
can be used for final deprotection of the peptide and release of
the peptide from the solid-state resin. In many cases air oxidation
is sufficient to achieve proper disulfide bond formation.
[0321] The ability of peptides and other agents to bind and/or
agonize to the intestinal GC-C receptor can be tested, for example,
in assays such as intestinal GC-C receptor binding assays. In one
example, cells of the T84 human colon carcinoma cell line (American
Type Culture Collection (Bethesda, Md.)) are grown to confluence in
24-well culture plates with a 1:1 mixture of Ham's F12 medium and
Dulbecco's modified Eagle's medium (DMEM), supplemented with 5%
fetal calf serum. Cells used in the assay are optionally between
passages 54-60. Briefly, T84 cell monolayers in 24-well plates are
washed twice with 1 ml of binding buffer (DMEM containing 0.05%
bovine serum albumin and 25 mM HEPES, pH 7.2), then incubated for
30 min at 37.degree. C. in the presence of mature radioactively
labeled E. coli ST peptide and the test material at various
concentrations. The cells are then washed four times with 1 ml of
DMEM and solubilized with 0.5 ml/well 1N NaOH. The level of
radioactivity in the solubilized material is determined using
standard methods.
[0322] Additional examples of GC-C agonist peptides are described,
for instance, in U.S. Pat. Nos. 7,041,786; 7,304,036; 7,371,727;
7,494,979; 7,704,947; 7,799,897; 7,745,409; 7,772,188; 7,879,802;
7,910,546; 8,034,782; 8,080,526; 8,101,579; 8,114,831; 8,110,553;
8,357,775; and 8,367,800; U.S. Application Nos. 2013/0096071;
2013/0190238; 2012/0040892; 2012/0040025; 2012/0213846;
2012/0289460; 2011/0118184; 2010/0152118; 2010/0048489;
2010/0120694; 2010/0261877; 2009/0253634; 2009/0192083;
2009/0305993; and PCT Publication Nos. WO 2006/086653 and WO
2002/098912, each of which is incorporated by reference in its
entirety.
[0323] D. Soluble Guanylate Cyclase Agonists
[0324] In certain embodiments, the compound is a soluble guanylate
cyclase (sGC) agonist. Guanine nucleotidyl (guanylyl; guanylate)
cyclases (GCs) are widely distributed signal transduction enzymes
that, in response to various cellular stimuli, convert GTP into the
second messenger cyclic GMP (cGMP). There are both
membrane-associated and soluble guanylate cyclases, both of which
can increase the intracellular concentrations of cGMP.
[0325] In the enterocytes of the intestine, increased cGMP
production inhibits intestinal Na+/H+ exchange activity, resulting
in alkalinization of the intestinal mucosa. See, e.g., Fawcus et
al., Comp Biochem. Physiol A Physiol. 118:291-295, 1997. Without
being bound by any one mechanism, in certain aspects a soluble
guanylate cyclase activator inhibits or reduces phosphate uptake in
the gastrointestinal tract increasing cGMP production and thereby
increasing the alkalinization of the intestinal mucosa.
[0326] General examples of sGC agonists include heme-dependent and
heme-independent activators. See, e.g., Evgenov et al., Nat. Rev.
Drug Discov. 5:755-768, 2006. According to one non-limiting theory,
these and other sGC activators can be used to selectively activate
sGC in the intestine, increase concentrations of cGMP, and thereby
inhibit phosphate uptake as described herein.
[0327] In some embodiments, and without being bound by any one
mechanism, a sGC agonist inhibits or reduces phosphate uptake in
the gastrointestinal tract by decreasing water absorption in the
small intestine.
[0328] Non-limiting examples of sGC agonists include Bay 41-2271,
Bay 58-2667, and the compounds shown in FIGS. 9A-9L. Additional
structures of exemplary sGC agonists are disclosed, together with
methods for their synthesis, in U.S. Pat. No. 7,087,644 and PCT
Publication No. WO 2013/101830, each of which is incorporated by
reference in its entirety.
[0329] E. Adenylate Cyclase Agonists
[0330] In certain embodiments, the compound is an adenylate cyclase
agonist, optionally a selective agonist. Adenylate cyclase (or
adenylyl cyclase) refers to a class of enzymes that catalyze the
conversion of ATP to 3',5'-cyclic AMP (cAMP) and pyrophosphate.
Divalent cations (e.g., Mg) are often involved in this enzymatic
activity. The cAMP produced by adenylate cyclase serves as a
regulatory signal via specific cAMP-binding proteins, including
transcription factors or other enzymes (e.g., cAMP-dependent
kinases).
[0331] Adenylyl cyclase is the effector molecule of one of the most
widely utilized signal transduction pathways. Its product, cAMP,
modulates cell growth and differentiation in organisms from
bacteria to higher eukaryotes. In animals, there are transmembrane
adenylyl-cyclases (tmACs) and soluble adenylate cyclase (sAC). See,
e.g., Tresguerres et al., Kidney Int. 79:1277-1288, 2011. Unlike
tmACs, sACs are not transmembrane proteins and are found
distributed throughout the cytoplasm and in specific organelles
where they are thought to be the source of second messenger
mediating the intracellular functions of cAMP. See, e.g., Buck and
Levin, Sensors. (Basel) 11:2112-2128, 2011. Thus, tmACs are
directly modulated by G proteins which transduce extracellular
signals into intracellular cAMP changes. In contrast, sAC isoforms
are regulated by intracellular signals, including bicarbonate,
calcium, and ATP.
[0332] Cystic fibrosis transmembrane regulator (CFTR) is a chloride
and bicarbonate ion channel that functions at the epithelium of
multiple tissues. This channel has been shown to be in charge of
HCO.sup.3- secretion in the small intestine, where said bicarbonate
determines the pH on the surface of the mucosa. See, e.g.,
Kunzelmann and Mall, Physiol Rev. 82:245-289, 2002. CFTR is
regulated by cAMP: phosphorylation of the CFTR regulatory domain by
cAMP-dependent protein kinase A (PKA) increases its activity.
Selective activation of this ion channel can thus result in
alkalinization of the luminal membrane and thereby reduce or
decrease the CEPG. According to one non-limiting theory, selective
stimulation of tmACs in the intestinal tract should therefore
increase intracellular cAMP, stimulate PKA, increase CFTR activity
and thereby inhibit the uptake of Pi via CEPG effects. In specific
aspects, the compound selectively activates tmACs, for instance,
relative to sACs.
[0333] Adenylate cyclase agonists such as forskolin have been shown
to increase cAMP-mediated duodenal bicarbonate secretion (without
increasing gastric bicarbonate secretion), optionally via signaling
of CFTR. See, e.g., Takeuchi et al., Am. J. Physiol. 272(3 Pt
1):G646-53, 1997. Without being bound by any one mechanism, in
certain aspects an adenylate cyclase agonist inhibits or reduces
phosphate uptake in the gastrointestinal tract by stimulating
bicarbonate secretion into the small intestine. In some
embodiments, and without being bound by any one mechanism, an
adenylate cyclase agonist inhibits or reduces phosphate uptake in
the gastrointestinal tract by decreasing water absorption in the
small intestine.
[0334] In particular embodiments, the compound is an agonist of
adenylate cyclase III (AC-III), optionally an agonist of one or
more of the AC-III isoforms ADCY1, ADCY2, ADCY3, ADCY4, ADCY5,
ADCY6, ADCY7, ADCY8, ADCY9, and/or ADCY10.
[0335] Particular examples of adenylate cyclase agonists include
labdane diterpenes such as forskolin and analogs/derivatives
thereof, including water-soluble forskolin analogs such as
colforsin (NKH477). Forskolin is a diterpene compound isolated from
plants that activates all mammalian tmACs with the exception of
tmAC IX (mammalian sAC is insensitive to forskolin). See, e.g.,
Kamenetsky et al., J. Mol. Biol. 362:623-639, 2006. Forskolin
stimulation can produce potent and prolonged cAMP changes. See,
e.g., Tresguerres et al., Kidney Int. 79:1277-1288, 2011. The
structure of forskolin and several forskolin analogs is illustrated
in FIG. 10. Water soluble derivatives of forskolin include those
acylated at C-6 or C-7 with a polar aliphatic amine. These
derivatives are typically more selective for ACs, with fewer
off-target activities. See, e.g., Hartzell and Budnitz, Molecular
Pharmacology 41:880-888, 1992. Thus, certain aspects include the
use of soluble forskolin analogs that selectively activate
adenylate cyclases in the cells lining the gastrointestinal
tract.
[0336] Particular examples of forskolin analogs/derivatives include
aminoalkylcarbamyl derivatives of forskolin, including
1-aminoalkylcarbamates, 9-aminoalkylcarbamates,
7-aminoalkylcarbamates, 6-aminoalkycarbamates,
6,7-diaminoalkylcarbamates, 1,6-diaminoalkylcarbamates,
1,7-diaminoalkylcarbamates, and 1,6,7-triaminoalkylcarbamates of
forskolin, which can be used as intermediates in the synthesis of
forskolin derivatives. See U.S. Pat. No. 5,350,864. Additional
examples of forskolin analogs/derivatives include 12-halogenated
forskolin derivatives, including 12-chlorodesacetylforskolin,
12-chloroforskolin, 12-bromodesacetylforskolin,
12-bromodesacetylforskolin, 12-fluorodesacetylforskolin, and
12-fluoroforskolin. See U.S. Pat. No. 4,871,764.
[0337] In some embodiments, the forskolin analog/derivative is
6-acetyl-7-deacetyl-forskolin, 7-deacetyl-forskolin,
7-deacetyl-6-(N-acetylglycyl)-forskolin,
7-deacetyl-7-.beta.-hemisuccunyl-forskolin,
7-deacetyl-7-(O--N-methylpiperazino)-.gamma.-butryl-dihydrochlonde-forsko-
lin, 7-HPP-forskolin, 6-HPP-forskolin, or colforsin daropate
hydrochloride (NKH477). See, e.g., U.S. Application Nos.
2011/0171195, 2006/0004090, and 2011/0077292; Laurenza et al., Mol
Pharmacol. 32:133-9, 1987; Lal et al., Bioorg Med Chem. 6:2075-83,
1998; Mori et al., J. Cardiovasc. Pharmacol. 24:310-6, 2004. See
also Levin, Tetrahedon Letters. 37:3079-3082, 1996 for exemplary
methods of synthesizing forskolin analogs, and Lal et al., Indian
J. Chemistry. 45B:232-246, 2006, for additional examples of water
soluble forskolin analogs and methods of synthesizing the same.
Additional structures of exemplary adenylate cyclase agonists are
disclosed, together with methods for their synthesis, in U.S. Pat.
No. 4,954,642 and Khandelwal et al., J Med Chem. 31:1872-9, 1988.
See also Cunliffe et al., Electrophoresis. 28:1913-20, 2007 for
exemplary methods/assays of detecting agonist-stimulated adenylate
cyclase activity. These references are incorporated by reference in
their entireties.
[0338] F. Imidazoline-1 Receptor Agonists
[0339] In certain embodiments, the compound is an imidazoline-1
receptor agonist, optionally a selective agonist. Imidazoline
receptors include a family of nonadrenergic high-affinity binding
sites for clonidine, idazoxan, and other imidazoles. There are
three classes of imidazoline receptors: the I1 receptor, which
mediates the sympatho-inhibitory actions of imidazolines to lower
blood pressure; the I2 receptor, an allosteric binding site of
monoamine oxidase and is involved in pain modulation and
neuroprotection; and the I3 receptor, which regulates insulin
secretion from pancreatic beta cells. In some aspects, the compound
is a selective imidazoline-1 receptor agonist, for instance,
relative to imidazoline-2 and/or imidazoline-3 receptors.
[0340] The subclass of imidazoline-1 receptors mediate in part the
central hypotensive effects of clonidine-like drugs. According to
one non-limiting theory, activated imidazoline-1 receptors trigger
the hydrolysis of phosphatidylcholine into DAG, which then triggers
the synthesis of second messengers such as arachidonic acid and
downstream eicosanoids such as PGE.sub.2. See, e.g., Ernsberger,
Ann. NY Acad. Sci. 881:35-53 1999. PGE.sub.2 is an endogenous
inducer of DBS. See, e.g., Takeuchi et al., Gastroenterology.
113:1553-1559, 1997). Without being bound by any one mechanism, in
some aspects an imidazoline-1 receptor agonist inhibits or reduces
phosphate uptake in the gastrointestinal tract by increasing
DBS.
[0341] According to another non-limiting theory, imidazoline-1
receptor agonists such as moxonidine have also been shown to
decrease acid secretion in the gastrointestinal tract. See, e.g.,
Glavin and Smyth, Br J Pharmacol. 114:751-4, 1995. Hence, and
without being bound by any one mechanism, in certain aspects an
imidazoline-1 receptor agonist inhibits or reduces phosphate uptake
in the gastrointestinal tract by inhibiting or reducing acid
secretion in the gastrointestinal tract, e.g., the small intestine.
In specific aspects, and without being bound by any one mechanism,
an imidazoline-1 receptor agonist inhibits or reduces phosphate
uptake in the gastrointestinal tract by increasing DBS and reducing
acid secretion in the small intestine.
[0342] In some embodiments, and without being bound by any one
mechanism, an imidazoline-2 receptor agonist inhibits or reduces
phosphate uptake in the gastrointestinal tract by decreasing water
absorption in the small intestine.
[0343] Non-limiting examples of imidazoline-1 receptor agonists
include agmatine, apraclonidine, clonidine, efaroxan, moxonidine,
rilmenidine, S-23515, S-23757, LNP-509, LNP-911, LNP-509, S-23515,
PMS-812, PMS-847, BU-98008 and TVP1022 (S-enantiomer of
rasagiline). See also Head and Mayorov, Cardiovasc Hematol Agents
Med Chem. 4:17-32, 2006, incorporated by reference in its
entirety.
[0344] Structures of exemplary imidazoline receptor agonists are
shown in FIG. 11, and are further disclosed, together with methods
for their synthesis, in U.S. Pat. Nos. 4,323,570; 5,686,477;
3,988,464; 6,300,366; 5,492,912; 5,492,912; and PCT Publication No.
WO200141764, each of which is incorporated by reference in its
entirety.
[0345] Additional examples of imidazoline receptor agonists include
those described in U.S. Pat. No. 7,309,706; U.S. Pat. No. 5,686,477
(EP 710,658); U.S. Pat. No. 5,925,665 (EP 846,688); WO 2001/41764;
and WO 2000/02878. The 5-(aryloxymethyl)-oxazoline derivatives
described in U.S. Pat. No. 5,686,477 are characterized by a
selective affinity for the imidazoline-1 receptor. The imidazoline
derivatives described in U.S. Pat. No. 5,925,665 bind to
imidazoline receptors without significantly binding to adrenergic
receptors. WO 2001/41764 describes isoquinoline and quinoline
derivatives which possess an affinity for imidazoline receptors. WO
2000/02878 describes exemplary .beta.-carboline derivatives as
potential ligands for imidazoline receptors. These references are
incorporated by reference in their entireties.
[0346] G. Cholinergic Agonists
[0347] In certain embodiments, the compound is a cholinergic
agonist, optionally a selective cholinergic agonist. Examples of
cholinergic agonists include indirect cholinergic agonists, which
stimulate the production or release of acetylcholine (e.g.,
actetylcholinesterase inhibitors), and direct cholinergic agonists,
which bind to and stimulate one or more acetylcholine receptors.
The neurotransmitter acetylcholine
(2-acetoxy-N,N,N-trimethylethanaminium) is an ester of acetic acid
and choline. General examples of acetylcholine receptors include
nicotinic acetylcholine receptors and muscarinic acetylcholine
receptors. Nicotinic acetylcholine receptors are ligand-gated ion
channels composed of five protein subunits.
[0348] Muscarinic acetylcholine receptors (i.e., M1, M2, M3, M4,
and M5) are G-protein-coupled receptors that activate other ionic
channels via a second messenger cascade. These receptors are
expressed in the digestive tract including the salivary glands and
the smooth muscle and mucosal cells in the stomach and the
intestine In certain embodiments, the compound is a pan-agonist of
muscarinic receptor subtypes. The endogenous agonist of all five
muscarinic receptor subtypes is acetylcholine, which exerts
physiological control by both hormonal and neuronal mechanisms.
See, e.g., Eglen, Ann. N. Y. Acad. Sci. 881:35-53, 2012. Several
naturally-occurring compounds also modulate the muscarinic
receptors (see FIG. 12), including agonists such as muscarine (a
toxin from the mushroom Aminita muscaria and from which the
receptor family derives its name) and pilocarpine, and antagonists
such as atropine or (-)-hyoscine (from the solanaceae plant
family). When administered in vivo, muscarinic agonists elicit
salivation whereas muscarinic antagonists cause dry mouth.
[0349] In some embodiments, the compound is a relatively selective
agonist of the M3 muscarinic receptor. The secretory response of M3
is stimulated physiologically by acetylcholine (ACh). Specifically,
ACh binds to the G protein-linked M3 muscarinic ACh receptor, which
causes phospholipase C to generate inositol 1,4,5-trisphosphate
(InP3). InP3 binds to and opens the InP3 receptor on the
endoplasmic reticulum, which, according to one non-limiting theory,
releases Ca.sup.2+. Increased [Ca.sup.2+], activates the apical
membrane Cl-- channel and the basolateral K+ channel. Efflux of
Cl.sup.- into the acinar lumen draws Na+ across the cells, and the
osmotic gradient generates fluid secretion. See, e.g., Tobin et
al., J. Physiol Pharmacol. 60:3-21, 2009. This fluid is bicarbonate
rich.
[0350] Muscarinic receptor control of bicarbonate secretion has
been demonstrated repeatedly: intravascularly or subcutaneously
administered muscarinic agonists increase bicarbonate release into
the intestinal lumen, a response blocked by muscarinic antagonists.
For instance, according to one non-limiting theory, cholinergic
agonists such as bethanechol (muscarinic receptor selective
agonist), carbachol (muscarinic and nicotinic acetylcholine
receptor agonist), and McN-A-343 (M1 receptor-selective agonist)
have been shown to increase duodenal bicarbonate secretion. See,
e.g., Safsten et al., Am J Physiol. 267(1 Pt 1):G10-7, 1994.
Without being bound by any one mechanism, in certain aspects a
cholinergic agonist inhibits or reduces phosphate uptake in the
gastrointestinal tract by stimulating bicarbonate secretion into
the small intestine.
[0351] In some embodiments, and without being bound by any one
mechanism, a cholinergic agonist inhibits or reduces phosphate
uptake in the gastrointestinal tract by decreasing water absorption
in the small intestine.
[0352] In some aspects, a muscarinic receptor agonist possesses a
conformationally-constrained structure with respect to the
endogenous ligand acetylcholine, such as the
cis-trimethyl-(2-methyl-[1,3]dioxolan-4-ylmethyl)ammonium iodide
structure in FIG. 12. See, e.g., Piergentili et al., Bioorganic
& Medicinal Chemistry 15:886-896, 2007. This structure contains
a ketal in place of the labile ester of acetylcholine, which is a
bioisostere that retains both hydrogen bond acceptors of ACh but is
much more stable. Similarly, carbechol and bethanechol (also shown
in FIG. 12) are examples of agonists because these structures
replace the labile ester group of ACh with non-hydrolyzable
carbamate functionality.
[0353] Non-limiting examples of indirect-acting cholinergic
agonists include acetylcholinesterase inhibitors such as carbamates
(e.g., physostigmine, neostigmine, pyridostigmine), piperidines
(e.g., donepizil), edrophonium, huperzine A, ladostigil,
ungeremine, lactucopicrin, tacrine, galantamine,
trans-delta-9-tetrahydrocannabinol, and phosphates (e.g.,
isoflurophate, echothiophate, parathion, malathion). Preferably,
the methods provided herein will employ reversible
acetylcholinesterase inhibitors.
[0354] Non-limiting examples of direct-acting cholinergic agonists
include acetylcholine, nicotine, succinylcholine, methacholine
(acetyl-.beta.-methylcholine), McN-A-343, carbachol
(carbamoylcholine), bethanecol (carbamoyl-.beta.-methlycholine),
muscarine, pilocarpine, oxotremorine, lobeline, and
dimethylphenylpiparazinium.
[0355] H. Prostaglandin EP4 Receptor Agonists
[0356] In certain embodiments, the compound is E-type prostanoid
receptor 4 (EP4) agonist (or prostaglandin EP4 receptor agonist),
optionally a selective agonist. The EP4 receptor was initially
described as a G.sub..alpha.s protein-coupled receptor leading to
stimulation of adenylate cyclase and elevation of intracellular
cAMP levels. When first cloned as a prostaglandin E2 (PGE.sub.2)
receptor that stimulated cAMP formation, the EP4 receptor was
designated as "EP2." However, after another cAMP-stimulating
PGE.sub.2 receptor had been discovered which was sensitive to
butaprost, the butaprost-insensitive receptor which mediated
vasorelaxation was renamed "EP4." It is one of four receptors
identified for PGE.sub.2.
[0357] According to one non-limiting theory, prostaglandin EP4
receptor agonists have been shown to stimulate duodenal bicarbonate
secretion, for instance, by a mechanism that is mediated by cAMP.
See, e.g., Aoi et al., Am J Physiol Gastrointest Liver Physiol.
287:G96-103, 2004; Lundgren, Acta Physiol Scand. 185:87, 2005;
Takeuchi et al., Gastroenterology. 113:1553-1559, 1997. Hence, and
without being bound by any one mechanism, in certain aspects a
prostaglandin EP4 receptor agonist inhibits or reduces phosphate
uptake in the gastrointestinal tract by stimulating bicarbonate
secretion into the small intestine.
[0358] In some embodiments, and without being bound by any one
mechanism, an EP4 agonist inhibits or reduces phosphate uptake in
the gastrointestinal tract by decreasing water absorption in the
small intestine.
[0359] Non-limiting examples of prostaglandin EP4 receptor agonists
include PGE.sub.2, PGE.sub.2 analogs, AE1-329, AGN205203, APS-999
Na, Cay10598 (19a), CP-044519-02, CJ-023,423, EP4RAG, ER-819762,
L-902688, lubiprostone, ONO-4819CD, ONO AE1-329, ONO AE1-734,
PGE.sub.1-OH, TCS2510, .gamma.-Lactam PGE analog 3,
11-Deoxy-PGE.sub.1, .gamma.-Lactam PGE analog 2a, .gamma.-Lactam
PGE analog 4. See, e.g., Konya et al., Pharmacol Ther. 138:485-502,
2013.
[0360] Non-limiting examples of PGE.sub.2 analogs include
16,16-dimethyl PGE.sub.2, 16-16 dimethylPGE.sub.2
p-(p-acetamidobenzamido)phenyl ester, 11-deoxy-16,16-dimethyl
PGE.sub.2, 9-deoxy-9-methylene-16, 16-dimethyl PGE.sub.2,
9-deoxy-9-methylene PGE.sub.2, 9-keto fluprostenol, 5-trans
PGE.sub.2, 17-phenyl-omega-trinor PGE.sub.2, PGE.sub.2 serinol
amide, PGE.sub.2 methyl ester, 16-phenyl tetranor PGE.sub.2,
15(S)-15-methyl PGE.sub.2, 15(R)-15-methyl PGE.sub.2, 8-iso-15-keto
PGE.sub.2, 8-iso PGE.sub.2 isopropyl ester, 20-hydroxy PGE.sub.2,
11-deoxy PGEi, nocloprost, sulprostone, butaprost, 15-keto PGE2,
and 19(R) hydroxyyPGE2. See, e.g., U.S. Application No.
2012/0202288.
[0361] Additional examples of prostaglandin EP4 receptor agonists
include those described in U.S. Application Nos. 2001/0056060,
2002/0040149, 2005/0164949, and 2011/0098481. Also included are
prostaglandin EP4 receptor agonists described (along with related
methods of synthesis) in U.S. Pat. Nos. 4,219,479; 4,049,582;
4,423,067; 4,474,802; 4,692,464; 4,708,963; 5,010,065; 5,013,758;
6,747,037; and 7,776,896; European Patent No. EP0084856; Canadian
Patent No. 1248525; U.S. Application Nos. 2004/0102499,
2005/049227, 2005/228185, 2006/106088, 2006/111430, 2007/0010495,
2007/0123568, 2007/0123569, 2005/0020686, 2008/0234337,
2010/0010222, 2010/0216689, 2004/0198701, 2004/0204590,
2005/0227969, 2005/0239872, 2006/0154899, 2006/0167081,
2006/0258726, 2006/0270721, 2009/0105234, 2009/0105321,
2009/0247596, 2009/0258918, 2009/0270395, 2004/0087624,
2004/0102508, 2006/0252799, 2009/0030061, 2009/0170931,
2010/0022650, 2009/0312388, 2009/0318523, 2010/0069457,
2010/0076048, 2007/0066618, 2004/0259921, 2005/0065133, and
2007/0191319; and PCT Publication Nos. WO 2004/4071428, WO
2006/052630, WO 2006/047476, WO 2006/058080, WO 2004/065365, WO
2003/047513, WO 2004/085421, WO 2004/085430, WO 2005/116010, WO
2005/116010, WO 2007/014454, WO 2006/080323, and WO 2006/137472,
each of which is incorporated by reference in its entirety.
[0362] Particular examples of EP4 receptor agonists are shown in
FIG. 13.
[0363] In specific embodiments, the EP4 receptor agonist is
lubiprostone (also a calcium-activated chloride channel agonist).
Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1
that acts by specifically activating C1C-2 chloride channels on the
apical aspect of gastrointestinal epithelial cells, producing a
chloride-rich fluid secretion. These secretions soften the stool,
increase motility, and promote spontaneous bowel movements (SBM).
Lubiprostone stimulates CFTR-dependent duodenal bicarbonate
secretion without changing net Cl-- secretion. See, e.g., Muzimori
et al., J Physiol. 573:827-842, 2006. Here, lubiprostone-induced
duodenal bicarbonate secretion was abolished by the co-perfusion of
the potent EP4 receptor antagonist AH23848, whereas an EP1/EP2
receptor antagonist AH6809 had no effect. These results suggest
that lubiprostone can increase duodenal bicarbonate secretion by
agonizing the prostaglandin EP4 receptor. Hence, in certain aspects
lubiprostone inhibits or reduces phosphate uptake in the
gastrointestinal tract by stimulating bicarbonate secretion into
the small intestine.
[0364] As noted above, certain aspects include a prostaglandin EP4
receptor selective agonist. EP4 selective agonists include
compounds having an IC.sub.50 at the EP1, EP2, and/or EP3 receptor
subtypes which is at least 5, at least 10, at least 20, at least
30, at least 40, or at least 50-fold greater than the IC.sub.50 at
the EP4 receptor subtype.
[0365] I. Dopamine D1 Receptor Agonists
[0366] In certain embodiments, the compound is a dopamine D-1
receptor agonist, optionally a selective agonist. The dopamine D1 G
protein-coupled receptor is the most highly expressed dopamine
receptor subtype among the dopamine receptor family. It stimulates
adenylate cyclase and activates cyclic AMP-dependent protein
kinases.
[0367] Based on one non-limiting theory, dopamine D1 receptor
agonists and the peripherally acting catechol-O-methyl-transferase
(COMT) inhibitor nitecapone (COMT inhibitors decrease tissue
degradation of catecholamines, including dopamine) have been shown
to stimulate bicarbonate secretion in the gut and increase the
production of cyclic AMP in isolated duodenal enterocytes. See,
e.g., Flemstrom and Safsten, Dig Dis Sci. 39:1839-42, 1994; and
Knutson et al., Gastroenterology. 104:1409-13 1993; Iwatsuki et
al., Eur J Pharmacol. 218:237-41, 1992; and Fraga et al., Cell
Physiol Biochem. 18:347-60, 2006. Without being bound by any one
mechanism, in certain aspects a dopamine D1 receptor agonist
inhibits or reduces phosphate uptake in the gastrointestinal tract
by stimulating bicarbonate secretion into the small intestine.
[0368] In some embodiments, and without being bound by any one
mechanism, a dopamine D1 agonist inhibits or reduces phosphate
uptake in the gastrointestinal tract by decreasing water absorption
in the small intestine.
[0369] Non-limiting examples of dopamine D1 receptor agonists
include dopamine (e.g., dopamine hydrochloride, NPEC-caged
dopamine), dihydrexidine (e.g., dihydrexidine hydrochloride),
benzazepaine, and analogs/derivatives thereof. Specific examples of
dihydrexidine derivatives include A86929, dinapsoline, dinoxyline
and doxanthrine, and specific examples of benzazepine derivatives
include SKF81297, SKF82958, SKF38393, fenoldopam, and 6-Br-APB.
Also included are the dopamine D1 receptor agonists shown in FIG.
14.
[0370] Additional non-limiting examples of dopamine D1 receptor
agonists include A68930, A77636, (R)-(-)-apomorphine hydrochloride,
CY208-243, SKF89145, SKF89626,
7,8-Dihydroxy-5-phenyl-octahydrobenzo[h]isoquinoline, YM435,
ABT-431, NNC01-0012, SCH23390, SKF7734, SKF81297, SKF38322,
SKF83959, cabergoline, fenoldopam (e.g., fenoldapam hydrochloride),
bromocriptine, ropinirole, pramipexole, entacapone, tolcapone,
dihexadine, IPX-750, and pergolide. See also Zhang et al., Med Res
Rev. 29:272-94, 2009; Yvonne Connolly Martin, International Journal
of Medicinal Chemistry, vol. 2011, Article ID 424535, 8 pages,
2011. doi:10.1155/2011/424535; Salmi et al., CNS Drug Rev.
10:230-42, 2004; Bourne, CNS Drug Rev. 7:399-414, 2001. Moreover,
D1 receptor agonists can be identified using standard screening
methods known in the art. As a non-limiting example, a cell based
functional assay for high-throughput drug screening for dopamine D1
receptor agonists is described in Jiang et al., Acta Pharmacol Sin.
26:1181-6, 2005. These references are incorporated by reference in
their entireties.
[0371] As noted above, certain aspects include a dopamine D1
receptor selective agonist. Dopamine D1 selective agonists include
compounds having an IC.sub.50 at the D2, D3, D4, and/or D5 receptor
subtypes which is at least 5, at least 10, at least 20, at least
30, at least 40, or at least 50-fold greater than the IC.sub.50 at
the D1 receptor subtype.
[0372] J. Melatonin Receptor Agonists
[0373] In certain embodiments, the compound is a melatonin receptor
agonist, optionally a selective agonist. Melatonin receptors refer
to a family of high-affinity G protein-coupled receptors which bind
to the pineal hormone melatonin. See Reppert, Biol Rhythms.
0.12:528-31, 1997.
[0374] Examples of melatonin receptors include the MT1 and MT2
receptors. In some aspects, the melatonin receptor agonists binds
to both of the MT1 and MT2 receptors. In some embodiments, the
melatonin receptor agonist binds selectively to the MT1 or MT2
receptor, e.g., binds to MT2 but not significantly to MT1, or binds
to MT1 but not significantly to MT2.
[0375] According to non non-limiting theory, melatonin receptor
agonists such as melatonin have been shown to stimulate duodenal
bicarbonate secretion, for example, via action at enterocyte
MT2-receptors. See, e.g., Sjoblom et al., J Clin Invest.
108:625-33, 2001; Sjoblom and Flemstrom, J. Pineal Res. 34:288-293,
2003. Without being bound by any one mechanism, in certain aspects
a melatonin receptor agonist inhibits or reduces phosphate uptake
in the gastrointestinal tract by stimulating bicarbonate secretion
into the small intestine.
[0376] In some embodiments, and without being bound by any one
mechanism, a melatonin receptor agonist inhibits or reduces
phosphate uptake in the gastrointestinal tract by decreasing water
absorption in the small intestine.
[0377] Examples of melatonin receptor agonists include melatonin
(N-acetyl-5-methoxytryptamine) and melatonin analogs which bind to
and activate the melatonin receptor. The general structure of
melatonin comprises an indole ring with methoxy group at position 5
(5-methoxy group) and an acylaminoethyl side-chain at position 3;
the two side-chains contribute to binding to and activating the
melatonin receptor(s). The indole ring has been evaluated at all
positions by the effect of substitutions. See, e.g., Rivara et al.,
Curr Top Med Chem. 8:954-68, 2008; and Sugen et al., Pigment Cell
Research. 17:454-460, 2004.
[0378] Particular examples of melatonin receptor agonists include
2-iodomelatonin, 6-chloromelatonin, 6,7-dichloro-2-methylmelatonin
and 8-hydroxymelatonin, all of which contain the 5-methoxy indole
ring as a moiety, in addition to circadin, agomelatine, ramelteon,
tasimelteon, beta-methyl-6-chloromelatonin (TIK-301 or LY156735),
TAK-375, VEC-162, GR196429, S20242, S23478, S24268, S25150,
GW290569, BMS-214778, 8-methoxy-2-chloroacetamidotetralin,
8-methoxy-2-propionamido-tetralin, N-acetyltryptamine,
6-chloromelatonin, 2-iodomelatonin, 8-M-PDOT, and
2-phenylmelatonin. See, e.g., U.S. Application No. 2005/0164987,
which is incorporated by reference in its entirety. Also included
are the exemplary melatonin receptor (MT2) agonists shown in FIG.
15.
[0379] Methods of screening for melatonin receptor agonists are
described, for example, in U.S. Application No. 2003/0044909, which
is incorporated by reference in its entirety.
[0380] K. 5HT4 Receptor Agonists
[0381] In certain embodiments, the compound is a 5HT4 receptor
agonist, optionally a selective agonist. The 5-hydroxytryptamine
receptor 4 (5HT4) is a G protein-coupled serotonin receptor, which
stimulates cAMP production in response to serotonin
(5-hydroxytryptamine or 5-HT) or other agonist.
[0382] Based on one non-limiting theory, serotonin has been shown
to increases protective duodenal bicarbonate secretion, for
example, via enteric ganglia, cAMP- and Ca2+-dependent signaling
pathways, and a 5HT4-dependent pathway. See, e.g., Safsten et al.,
Scand J Gastroenterol. 41:1279-89, 2006; Tuo et al., Am J Physiol
Gastrointest Liver Physiol 286:G444-G451, 2004. Without being bound
by any one mechanism, in certain aspects a 5HT4 receptor agonist
inhibits or reduces phosphate uptake in the gastrointestinal tract
by stimulating bicarbonate secretion into the small intestine.
[0383] In some embodiments, and without being bound by any one
mechanism, a 5HT4 agonist inhibits or reduces phosphate uptake in
the gastrointestinal tract by decreasing water absorption in the
small intestine.
[0384] Non-limiting examples of 5HT4 agonists include serotonin and
its analogs, BIMU-8, cisapride, cleobopride, CL033466, ML10302,
mosapride, prucalopride, renzapride, RS67506, RS67333, SL650155,
tegaserod, zacopride, naronopride (ATI-7505), velusetrag
(TD-5108).
[0385] In some embodiments, the 5HT4 receptor agonist or partial
agonist is a substituted benzamide, such as cisapride, including
individual or combinations of cisapride enantiomers ((+) cisapride
and (-) cisapride), mosapride, or renzapride. In some embodiments,
the 5HT4 receptor agonist is a benzofuran derivative, such as
prucalopride, an indole such as tegaserod, or a benzimidazolone.
Other non-limiting examples of 5HT4 receptor agonists or partial
agonists include zacopride (CAS RN 90182-92-6), SC-53116 (CAS RN
141196-99-8) and its racemate SC-49518 (CAS RN 146388-57-0), BIMU1
(CAS RN 127595-43-1), TS-951 (CAS RN 174486-39-6), ML10302 (CAS RN
148868-55-7), metoclopramide, 5-methoxytryptamine, RS67506,
2-[1-(4-piperonyl)piperazinyl]benzothiazole, RS66331, BIMU8, SB
205149 (the n-butyl quaternary analog of renzapride), and an indole
carbazimidamide described in Buchheit et al., J Med. Chem.
38:2331-8, 1995. Also included are norcisapride (CAS RN
102671-04-5), which is the metabolite of cisapride; mosapride
citrate; the maleate form of tegaserod (CAS RN 189188-57-6);
zacopride hydrochloride (CAS RN 99617-34-2); mezacopride (CAS RN
89613-77-4); SK-951
((+-)-4-amino-N-(2-(1-azabicyclo(3.3.0)octan-5-yl)ethyl)-5-chloro-2,3-dih-
ydro-2-methylbenzo[b]furan-7-carboxamide hemifumarate); ATI-7505, a
cisapride analog; SDZ-216-454, a selective 5HT4 receptor agonist
that stimulates cAMP formation in a concentration dependent manner
(see, e.g., Markstein et al., Naunyn-Schmiedebergs Arch Pharmacol.
359:454-9, 1999); SC-54750, or aminomethylazaadamantane; Y-36912,
or
4-amino-N-[1-[3-(benzylsulfonyl)propyl]piperidin-4-ylmethyl]-5-chloro-2-m-
ethoxybenzamide (see Sonda et al., Bioorg Med. Chem. 12:2737-47,
2004); TKS159, or
4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidi-
nyl]benzamide; RS67333, or
1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-n-butyl-4-piperidinyl)-1-propan-
one; KDR-5169, or
4-amino-5-chloro-N-[1-(3-fluoro-4-methoxybenzyl)piperidin-4-yl]-2-(2-hydr-
-oxyethoxy)benzamide hydrochloride dihydrate (see Tazawa, et al.,
Eur J Pharmacol. 434: 169-76, 2002); SL65.0155, or
5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-[1-(2-phenylethyl-
)-4-piperidinyl]-1,3,4-oxadiazol-2 (3H)-one monohydrochloride; and
Y-34959, or
4-amino-5-chloro-2-methoxy-N-[1-[5-(1-methylindol-3-ylcarbonylamino)penty-
l]piperidin-4-ylmethyl]benzamide.
[0386] Additional examples of 5HT4 receptor agonists and partial
agonists metoclopramide (CAS RN 364-62-5), 5-methoxytryptamine (CAS
RN 608-07-1), RS67506 (CAS RN 168986-61-6),
2-[1-(4-piperonyl)piperazinyl]benzothiazole (CAS RN 155106-73-3),
RS66331 (see Buccafusco et al., Pharmacology. 295:438-446, 2000);
BIMU8 (endo-N-8-methyl-8-azabicyclo[3
0.2.1]oct-3-yl)-2,3-dehydro-2-oxo-3-(prop-2-yl)-1H-benzimid-azole-1-carbo-
xamide), or SB 205149 (the n-butyl quaternary analog of
renzapride). Also included are compounds related to metoclopramide,
such as metoclopramide dihydrochloride (CAS RN 2576-84-3),
metoclopramide dihydrochloride (CAS RN 5581-45-3), and
metoclopramide hydrochloride (CAS RN 7232-21-5 or 54143-57-6). See,
e.g., U.S. Application No. 2009/0325949; De Maeyer et al.,
Neurogastroenterology and Motility. 20:99-112, 2008; Manabe et al.,
Expert Opin Investig Drugs. 19:765-75, 2010; Tack et al.,
Alimentary Pharmacology & Ther. 35:745-767, 2012. These
references are incorporated by reference in their entireties.
[0387] L. Atrial Natriuretic Peptide Receptor Agonists
[0388] In some embodiments, the compound is an atrial natriuretic
peptide (NP) receptor agonist. NP receptors are single
transmembrane catalytic receptors with intracellular guanylyl
cyclase (GC) activity. There are three isoforms of NP receptors;
NPR1, NPR2 and NPR3. These receptors have conserved catalytic and
regulatory domains and divergent ligand binding domains.
[0389] Natriuretic peptide receptors are found in the brain,
vasculature kidney, and gastrointestinal tract and bind
.alpha.-atrial natriuretic peptide, brain natriuretic peptide, and
type C-natriuretic peptide with varying affinities. The main
physiological role of NP receptors is the homeostasis of body fluid
volume. According to one non-limiting theory, exogenous natriuretic
peptide stimulates GC activity in the gastrointestinal tract. See,
e.g., Rambotti et al., Histochem. J. 29:117-126, 1997.
[0390] Without being bound by any one mechanism, in certain aspects
an NP receptor agonist inhibits or reduces phosphate uptake in the
gastrointestinal tract by stimulating bicarbonate secretion and/or
inhibiting acid secretion in the small intestine.
[0391] In some embodiments, and without being bound by any one
mechanism, an NP receptor agonist inhibits or reduces phosphate
uptake in the gastrointestinal tract by decreasing water absorption
in the small intestine.
[0392] The structures of exemplary peptide agonists of the NP
receptor(s) are shown in FIG. 16, and described, for example, in
von Geldern et al., J. Med. Chem. 35:808-816, 1992, which is
incorporated by reference in its entirety.
[0393] In certain embodiments, the NP receptor agonist comprises,
consists, or consists essentially of the atrial natriuretic peptide
amino acid sequence: Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg
Ile Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
(SEQ ID NO:7), including active variants thereof having 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, or 12 deletions, insertions, and/or
substitutions. Specific examples of deletion mutants include those
having the sequence; Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala
Gln Ser Gly Leu Gly Cys (SEQ ID NO:8); and Ser Ser Cys Phe Gly Gly
Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg
(SEQ ID NO:9). As described elsewhere herein, such peptides can be
composed of any combination of naturally-occurring and
non-naturally-occurring amino acids.
[0394] M. Carbonic Anhydrase Inhibitors
[0395] In some embodiments, the compound is a carbonic anhydrase
inhibitor. Bicarbonate uptake into epithelial cells occurs by
CO.sub.2 diffusion with subsequent conversion to HCO.sub.3.sup.-
and H.sup.+ by cellular carbonic anhydrase (CA). Bicarbonate is
then secreted across the apical membrane by anion exchange. CA is
the enzyme that hydrates CO.sub.2 to produce HCO.sub.3.sup.- and
H.sup.+ and is present in most tissues, including duodenal
epithelial cells. See, e.g., Kaunitz and Akiba, 2006. This
endogenously produced HCO.sub.3.sup.- is a significant source of
transported bicarbonate.
[0396] There are at least 15 isoforms of carbonic anhydrase.
Carbonic anhydrase IV (CAIV) is a membrane-bound isoform, while
CAII is cytosolic, ubiquitous and highly active (turnover rate
.about.10.sup.6 s.sup.-1). See, e.g., Shandro and Casey, 2007.
Carbonic anhydrase II appears to be functionally coupled--directly
and indirectly--with bicarbonate transporting proteins such as
CFTR, SLC26A6 and DRA. See, e.g., Seidler and Sjoblom, 2012. In
general, the COOH-terminal tail of all bicarbonate transport
proteins, with the exception of DRA, possesses a consensus carbonic
anhydrase II-binding motif. See, e.g., Dudeja and Ramaswamy,
2006.
[0397] Carbonic anhydrases are involved in several physiological
processes, including pH homeostasis. The classical carbonic
anhydrase inhibitors, such as acetazolamide and benzolamide, have
been shown to inhibit multiple CA isoforms, including CAII and
CAIV. See, e.g., Scozzafava et al., J. Med. Chem. 45:1466-1476,
2002. According to one non-limiting theory, inhibition of carbonic
anhydrase would be expected to decrease subapical intracellular
pH.sub.i. Without being bound by any one mechanism, selective
inhibition of CA in the enterocytes of the duodenum could thereby
decrease the CEPG, resulting in a decrease in phosphate
transport.
[0398] In some embodiments, and without being bound by any one
mechanism, a carbonic anhydrase inhibitor inhibits or reduces
phosphate uptake in the gastrointestinal tract by decreasing water
absorption in the small intestine.
[0399] FIG. 17 shows the structures of exemplary carbonic anhydrase
inhibitors, including dorzolamide and brinzolamide, among others.
In certain aspects, carbonic anhydrase inhibitors can be used in
combination with classes of compounds capable of elevating cAMP,
cGMP, calcium or other second messengers in apical mucosal cells of
the gastrointestinal tract.
[0400] N. Phosphodiesterase Inhibitors
[0401] In some embodiments, the compound is a phosphodiesterase
inhibitor. Phosphodiesterases (PDEs) are a family of related
phosphohydrolyases that selectively catalyze the hydrolysis of 3'
cyclic phosphate bonds in adenosine and/or guanine 3',5' cyclic
monophosphate (cAMP and/or cGMP). They regulate the cellular
levels, localization and duration of action of these second
messengers by controlling the rate of their degradation.
[0402] There are 11 subtypes of PDEs, named PDE1-11; PDE4, 7 and 8
selectively degrade cAMP, PDE5, 6 and 9 selectively degrade cGMP
and PDE1, 2, 3, 10 and 11 degrade both cyclic nucleotides. PDEs are
expressed ubiquitously, with each subtype having a specific tissue
distribution. FIG. 18 shows the structures of exemplary
phosphodiesterase inhibitors with varied subtype specificity,
including theophylline, cilostazol, vinpocetine, amrinone, EHNA,
trequinsin, drotaverine, roflumilast, and sildenafil.
[0403] According to one non-limiting theory, phosphodiesterase
inhibitors are capable of modulating duodenal bicarbonate secretion
(DBS) alone and in combination with agents that increase cytosolic
cAMP and cGMP by maintaining the level of these second messengers
in enterocytes. PDE1 and PDE3 inhibitors are specifically
implicated in modulating DBS. See, e.g., Hayashi, Biochem.
Pharmacol. 74:1507-1513, 2007. Without being bound by any one
mechanism, in certain embodiments a phosphodiesterase inhibitor
inhibits or reduces phosphate uptake in the gastrointestinal tract
by stimulating bicarbonate secretion into the small intestine or
DBS.
[0404] In some embodiments, and without being bound by any one
mechanism, a phosphodiesterase inhibitor inhibits or reduces
phosphate uptake in the gastrointestinal tract by decreasing water
absorption in the small intestine.
[0405] In certain embodiments, PDE inhibitors slow the degradation
of cyclic AMP (cAMP) and/or cyclic GMP (cGMP), which can then lead
to a relative increase in the intracellular concentration of cAMP
and/or cGMP. General examples include PDE1 inhibitors, PDE3
inhibitors, PDE4 inhibitors, PDE5 inhibitors, PDE3/4 inhibitors,
and PDE3/4/5 inhibitors. Merely by way of non-limiting example, PDE
inhibitors may include those disclosed in the following patent
applications and patents: DE1470341, DE2108438, DE2123328,
DE2305339, DE2305575, DE2315801, DE2402908, DE2413935, DE2451417,
DE2459090, DE2646469, DE2727481, DE2825048, DE2837161, DE2845220,
DE2847621, DE2934747, DE3021792, DE3038166, DE3044568, DE3142982,
DE1116676, DE2162096, EP000718, EP0008408, EP0010759, EP0059948,
EP0075436, EP0096517, EP0112987, EP0116948, EP0150937, EP0158380,
EP0161632, EP0161918, EP0167121, EP0199127, EP0220044, EP0247725,
EP0258191, EP0272910, EP0272914, EP0294647, EP0300726, EP0335386,
EP0357788, EP0389282, EP0406958, EP0426180, EP0428302, EP0435811,
EP0470805, EP0482208, EP0490823, EP0506194, EP0511865, EP0527117,
EP0626939, EP0664289, EP0671389, EP0685474, EP0685475, EP0685479,
EP0293063, EP0463756, EP0482208, EP0579496, EP0667345, EP0163965,
EP0393500, EP0510562, EP0553174, JP92234389, JP94329652,
JP95010875, U.S. Pat. Nos. 4,963,561; 5,141,931; and 6,331,543;
International Patent Application Publication Nos. WO9117991,
WO9200968, WO9212961, WO9307146, WO9315044, WO9315045, WO9318024,
WO9319068, WO9319720, WO9319747, WO9319749, WO9319751, WO9325517,
WO9402465, WO9406423, WO9412461, WO9420455, WO9422852, WO9425437,
WO9427947, WO9500516, WO9501980, WO9503794, WO9504045, WO9504046,
WO9505386, WO9508534, WO9509623, WO9509624, WO9509627, WO9509836,
WO9514667, WO9514680, WO9514681, WO9517392, WO9517399, WO9519362,
WO9522520, WO9524381, WO9527692, WO9528926, WO9535281, WO9535282,
WO9600218, WO9601825, WO9602541, WO9611917, WO9307124, WO9501338
and WO9603399; and U.S. Application No. 2005/0004222 (including
those disclosed in formulas I-XIII and paragraphs 37-39, 85-0545
and 557-577), each of which is incorporated by reference in its
entirety.
[0406] Examples of PDE5 inhibitors include RX-RA-69, SCH-51866,
KT-734, vesnarinone, zaprinast, SKF-96231, ER-21355, BF/GP-385,
NM-702 and sildenafil (Viagra.RTM.). Examples of PDE4 inhibitors
include RO-20-1724, MEM 1414 (R1533/R1500; Pharmacia Roche),
DENBUFYLLINE, ROLIPRAM, OXAGRELATE, NITRAQUAZONE, Y-590, DH-6471,
SKF-94120, MOTAPIZONE, LIXAZINONE, INDOLIDAN, OLPRINONE, ATIZORAM,
KS-506-G, DIPAMFYLLINE, BMY-43351, ATIZORAM, AROFYLLINE,
FILAMINAST, PDB-093, UCB-29646, CDP-840, SKF-107806, PICLAMILAST,
RS-17597, RS-25344-000, SB-207499, TIBENELAST, SB-210667,
SB-211572, SB-211600, SB-212066, SB-212179, GW-3600, CDP-840,
MOPIDAMOL, ANAGRELIDE, IBUDILAST, AMRINONE, PIMOBENDAN, CILOSTAZOL,
QUAZINONE, and
N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy4-difluoromethoxybenzamide-
. Examples of PDE3 inhibitors include SULMAZOLE, AMPIZONE,
CILOSTAMIDE, CARBAZERAN, PIROXIMONE, IMAZODAN, CI-930, SIGUAZODAN,
ADIBENDAN, SATERINONE, SKF-95654, SDZ-MKS-492, 349-U-85, EMORADAN,
EMD-53998, EMD-57033, NSP-306, NSP-307, REVIZINONE, NM-702,
WIN-62582 and WIN-63291, ENOXIMONE, and MILRINONE. Examples of
PDE3/4 inhibitors include BENAFENTRINE, TREQUINSIN, ORG-30029,
ZARDAVERINE, L-686398, SDZ-ISQ-844, ORG-20241, EMD-54622, and
TOLAFENTRINE. Other examples of PDE inhibitors include cilomilast,
pentoxifylline, roflumilast, tadalafil (Cialis.RTM.), theophylline,
vardenafil (Levitra.RTM.), and zaprinast (PDE5 specific).
[0407] In certain aspects, phosphodiesterase inhibitors can be used
in combination with classes of compounds capable of elevating cAMP,
cGMP, calcium or other second messengers in apical mucosal cells of
the gastrointestinal tract.
[0408] O. Agonists of DRA (SLC26A3)
[0409] In certain embodiments, the compound is an agonist of the
chloride/bicarbonate antiporter SLC26A3, also referred to as
Down-Regulated in Adenoma (DRA). One non-limiting function of DRA
in the gut is to absorb luminal chloride and secrete bicarbonate
ions. Pharmacological stimulation of DRA is expected reduce pHi,
for instance, by increasing the pH of the UWL, and provide a
phosphate lowering effect as described herein.
[0410] Examples of DRA agonists include lysophosphatic acid (LPA)
and structurally related compounds. This class of compounds is
thought to be acting on DRA activity via stimulation of LPA
receptor (for instance LPA2) signaling through the Pi3K/AKT
pathway, which is thought to not only activate DRA gene
transcription but also increase DRA surface accumulation (Singla et
al. Am. J. Physiol Gastrointest. Liver Physiol. 298: G182-G189,
2010; Singla et al. Am. J. Physiol. Gastrointest. Liver Physiol.
302: G618-G627, 2012). Examples of LPA related compounds with
potential role in DRA stimulation are described in Jiang et al.,
Bioorg. Med. Chem. Lett. 23:1865-1869, 2013; Kiss et al., Molecular
Pharmacology 82:1162-1173, 2012; Kozian et al., Bioorg. Med. Chem.
Lett. 22: 5239-5243, 2012; Parrill, Expert. Opin. Ther. Pat.
21:281-286, 2011; Gupte et al., Bioorg. Med. Chem. Lett. 20:
7525-7528, 2010; Liliom et al., Biochim. Biophys. Acta
1761:1506-1514, 2006; and Durgam et al., Journal of Medicinal
Chemistry 48: 4919-4930, 2005.
[0411] According to one non-limiting theory, protein Kinase C
inhibitors may also increase DRA activity and similarly create a
cross-epithelial pH gradient. For example, phorbol 12-myristate
13-acetate (PMA), an in vitro PKC agonist, was shown to directly
inhibit the apical membrane Cl.sup.-/HCO.sub.3.sup.- activity (Gill
et al., Physiology of the Gastrointestinal Tract, Chapter 67,
2012). Without being bound by any one mechanism, inhibition of the
appropriate PKC isoforms could conversely increase
Cl.sup.-/HCO.sub.3.sup.- activity and thereby inhibit phosphate
uptake via the mechanisms described in the disclosure.
[0412] FIGS. 21A-B (Mochly-Rosen et al., Nature Reviews Drug
Discovery 11, 937-957, 2012) depict representative examples of
subtype selective PKC inhibitors with the potential to increase
Cl.sup.-/HCO.sub.3.sup.- activity, among other potential mechanisms
of action. Other potential DRA agonists include All-trans-retinoic
acid (ATRA) and related compounds, more generally compounds
activating the retinoic acid receptors (RAR's) .alpha., .beta. and
.gamma., preferably the RAR-13. RAR-13 agonists are believed to
induce DRA at the transcriptional level (All-Trans-Retinoic Acid
Increases SLC26A3 (DRA) Expression via HNF-1 (Priyamvada et al.,
DDW 2013, Orlando). Another exemplary compound is 520787, which was
shown to stimulate the activity of human DRA expressed in oocytes
(Chernova et al., J. Physiol., 549, 1, 3-19, 2003). Agonists of
neuropeptide Y1 and Y2 receptor stimulate DRA activity in caco2
monolayers. Stimulation DRA by NPY was found to be independent of
membrane trafficking and associated with localization of DRA to
lipid rafts (Saksena et al. Am. J. Physiol Gastrointest Liver
Physiol. 299: G1334-G1343, 2010). Examples of representative NPY1
and NPY2 agonists include NPY, [Leu31, Pro34]-NPY, NPY 13-36,
Peptide YY (3-36) and GR 231118.
II. Substantially Systemically Non-Bioavailable Compounds
[0413] A. Physical and Performance Properties of Compounds
Localizable to the GI Tract
[0414] Certain of the compounds described herein are designed to be
substantially active or localized in the gastrointestinal lumen of
a human or animal subject. The term "gastrointestinal lumen" is
used interchangeably herein with the term "lumen," to refer to the
space or cavity within a gastrointestinal tract (GI tract, which
can also be referred to as the gut), delimited by the apical
membrane of GI epithelial cells of the subject. In some
embodiments, the compounds are not absorbed through the layer of
epithelial cells of the GI tract (also known as the GI epithelium).
"Gastrointestinal mucosa" refers to the layer(s) of cells
separating the gastrointestinal lumen from the rest of the body and
includes gastric and intestinal mucosa, such as the mucosa of the
small intestine. A "gastrointestinal epithelial cell" or a "gut
epithelial cell" as used herein refers to any epithelial cell on
the surface of the gastrointestinal mucosa that faces the lumen of
the gastrointestinal tract, including, for example, an epithelial
cell of the stomach, an intestinal epithelial cell, a colonic
epithelial cell, and the like.
[0415] "Substantially systemically non-bioavailable" and/or
"substantially impermeable" as used herein (as well as variations
thereof) generally refer to situations in which a statistically
significant amount, and in some embodiments essentially all of the
compound remains in the gastrointestinal lumen. For example, in
accordance with one or more embodiments of the present disclosure,
preferably at least about 60%, about 70%, about 75%, about 80%,
about 85%, about 90%, about 95%, about 96%, about 97%, about 98%,
about 99%, or even about 99.5%, of the compound remains in the
gastrointestinal lumen. In such cases, localization to the
gastrointestinal lumen refers to reducing net movement of a
compound across a gastrointestinal layer of epithelial cells, for
example, by way of both transcellular and paracellular transport,
as well as by active and/or passive transport. The compound in such
embodiments is hindered from net permeation of a layer of
gastrointestinal epithelial cells in transcellular transport, for
example, through an apical membrane of an epithelial cell of the
small intestine. The compound in these embodiments is also hindered
from net permeation through the "tight junctions" in paracellular
transport between gastrointestinal epithelial cells lining the
lumen.
[0416] In this regard it is to be noted that, in one particular
embodiment, the compound is essentially not absorbed at all by the
GI tract or gastrointestinal lumen. As used herein, the terms
"substantially impermeable" or "substantially systemically
non-bioavailable" includes embodiments where no detectable amount
of absorption or permeation or systemic exposure of the compound is
detected, using means generally known in the art.
[0417] In this regard it is to be further noted, however, that in
alternative embodiments "substantially impermeable" or
"substantially systemically non-bioavailable" provides or allows
for some limited absorption in the GI tract, and more particularly
the gut epithelium, to occur (e.g., some detectable amount of
absorption, such as for example at least about 0.1%, 0.5%, 1% or
more and less than about 30%, 20%, 10%, 5%, etc., the range of
absorption being for example between about 1% and 30%, or 5% and
20%, etc.); stated another way, "substantially impermeable" or
"substantially systemically non-bioavailable" may refer to
compounds that exhibit some detectable permeability to an
epithelial layer of cells in the GI tract of less than about 20% of
the administered compound (e.g., less than about 15%, about 10%, or
even about 5%, 4%, 3%, or 2%, and for example greater than about
0.5%, or 1%), but then are cleared by the liver (i.e., hepatic
extraction) and/or the kidney (i.e., renal excretion).
[0418] In this regard it is to be further noted, that in certain
embodiments, due to the substantial impermeability and/or
substantial systemic non-bioavailability of the compounds of the
present invention, greater than about 50%, 60%, 70%, 80%, 90%, or
95% of a compound of the invention is recoverable from the feces
over, for example, a 24, 36, 48, 60, 72, 84, or 96 hour period
following administration to a subject in need thereof. In this
respect, it is understood that a recovered compound can include the
sum of the parent compound and its metabolites derived from the
parent compound, e.g., by means of hydrolysis, conjugation,
reduction, oxidation, N-alkylation, glucuronidation, acetylation,
methylation, sulfation, phosphorylation, or any other modification
that adds atoms to or removes atoms from the parent compound, where
the metabolites are generated via the action of any enzyme or
exposure to any physiological environment including, pH,
temperature, pressure, or interactions with foodstuffs as they
exist in the digestive milieu.
[0419] Measurement of fecal recovery of compound and metabolites
can be carried out using standard methodology. For example, a
compound can be administered orally at a suitable dose (e.g., 10
mg/kg) and feces are then collected at predetermined times after
dosing (e.g., 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 96
hours). Parent compound and metabolites can be extracted with
organic solvent and analyzed quantitatively using mass
spectrometry. A mass balance analysis of the parent compound and
metabolites (including, parent=M, metabolite 1 [M+16], and
metabolite 2 [M+32]) can be used to determine the percent recovery
in the feces.
[0420] (i) Permeability
[0421] In this regard it is to be noted that, in various
embodiments, the ability of the compound to be substantially
systemically non-bioavailable is based on the compound charge,
size, and/or other physicochemical parameters (e.g., polar surface
area, number of hydrogen bond donors and/or acceptors therein,
number of freely rotatable bonds, etc.). More specifically, it is
to be noted that the absorption character of a compound can be
selected by applying principles of pharmacokinetics, for example,
by applying Lipinski's rule, also known as "the rule of five."
Although not a rule, but rather a set of guidelines, Lipinski shows
that small molecule drugs with (i) a molecular weight, (ii) a
number of hydrogen bond donors, (iii) a number of hydrogen bond
acceptors, and/or (iv) a water/octanol partition coefficient
(Moriguchi Log P), greater than a certain threshold value,
generally do not show significant systemic concentration (i.e., are
generally not absorbed to any significant degree). (See, e.g.,
Lipinski et al., Advanced Drug Delivery Reviews, 46:3-26, 2001
incorporated herein by reference.) Accordingly, substantially
systemically non-bioavailable compounds can be designed to have
molecular structures exceeding one or more of Lipinski's threshold
values. (See also Lipinski et al., Experimental and Computational
Approaches to Estimate Solubility and Permeability in Drug
Discovery and Development Settings, Adv. Drug Delivery Reviews,
46:3-26, 2001; and Lipinski, Drug-like Properties and the Causes of
Poor Solubility and Poor Permeability, J. Pharm. & Toxicol.
Methods, 44:235-249, 2000, which are incorporated by reference in
their entireties.
[0422] In some embodiments, for example, a substantially
impermeable or substantially systemically non-bioavailable compound
of the present disclosure can be constructed to feature one or more
of the following characteristics: (i) a MW greater than about 500
Da, about 600 Da, about 700 Da, about 800 Da, about 900 Da, about
1000 Da, about 1200 Da, about 1300 Da, about 1400 Da, about 1500
Da, about 1600 Da, about 1800 Da, about 2000 Da, about 2500 Da,
about 3000 Da, about 4000 Da, about 5000 Da, about 7500 Da, about
10,000 Da or more (in the non-salt form of the compound); (ii) a
total number of NH and/or OH and/or other potential hydrogen bond
donors greater than about 5, about 6, about 7, about 8, about 9,
about 10, about 11, about 12, about 13, about 14, about 15, about
20 or more; (iii) a total number of O atoms and/or N atoms and/or
other potential hydrogen bond acceptors greater than about 5, about
6, about 7, about 8, about 9, about 10, about 11, about 12, about
13, about 14, about 15, about 20 or more; (iv) a Moriguchi
partition coefficient greater than about 10.sup.5 (i.e., Log P
greater than about 5, about 6, about 7, about 8, about 9, about 10
etc.), or alternatively less than about 10 (i.e., a Log P of less
than 1, or even 0); and/or (v) a total number of rotatable bonds
greater than about 5, about 10 or about 15, or more. In specific
embodiments, the compound has a Log P that is not 14 or is less
than about 14, for instance, a Log P that is in the range of about
6-7, 6-8, 6-9, 6-10, 6-11, 6-12, 6-13, 7-8, 7-9, 7-10, 7-11, 7-12,
7-13, 8-9, 8-10, 8-11, 8-12, 8-13, 9-10, 9-11, 9-12, 9-13, 10-11,
10-12, 10-13, 11-12, 11-13, or 12-13.
[0423] In addition to the parameters noted above, the molecular
polar surface area (i.e., "PSA"), which may be characterized as the
surface belonging to polar atoms, is a descriptor that has also
been shown to correlate well with passive transport through
membranes and, therefore, allows prediction of transport properties
of drugs. It has been successfully applied for the prediction of
intestinal absorption and Caco2 cell monolayer penetration. For
exemplary Caco2 cell monolayer penetration test details, see for
example the description of the Caco2 Model provided in U.S. Pat.
No. 6,737,423, incorporated by reference, particularly the text
describing the Caco2 Model, which may be applied for example to the
evaluation or testing of the compounds of the present invention.
PSA is expressed in .ANG..sup.2 (squared angstroms) and is computed
from a three-dimensional molecular representation. A fast
calculation method is also available (see, e.g., Ertl et al.,
Journal of Medicinal Chem. 43:3714-3717, 2000 the entire contents
of which are incorporated herein by reference for all relevant and
consistent purposes) using a desktop computer and commercially
available chemical graphic tools packages, such as ChemDraw. The
term "topological PSA" (tPSA) has been coined for this
fast-calculation method. tPSA is well correlated with human
absorption data with common drugs (see Table 1, from Ertl et al.,
J. Med. Chem. 43:3714-3717, 2000):
TABLE-US-00013 TABLE 1 name % FA.sup.a TPSA.sup.b metoprolol 102
50.7 nordiazepam 99 41.5 diazepam 97 32.7 oxprenolol 97 50.7
phenazone 97 26.9 oxazepam 97 61.7 alprenolol 96 41.9 practolol 95
70.6 pindolol 92 57.3 ciprofloxacin 69 74.6 metolazone 64 92.5
tranexamic acid 55 63.3 atenolol 54 84.6 sulpiride 36 101.7
mannitol 26 121.4 foscarnet 17 94.8 sulfasalazine 12 141.3
olsalazine 2.3 139.8 lactulose 0.6 197.4 raffinose 0.3 268.7
[0424] Accordingly, in some embodiments, the compounds of the
present disclosure may be constructed to exhibit a tPSA value
greater than about 100 .ANG..sup.2, about 116 .ANG..sup.2, about
120 .ANG..sup.2, about 130 .ANG..sup.2, or about 140 .ANG..sup.2,
and in some instances about 150 .ANG..sup.2, about 160 .ANG..sup.2,
about 170 .ANG..sup.2, about 180 .ANG..sup.2, about 190
.ANG..sup.2, about 200 .ANG..sup.2, about 225 .ANG..sup.2, about
250 .ANG..sup.2, about 270 .ANG..sup.2, about 300 .ANG..sup.2,
about 350 .ANG..sup.2, about 400 .ANG..sup.2, about 450
.ANG..sup.2, about 500 .ANG..sup.2, about 750 .ANG..sup.2, or even
about 1000 .ANG..sup.2, or in the range of about 100-120
.ANG..sup.2, 100-130 .ANG..sup.2, 100-140 .ANG..sup.2, 100-150
.ANG..sup.2, 100-160 .ANG..sup.2, 100-170 .ANG..sup.2, 100-170
.ANG..sup.2, 100-190 .ANG..sup.2, 100-200 .ANG..sup.2, 100-225
.ANG..sup.2, 100-250 .ANG..sup.2, 100-300 .ANG..sup.2, 100-400
.ANG..sup.2, 100-500 .ANG..sup.2, 100-750 .ANG..sup.2, 100-1000
.ANG..sup.2, 116-120 .ANG..sup.2, 116-130 .ANG..sup.2, 116-140
.ANG..sup.2, 116-150 .ANG..sup.2, 116-160 .ANG..sup.2, 116-170
.ANG..sup.2, 116-170 .ANG..sup.2, 116-190 .ANG..sup.2, 116-200
.ANG..sup.2, 116-225 .ANG..sup.2, 116-250 .ANG..sup.2, 116-300
.ANG..sup.2, 116-400 .ANG..sup.2, 116-500 .ANG..sup.2, 116-750
.ANG..sup.2, 116-1000 .ANG..sup.2, 120-130 .ANG..sup.2, 120-140
.ANG..sup.2, 120-150 .ANG..sup.2, 120-160 .ANG..sup.2, 120-170
.ANG..sup.2, 120-170 .ANG..sup.2, 120-190 .ANG..sup.2, 120-200
.ANG..sup.2, 120-225 .ANG..sup.2, 120-250 .ANG..sup.2, 120-300
.ANG..sup.2, 120-400 .ANG..sup.2, 120-500 .ANG..sup.2, 120-750
.ANG..sup.2, 120-1000 .ANG..sup.2, 130-140 .ANG..sup.2, 130-150
.ANG..sup.2, 130-160 .ANG..sup.2, 130-170 .ANG..sup.2, 130-170
.ANG..sup.2, 130-190 .ANG..sup.2, 130-200 .ANG..sup.2, 130-225
.ANG..sup.2, 130-250 .ANG..sup.2, 130-300 .ANG..sup.2, 130-400
.ANG..sup.2, 130-500 .ANG..sup.2, 130-750 .ANG..sup.2, 130-1000
.ANG..sup.2, 140-150 .ANG..sup.2, 140-160 .ANG..sup.2, 140-170
.ANG..sup.2, 140-170 .ANG..sup.2, 140-190 .ANG..sup.2, 140-200
.ANG..sup.2, 140-225 .ANG..sup.2, 140-250 .ANG..sup.2, 140-300
.ANG..sup.2, 140-400 .ANG..sup.2, 140-500 .ANG..sup.2, 140-750
.ANG..sup.2, 140-1000 .ANG..sup.2, 150-160 .ANG..sup.2, 150-170
.ANG..sup.2, 150-170 .ANG..sup.2, 150-190 .ANG..sup.2, 150-200
.ANG..sup.2, 150-225 .ANG..sup.2, or 150-250 .ANG..sup.2, 150-300
.ANG..sup.2, 150-400 .ANG..sup.2, 150-500 .ANG..sup.2, 150-750
.ANG..sup.2, 150-1000 .ANG..sup.2, 200-250 .ANG..sup.2, 200-300
.ANG..sup.2, 200-400 .ANG..sup.2, 200-500 .ANG..sup.2, 200-750
.ANG..sup.2, 200-1000 .ANG..sup.2, 250-250 .ANG..sup.2, 250-300
.ANG..sup.2, 250-400 .ANG..sup.2, 20-500 .ANG..sup.2, 250-750
.ANG..sup.2, or 250-1000 .ANG..sup.2, such that the compounds are
substantially impermeable (e.g., cell impermeable) or substantially
systemically non-bioavailable (as defined elsewhere herein).
[0425] Because there are exceptions to Lipinski's "rule," or the
tPSA model, the permeability properties of the compounds of the
present disclosure may be screened experimentally. The permeability
coefficient can be determined by methods known to those of skill in
the art, including for example by Caco-2 cell permeability assay
and/or using an artificial membrane as a model of a
gastrointestinal epithelial cell. A synthetic membrane impregnated
with, for example, lecithin and/or dodecane to mimic the net
permeability characteristics of a gastrointestinal mucosa may be
utilized as a model of a gastrointestinal mucosa. The membrane can
be used to separate a compartment containing the compound of the
present disclosure from a compartment where the rate of permeation
will be monitored. Also, parallel artificial membrane permeability
assays (PAMPA) can be performed. Such in vitro measurements can
reasonably indicate actual permeability in vivo (see Wohnsland et
al., J. Med. Chem. 44:923-930, 2001; Schmidt et al., Millipore
Corp. Application Note, 2002, n AN1725EN00, and n AN1728EN00,
incorporated herein by reference).
[0426] Accordingly, in some embodiments, the compounds utilized in
the methods of the present disclosure may have a permeability
coefficient, P.sub.app, of less than about 100.times.10.sup.-6
cm/s, or less than about 10.times.10.sup.-6 cm/s, or less than
about 1.times.10.sup.-6 cm/s, or less than about
0.1.times.10.sup.-6 cm/s, when measured using means known in the
art (such as for example the permeability experiment described in
Wohnsland et al., 2001, supra).
[0427] As previously noted, in accordance with the present
disclosure, compounds may be modified to hinder their net
absorption through a layer of gut epithelial cells, rendering them
substantially systemically non-bioavailable. In some particular
embodiments, the compounds of the present disclosure comprise a
compound that is linked, coupled or otherwise attached to a
non-absorbable moiety, which may be an oligomer moiety, a polymer
moiety, a hydrophobic moiety, a hydrophilic moiety, and/or a
charged moiety, which renders the overall compound substantially
impermeable or substantially systemically non-bioavailable. In some
preferred embodiments, the compound is coupled to a multimer or
polymer portion or moiety, such that the resulting molecule is
substantially impermeable or substantially systemically
non-bioavailable. The multimer or polymer portion or moiety may be
of a molecular weight greater than about 500 Daltons (Da), about
1000 Da, about 2500 Da, about 5000 Da, about 10,000 Da or more, and
in particular may have a molecular weight in the range of about
1000 Daltons (Da) to about 500,000 Da, preferably in the range of
about 5000 to about 200,000 Da, and more preferably may have a
molecular weight that is sufficiently high to essentially preclude
any net absorption through a layer of gut epithelial cells of the
compound. In these or other particular embodiments, the compound is
modified to substantially hinder its net absorption through a layer
of gut epithelial cells.
[0428] (ii) C.sub.max and IC.sub.50 or EC.sub.50
[0429] In some embodiments, the substantially systemically
non-bioavailable compounds detailed herein, when administered
(e.g., enterally) either alone or in combination with one or more
additional pharmaceutically active compounds or agents to a subject
in need thereof, exhibit a maximum concentration detected in the
serum, defined as C.sub.max, that is about the same as or less than
the phosphate ion (Pi) transport or uptake inhibitory concentration
IC.sub.50 of the compound. In some embodiments, for instance, the
C.sub.max is about or at least about 5%, 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, or 100% less than the IC.sub.50 for inhibiting
Pi transport or uptake. In some embodiments, the C.sub.max is about
0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2,
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9.times. (0.9 times) the IC.sub.50
for inhibiting Pi transport or uptake.
[0430] In certain embodiments, one or more of the substantially
systemically non-bioavailable compounds detailed herein, when
administered (e.g., enterally) to a subject in need thereof, may
have a ratio of C.sub.max:IC.sub.50 (for inhibiting Pi transport or
update), where C.sub.max and IC.sub.50 are expressed in terms of
the same units, of at about or less than about 0.01, 0.02, 0.03,
0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6,
0.7, 0.8, 0.9, or 1.0, or a range in between about 0.01-1.0,
0.01-0.9, 0.01-0.8, 0.01-0.7, 0.01-0.6, 0.01-0.5, 0.01-0.4,
0.01-0.3, 0.01-0.2, or 0.01-0.1, or a range in between about
0.1-1.0, 0.1-0.9, 0.1-0.8, 0.1-0.7, 0.1-0.6, 0.1-0.5, 0.1-0.4,
0.1-0.3, or 0.1-0.2.
[0431] In some embodiments, the substantially systemically
non-bioavailable compounds detailed herein, when administered
(e.g., enterally) either alone or in combination with one or more
additional pharmaceutically active compounds or agents to a subject
in need thereof, exhibit a maximum concentration detected in the
serum, defined as C.sub.max, that is about the same as or less than
EC.sub.50 of the compound for increasing fecal output of phosphate,
where fecal output is increased by about or at least about 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In some
embodiments, for instance, the C.sub.max is about or at least about
5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% less than
the EC.sub.50 for increasing fecal output of phosphate. In some
embodiments, the C.sub.max is about 0.01, 0.02, 0.03, 0.04, 0.05,
0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8,
0.9.times. (0.9 times) the EC.sub.50 for increasing fecal output of
phosphate.
[0432] In some embodiments, one or more of the substantially
systemically non-bioavailable compounds detailed herein, when
administered (e.g., enterally) either alone or in combination with
one or more additional pharmaceutically active compounds or agents
to a subject in need thereof, or measured in an animal model or
cell-based assay, may have an EC.sub.50 for increasing fecal output
of phosphate of about or less than about 10 .mu.M, 9 .mu.M, 8
.mu.M, 7 .mu.M, 7.5 .mu.M, 6 .mu.M, 5 .mu.M, 4 .mu.M, 3 .mu.M, 2.5
.mu.M, 2 .mu.M, 1 .mu.M, 0.5 .mu.M, 0.1 .mu.M, 0.05 .mu.M, or 0.01
.mu.M, or less, the IC.sub.50 being, for example, within the range
of about 0.01 .mu.M to about 10 .mu.M, or about 0.01 .mu.M to about
7.5 .mu.M, or about 0.01 .mu.M to about 5 .mu.M, or about 0.01
.mu.M to about 2.5 .mu.M, or about 0.01 .mu.M to about 1.0, or
about 0.1 .mu.M to about 10 .mu.M, or about 0.1 .mu.M to about 7.5
.mu.M, or about 0.1 .mu.M to about 5 .mu.M, or about 0.1 .mu.M to
about 2.5 .mu.M, or about 0.1 .mu.M to about 1.0, or about .mu.M
0.5 .mu.M to about 10 .mu.M, or about 0.5 .mu.M to about 7.5 .mu.M,
or about 0.5 .mu.M to about 5 .mu.M, or about 0.5 .mu.M to about
2.5 .mu.M, or about 0.5 .mu.M to about 1.0 .mu.M.
[0433] In particular embodiments, the substantially systemically
non-bioavailable compounds detailed herein, when administered
(e.g., enterally) either alone or in combination with one or more
additional pharmaceutically active compounds or agents to a subject
in need thereof, exhibit a maximum concentration detected in the
serum, defined as C.sub.max, that is about the same as or less than
EC.sub.50 of the compound for reducing urinary output of phosphate,
where urinary output is reduced by about or at least about 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In some
embodiments, for instance, the C.sub.max is about or at least about
5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% less than
the EC.sub.50 for reducing urinary output of phosphate. In some
embodiments, the C.sub.max is about 0.01, 0.02, 0.03, 0.04, 0.05,
0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8,
0.9.times. (0.9 times) the EC.sub.50 for reducing urinary output of
phosphate.
[0434] In some embodiments, one or more of the substantially
systemically non-bioavailable compounds detailed herein, when
administered (e.g., enterally) either alone or in combination with
one or more additional pharmaceutically active compounds or agents
to a subject in need thereof, or measured in an animal model or
cell-based assay, may have an EC.sub.50 for reducing urinary output
of phosphate of about or less than about 10 .mu.M, 9 .mu.M, 8
.mu.M, 7 .mu.M, 7.5 .mu.M, 6 .mu.M, 5 .mu.M, 4 .mu.M, 3 .mu.M, 2.5
.mu.M, 2 .mu.M, 1 .mu.M, 0.5 .mu.M, 0.1 .mu.M, 0.05 .mu.M, or 0.01
.mu.M, or less, the IC.sub.50 being, for example, within the range
of about 0.01 .mu.M to about 10 .mu.M, or about 0.01 .mu.M to about
7.5 .mu.M, or about 0.01 .mu.M to about 5 .mu.M, or about 0.01
.mu.M to about 2.5 .mu.M, or about 0.01 .mu.M to about 1.0, or
about 0.1 .mu.M to about 10 .mu.M, or about 0.1 .mu.M to about 7.5
.mu.M, or about 0.1 .mu.M to about 5 .mu.M, or about 0.1 .mu.M to
about 2.5 .mu.M, or about 0.1 .mu.M to about 1.0, or about .mu.M
0.5 .mu.M to about 10 .mu.M, or about 0.5 .mu.M to about 7.5 .mu.M,
or about 0.5 .mu.M to about 5 .mu.M, or about 0.5 .mu.M to about
2.5 .mu.M, or about 0.5 .mu.M to about 1.0 .mu.M.
[0435] In certain embodiments, one or more of the substantially
systemically non-bioavailable compounds detailed herein, when
administered (e.g., enterally) to a subject in need thereof, may
have a ratio of C.sub.max:EC.sub.50 (e.g., for increasing fecal
output of phosphate, for decreasing urinary output of phosphate),
where C.sub.max and EC.sub.50 are expressed in terms of the same
units, of at about or less than about 0.01, 0.02, 0.03, 0.04, 0.05,
0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8,
0.9, or 1.0, or a range in between about 0.01-1.0, 0.01-0.9,
0.01-0.8, 0.01-0.7, 0.01-0.6, 0.01-0.5, 0.01-0.4, 0.01-0.3,
0.01-0.2, or 0.01-0.1, or a range in between about 0.1-1.0,
0.1-0.9, 0.1-0.8, 0.1-0.7, 0.1-0.6, 0.1-0.5, 0.1-0.4, 0.1-0.3, or
0.1-0.2.
[0436] Additionally, or alternatively, one or more of the
substantially systemically non-bioavailable compounds detailed
herein, when administered (e.g., enterally) either alone or in
combination with one or more additional pharmaceutically active
compounds or agents to a subject in need thereof, may have a
C.sub.max of about or less than about 10 ng/ml, about 7.5 ng/ml,
about 5 ng/ml, about 2.5 ng/ml, about 1 ng/ml, or about 0.5 ng/ml,
the C.sub.max being for example within the range of about 1 ng/ml
to about 10 ng/ml, or about 2.5 ng/ml to about 7.5 ng/ml.
III. Pharmaceutical Compositions and Methods of Treatment
[0437] For the purposes of administration, the compounds of the
present invention may be administered to a patient or subject as a
raw chemical or may be formulated as pharmaceutical compositions.
Pharmaceutical compositions of the present invention generally
comprise a compound of the invention and a pharmaceutically
acceptable carrier, diluent, or excipient. The compound is present
in the composition in an amount which is effective to treat a
particular disease or condition of interest, as described herein,
and preferably with acceptable toxicity to the subject. The
activity of compound(s) can be determined by one skilled in the
art, for example, as described herein and in the Examples below.
Appropriate concentrations and dosages can be readily determined by
one skilled in the art.
[0438] A compound or composition of the invention may be used in a
method for treating essentially any disease or other condition in a
subject which would benefit from phosphate uptake inhibition in the
gastrointestinal tract.
[0439] For example, by way of explanation, but not limitation,
kidney damage reduces the production and activity of renal 1-alpha
hydroxylase, leading to lower 1,25-dihydroxy vitamin D. Decreased
vitamin D levels limit gastrointestinal calcium absorption, leading
to a decline in serum calcium levels. The combination of lower
1,25-dihydroxy vitamin D and lower serum calcium levels
synergistically stimulate parathyroid tissue to produce and secrete
PTH. A loss of nephrons also impairs Pi excretion, but serum P
levels are actively defended by the actions of PTH and FGF-23, and
by higher serum P levels, which considerably enhance urinary
PO.sub.4 excretion. However, tubular actions of PTH and FGF-23
cannot maintain serum P levels in the face of continual nephron
loss. Once renal insufficiency progresses to the loss of about
40-50% of renal function, the decrease in the amount of functioning
renal tissue does not allow excretion of the full amount of
ingested phosphate required to maintain homeostasis. As a result,
hyperphosphatemia develops. In addition, a rise in serum P levels
impedes renal 1-alpha hydroxylase activity, further suppressing
activated vitamin D levels, and further stimulating PTH, leading to
secondary hyperparathyroidism (sHPTH).
[0440] Phosphorus imbalance, however, does not necessarily equate
with hyperphosphatemia. Rather, the vast majority of CKD patients
not yet on dialysis are normophosphatemic but their phosphorus
balance is positive with the excess phosphorus being disposed in
the vasculature in the form of ectopic calcification, e.g.
intima-localized vascular calcification. Clinically, patients with
CKD have elevated levels of FGF-23 that are significantly
associated with deteriorating renal function and with decreased
calcitriol levels, and it has been hypothesized that the synthesis
of FGF-23 is induced by the presence of excess P in the body
consecutive to renal failure.
[0441] Furthermore, an unrecognized effect on cardiovascular
disease is post-prandial phosphatemia, i.e. serum P excursion
secondary to meal intake. Further still, studies have investigated
the acute effect of phosphorus loading on endothelial function in
vitro and in vivo. Exposing bovine aortic endothelial cells to a
phosphorus load increased production of reactive oxygen species and
decreased nitric oxide, a known vasodilator agent. In the acute P
loading study in healthy volunteers described above, it was found
that the flow mediated dilation correlated inversely with
postprandial serum P (see, e.g., Shuto et al., J. Am. Soc. Nephrol.
20:1504-12, 2009).
[0442] Accordingly, in certain embodiments, a compound or
composition of the invention can be used in a method selected from
one or more of the following: a method for treating
hyperphosphatemia, optionally postprandial hyperphosphatemia; a
method for treating a renal disease (e.g., chronic kidney disease
(CKD), end stage renal disease (ESRD)); a method for reducing serum
creatinine levels; a method for treating proteinuria; a method for
delaying time to renal replacement therapy (RRT) such as dialysis;
a method for reducing FGF23 levels; a method for reducing the
hyperphosphatemic effect of active vitamin D; a method for
attenuating hyperparathyroidism such as secondary
hyperparathyroidism; a method for reducing serum parathyroid
hormone (PTH or iPTH); a method for improving endothelial
dysfunction optionally induced by postprandial serum phosphorus; a
method for reducing vascular calcification or attenuating
intima-localized vascular calcification; a method for reducing
urinary phosphorus; a method for normalizing serum phosphorus
levels; a method for reducing phosphate burden in an elderly
patient; a method for decreasing dietary phosphate uptake; a method
for reducing postprandial calcium absorption; a method for reducing
renal hypertrophy; and a method for reducing heart hypertrophy. In
certain embodiments, the subject in need of phosphate lowering has
one or more of the foregoing conditions. In some embodiments, the
method comprises selecting or identifying such a subject prior to
treatment, optionally based on one or more of the clinical or
diagnostic parameters described herein.
[0443] Hyperphosphatemia refers to a condition in which there is an
elevated level of phosphate in the blood. Average serum phosphorus
mass in a human adult typically range from about 2.5-4.5 mg/dL
(about 0.81-1.45 mmol/L). Levels are often about 50% higher in
infants and about 30% higher in children because of growth hormone
effects. Hence, certain methods include treating an adult human
patient having hyperphosphatemia, where the patient has serum
phosphorus mass of about or at least about 4.5, 4.6, 4.7, 4.8, 4.9,
5.0, 5.1, 5.2, 5.3, 5.4, or 5.5 mg/dL. In some aspects, the
treatment reduces serum phosphorus concentrations or levels in a
hyperphosphatemic subject to about 150%, 145%, 140%, 135%, 130%,
125%, 120%, 115%, 110%, 105%, or 100% (normalized) of the normal
serum phosphorus levels (e.g., 2.5-4.5 mg/dL or 0.81-1.45 mmol/L
for an adult). In some aspects, the treatment regimen results in
and/or includes monitoring phosphate levels so that they remain
within the range of about 2.5-4.5 mg/dL (about 0.81-1.45 mmol/L).
In some aspects, the treatment shifts the external phosphorus
balance towards net excretion, for example, by increasing net
excretion of phosphorous by about or at least about 5%, 10%, 20%,
30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% or more relative to an
untreated state, with or without reducing serum phosphorus
concentrations or levels.
[0444] Also included are methods of treating a child or adolescent
human patient, where the patient has serum phosphorus mass of about
or at least about 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9,
7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0 mg/dL. As
noted herein, in these and related embodiments, administration of a
compound or composition described herein may reduce serum
phosphorus mass in the subject by about or at least about 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more.
[0445] Certain embodiments relate to methods of treating chronic
kidney disease (CKD), a condition characterized by the progressive
loss of renal function. Common causes of CKD include diabetes
mellitus, hypertension, and glomerulonephritis. Hence, certain
methods include treating a subject with CKD, where the subject
optionally also has one or more of the foregoing conditions.
[0446] In some aspects, a subject is classified as having CKD if
they have a glomerular filtration rate (GFR) of less than 60
mL/min/1.73 m.sup.2 for about 3 months, whether or not they also
present with kidney damage. Certain methods thus include treating a
subject with a GFR (e.g., an initial GFR, prior to treatment) of
about or less than about 60, 55, 50, 45, 40, 30, 35, 20, 25, 20,
15, or 10 mL/min/1.73 m.sup.2 or so. In certain embodiments,
administration of a compound or composition described herein may
result in an increase in GFR of about or at least about 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more.
[0447] CKD is most often characterized according to the stage of
disease: Stage 1, Stage 2, Stage, 3, Stage 4, and Stage 5. Stage 1
CKD includes subjects with kidney damage and a normal or relatively
high
[0448] GFR of about or greater than about 90 mL/min/1.73 m.sup.2.
Stage 2 CKD includes subjects with kidney damage and a GFR of about
60-89 mL/min/1.73 m.sup.2. Stage 3 CKD includes subjects with
kidney damage and a GFR of about 30-59 mL/min/1.73 m.sup.2. Stage 4
CKD includes subjects with kidney damage and a GFR of about 15-29
mL/min/1.73 m.sup.2. Stage 5 CKD includes subjects with established
kidney failure and a GFR of less than about 15 mL/min/1.73 m.sup.2.
Stage 5 CKD is also referred to as end-stage renal disease (ESRD).
Accordingly, in certain methods, a subject has Stage 1, 2, 3, 4, or
5, CKD and one or more of its associated clinical characteristics
(e.g., defined GFR, kidney damage). In some embodiments, the
subject has ESRD and any one or more of its associated clinical
characteristics, as described herein and known in the art.
[0449] CKD can be characterized according to the affected parts of
the kidney. For instance, in certain aspects, CKD includes
vascular-associated CKD, including large vessel disease such as
bilateral renal artery stenosis, and small vessel disease such as
ischemic nephropathy, hemolytic-uremic syndrome and vasculitis. In
certain aspects, CKD includes glomerular-associated CKD, including
primary glomerular disease such as focal segmental
glomerulosclerosis and IgA nephritis, and secondary Glomerular
diseases such as diabetic nephropathy and lupus nephritis. Also
included is tubulointerstitial-associated CKD, including polycystic
kidney disease, drug and toxin-induced chronic tubulointerstitial
nephritis, and reflux nephropathy. Certain subjects being treated
for CKD may thus have one or more foregoing CKD-associated
characteristics.
[0450] Certain aspects relate to methods of treating a subject with
kidney damage or one or more symptoms/clinical signs of kidney
damage. Examples of kidney damage (e.g., CKD-associated kidney
damage) and its related symptoms include pathological abnormalities
and markers of damage, including abnormalities identified in blood
testing (e.g., high blood or serum levels of creatinine, creatinine
clearance), urine testing (e.g., proteinuria), and/or imaging
studies.
[0451] Creatinine is a break-down product of creatine phosphate in
muscle, and provides an easily-measured and useful indicator of
renal health. Normal human reference ranges for blood or serum
creatinine range from about 0.5 to 1.0 mg/dL (about 45-90
.mu.mol/l) for women and about 0.7 to 1.2 mg/dL (about 60-110
.mu.mol/L) for men. Hence, certain subjects for treatment according
to the methods described herein (e.g., initially, prior to
treatment) may have blood or serum creatine levels that are about
or greater than about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8,
1.9, 2.0 mg/dL. In these and related embodiments, administration of
a compound or composition described herein may reduce overall blood
or serum creatinine levels in a subject by about or at least about
5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200% or
more.
[0452] Creatinine clearance rate (C.sub.Cr or CrCl) refers to the
volume of blood plasma that is cleared of creatinine per unit time;
it is measured by comparing the levels of creatinine in blood
relative to urine over a period of time (e.g., 24 hours). Creatine
clearance is often measured as milliliters/minute (ml/min) or as a
function of body mass (ml/min/kg). Depending on the test performed,
normal values range from about 97-137 ml/min for males and about
88-128 ml/min for females. Reduced creatinine clearance provides a
useful sign of kidney damage. Hence, certain male subjects for
treatment according to the methods described herein (e.g.,
initially, prior to treatment) may have a C.sub.Cr of about or less
than about 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84,
83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67,
66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50
or less. Certain female subjects for treatment according to the
methods described herein (e.g., initially, prior to treatment) may
have a C.sub.Cr of about or less than about 88, 87, 86, 85, 84, 83,
82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66,
65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49,
47, 46, 45, 44, 43, 42, 41, 40 or less. In some embodiments,
administration of a compound or composition described herein may
maintain or increase the C.sub.Cr in a subject by about or at least
about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or
200% or more.
[0453] Proteinuria refers to a condition of excess protein in the
urine. It is associated with variety of disease conditions
including kidney damage. Proteinuria is often characterized as a
urine protein/creatinine ratio of greater than about 45 mg/mmol, or
in specific tests an albumin/creatine ratio of greater than about
30 mg/mmol Certain subjects for treatment according to the methods
provided herein (e.g., prior to treatment) have proteinuria, alone
or in combination with CKD or other kidney damage, including
subjects with a urine protein/creatinine ratio of about or greater
than about 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105,
110, 115, or 120 mg/mmol and/or a urine albumin/creatinine ratio of
about or greater than about 30, 35, 40, 50, 55, 60, 65, 70, 75, 80,
85, 90, 95, 100, 105, 110, 115, or 120 mg/mmol. In these and
related embodiments, administration of a compound or composition
described herein may treat proteinuria, for instance, by reducing
the urine protein/creatinine ratio and/or the urine
albumin/creatinine ratio by about or at least about 5%, 10%, 20%,
30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200% or more.
[0454] CKD is associated with a variety of clinical symptoms.
Examples include high blood pressure (hypertension), urea
accumulation, hyperkalemia, anemia, hyperphosphatemia,
hypocalcemia, metabolic acidosis, and atherosclerosis. Thus, in
certain methods, a subject with CKD may also have or be at risk for
having one or more of the foregoing clinical symptoms. In specific
aspects, the subject with CKD has or is at risk for having
hyperphosphatemia, as described herein.
[0455] Renal replacement therapy (RRT) relates to the various
life-supporting treatments for renal failure, including those
initiated in the later stages of CKD and ESRD. Examples of RRT
include dialysis, hemodialysis, hemofiltration, and renal
transplantation. In certain embodiments, a subject for treatment
according to the methods provided herein is about to undergo, is
undergoing, or has undergone one or more types of RRT. In some
embodiments, the subject is not yet undergoing RRT, and
administration of a compound described herein delays the time to
initiating RRT (e.g., relative to an untreated state) by about or
at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks, or by
about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
months, or by about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12 years or more.
[0456] Fibroblast growth factor 23 (FGF23) regulates phosphorus and
vitamin D metabolism. It also promotes phosphaturia and decreases
production of calcitriol. Increased FGF23 levels associate with
mortality, left ventricular hypertrophy (or left ventricular mass
index), myocardial performance, endothelial dysfunction, and
progression of CKD. Indeed, FGF23 levels increase progressively in
early CKD, presumably as a physiological adaptation to maintain
normal serum phosphorus levels or normal phosphorus balance. FGF23
levels might also contribute directly to tissue injury in the
heart, vessels, and kidneys. Certain embodiments thus relate to the
treatment of subjects having increased FGF23 levels in blood or
serum (see, e.g., Kirkpantur et al., Nephrol Dial Transplant.
26:1346-54, 2011), including subjects with CKD and subjects
undergoing dialysis/hemodialysis. In some aspects, administration
of a compound or composition described herein reduces the logarithm
of FGF23 levels in blood or serum by about or at least about 5%,
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200% or
more.
[0457] Vitamin D stimulates, inter alia, the absorption of
phosphate ions in the small intestine. Hence, excess levels or
activity of Vitamin D can lead to increased phosphate levels and
hyperphosphatemia. Certain embodiments thus relate to methods for
reducing the hyperphosphatemic effect of active vitamin D, for
instance, in a subject having elevated levels or activity of
Vitamin D. In some aspects, the subject has Vitamin D toxicity due
to over-ingestion of Vitamin D.
[0458] Hyperparathyroidism is a disorder in which the parathyroid
glands produce too much parathyroid hormone (PTH). Secondary
hyperparathyroidism is characterized by the excessive secretion of
PTH in response to hypocalcemia and associated hypertrophy of the
parathyroid glands. CKD is the most common cause of secondary
hyperparathyroidism, generally because the kidneys fail to convert
sufficient vitamin D into its active form and to excrete sufficient
phosphate. Insoluble calcium phosphate forms in the body and thus
removes calcium from the circulation, leading to hypocalcemia. The
parathyroid glands then further increase the secretion of PTH in an
attempt to increase serum calcium levels. Certain subjects for
treatment according to the methods provided herein may thus present
(e.g., initially, prior to treatment) with hyperparathyroidism
and/or increased PTH levels, optionally in combination with CKD,
hyperphosphatemia, hypocalcemia, or other condition or symptom
described herein. In some aspects, administration of a compound or
composition described herein may reduce hyperparathyroidism
including secondary hyperparathyroidism in a subject in need
thereof. In some aspects, administration of a compound or
composition described herein may reduce PTH levels by about or at
least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%,
or 200% or more, for instance, by reducing serum phosphorus levels
and the associated formation of insoluble calcium phosphate,
increasing available calcium, and thereby reducing the
hypocalcemia-induced production of PTH.
[0459] In certain embodiments, the administration of a compound
described herein can provide multiple therapeutic effects to a
subject with CKD. In some instances, the administration of a
compound reduces FGF23 levels and serum parathyroid hormone (PTH)
levels by about or at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 100%, or 200% or more relative to an untreated
state, reduces blood pressure, and reduces proteinuria by at least
about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or
200% or more relative to an untreated state.
[0460] In particular embodiments, the administration of a compound
described herein can provide multiple therapeutic effects to a
subject with ESRD (or Stage 5 CKD). In specific instances, the
administration of a compound reduces serum phosphorus
concentrations or levels by about or at least about 5%, 10%, 20%,
30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or 200% or more relative
to an untreated state.
[0461] Hyperphosphatemia can lead to endothelial dysfunction in
both healthy subjects and those with kidney disease, independently
of vascular calcification (see, e.g., Di Marco et al., Kidney
International. 83:213-222, 2013). Management of serum phosphorus
level by dietary phosphate restriction or phosphate binders can
prevent such subjects from developing cardiovascular disease.
Studies have also shown that dietary phosphate restriction can
improve aortic endothelial dysfunction (e.g., in CKD with
hyperphosphatemia) by increasing the activatory phosphorylation of
endothelial nitric oxide synthase and Akt (see, e.g., Van et al., J
Clin Biochem Nutr. 51:27-32, 2012). Certain subjects for treatment
according to the methods provided herein may have or be at risk for
having endothelial dysfunction, optionally combined with
hyperphosphatemia, kidney disease, or any other condition described
herein. By reducing postprandial or dietary phosphate uptake, alone
or in combination with dietary phosphate restriction,
administration of a compound or composition described herein may
reduce the risk of developing endothelial dysfunction, or may
improve already-existing endothelial dysfunction, including
endothelial dysfunction induced by postprandial serum
phosphorus.
[0462] Hyperphosphatemia is a primary inducer of vascular
calcification (see Giachelli, Kidney Int. 75:890-897, 2009).
Calcium phosphate deposition, mostly in the form of apatite, is the
hallmark of vascular calcification and can occur in the blood
vessels, myocardium, and cardiac valves. Together with passive
deposition of calcium-phosphate in extra-skeletal tissues,
inorganic phosphate can also induce arterial calcification directly
through "ossification" of the tunica media in the vasculature.
Moreover, vascular smooth muscle cells respond to elevated
phosphate levels by undergoing an osteochondrogenic phenotype
change and mineralizing their extracellular matrix through a
mechanism requiring sodium-dependent phosphate cotransporters.
[0463] Intimal calcification is usually found in atherosclerotic
lesions. Medial calcification is commonly observed in
age-associated arteriosclerosis and diabetes, and is the major form
of calcification observed in ESRD. Indeed, extensive calcification
of the arterial wall and soft tissues is a frequent feature of
patients with CKD, including those with ESRD. In valves,
calcification is a defining feature of aortic valve stenosis, and
occurs in both the leaflets and ring, predominantly at sites of
inflammation and mechanical stress. These mechanical changes are
associated with increased arterial pulse wave velocity and pulse
pressure, and lead to impaired arterial distensibility, increased
afterload favoring left ventricular hypertrophy, and compromised
coronary perfusion (see Guerin et al., Circulation. 103:987-992,
2001). Both intimal and medial calcifications may thus contribute
to the morbidity and mortality associated with cardiovascular
disease, and are likely to be major contributors to the significant
increase in cardiovascular mortality risk observed in CKD and ESRD
patients. Control of serum phosphorus may thus reduce the formation
of calcium/phosphate products and thereby reduce vascular
calcification. Accordingly, certain of the subjects for treatment
according to the methods provided herein may have or be at risk for
developing vascular calcification, including intimal and/or medial
calcification, optionally combined with any of hyperphosphatemia,
CKD, and ESRD. In some embodiments, administration of a compound or
composition described herein reduces the risk of developing or
reduces the formation or levels of vascular calcification in a
subject in need thereof. In particular embodiments, administration
of a compound or composition described herein may reduce vascular
calcification by about or at least about 5%, 10%, 20%, 30%, 40%,
50%, 60%, 70%, 80%, 90%, 100%, or 200% or more, for example,
relative to an untreated state.
[0464] Elderly patients can be especially susceptible to increased
phosphate. For instance, dietary and genetic manipulation studies
provide in vivo evidence that phosphate toxicity accelerates the
aging process and suggest a novel role for phosphate in mammalian
aging (see, e.g., Ohnishi and Razzaque, FASEB J. 24:3562-71, 2010).
These studies show that excess phosphate associates with many signs
of premature aging, including kyphosis, uncoordinated movement,
hypogonadism, infertility, skeletal muscle wasting, emphysema, and
osteopenia, as well as generalized atrophy of the skin, intestine,
thymus, and spleen. Certain embodiments thus relate to reducing
phosphate burden in an elderly patient, for instance, to reduce any
one or more signs of premature aging, comprising administering to
the elderly patient a compound described herein. In some instances,
an elderly patient is about or at least about 60, 61, 62, 63, 64,
65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,
82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, 100 or more years of age.
[0465] Hypertrophy refers to the increase in the volume of an organ
or tissue due to the enlargement of its component cells.
Hyperphosphatemia associates with myocardial hypertrophy including
left ventricular hypertrophy (see Neves et al., Kidney Int.
66:2237-44, 2004; and Achinger and Ayus, Am Soc Nephrol. 17(12
Suppl 3):S255-61, 2006) and compensatory renal hypertrophy
including glomerular hypertrophy, the latter being often-observed
in CKD. Certain subjects for treatment according to the methods
provided herein may have (e.g., initially, prior to treatment)
myocardial hypertrophy, renal hypertrophy, or both, alone or in
combination with CKD or kidney damage. In some embodiments,
administration of a compound described herein may reduce myocardial
hypertrophy and/or renal hypertrophy by about or at least about 5%,
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more
relative to an untreated state.
[0466] Administration of the compounds of the invention, or their
pharmaceutically acceptable salts, in pure form or in an
appropriate pharmaceutical composition, can be carried out via any
of the accepted modes of administration of agents for serving
similar utilities. The pharmaceutical compositions of the invention
can be prepared by combining a compound of the invention with an
appropriate pharmaceutically acceptable carrier, diluent or
excipient, and may be formulated into preparations in solid,
semi-solid, liquid or gaseous forms, such as tablets, capsules,
powders, granules, ointments, solutions, suppositories, injections,
inhalants, gels, microspheres, and aerosols. Typical routes of
administering such pharmaceutical compositions include, without
limitation, oral, topical, transdermal, inhalation, parenteral,
sublingual, buccal, rectal, vaginal, and intranasal. The term
parenteral as used herein includes subcutaneous injections,
intravenous, intramuscular, intrasternal injection or infusion
techniques. Pharmaceutical compositions of the invention are
formulated so as to allow the active ingredients contained therein
to be bioavailable upon administration of the composition to a
patient. Compositions that will be administered to a subject or
patient take the form of one or more dosage units, where for
example, a tablet may be a single dosage unit, and a container of a
compound of the invention in aerosol form may hold a plurality of
dosage units. Actual methods of preparing such dosage forms are
known, or will be apparent, to those skilled in this art; for
example, see Remington: The Science and Practice of Pharmacy, 20th
Edition (Philadelphia College of Pharmacy and Science, 2000). The
composition to be administered will, in any event, contain a
therapeutically effective amount of a compound of the invention, or
a pharmaceutically acceptable salt thereof, for treatment of a
disease or condition of interest in accordance with the teachings
of this invention.
[0467] A pharmaceutical composition of the invention may be in the
form of a solid or liquid. In one aspect, the carrier(s) are
particulate, so that the compositions are, for example, in tablet
or powder form. The carrier(s) may be liquid, with the compositions
being, for example, an oral syrup, injectable liquid or an aerosol,
which is useful in, for example, inhalatory administration.
[0468] When intended for oral administration, the pharmaceutical
composition is preferably in either solid or liquid form, where
semi-solid, semi-liquid, suspension and gel forms are included
within the forms considered herein as either solid or liquid.
[0469] As a solid composition for oral administration, the
pharmaceutical composition may be formulated into a powder,
granule, compressed tablet, pill, capsule, chewing gum, wafer or
the like form. Such a solid composition will typically contain one
or more inert diluents or edible carriers. In addition, one or more
of the following may be present: binders such as
carboxymethylcellulose, ethyl cellulose, microcrystalline
cellulose, gum tragacanth or gelatin; excipients such as starch,
lactose or dextrins, disintegrating agents such as alginic acid,
sodium alginate, Primogel, corn starch and the like; lubricants
such as magnesium stearate or Sterotex; glidants such as colloidal
silicon dioxide; sweetening agents such as sucrose or saccharin; a
flavoring agent such as peppermint, methyl salicylate or orange
flavoring; and a coloring agent.
[0470] When the pharmaceutical composition is in the form of a
capsule, for example, a gelatin capsule, it may contain, in
addition to materials of the above type, a liquid carrier such as
polyethylene glycol or oil.
[0471] The pharmaceutical composition may be in the form of a
liquid, for example, an elixir, syrup, solution, emulsion or
suspension. The liquid may be for oral administration or for
delivery by injection, as two examples. When intended for oral
administration, preferred composition contain, in addition to the
present compounds, one or more of a sweetening agent,
preservatives, dye/colorant and flavor enhancer. In a composition
intended to be administered by injection, one or more of a
surfactant, preservative, wetting agent, dispersing agent,
suspending agent, buffer, stabilizer and isotonic agent may be
included.
[0472] The liquid pharmaceutical compositions of the invention,
whether they be solutions, suspensions or other like form, may
include one or more of the following adjuvants: sterile diluents
such as water for injection, saline solution, preferably
physiological saline, Ringer's solution, isotonic sodium chloride,
fixed oils such as synthetic mono or diglycerides which may serve
as the solvent or suspending medium, polyethylene glycols,
glycerin, propylene glycol or other solvents; antibacterial agents
such as benzyl alcohol or methyl paraben; antioxidants such as
ascorbic acid or sodium bisulfite; chelating agents such as
ethylenediaminetetraacetic acid; buffers such as acetates, citrates
or phosphates and agents for the adjustment of tonicity such as
sodium chloride or dextrose. The parenteral preparation can be
enclosed in ampoules, disposable syringes or multiple dose vials
made of glass or plastic. Physiological saline is a preferred
adjuvant. An injectable pharmaceutical composition is preferably
sterile.
[0473] A liquid pharmaceutical composition of the invention
intended for either parenteral or oral administration should
contain an amount of a compound of the invention such that a
suitable dosage will be obtained.
[0474] The pharmaceutical composition of the invention may be
intended for topical administration, in which case the carrier may
suitably comprise a solution, emulsion, ointment or gel base. The
base, for example, may comprise one or more of the following:
petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil,
diluents such as water and alcohol, and emulsifiers and
stabilizers. Thickening agents may be present in a pharmaceutical
composition for topical administration. If intended for transdermal
administration, the composition may include a transdermal patch or
iontophoresis device.
[0475] The pharmaceutical composition of the invention may be
intended for rectal administration, in the form, for example, of a
suppository, which will melt in the rectum and release the drug.
The composition for rectal administration may contain an oleaginous
base as a suitable nonirritating excipient. Such bases include,
without limitation, lanolin, cocoa butter and polyethylene
glycol.
[0476] The pharmaceutical composition of the invention may include
various materials, which modify the physical form of a solid or
liquid dosage unit. For example, the composition may include
materials that form a coating shell around the active ingredients.
The materials that form the coating shell are typically inert, and
may be selected from, for example, sugar, shellac, and other
enteric coating agents. Alternatively, the active ingredients may
be encased in a gelatin capsule.
[0477] The pharmaceutical composition of the invention in solid or
liquid form may include an agent that binds to the compound of the
invention and thereby assists in the delivery of the compound.
Suitable agents that may act in this capacity include a monoclonal
or polyclonal antibody, a protein or a liposome.
[0478] The pharmaceutical composition of the invention may consist
of dosage units that can be administered as an aerosol. The term
aerosol is used to denote a variety of systems ranging from those
of colloidal nature to systems consisting of pressurized packages.
Delivery may be by a liquefied or compressed gas or by a suitable
pump system that dispenses the active ingredients. Aerosols of
compounds of the invention may be delivered in single phase,
bi-phasic, or tri-phasic systems in order to deliver the active
ingredient(s). Delivery of the aerosol includes the necessary
container, activators, valves, subcontainers, and the like, which
together may form a kit. One skilled in the art, without undue
experimentation may determine preferred aerosols.
[0479] The pharmaceutical compositions of the invention may be
prepared by methodology well known in the pharmaceutical art. For
example, a pharmaceutical composition intended to be administered
by injection can be prepared by combining a compound of the
invention with sterile, distilled water so as to form a solution. A
surfactant may be added to facilitate the formation of a
homogeneous solution or suspension. Surfactants are compounds that
non-covalently interact with the compound of the invention so as to
facilitate dissolution or homogeneous suspension of the compound in
the aqueous delivery system.
[0480] The compounds of the invention, or their pharmaceutically
acceptable salts, are administered in a therapeutically effective
amount, which will vary depending upon a variety of factors
including the activity of the specific compound employed; the
metabolic stability and length of action of the compound; the age,
body weight, general health, sex, and diet of the patient; the mode
and time of administration; the rate of excretion; the drug
combination; the severity of the particular disorder or condition;
and the subject undergoing therapy.
[0481] In certain embodiments, a typical dosage of the
substantially impermeable or substantially systemically
non-bioavailable, compound may be between about 0.2 mg per day and
about 2 g per day, or between about 1 mg and about 1 g per day, or
between about 5 mg and about 500 mg, or between about 10 mg and
about 250 mg per day, which is administered to a subject in need of
treatment.
[0482] The frequency of administration of the compounds and
compositions described herein may vary from once-a-day (QD) to
twice-a-day (BID) or thrice-a-day (TID), etc., the precise
frequency of administration varying with, for example, the
patient's condition, the dosage, etc.
[0483] Compounds of the invention, or pharmaceutically acceptable
derivatives thereof, may also be administered simultaneously with,
prior to, or after administration of one or more other therapeutic
or biologically active agents, dietary supplements, or any
combination thereof. Such combination therapy includes
administration of a single pharmaceutical dosage formulation which
contains a compound of the invention and one or more additional
active agents, as well as administration of the compound of the
invention and each active agent in its own separate pharmaceutical
dosage formulation. For example, a compound of the invention and
the other active agent can be administered to the patient together
in a single oral dosage composition such as a tablet or capsule, or
each agent administered in separate oral dosage formulations. Where
separate dosage formulations are used, the compounds of the
invention and one or more additional active agents can be
administered at essentially the same time, i.e., concurrently, or
at separately staggered times, i.e., sequentially; combination
therapy is understood to include all these regimens.
[0484] For example, in certain embodiments, the additional
biologically active agent included in a pharmaceutical composition
(or method) of the invention is selected, for example, from vitamin
D.sub.2 (ergocalciferol), vitamin D.sub.3 (cholecalciferol), active
vitamin D (calcitriol) and active vitamin D analogs (e.g.
doxercalciferol, paricalcitol).
[0485] In other specific embodiments, the additional biologically
active agent included in a pharmaceutical composition (or method)
of the invention is a phosphate binder, such as sevelamer (e.g.,
Renvela.RTM. (sevelamer carbonate), Renagel.RTM. (sevelamer
hydrochloride)), lanthanum carbonate (e.g., Fosrenol.RTM.), calcium
carbonate (e.g., Calcichew.RTM., Titralac.RTM.), calcium acetate
(e.g. PhosLo.RTM., Phosex.RTM.), calcium acetate/magnesium
carbonate (e.g., Renepho.RTM., OsvaRen.RTM.), MCI-196, ferric
citrate (e.g., Zerenex.TM.), magnesium iron hydroxycarbonate (e.g.,
Fermagate.TM.), aluminum hydroxide (e.g., Alucaps.RTM.,
Basaljel.RTM.), APS1585, SBR-759, PA-21, and the like.
[0486] In some embodiments, the additional biologically active
agent is an inhibitor of the intestinal sodium-dependent phosphate
transporter (NaPi2b inhibitor). Examples of NaPi2b inhibitors can
be found, for instance, in International Application Nos.
PCT/US2011/043267; PCT/US2011/043261; PCT/US2011/043232;
PCT/US2011/043266; and PCT/US2011/043263; and U.S. Pat. No.
8,134,015, each of which is incorporated by reference in its
entirety.
[0487] In certain embodiments, the additional biologically active
agent is niacin or nicotinamide.
[0488] In some embodiments, the subject has or being treated for
CKD, and the additional biologically active agent is a compound
used in the treatment or management of CKD. Examples of such
compounds include high blood pressure medications such as ACE
inhibitors, antiogensin II receptor blockers, beta-blockers,
calcium channel blockers, direct renin inhibitors, diuretics, and
vasodilators; medications to treat symptoms and complications of
CKD such as erythropoietin therapy and/or iron replacement therapy
for anemia, electrolytes for electrolyte imbalances, diuretics, ACE
inhibitors, and antiogensin II receptor blockers, inhibitors of
advanced glycation end products (e.g., aminoguanidine,
pyridoxamine) and vitamin D; lipid-lowering agents such as HMG-CoA
(3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitors or statins
(e.g., atorvastatin, fluvastatin, lovastatin, pitavastatin,
pravastatin, rosuvastatin, simvastatin).
[0489] It is understood that in the present description,
combinations of substituents and/or variables of the depicted
formulae are permissible only if such contributions result in
stable or reasonably stable compounds.
[0490] It will also be appreciated by those skilled in the art that
in the process described herein the functional groups of
intermediate compounds may need to be protected by suitable
protecting groups. Such functional groups include hydroxy, amino,
mercapto, and carboxylic acid. Suitable protecting groups for
hydroxy include trialkylsilyl or diarylalkylsilyl (for example,
t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl),
tetrahydropyranyl, benzyl, and the like. Suitable protecting groups
for amino, amidino and guanidino include t-butoxycarbonyl,
benzyloxycarbonyl, and the like. Suitable protecting groups for
mercapto include --C(O)--R'' (where R'' is alkyl, aryl or
arylalkyl), p-methoxybenzyl, trityl and the like. Suitable
protecting groups for carboxylic acid include alkyl, aryl or
arylalkyl esters. Protecting groups may be added or removed in
accordance with standard techniques, which are known to one skilled
in the art and as described herein. The use of protecting groups is
described in detail in Green, T. W. and P. G. M. Wutz, Protective
Groups in Organic Synthesis (1999), 3rd Ed., Wiley. As one of skill
in the art would appreciate, the protecting group may also be a
polymer resin such as a Wang resin, Rink resin or a
2-chlorotrityl-chloride resin.
[0491] It will also be appreciated by those skilled in the art,
although such protected derivatives of compounds of this invention
may not possess pharmacological activity as such, they may be
administered to a mammal and thereafter metabolized in the body to
form compounds of the invention which are pharmacologically active.
Such derivatives may therefore be described as "prodrugs". All
prodrugs of compounds of this invention are included within the
scope of the invention.
[0492] Furthermore, all compounds of the invention which exist in
free base or acid form can be converted to their pharmaceutically
acceptable salts by treatment with the appropriate inorganic or
organic base or acid by methods known to one skilled in the art.
Salts of the compounds of the invention can be converted to their
free base or acid form by standard techniques.
IV. Drug Discovery
[0493] Also included are methods relating to the discovery of
compounds that can inhibit phosphate uptake in the gastrointestinal
tract. Particular embodiments include in vitro methods of drug
screening which employ cell cultures such as intestinal cell
cultures or cell lines, including mammalian cell lines.
[0494] Certain embodiments therefore relate to methods of screening
for an inhibitor of phosphate uptake, comprising culturing cells,
contacting the cultured cells with a test compound, and measuring
one or more of the following: the pH at the apical surface of the
cells, the intracellular pH of the cells, bicarbonate secretion by
the cells, acid secretion by the cells, water absorption, and/or
phosphate uptake by the cells.
[0495] Also included is the step of identifying the test compound
as an inhibitor of phosphate uptake, where one or more of the
following occurs: the pH at the apical surface of the cells
increases relative to a control, the intracellular pH of the cells
decreases relative to a control, bicarbonate secretion by the cells
increases relative to a control, acid secretion by the cells
decreases relative to a control, water absorption decreases
relative to a control, and/or phosphate uptake by the cells
decreases relative to a control. In some aspects, the increase or
decrease is statistically significant. The terms "increase" and
"decrease" and "statistically significant" are described elsewhere
herein. A control can include no compound (e.g., vehicle only) or
compound that is known not to possess any of the above-described
activities. A control can also include a pre-determined reference
value.
[0496] In certain embodiments, the cells are intestinal cells.
Non-limiting examples of intestinal cell cultures include
intestinal cell monolayers, enteroids, and intestinal cell
organoids. Intestinal cell monolayers can be prepared according to
routine techniques in the art. Non-limiting examples of intestinal
cell monolayers include cell lines such as Caco-2, HCT-8, and T84
cell lines (see, e.g., Watson et al., Am J Physiol Cell Physiol.
281:C388-9, 2001; Shah et al., Biotechnol Prog. 22:186-9, 2006) and
neonatal piglet jejunal IPEC-J2 cell monolayers (see, e.g., Chapman
et al., Pediatr Res. 72:576-82, 2012).
[0497] The term "enteroid" includes intestinal cell cultures
obtained from intestinal crypts from segment(s) of intestinal
tissue, which optionally maintain the structural integrity (e.g.,
three-dimensional structure of intestinal epithelium) and cell
types of intestinal tissue, and replicate the genotypic and
phenotypic profiles of primary intestinal tissue. Enteroid cell
cultures can be prepared according to techniques known in the art.
(see, e.g., U.S. Application No. 2010/0047853; WO 2010/090513; US
Application No. 2012/0196312; and WO 2012/168930).
[0498] The term "organoid" or "intestinal organoid" includes
intestinal cell cultures made primarily from precursor cell such as
isolated embryonic stem cells, endoderm cells, or other pluripotent
stem cells. Organoids can be prepared, for instance, by the
step-wise differentiation of precursor cells into complex,
three-dimensional intestinal tissues (see, e.g., WO 2011/140441),
including intestinal tissues which can comprise a polarized,
columnar epithelium surrounded by mesenchyme that includes a smooth
muscle-like layer. In some aspects, the epithelium is patterned
into crypt-like proliferative zones and villus-like structures
having most if not all of the major functional cell types of the
intestine. In some aspects, the precursor cells are first selected
or enriched for the expression of markers such as LGR5 and/or
LGR6.
[0499] Also included are cultures that comprise whole-thickness
intestinal preparations (see, e.g., Binder et al., Am J Physiol.
225:1232-1239, 1973) and those prepared by pharmacological
treatment and seromusculature "stripping" to minimize the influence
of the intrinsic neuromuscular system (see, e.g., Clarke, Am. J.
Physiol. Gastrointestin. Liver Physiol. 296:G1151-66, 2009).
Seromusculature stripping removes the serosa (visceral peritoneum)
and the longitudinal/circular muscle layers of the intestinal wall,
leaving only the underlying submucosal elements, remnants of
muscle, and the epithelium. These cultures can be particularly
useful when employing a Ussing chamber.
[0500] Certain embodiments may employ an Ussing Chamber. The Ussing
chamber provides a physiological system to measure the transport of
ions, nutrients, and drugs across various epithelial tissues such
as intestinal tissues (see, e.g., Clarke et al., supra). For
instance, some methods can employ pH stat techniques to measure
transepithelial bicarbonate secretion and/or isotopic flux methods
to measure net secretion or absorption of substrates. In particular
embodiments, the Ussing Chamber is adapted for use with a mouse or
rat intestines, including whole-thickness intestinal preparations
and those prepared by seromusculature stripping (see, e.g., Clarke
et al., supra).
[0501] Certain screening methods may employ various non-intestinal
cell lines, including mammalian cell lines. Exemplary mammalian
cell lines include human embryonic kidney cell lines (e.g., HEK
293-cells), monkey kidney CV1 line transformed by SV40 (COS-7, ATCC
CRL 1651); baby hamster kidney cells (BHK, ATCC CCL 10); mouse
sertoli cells (TM4); monkey kidney cells (CV1 ATCC CCL 70); African
green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical
carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC
CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human
lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB
8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TR1 cells; MRC
5 cells; FS4 cells; and a human hepatoma line (Hep G2). Other
useful mammalian cell lines include Chinese hamster ovary (CHO)
cells, including DHFR-CHO cells and myeloma cell lines such as NSO
and Sp2/0.
[0502] Techniques for measuring changes in pH, bicarbonate
secretion, acid secretion, water absorption, and phosphate uptake
are known in the art. For example, changes in intracellular pH can
be measured by contacting cells or tissues with a pH-sensitive
fluorescent dye or probe and measuring fluorescence of the dye or
probe. Examples of pH-sensitive dyes include
2'',7''-Bis-(2-carboxyethyl)-5-(and -6-) carboxyfluorescein 4
(BCECF), 2'',7''-bis-(2-carboxypropyl)-5-(and
-6-)-carboxyfluorescein (BCPCF 11), 5-(and
6)-carboxynaphthofluorescein, and others (see, e.g., FIGS. 8A and
8B; Han and Burgess, Chem Rev. 110:2709-28, 2010). Techniques for
measuring bicarbonate transport (in vitro) through single ion
channels, individual cells, and intact epithelial layers are
described, for example, in Hug et al., Methods Mol Biol.
741:489-509, 2011; Feldman et al., Am. J. Physiol. 254:C383-90,
1988. As noted above, changes in pH, bicarbonate secretion, and/or
acid secretion can also be measured in an Ussing chamber, for
example, using pH stat or isotopic flux methods. Phosphate uptake
can be measured, for instance, by contacting cells or tissues with
.sup.33P-labeled phosphate ions and measuring uptake of the labeled
phosphate ions (see the Examples; Matsuo et al., Eur. J. Pharmacol.
517:111-19, 2005). Other techniques for measuring pH, bicarbonate
secretion, acid secretion, and phosphate uptake will be apparent to
persons skilled in the art.
[0503] In certain aspects, the test compound is a small molecule or
peptide that is known or suspected to stimulate bicarbonate
secretion (e.g., DBS), inhibit acid secretion, and/or decrease
water absorption in the gastrointestinal tract, including the small
intestine. Examples of such compounds include, without limitation,
P2Y agonists, adenosine A2b receptor agonists, guanylate cyclase C
receptor agonists (e.g., peptide agonists), soluble guanylate
cyclase agonists, adenylate cyclase receptor agonists,
imidazoline-1 receptor agonists, cholinergic agonists,
prostaglandin EP4 receptor agonists, dopamine D1 agonists,
melatonin receptor agonists, 5HT4 agonists, atrial natriuretic
peptide receptor agonists, carbonic anyhdrase inhibitors, and
phosphodiesterase inhibitors. Non-limiting examples of such
compounds are described elsewhere herein. In some embodiments, the
compound is a derivative or analog of one or more of such
compounds. Such derivatives or analogs can include modifications,
for instance, to increase the system non-bioavailability of the
compound, as described herein.
[0504] Also included are any of the above methods, or other
screening methods known in the art, which are adapted for
high-throughput screening (HTS). HTS typically uses automation to
run a screen of an assay against a library of candidate agents, for
instance, an assay that measures an increase or a decrease in
binding and/or activity, as described herein.
[0505] Any of the screening methods provided herein may utilize
small molecule libraries or libraries generated by combinatorial
chemistry. As one example, such libraries can be used to screen for
small molecules that associate or interact with a target molecule
or elicit the desired physiological response (e.g., decrease
intracellular pH of intestinal cells, inhibit phosphate uptake).
Libraries of chemical and/or biological mixtures, such as fungal,
bacterial, or algal extracts, are known in the art. Examples of
methods for the synthesis of molecular libraries can be found in:
(Carell et al., 1994a; Carell et al., 1994b; Cho et al., 1993;
DeWitt et al., 1993; Gallop et al., 1994; Zuckermann et al.,
1994).
[0506] Libraries of agents may be presented in solution (Houghten
et al., 1992) or on beads (Lam et al., 1991), on chips (Fodor et
al., 1993), bacteria, spores (Ladner et al., U.S. Pat. No.
5,223,409, 1993), plasmids (Cull et al., 1992) or on phage (Cwirla
et al., 1990; Devlin et al., 1990; Felici et al., 1991; Ladner et
al., U.S. Pat. No. 5,223,409, 1993; Scott and Smith, 1990).
Libraries useful for the purposes of the invention include, but are
not limited to, (1) chemical libraries, (2) natural product
libraries, and (3) combinatorial libraries comprised of random
peptides, oligonucleotides and/or organic molecules.
[0507] Chemical libraries consist of structural analogs of known
agents or agents that are identified as "hits" or "leads" via
natural product screening. Natural product libraries are derived
from collections of microorganisms, animals, plants, or marine
organisms which are used to create mixtures for screening by: (1)
fermentation and extraction of broths from soil, plant or marine
microorganisms or (2) extraction of plants or marine organisms.
Natural product libraries include polyketides, non-ribosomal
peptides, and variants (non-naturally occurring) thereof. See,
e.g., Cane et al., Science 282:63-68, 1998. Combinatorial libraries
may be composed of large numbers of peptides or organic compounds
as a mixture. They are relatively easy to prepare by traditional
automated synthesis methods, PCR, cloning or proprietary synthetic
methods.
[0508] More specifically, a combinatorial chemical library is a
collection of diverse chemical agents generated by either chemical
synthesis or biological synthesis, by combining a number of
chemical "building blocks" such as reagents. For example, a linear
combinatorial chemical library such as a polypeptide library is
formed by combining a set of chemical building blocks (amino acids)
in every possible way for a given compound length (i.e., the number
of amino acids in a polypeptide agent). Millions of chemical agents
can be synthesized through such combinatorial mixing of chemical
building blocks.
[0509] For a review of combinatorial chemistry and libraries
created therefrom, see, e.g., Huc and Nguyen, (2001) Comb. Chem.
High Throughput Screen. 4:53-74; Lepre, (2001) Drug Discov. Today
6:133-140; Peng, (2000) Biomed. Chromatogr. 14:430-441; Bohm, H. J.
and Stahl, M. (2000) Curr. Opin. Chem. Biol. 4:283-286; Barnes and
Balasubramanian, (2000) Curr. Opin. Chem. Biol. 4:346-350; Lepre et
al., (2000) Mass Spectrom Rev. 19:139-161; Hall, (2000) Nat.
Biotechnol. 18:262-262; Lazo and Wipf, (2000) J. Pharmacol. Exp.
Ther. 293:705-709; Houghten, (2000) Ann. Rev. Pharmacol. Toxicol.
40:273-282; Kobayashi (2000) Curr. Opin. Chem. Biol. (2000)
4:338-345; Kopylov Spiridonova, (2000) Mol. Biol. (Mosk)
34:1097-1113; Weber, (2000) Curr. Opin. Chem. Biol. 4:295-302;
Dolle, (2000) J. Comb. Chem. 2:383-433; Floyd et al., (1999) Prog.
Med. Chem. 36:91-168; Kundu et al., (1999) Prog. Drug Res.
53:89-156; Cabilly, (1999) Mol. Biotechnol. 12:143-148; Lowe,
(1999) Nat. Prod. Rep. 16:641-651; Dolle and Nelson, (1999) J.
Comb. Chem. 1:235-282; Czarnick and Keene, (1998) Curr. Biol.
8:R705-R707; Dolle, (1998) Mol. Divers. 4:233-256; Myers, (1997)
Curr. Opin. Biotechnol. 8:701-707; and Pluckthun and Cortese,
(1997) Biol. Chem. 378:443.
[0510] Devices for the preparation of combinatorial libraries are
commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem
Tech, Louisville Ky., Symphony, Rainin, Woburn, Mass., 433A Applied
Biosystems, Foster City, Calif., 9050 Plus, Millipore, Bedford,
Mass.). In addition, numerous combinatorial libraries are
themselves commercially available (see, e.g., ComGenex, Princeton,
N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, Mo., ChemStar,
Ltd., Moscow, RU, 3D Pharmaceuticals, Exton, Pa., Martek
Biosciences, Columbia, Md., etc.).
DEFINITIONS AND TERMINOLOGY
[0511] "Amino" refers to the --NH.sub.2 radical.
[0512] "Aminocarbonyl" refers to the --C(.dbd.O)NH.sub.2
radical.
[0513] "Carboxy" refers to the --CO.sub.2H radical. "Carboxylate"
refers to a salt or ester thereof.
[0514] "Cyano" refers to the --CN radical.
[0515] "Hydroxy" or "hydroxyl" refers to the --OH radical.
[0516] "Imino" refers to the .dbd.NH radical.
[0517] "Nitro" refers to the --NO.sub.2 radical.
[0518] "Oxo" or "carbonyl" refers to the .dbd.O radical.
[0519] "Thioxo" refers to the .dbd.S radical.
[0520] "Guanidinyl" (or "guanidine") refers to the
--NHC(.dbd.NH)NH.sub.2 radical.
[0521] "Amidinyl" (or "amidine") refers to the --C(.dbd.NH)NH.sub.2
radical.
[0522] "Phosphate" refers to the --OP(.dbd.O)(OH).sub.2
radical.
[0523] "Phosphonate" refers to the --P(.dbd.O)(OH).sub.2
radical.
[0524] "Phosphinate" refers to the --PH(.dbd.O)OH radical, where
each R.sup.a is independently an alkyl group as defined herein.
[0525] "Sulfate" refers to the --OS(.dbd.O).sub.2OH radical.
[0526] "Sulfonate" or "hydroxysulfonyl" refers to the
--S(.dbd.O).sub.2OH radical.
[0527] "Sulfinate" refers to the --S(.dbd.O)OH radical.
[0528] "Sulfonyl" refers to a moiety comprising a --SO.sub.2--
group. For example, "alkysulfonyl" or "alkylsulfone" refers to the
--SO.sub.2--R.sup.a group, where R.sup.a is an alkyl group as
defined herein.
[0529] "Alkyl" refers to a straight or branched hydrocarbon chain
radical consisting solely of carbon and hydrogen atoms, which is
saturated or unsaturated (i.e., contains one or more double and/or
triple bonds), having from one to twelve carbon atoms (C.sub.1-12
alkyl), preferably one to eight carbon atoms (C.sub.1-C.sub.8
alkyl) or one to six carbon atoms (C.sub.1-C.sub.6 alkyl), and
which is attached to the rest of the molecule by a single bond,
e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl,
n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl,
2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl,
penta-1,4-dienyl, ethynyl, propynyl, butyryl, pentynyl, hexynyl,
and the like. Unless stated otherwise specifically in the
specification, an alkyl group may be optionally substituted.
[0530] "Alkylene" or "alkylene chain" refers to a straight or
branched divalent hydrocarbon chain linking the rest of the
molecule to a radical group, consisting solely of carbon and
hydrogen, which is saturated or unsaturated (i.e., contains one or
more double and/or triple bonds), and having from one to twelve
carbon atoms, e.g., methylene, ethylene, propylene, n-butylene,
ethenylene, propenylene, n-butenylene, propynylene, n-butynylene,
and the like. The alkylene chain is attached to the rest of the
molecule through a single or double bond and to the radical group
through a single or double bond. The points of attachment of the
alkylene chain to the rest of the molecule and to the radical group
can be through one carbon or any two carbons within the chain.
Unless stated otherwise specifically in the specification, an
alkylene chain may be optionally substituted.
[0531] "Alkoxy" refers to a radical of the formula --OR.sub.a where
R.sub.a is an alkyl radical as defined above containing one to
twelve carbon atoms. Unless stated otherwise specifically in the
specification, an alkoxy group may be optionally substituted.
[0532] "Alkylamino" refers to a radical of the formula --NHR.sub.a
or --NR.sub.aR.sub.a where each R.sub.a is, independently, an alkyl
radical as defined above containing one to twelve carbon atoms.
Unless stated otherwise specifically in the specification, an
alkylamino group may be optionally substituted.
[0533] "Thioalkyl" refers to a radical of the formula --SR.sub.a
where R.sub.a is an alkyl radical as defined above containing one
to twelve carbon atoms. Unless stated otherwise specifically in the
specification, a thioalkyl group may be optionally substituted.
[0534] "Aryl" refers to a hydrocarbon ring system radical
comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic
ring. For purposes of this invention, the aryl radical may be a
monocyclic, bicyclic, tricyclic or tetracyclic ring system, which
may include fused or bridged ring systems. Aryl radicals include,
but are not limited to, aryl radicals derived from aceanthrylene,
acenaphthylene, acephenanthrylene, anthracene, azulene, benzene,
chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane,
indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene,
and triphenylene. Unless stated otherwise specifically in the
specification, the term "aryl" or the prefix "ar-" (such as in
"aralkyl") is meant to include aryl radicals that are optionally
substituted.
[0535] "Aralkyl" refers to a radical of the formula
--R.sub.b-R.sub.c where R.sub.b is an alkylene chain as defined
above and R.sub.c is one or more aryl radicals as defined above,
for example, benzyl, diphenylmethyl and the like. Unless stated
otherwise specifically in the specification, an aralkyl group may
be optionally substituted.
[0536] "Cycloalkyl" or "carbocyclic ring" refers to a stable
non-aromatic monocyclic or polycyclic hydrocarbon radical
consisting solely of carbon and hydrogen atoms, which may include
fused or bridged ring systems, having from three to fifteen carbon
atoms, preferably having from three to ten carbon atoms, and which
is saturated or unsaturated and attached to the rest of the
molecule by a single bond. Monocyclic radicals include, for
example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, and cyclooctyl. Polycyclic radicals include, for
example, adamantyl, norbornyl, decalinyl,
7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise
stated specifically in the specification, a cycloalkyl group may be
optionally substituted.
[0537] "Cycloalkylalkyl" refers to a radical of the formula
--R.sub.bR.sub.d where R.sub.d is an alkylene chain as defined
above and R.sub.g is a cycloalkyl radical as defined above. Unless
stated otherwise specifically in the specification, a
cycloalkylalkyl group may be optionally substituted.
[0538] "Fused" refers to any ring structure described herein which
is fused to an existing ring structure in the compounds of the
invention. When the fused ring is a heterocyclyl ring or a
heteroaryl ring, any carbon atom on the existing ring structure
which becomes part of the fused heterocyclyl ring or the fused
heteroaryl ring may be replaced with a nitrogen atom.
[0539] "Halo" or "halogen" refers to bromo, chloro, fluoro or
iodo.
[0540] "Haloalkyl" refers to an alkyl radical, as defined above,
that is substituted by one or more halo radicals, as defined above,
e.g., trifluoromethyl, difluoromethyl, trichloromethyl,
2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl,
1,2-dibromoethyl, and the like. Unless stated otherwise
specifically in the specification, a haloalkyl group may be
optionally substituted.
[0541] "Heterocyclyl" or "heterocyclic ring" refers to a stable 3-
to 18-membered non-aromatic ring radical which consists of two to
twelve carbon atoms and from one to six heteroatoms selected from
the group consisting of nitrogen, oxygen and sulfur. Unless stated
otherwise specifically in the specification, the heterocyclyl
radical may be a monocyclic, bicyclic, tricyclic or tetracyclic
ring system, which may include fused or bridged ring systems; and
the nitrogen, carbon or sulfur atoms in the heterocyclyl radical
may be optionally oxidized; the nitrogen atom may be optionally
quaternized; and the heterocyclyl radical may be partially or fully
saturated. Examples of such heterocyclyl radicals include, but are
not limited to, dioxolanyl, thienyl[1,3]dithianyl,
decahydroisoquinolyl, imidazolinyl, imidazolidinyl,
isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl,
octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl,
4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,
thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,
thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and
1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in
the specification, Unless stated otherwise specifically in the
specification, a heterocyclyl group may be optionally
substituted.
[0542] "N-heterocyclyl" refers to a heterocyclyl radical as defined
above containing at least one nitrogen and where the point of
attachment of the heterocyclyl radical to the rest of the molecule
is through a nitrogen atom in the heterocyclyl radical. Unless
stated otherwise specifically in the specification, a
N-heterocyclyl group may be optionally substituted.
[0543] "Heterocyclylalkyl" refers to a radical of the formula
--R.sub.bR.sub.e where R.sub.b is an alkylene chain as defined
above and R.sub.e is a heterocyclyl radical as defined above, and
if the heterocyclyl is a nitrogen-containing heterocyclyl, the
heterocyclyl may be attached to the alkyl radical at the nitrogen
atom. Unless stated otherwise specifically in the specification, a
heterocyclylalkyl group may be optionally substituted.
[0544] "Heteroaryl" refers to a 5- to 14-membered ring system
radical comprising hydrogen atoms, one to thirteen carbon atoms,
one to six heteroatoms selected from the group consisting of
nitrogen, oxygen and sulfur, and at least one aromatic ring. For
purposes of this invention, the heteroaryl radical may be a
monocyclic, bicyclic, tricyclic or tetracyclic ring system, which
may include fused or bridged ring systems; and the nitrogen, carbon
or sulfur atoms in the heteroaryl radical may be optionally
oxidized; the nitrogen atom may be optionally quaternized. Examples
include, but are not limited to, azepinyl, acridinyl,
benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl,
benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl,
benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl,
benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl,
benzopyranonyl, benzofuranyl, benzopyranonyl, benzothienyl
(benzothiophenyl), benzotriazolyl,
benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl,
dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl,
isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl,
isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl,
isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl,
oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl,
1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl,
phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl,
pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl,
isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl,
triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl).
Unless stated otherwise specifically in the specification, a
heteroaryl group may be optionally substituted.
[0545] "N-heteroaryl" refers to a heteroaryl radical as defined
above containing at least one nitrogen and where the point of
attachment of the heteroaryl radical to the rest of the molecule is
through a nitrogen atom in the heteroaryl radical. Unless stated
otherwise specifically in the specification, an N-heteroaryl group
may be optionally substituted.
[0546] "Heteroarylalkyl" refers to a radical of the formula
--R.sub.bR.sub.f where R.sub.b is an alkylene chain as defined
above and R.sub.f is a heteroaryl radical as defined above. Unless
stated otherwise specifically in the specification, a
heteroarylalkyl group may be optionally substituted.
[0547] The term "substituted" used herein means any of the above
groups (i.e., alkyl, alkylene, alkoxy, alkylamino, thioalkyl, aryl,
aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl,
N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or
heteroarylalkyl) where at least one hydrogen atom is replaced by a
bond to a non-hydrogen atoms such as, but not limited to: a halogen
atom such as F, Cl, Br, and I; an oxygen atom in groups such as
hydroxyl groups, carboxyl groups, phosphate groups, sulfate groups,
alkoxy groups, and ester groups; a sulfur atom in groups such as
thiol groups, thioalkyl groups, sulfinate groups, sulfone groups,
sulfonyl groups, and sulfoxide groups; a phosphorus atom in groups
such as phosphinate groups and phosphonate groups; a nitrogen atom
in groups such as guanidine groups, amines, amides, alkylamines,
dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides,
imides, and enamines; a silicon atom in groups such as
trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl
groups, and triarylsilyl groups; and other heteroatoms in various
other groups. "Substituted" also means any of the above groups in
which one or more hydrogen atoms are replaced by a higher-order
bond (e.g., a double- or triple-bond) to a heteroatom such as
oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen
in groups such as imines, oximes, hydrazones, and nitriles. For
example, "substituted" includes any of the above groups in which
one or more hydrogen atoms are replaced with --NR.sub.gR.sub.h,
--NR.sub.gC(.dbd.O)R.sub.h, --NR.sub.gC(.dbd.O)NR.sub.gR.sub.h,
--NR.sub.gC(.dbd.O)OR.sub.h, --NR.sub.gSO.sub.2R.sub.h,
--OC(.dbd.O)NR.sub.gR.sub.h, --OR.sub.g, --SR.sub.g, --SOR.sub.g,
--SO.sub.2R.sub.g, --OSO.sub.2R.sub.g, --SO.sub.2OR.sub.g,
.dbd.NSO.sub.2R.sub.g, and --SO.sub.2NR.sub.gR.sub.h. "Substituted"
also means any of the above groups in which one or more hydrogen
atoms are replaced with --C(.dbd.O)R.sub.g, --C(.dbd.O)OR.sub.g,
--C(.dbd.O)NR.sub.gR.sub.h, --CH.sub.2SO.sub.2R.sub.g,
--CH.sub.2SO.sub.2NR.sub.gR.sub.h,
--(CH.sub.2CH.sub.2O).sub.1-10R.sub.g,
--(CH.sub.2CH.sub.2O).sub.2-10R.sub.g,
--(OCH.sub.2CH.sub.2).sub.1-10R.sub.g and
--(OCH.sub.2CH.sub.2).sub.2-10R.sub.g. In the foregoing, R.sub.g
and R.sub.h are the same or different and independently hydrogen,
alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl,
heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
"Substituted" further means any of the above groups in which one or
more hydrogen atoms are replaced by a bond to an amino, cyano,
hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy,
alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl,
heteroaryl, N-heteroaryl and/or heteroarylalkyl group. The above
non-hydrogen groups are generally referred to herein as
"substituents" or "non-hydrogen substituents". In addition, each of
the foregoing substituents may also be optionally substituted with
one or more of the above substituents.
[0548] The articles "a" and "an" are used herein to refer to one or
to more than one (i.e., to at least one) of the grammatical object
of the article. By way of example, "an element" means one element
or more than one element.
[0549] By "about" is meant a quantity, level, value, number,
frequency, percentage, dimension, size, amount, weight or length
that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3,
2, or 1% to a reference quantity, level, value, number, frequency,
percentage, dimension, size, amount, weight, length, or other unit
described herein.
[0550] The term "activate" refers to the application of physical,
chemical, or biochemical conditions, substances or processes that a
receptor (e.g., pore receptor) to structurally change in a way that
allows passage of ions, molecules, or other substances.
[0551] The term "active state" refers to the state or condition of
a receptor in its non-resting condition.
[0552] "Efflux" refers to the movement or flux of ions, molecules,
or other substances from an intracellular space to an extracellular
space.
[0553] "Enteral" or "enteric" administration refers to
administration via the gastrointestinal tract, including oral,
sublingual, sublabial, buccal, and rectal administration, and
including administration via a gastric or duodenal feeding
tube.
[0554] The term "inactive state" refers to the state of a receptor
in its original endogenous state, that is, its resting state.
[0555] The term "modulating" includes "increasing" or "enhancing,"
as well as "decreasing" or "reducing," typically in a statistically
significant or a physiologically significant amount as compared to
a control. An "increased" or "enhanced" amount is typically a
"statistically significant" amount, and may include an increase
that is about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0,
2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.2, 3.4, 3.6,
3.8, 4.0, 4.2, 4.3, 4.4, 4.6, 4.8, 5, 6, 7, 8, 9, 10, 15, 20, 30,
40, 50 or more times (e.g., 100, 200, 500, 1000 times) (including
all integers and decimal points and ranges in between and above 1,
e.g., 5.5, 5.6, 5.7. 5.8, etc.) the amount produced by a control
(e.g., the absence or lesser amount of a compound, a different
compound or treatment), or the amount of an earlier time-point
(e.g., prior to treatment with a compound). A "decreased" or
"reduced" amount is typically a "statistically significant" amount,
and may include a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%,
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%
decrease (including all integers and decimal points and ranges in
between) in the amount or activity produced by a control (e.g., the
absence or lesser amount of a compound, a different compound or
treatment), or the amount of an earlier time-point (e.g., prior to
treatment with a compound).
[0556] "Prodrug" is meant to indicate a compound that may be
converted under physiological conditions or by solvolysis to a
biologically active compound of the invention. Thus, the term
"prodrug" refers to a metabolic precursor of a compound of the
invention that is pharmaceutically acceptable. A prodrug may be
inactive when administered to a subject in need thereof, but is
converted in vivo to an active compound of the invention. Prodrugs
are typically rapidly transformed in vivo to yield the parent
compound of the invention, for example, by hydrolysis in blood. The
prodrug compound often offers advantages of solubility, tissue
compatibility or delayed release in a mammalian organism (see,
Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier,
Amsterdam)). A discussion of prodrugs is provided in Higuchi, T.,
et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible
Carriers in Drug Design, Ed. Edward B. Roche, American
Pharmaceutical Association and Pergamon Press, 1987.
[0557] The term "prodrug" is also meant to include any covalently
bonded carriers, which release the active compound of the invention
in vivo when such prodrug is administered to a mammalian subject.
Prodrugs of a compound of the invention may be prepared by
modifying functional groups present in the compound of the
invention in such a way that the modifications are cleaved, either
in routine manipulation or in vivo, to the parent compound of the
invention. Prodrugs include compounds of the invention where a
hydroxy, amino or mercapto group is bonded to any group that, when
the prodrug of the compound of the invention is administered to a
mammalian subject, cleaves to form a free hydroxy, free amino or
free mercapto group, respectively. Examples of prodrugs include,
but are not limited to, acetate, formate and benzoate derivatives
of alcohol or amide derivatives of amine functional groups in the
compounds of the invention and the like.
[0558] The invention disclosed herein is also meant to encompass
the in vivo metabolic products of the disclosed compounds. Such
products may result from, for example, the oxidation, reduction,
hydrolysis, amidation, esterification, and the like of the
administered compound, primarily due to enzymatic processes.
Accordingly, the invention includes compounds produced by a process
comprising administering a compound of this invention to a mammal
for a period of time sufficient to yield a metabolic product
thereof. Such products are typically identified by administering a
radiolabelled compound of the invention in a detectable dose to an
animal, such as rat, mouse, guinea pig, monkey, or to human,
allowing sufficient time for metabolism to occur, and isolating its
conversion products from the urine, blood or other biological
samples.
[0559] "Mammal" includes humans and both domestic animals such as
laboratory animals and household pets (e.g., cats, dogs, swine,
cattle, sheep, goats, horses, rabbits), and non-domestic animals
such as wildlife and the like.
[0560] "Optional" or "optionally" means that the subsequently
described event or circumstances may or may not occur, and that the
description includes instances where said event or circumstance
occurs and instances in which it does not. For example, "optionally
substituted aryl" means that the aryl radical may or may not be
substituted and that the description includes both substituted aryl
radicals and aryl radicals having no substitution.
[0561] "Pharmaceutically acceptable carrier, diluent or excipient"
includes without limitation any adjuvant, carrier, excipient,
glidant, sweetening agent, diluent, preservative, dye/colorant,
flavor enhancer, surfactant, wetting agent, dispersing agent,
suspending agent, stabilizer, isotonic agent, solvent, or
emulsifier which has been approved by the United States Food and
Drug Administration as being acceptable for use in humans or
domestic animals.
[0562] "Pharmaceutically acceptable salt" includes both acid and
base addition salts.
[0563] "Pharmaceutically acceptable acid addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free bases, which are not biologically or
otherwise undesirable, and which are formed with inorganic acids
such as, but are not limited to, hydrochloric acid, hydrobromic
acid, sulfuric acid, nitric acid, phosphoric acid and the like, and
organic acids such as, but not limited to, acetic acid,
2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid,
aspartic acid, benzenesulfonic acid, benzoic acid,
4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid,
capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic
acid, citric acid, cyclamic acid, dodecylsulfuric acid,
ethane-1,2-disulfonic acid, ethanesulfonic acid,
2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric
acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic
acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid,
glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric
acid, lactic acid, lactobionic acid, lauric acid, maleic acid,
malic acid, malonic acid, mandelic acid, methanesulfonic acid,
mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic
acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid,
orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic
acid, pyroglutamic acid, pyruvic acid, salicylic acid,
4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid,
tartaric acid, thiocyanic acid, p-toluenesulfonic acid,
trifluoroacetic acid, undecylenic acid, and the like.
[0564] "Pharmaceutically acceptable base addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free acids, which are not biologically or
otherwise undesirable. These salts are prepared from addition of an
inorganic base or an organic base to the free acid. Salts derived
from inorganic bases include, but are not limited to, the sodium,
potassium, lithium, ammonium, calcium, magnesium, iron, zinc,
copper, manganese, aluminum salts and the like. Preferred inorganic
salts are the ammonium, sodium, potassium, calcium, and magnesium
salts. Salts derived from organic bases include, but are not
limited to, salts of primary, secondary, and tertiary amines,
substituted amines including naturally occurring substituted
amines, cyclic amines and basic ion exchange resins, such as
ammonia, isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, diethanolamine, ethanolamine,
deanol, 2-dimethylamino ethanol, 2-diethylaminoethanol,
dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,
hydrabamine, choline, betaine, benethamine, benzathine,
ethylenediamine, glucosamine, methylglucamine, theobromine,
triethanolamine, tromethamine, purines, piperazine, piperidine,
N-ethylpiperidine, polyamine resins and the like. Particularly
preferred organic bases are isopropylamine, diethylamine,
ethanolamine, trimethylamine, dicyclohexylamine, choline and
caffeine.
[0565] Often crystallizations produce a solvate of the compound of
the invention. As used herein, the term "solvate" refers to an
aggregate that comprises one or more molecules of a compound of the
invention with one or more molecules of solvent. The solvent may be
water, in which case the solvate may be a hydrate. Alternatively,
the solvent may be an organic solvent. Thus, the compounds of the
present invention may exist as a hydrate, including a monohydrate,
dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and
the like, as well as the corresponding solvated forms. The compound
of the invention may be true solvates, while in other cases, the
compound of the invention may merely retain adventitious water or
be a mixture of water plus some adventitious solvent.
[0566] A "pharmaceutical composition" refers to a formulation of a
compound of the invention and a medium generally accepted in the
art for the delivery of the biologically active compound to
mammals, e.g., humans. Such a medium includes all pharmaceutically
acceptable carriers, diluents or excipients therefor.
[0567] The compounds of the invention, or their pharmaceutically
acceptable salts may contain one or more asymmetric centers and may
thus give rise to enantiomers, diastereomers, and other
stereoisomeric forms that may be defined, in terms of absolute
stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino
acids. The present invention is meant to include all such possible
isomers, as well as their racemic and optically pure forms.
Optically active (+) and (-), (R)- and (S)-, or (D)- and
(L)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques, for example,
chromatography and fractional crystallization. Conventional
techniques for the preparation/isolation of individual enantiomers
include chiral synthesis from a suitable optically pure precursor
or resolution of the racemate (or the racemate of a salt or
derivative) using, for example, chiral high pressure liquid
chromatography (HPLC). When the compounds described herein contain
olefinic double bonds or other centres of geometric asymmetry, and
unless specified otherwise, it is intended that the compounds
include both E and Z geometric isomers. Likewise, all tautomeric
forms are also intended to be included.
[0568] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0569] By "statistically significant," it is meant that the result
was unlikely to have occurred by chance. Statistical significance
can be determined by any method known in the art. Commonly used
measures of significance include the p-value, which is the
frequency or probability with which the observed event would occur,
if the null hypothesis were true. If the obtained p-value is
smaller than the significance level, then the null hypothesis is
rejected. In simple cases, the significance level is defined at a
p-value of 0.05 or less.
[0570] "Substantially" or "essentially" includes nearly totally or
completely, for instance, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
greater of some given quantity.
[0571] The term "secondary" refers to a condition or state that can
occur with another disease state, condition, or treatment, can
follow on from another disease state, condition, or treatment, or
can result from another disease state, condition or treatment. The
term also refers to situations where a disease state, condition, or
treatment can play only a minor role in creating symptoms or a
response in a patient's final diseased state, symptoms or
condition.
[0572] "Subjects" or "patients" (the terms are used interchangeably
herein) in need of treatment with a compound of the present
disclosure include, for instance, subjects "in need of phosphate
lowering," which can include subjects in need of "phosphate
management," e.g., prophylactic management of phosphate or
phosphorus levels. Included are mammals having or at risk for
having the diseases and/or conditions described herein,
particularly diseases and/or conditions that can be treated with
the compounds of the invention, with or without other active
agents, to achieve a beneficial therapeutic and/or prophylactic
result. A beneficial outcome includes a decrease in the severity of
symptoms, a delay in the onset of symptoms, maintenance of
normophosphatemia, reduction in the risk of developing
hyperphosphatemia, modulation of one or more indications described
herein (e.g., reduced phosphorus levels in serum or blood of
patients with or at risk for hyperphosphatemia, increased fecal
output of phosphate ions in patients with or at risk for
hyperphosphatemia), increased longevity, and/or more rapid or more
complete resolution of the disease or condition.
[0573] A "stereoisomer" refers to a compound made up of the same
atoms bonded by the same bonds but having different
three-dimensional structures, which are not interchangeable. The
present invention contemplates various stereoisomers and mixtures
thereof and includes "enantiomers", which refers to two
stereoisomers whose molecules are nonsuperimposeable mirror images
of one another.
[0574] A "tautomer" refers to a proton shift from one atom of a
molecule to another atom of the same molecule. The present
invention includes tautomers of any said compounds.
[0575] A "therapeutically effective amount" or "effective amount"
includes an amount of a compound of the invention which, when
administered to a mammal, preferably a human, is sufficient to
inhibit or otherwise reduce the transport of phosphate ions from
the gastrointestinal lumen, increase fecal output of phosphate
ions, reduce serum levels of phosphate ions, treat
hyperphosphatemia in the mammal, preferably a human, and/or treat
any one or more other conditions described herein. The amount of a
compound of the invention which constitutes a "therapeutically
effective amount" will vary depending on the compound, the
condition and its severity, the manner of administration, and the
age of the mammal to be treated, but can be determined routinely by
one of ordinary skill in the art having regard to his own knowledge
and to this disclosure.
[0576] "Treating" or "treatment" as used herein covers the
treatment of the disease or condition of interest in a mammal,
preferably a human, having the disease or condition of interest,
and includes:
[0577] (i) preventing the disease or condition from occurring in a
mammal, in particular, when such mammal is predisposed to the
condition but has not yet been diagnosed as having it;
[0578] (ii) inhibiting the disease or condition, i.e., arresting
its development;
[0579] (iii) relieving the disease or condition, i.e., causing
regression of the disease or condition; or
[0580] (iv) relieving the symptoms resulting from the disease or
condition, i.e., relieving pain without addressing the underlying
disease or condition. As used herein, the terms "disease" and
"condition" may be used interchangeably or may be different in that
the particular malady or condition may not have a known causative
agent (so that etiology has not yet been worked out) and it is
therefore not yet recognized as a disease but only as an
undesirable condition or syndrome, where a more or less specific
set of symptoms have been identified by clinicians.
EXAMPLES
Example 1
Increased Intracellular pH Results in Decreased Phosphate Uptake in
Cells
[0581] Experiments were performed to test the relationship between
alterations in intracellular pH and the uptake of phosphate ions
(Pi) in human embryonic kidney cells (HEK-293 cells).
[0582] HEK-293 cells were seeded into 96-well plates at 25,000
cells/well and cultured overnight. Cells were then transfected with
either rat or human NaP2b cDNA, or were mock transfected (no DNA)
using Lipofectamine 2000 (Invitrogen). Cells were allowed to
approach confluence during a second overnight incubation.
[0583] An ammonium pulse procedure was used to reduce the
intracellular pH from .about.7.4 to .about.6.8. Medium was
aspirated from the wells, cells were washed twice with NaCl-HEPES
buffer (100 mM NaCl, 50 mM HEPES, 10 mM glucose, 5 mM KCl, 2 mM
CaCl.sub.2, 1 mM MgCl.sub.2, pH 7.4), then incubated for 30 min at
room temperature with NH4Cl-HEPES buffer (20 mM NH.sub.4Cl, 80 mM
NaCl, 50 mM HEPES, 5 mM KCl, 2 mM CaCl.sub.2, 1 mM MgCl.sub.2, pH
7.4) containing 5 .mu.M BCECF-AM. Cells were washed twice with
ammonium free, Na.sup.+-free HEPES (100 mM choline, 50 mM HEPES, 10
mM glucose, 5 mM KCl, 2 mM CaCl.sub.2, 1 mM MgCl.sub.2, pH 7.4) and
incubated in the same buffer for 10 minutes at room temperature to
lower intracellular pH. The reduction in intracellular pH to
approximately pH 6.8 was verified by monitoring the pH sensitive
changes in BCECF fluorescence (.lamda.ex 505 nm, .lamda.em 538 nm)
normalized to the pH insensitive BCECF fluorescence (.lamda.ex 439
nm, .lamda.em 538 nm). A control was included which omitted the
ammonium pulse procedure, and BCECF was used to show a normal
intracellular pH of 7.4.
[0584] Cells were then washed with sodium free uptake buffer (14 mM
Tris, 137 mM choline chloride, 5.4 mM KCl, 2.8 mM CaCl2, 1.2 mM
MgSO.sub.4, 100 .mu.M KH.sub.2PO.sub.4, 1 mg/mL Bovine Serum
Albumin, pH 7.4), and .sup.33P uptake was initiated by overlaying
the cells with sodium-containing uptake buffer (14 mM Tris, 137 mM
sodium chloride, 5.4 mM KCl, 2.8 mM CaCl.sub.2, 1.2 mM MgSO.sub.4,
100 .mu.M KH.sub.2PO.sub.4, 1 mg/mL Bovine Serum Albumin, pH 7.4).
For cell lines transfected with rat or human NaP2b, the endogenous
PiT activity was suppressed with a PiT silencing agent, so that the
only sodium-dependent .sup.33P uptake is due to NaP2b. The PiT
silencing agent was not used on the mock transfected cells, so
sodium-dependent .sup.33P is only due to PiT.
[0585] Uptake of .sup.33P was measured in the presence and absence
of 5 .mu.M EIPA, a specific inhibitor of NHE1. After 23 minutes at
room temperature, assay mixtures were removed, and the cells were
washed twice with ice cold sodium free uptake buffer. Cells were
lysed by addition of 20 .mu.L 0.1% Tween 80 followed by 100 .mu.L
scintillation fluid, and counted using a TopCount (Perkin
Elmer).
[0586] As shown in FIGS. 22A-22C, intracellular acidification
caused a >75% decrease in either PiT (22A) or NaPi2b (22B-22C)
mediated .sup.33P uptake. EIPA, which blocks NHE1-mediated proton
export from the cytoplasm, also caused a small yet significant
decrease in Pi uptake in cells that were not pretreated to lower
their intracellular pH.
Example 2
Guanylate Cyclase C (GC-C) Receptor Agonist Decreases Phosphate
Absorption
[0587] Experiments were performed to determine whether guanylate
cyclase C (GC-C) receptor agonists can decrease phosphate
absorption/uptake in the small intestine as measured by .sup.33P
uptake. Rats were simultaneously dosed with .sup.33P and
linaclotide as shown below:
[0588] 1. Vehicle (N=5/group)
[0589] 2. Linaclotide at 0.1 mg/kg (N=6/group)
[0590] 3. Linaclotide at 0.3 mg/kg (N=4/group)
[0591] Blood was collected at 5, 15, 30, 45, and 60 minutes
post-.sup.33P administration and plasma scintillation counting was
performed. The results are shown in FIGS. 1A-1B. FIG. 1A shows the
results of two-way ANOVA with repeated measures followed by
Dunnett's multiple comparison test, and FIG. 1B shows the results
of one-way ANOVA followed by Dunnett's multiple comparison test.
These results show that both doses of linaclotide decreased the
absorption of phosphate in the gastrointestinal tract.
Example 3
I1 Receptor Agonist and Adenylate Cyclase Agonist Decrease
Phosphate Absorption
[0592] Experiments were performed to determine whether other
classes of drugs can decrease phosphate absorption/uptake in the
small intestine as measured by .sup.33P uptake. Rats were
simultaneously dosed with .sup.33P and either an imidazoline
subtype 1 (I.sub.1) receptor agonist (moxonidine) or an adenylate
cyclase agonist (the water-soluble forskolin analog NKH477) as
shown below:
[0593] 1. Vehicle
[0594] 2. Moxonidine at 2 mg/kg
[0595] 3. Moxonidine at 6 mg/kg
[0596] 4. NKH477 at 1 mg/kg
[0597] 5. NKH477 at 3 mg/kg
[0598] Blood was collected at 5, 15, 30, 45, and 60 minutes
post-.sup.33P administration and plasma scintillation counting was
performed. The results are shown in FIGS. 2A-2B. FIG. 2A shows the
results of two-way ANOVA with repeated measures followed by
Dunnett's multiple comparison test, and FIG. 2B shows the results
of one-way ANOVA followed by Dunnett's multiple comparison test.
These results show that all test compounds significantly decreased
.sup.33P uptake/absorption at 15 minutes.
Example 4
A2B Agonist and P2Y2 Agonist Decrease Phosphate Absorption
[0599] Experiments were performed to determine whether increasing
intracellular calcium (Ca.sup.++) by different mechanisms can also
decrease phosphate absorption in the small intestine as measured by
.sup.33P uptake. Rats were simultaneously dosed with .sup.33P and
test compounds as shown below:
[0600] 1. Vehicle, n=6
[0601] 2. BAY 60-6583 at 10 mg/kg (adenosine A2B agonist)
[0602] 3. Up.sub.4U at 15 mg/kg (P2Y2 receptor agonist)
[0603] Blood was collected at 5, 15, 30, 45, and 60 minutes
post-.sup.33P administration and plasma scintillation counting was
performed. FIG. 3 shows that the P2Y2 receptor agonist Up.sub.4U
(15 mg/kg) significantly decreased .sup.33P uptake/absorption.
Example 5
Pharmacodynamic Effects on Acute Phosphate Uptake in Rats
[0604] Compounds were tested for the ability to reduce the
appearance of circulating radiolabeled phosphate subsequent to
administration to the alimentary canal in rats. The rate of
radiolabeled phosphate tracer accumulation in the blood of rats was
taken as a surrogate for the intestinal absorption rate of a
phosphate meal from the gastrointestinal tract. To this end,
circulating radiolabeled phosphate was monitored after intragastric
co-administration to rats of a phosphate tracer meal along with
example compounds. However, since some of the compounds tested
potentially had properties that may hinder this assay, such as
having putative gastrointestinal motility effects (e.g., delaying
gastric emptying) or being purposefully chemically unstable in the
gastrointestinal tract, direct intraduodenal administrations of the
phosphate tracer bolus was also performed at times.
[0605] Male Sprague-Dawley rats that were 8-weeks of age were
purchased from Charles River Laboratories (Hollister, Calif.). To
enable blood sampling, rats were purchased with catheters
surgically implanted in the jugular vein by the vendor. For studies
requiring intraduodenal administration, an additional catheter was
surgically implanted by the vendor to allow for direct infusion to
the lumen of the duodenum. Rats were fed a normal, grain-based chow
(Harlan Teklad, Madison, Wis.; 2018 Teklad Global 18% Protein
Rodent Diet) containing 0.65% P, 1% Ca, and 1.5 iu/g Vitamin
D.sub.3 and given water ad libitum leading up to the study.
[0606] Following an overnight fast, rats were administered a
phosphate solution containing [.sup.33P]orthophosphate
(PerkinElmer, Waltham, Mass.) as a tracer with or without test
articles dispersed in the solution at the indicated dosage. This
dosing solution typically contained 8 mM monobasic sodium phosphate
(1.25 .mu.Ci [.sup.33P]orthophosphate/mol), 4 mM calcium chloride,
0.4% hydroxypropyl methocellulose (w/v), and 2% dimethylsulfoxide
(w/v). The dosing solutions were prepared in water for intragastric
gavage at 10 ml/kg and in saline if administered intraduodenally
using a previously implanted catheter at 5 ml/kg as a bolus.
[0607] Blood was sampled from the jugular vein via implanted
catheters from conscious rats following dosing and the radioisotope
associated with the resulting plasma was determined by
scintillation counting. The relative amount of phosphate uptake
from the administered dose to the plasma was assessed using body
weight estimation of total circulating plasma. See Bijsterbosch et
al., Experientia. 37: 381-382, 1981 (The plasma volume of the
Wistar rat in relation to the body weight). The comparative amount
of phosphate uptake at 15 min post-dose for each group (n=6) was
expressed as a percentage relative to the study vehicle group (n=6)
as mean.+-.SEM. Statistical comparisons of the means of each test
group compared to the mean of the vehicle group were determined by
one-way analysis of variance followed by the Dunnett's posthoc test
and P<0.05 was accepted as statistically significant (ns, not
significant; *, P<0.05; **, P<0.01; and ***, P<0.001).
[0608] The results of the studies testing example compounds with
intragastric dosing are summarized in Table E1 below.
TABLE-US-00014 TABLE E1 Uptake of phosphate tracer to plasma 15 min
after intragastric co-administration of a phosphate test meal and
compounds in rats Compound Name Primary Target/Compound Class Dose
% of study vehicle Prucalopride 5-HT.sub.4 receptor agonist 10
mg/kg >75% BAY 60-6583 A2B receptor agonist 10 mg/kg >75%
6-guanyl NECA A2B receptor agonist 10 mg/kg >75% FIG. 6C.
Structure 1 A2B receptor agonist 10 mg/kg 50-75% FIG. 6C. Structure
2 A2B receptor agonist 10 mg/kg 50-75% Dorzolamide Carbonic
anhydrase inhibitor 20 mg/kg 50-75% A68930 Dopamine D1 receptor
agonist 10 mg/kg 50-75% Rilmenidine Imidazoline I1 receptor agonist
3 mg/kg >75% Moxonidine Imidazoline I1 receptor agonist 2 mg/kg
50-75% 6 mg/kg 25-50% FIG. 11. Structure 4 Imidazoline I1 receptor
agonist 6 mg/kg >75% Linaclotide Guanylate Cyclase 2C agonist
0.03 mg/kg 50-75% 0.1 mg/kg 50-75% 0.3 mg/kg 25-50% Bethanechol
Muscarinic receptor agonist 10 mg/kg >75% Melatonin MT2
melatonin receptor agonist 10 mg/kg 50-75% Sodium nitroprusside NO
release 10 mg/kg 25-50% UTP-.gamma.-s Agonist of P2Y.sub.2/.sub.4
receptors 4 mg/kg >75% Up.sub.4U P2Y2 receptor agonist 5 mg/kg
>75% 15 mg/kg >75% 50 mg/kg >75% 16,16-dimethyl-PGE2
Agonist of EP receptors 3 .mu.g/kg >75% Bay 41-2271 Soluble
guanylyl cyclase activator 10 mg/kg >75% Bay 58-2667 Soluble
guanylyl cyclase activator 10 mg/kg 50-75% Vinpocetine PDE1
inhibitor 1 mg/kg >75% 10 mg/kg >75% 1 mg/kg + 50-75% 0.03
mg/kg Linacolitde 10 mg/kg + 25-50% 0.03 mg/kg Linacolitde NKH 477
Water-soluble analog of forskolin 0.3 mg/kg 50-75% 1 mg/kg 25-50% 3
mg/kg 0-25% 10 mg/kg 0-25%
[0609] The results of the studies testing example compounds with
intraduodenal dosing in Table E2 below.
TABLE-US-00015 TABLE E2 Uptake of phosphate tracer to plasma 15 min
after intraduodenal co-administration of a phosphate test meal and
compounds in rats. Primary Target/ % of Compound Name Compound
Class Dose study vehicle 2-methylthio-ADP P2Y.sub.1 receptor
agonist 10 mg/kg >75% PSB1114 P2Y.sub.2 receptor agonist 15
mg/kg >75% NKH477 Water-soluble analog 1 mg/kg 25-50% of
forskolin FIG. 11. Structure 4 Imidazoline I1 6 mg/kg >75%
receptor agonist Sodium nitroprusside NO release 10 mg/kg >75%
Atrial natriuretic Atrial natriuretic 0.2 mg/kg >75% peptide
peptide receptor agonist
[0610] Test compounds that were examples of an A2B receptor
agonist, a carbonic anhydrase inhibitor, a dopamine D1 receptor
agonist, an imidazoline I1 receptor agonist, a guanylate Cyclase 2C
agonist, an MT2 melatonin receptor agonist, an NO releasing agent,
a soluble guanylyl cyclase activator, and a soluble analog of
forskolin all individually significantly reduced the acute uptake
of phosphate from a gastrically delivered meal. Additionally, it
was determined that a soluble analog of forskolin dosed directly to
the duodenum of the small intestine inhibited the phosphate uptake
from a co-administered test bolus.
Example 6
Ussing Chamber
[0611] Segments of duodenum and jejunum are immediately removed
from anesthetized animals and opened along the mesenteric line and
fixed on a Pyrex plate with the mucosal surface uppermost.
Epithelial tissues are stripped off the muscle layers and mounted
in computer-controlled Ussing chambers (National Physiology
Instrument, California) with an exposed area of 100 mm.sup.2 The
tissues are incubated on both sides with 13 mL of an isotonic
buffer solution (pH 6.0 or pH7.4) containing (mmol/L) NaCl 125.4,
KCl 5.4, CaCl.sub.2, 1.2, NaHCO.sub.3, 21, NaHPO, 0.3,
NaH.sub.2PO.sub.4, 1.2. The functional viability and the integrity
of the tissues at the start and the end of flux measurements will
be ensured with the measurement of short-circuit current (I.sub.sc)
in response to either theophylline (10 mM serosal) or glucose (10
mM mucosal) or L-alanine (5 mM mucosal).
[0612] For calculations of unidirectional Pi flux rates (J.sub.ms:
flux from mucosal to serosal side, J.sub.sm: flux in the opposite
direction), 185 KBq [.sup.33P]-orthophosphate (370 MBq/mL,
Perkin-Elmer) and test compounds are added to one side of the
tissue. Samples (0.1 ml) are taken from the labeled side 20 minutes
later and subsequently in at least three 10 min intervals from the
unlabeled side (0.5 mL) of the Ussing chamber. All samples taken
from the unlabeled side are replaced by equal volumes of isosmotic
bathing fluid. Net fluxes (J.sub.net) are calculated as differences
between J.sub.ms and J.sub.sm of paired tissues whose conductances
do not differ by more than 25%. In another series of experiments
flux measurements are done before and after the addition of
arsenate (mucosal) or ouabain (serosal) to the bathing solution.
Radioactivity measurements are measured in a TopCount (Perkin
Elmer) liquid scintillation counter.
Example 7
In Vitro--Ex Vivo Assays
[0613] Segments of duodenum and jejunum (5 cm) are removed from
animals anesthetized with pentobarbitone sodium, flushed with
ice-cold 0.9% saline and everted on glass rods. Samples are
securely mounted on the rod and then preincubated for 5 min at
37.degree. C. in oxygenated buffer, pH 7.4 or 6.0, containing in
mM: hydroxyethylpiperazine-N'-2-ethanesulfonic acid 16, glucose 10,
KCl 3.5, MgSO.sub.4 10, CaCl.sub.2 1, NaCl 125, followed by 2 min
incubation in the same buffer containing 100 mM .sup.33Pi
(.sup.33Pi-specific activity 1.85 MBq/mL) and test compounds. The
buffer is rapidly stirred using a magnetic flea to minimize the
effects of static water layers at the mucosal surface.
[0614] Uptake is terminated by exposing the tissue for 10 minutes
at room temperature to phosphate-buffered saline containing a
10-fold excess of nonradioactive phosphate. This procedure is
followed by a further 10 minute wash in phosphate-buffered saline
at room temperature and samples are then blotted dry and the weight
recorded. Samples are digested overnight in Protosol (PerkinElmer).
Scintillation counting of the digested sample and initial uptake
solution permits calculation of phosphate retention of tissue (in
nmol/g).
Example 8
Target-Based Screening Assays
[0615] Activation of gut receptors can result in signaling that
causes in either direct or indirect inhibition of phosphate
absorption (e.g. by changing the local pH of the luminal membranes
of the gut). Measurement of a compound's ability to interact with
these targets may be accomplished using commercial cell lines that
heterologously express the target of interest. These cell lines are
commonly available from companies such as Perkin Elmer or
Multispan. Alternatively, primary cells expressing the target of
interest are also commonly used.
[0616] Measurement of the interaction of a putative ligand may be
accomplished by either of two approaches (see Table E3 below): (1)
displacement of a radioisotopically labeled standard ligand from
either intact cells or membranes prepared from such cells, or (2)
measurement of a secondary messenger production upon treatment with
the test compound. For measurement of secondary messengers,
numerous commercial kits are available to measure intracellular
cAMP, cGMP (e.g. from Cis Bio) and Calcium (e.g. Calcium 6 dye from
Molecular Devices).
TABLE-US-00016 TABLE E3 2.sup.nd messenger Target Radioligand probe
assay Purinergic receptor P2Y2 .sup.33P-.gamma.-S-ATP or
.sup.33P-ATP Ca.sup.2+ Purinergic receptor P2Y1 [.sup.3H]Diquafosol
Ca.sup.2+ Adenosine receptor A2B [.sup.3H]MRS 1754 cAMP
Acetylcholine receptors [.sup.3H]AF-DX 116 Ca.sup.2+ Prostaglandin
EP4 receptor [.sup.3H] Prostaglandin E2 cAMP Dopamine D1 receptor
[.sup.3H]SCH23390 cAMP or Ca.sup.2+ Melatonin M2 receptor
[.sup.125I]melatonin Ca.sup.2+ Seratonin 5H4 receptor [.sup.3H]
GR112808 Ca.sup.2+ Guanylin receptor .sup.125I-ST1 cGMP
(NSSNYCCELCCNPACTGCY) (SEQ ID NO: 529) Atrial Natriuretic
.sup.125I-Tyr28ANP(1-28) cGMP Peptide receptor Adenylate cyclase
.sup.33P-ATP or .sup.33P-.gamma.-S-ATP cAMP Imidazoline 1 receptor
[.sup.3H]Clonidine NO
[0617] In cases where the activity of a soluble enzyme is directly
affected, an enzyme assay may be employed in which a purified
enzyme preparation is used, and the product of the enzymatic
reaction is monitored (see Table E4 below).
TABLE-US-00017 TABLE E4 Enzyme Product soluble guanylate cyclase
cGMP Carbonic anhydrase H+ (lower pH) PDE inhibitors cAMP and/or
cGMP
Example 9
Inhibition of Intestinal Sodium and Phosphate Absorption
[0618] To assess the ability of selected example compounds to
inhibit the absorption of phosphate from the intestinal lumen, the
intake and excretion balance of phosphate is measured in rats.
Eight week old Sprague Dawley rats are purchased from Charles River
Laboratories (Hollister, Calif.) and acclimated for at least 6 days
with free access to food and water. During this time and throughout
the study, rats may be fed a standard diet (Harlan Teklad, Madison,
Wis.; 2018 Teklad Global 18% Protein Rodent Diet) or a purified egg
white synthetic diet consisting of 0.6% Ca and 0.35 or 0.6%
phosphorus (Harlan Teklad; TD.84122 and TD.130318,
respectively).
[0619] A day prior to the initiation of the study, rats are
acclimated to individual metabolic cages with free access to water
and a powdered version of the diets listed above Animals are dosed
approximately 1 hour prior to the commencement to the dark phase
either PO at 10 ml/kg with an effective dose of the test article or
via drug-admixed food) based on the daily mass of chow rats have
been determined to consume. With both dosing paradigms, each rat is
given free access to water and an aliquot of powdered chow for each
day they are housed in the metabolic cage that is the daily average
of ad libitum consumption for that type of chow, for the same type
of rats (i.e., male rats at 8 weeks of age consume an average of 18
g/d of the purified diets listed above). This is done to reduce
variability and streamline subsequent 24 hour consumption and
excretion measurements. Daily water and chow consumption
measurements as well as daily urine and fecal collections follow
from 1 to 4 consecutive days.
[0620] The phosphate, sodium, and potassium content of urine
samples are determined by ion chromatography. Urine samples are
processed by gravimetric volume determinations followed by
acidification with 6 N HCl. Acidified samples are briefly
centrifuged (3,600.times.g) and the supernatants are then diluted
with 10 mM HCl. The diluted samples, calibration standards
(Sigma/Fluka Analytical), and QC samples (standards prepared
in-house) are filtered prior to injection on an ion exchange
chromatography system (Dionex ICS-3000). Sodium and potassium are
resolved using an isocratic method consisting of a 25 mM
methanesulfonic acid mobile phase and a Dionex CS12A cation
exchange analytical column. Phosphate is resolved using an
isocratic method consisting of a 35 mM potassium hydroxide mobile
phase and a Dionex AS 18 anion exchange analytical column.
Quantitative analysis is performed using Dionex Chromeleon
software. All sample concentrations are interpolated from a
calibration curve based on chromatographic peak areas.
[0621] The phosphate, sodium, calcium, and potassium content of
each 24 hour fecal sample are determined by atomic emission
spectroscopy. Dried fecal pellets or a representative sample from
dried homogenized feces are digested with repeated additions of
concentrated nitric acid and hydrogen peroxide over 2-3 hours at
65-95.degree. C. The sample solutions are then diluted with 1%
nitric acid prior to analysis with an atomic emission spectrometer
(Agilent 4100 MP-AES) at the following element emission
wavelengths: calcium (422.673 nm), sodium (588.995 nm), potassium
(766.491 nm), and phosphorus (214.915 or 213.618 nm). A cesium
solution is used as both an ionization buffer and an internal
standard. Data analysis is performed using Agilent MP Expert
software.
[0622] Daily urinary and fecal phosphate output relative to the P
consumed in the diet for each animal on each day measured is
calculated. The percentage inhibition of phosphorus absorption is
expressed by determining the reduction of these ratios compared to
the control group (animals with no drug in chow). This may also be
done with other ions of interest. If there are multiple days
tested, these may represent replicates for steady-state measurement
of phosphate balance for each rat, in which case regular daily
consumption by the animals is a prerequisite. Increased fecal
phosphate with an approximate concomitant decrease in urinary P to
maintain neutral balance in the rats is an indication of overall
decreased phosphate absorption in rats treated with example
compounds.
Example 10
Effects in a Rat Chronic Kidney Disease (CKD) Model
[0623] To assess the ability of selected example compounds to
impact soft tissue calcification often associated with later stages
of CKD, the 5/6 nephrectomy (5/6Nx) rat model is utilized to
examine mineral homeostasis in a diseased state. A commonly used
model to study various aspects of CKD, the 5/6Nx rat is not
normally hyperphosphatemic unless challenged with dietary phosphate
(see Shobeiri et. al., Am J Nephrol. 31:471-481, 2010, Vascular
Calcification in Animal Models of CKD: A Review). Therefore, to
ensure efficient and steady phosphatemic vascular calcification
progression in these animals, a combination of enhanced
bioavailable phosphate in the diet and Vitamin D.sub.3 treatment is
implemented as adapted from the protocol developed by the Lopez
group (see Lopez et al., J Am Soc Nephrol. 17: 795-804, 2006.
Calcimimetic R-568 Decreases Extraosseous Calcifications in Uremic
Rats Treated with Calcitriol).
[0624] Male Sprague-Dawley 5/6th nephrectomized rats are purchased
from Charles River Laboratories (Hollister, Calif.) with surgical
procedures performed by the vendor. Reduction in functional renal
mass is achieved by two surgeries: sub-total nephrectomy of the
left kidney followed by a 1-week recovery prior to uninephrectomy
of the right kidney. After a 3 day recovery period from the second
surgery, the rats are transported to the testing facility at 9
weeks of age.
[0625] Upon arrival and throughout the study, rats are fed a
purified powdered diet consisting of 0.9% inorganic P (phosphorus)
and 0.6% Ca (TD.10809, Harlan-Teklad, Madison, Wis.). Matinal serum
is obtained by retroorbital or tail vein bleeding and only animals
with serum creatinine levels of 0.9 to 1.2 mg/dl are enrolled to
the study with groups (n=12) stratified based on serum creatinine
and body weight. Enrolled rats in treatment groups are dosed
drug-in-chow using the same diet as the vehicle group described
above. Additionally, a regimen of calcitriol (active Vitamin
D.sub.3 80 ng/kg i.p.) administration 3 times per week is
initiated.
[0626] Kidney function, phosphatemic state as well as other
parameters are monitored weekly with appropriate serum marker
measurements via standard clinical chemistry or ELISA analysis.
Rats with serum creatinine greater than 2 mg/dL or with a body
weight of 80% or less of the mean cohort body weight are removed
form study due to advanced diseased state. Urine markers for kidney
function may also be measured by placing rats in metabolic cages to
allow for the collection of excretions.
[0627] After 4 weeks, rats are euthanized and organs are collected
and weighed. The mineralization of the aortic arch, heart, stomach
and kidney remnant are determined. Whole tissue samples are
digested with repeated additions of concentrated nitric acid and
hydrogen peroxide over 2-3 hours at 65-95.degree. C. The sample
solutions are then diluted with 1% nitric acid prior to analysis
with an atomic emission spectrometer (Agilent 4100 MP-AES) at the
following element emission wavelengths: calcium (422.673 nm),
sodium (588.995 nm), potassium (766.491 nm), and phosphorus
(214.915 or 213.618 nm). A cesium solution is used as an ionization
buffer and internal standard. Data analysis is performed using
Agilent MP Expert software.
[0628] A reduction in vascular calcification in animals treated
with test articles compared to their untreated counterparts is
consistent with the reported inhibition of dietary phosphate
absorption that is needed to drive the disease state in this CKD
rat model.
Sequence CWU 1
1
756121PRTArtificial Sequenceguanylate cyclase C receptor (GC-C)
agonist 1Xaa Xaa Xaa Xaa Tyr Cys Cys Xaa Xaa Cys Cys Xaa Xaa Xaa
Cys Xaa 1 5 10 15 Xaa Cys Xaa Xaa Xaa 20 25PRTArtificial
SequenceFragment of guanylate cyclase C receptor (GC-C) agonist
2Asn Ser Ser Asn Tyr 1 5 319PRTArtificial SequenceGuanylate cyclase
C receptor (GC-C) agonist 3Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 414PRTArtificial
SequenceGuanylate cyclase C receptor (GC-C) agonist 4Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 516PRTArtificial
SequenceGuanylate cyclase C receptor (GC-C) agonist 5Xaa Xaa Xaa
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 1 5 10 15
616PRTArtificial SequenceGuanylate cyclase C receptor (GC-C)
agonist 6Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly
Cys Leu 1 5 10 15 728PRTArtificial SequenceAtrial natriuretic
peptide receptor agonist 7Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly
Arg Ile Asp Arg Ile Gly 1 5 10 15 Ala Gln Ser Gly Leu Gly Cys Asn
Ser Phe Arg Tyr 20 25 817PRTArtificial SequenceAtrial natriuretic
peptide receptor agonist 8Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly
Ala Gln Ser Gly Leu Gly 1 5 10 15 Cys 923PRTArtificial
SequenceAtrial natriuretic peptide receptor agonist 9Ser Ser Cys
Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly 1 5 10 15 Leu
Gly Cys Asn Ser Phe Arg 20 1019PRTEscherichia coli 10Asn Ser Ser
Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 1118PRTEscherichia coli 11Asn Thr Phe Tyr Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Ala Gly 1 5 10 15 Cys Tyr
1218PRTEscherichia coli 12Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys
Tyr Pro Ala Cys Ala Gly 1 5 10 15 Cys Asn 1318PRTCitrobacter
freundii 13Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys
Ala Gly 1 5 10 15 Cys Tyr 1430PRTYersinia enterocolitica 14Gln Ala
Cys Asp Pro Pro Ser Pro Pro Ala Glu Val Ser Ser Asp Trp 1 5 10 15
Asp Cys Cys Asp Val Cys Cys Asn Pro Ala Cys Ala Gly Cys 20 25 30
1530PRTYersinia enterocolitica 15Gln Ala Cys Asp Pro Pro Leu Pro
Pro Ala Glu Val Ser Ser Asp Trp 1 5 10 15 Asp Cys Cys Asp Val Cys
Cys Asn Pro Ala Cys Ala Gly Cys 20 25 30 1630PRTYersinia
enterocolitica 16Lys Ala Cys Asp Thr Gln Thr Pro Ser Pro Ser Glu
Glu Asn Asp Asp 1 5 10 15 Trp Cys Cys Glu Val Cys Cys Asn Pro Ala
Cys Ala Gly Cys 20 25 30 1753PRTYersinia enterocolitica 17Gln Glu
Thr Ala Ser Gly Gln Val Gly Asp Val Ser Ser Ser Thr Ile 1 5 10 15
Ala Thr Glu Val Ser Glu Ala Glu Cys Gly Thr Gln Ser Ala Thr Thr 20
25 30 Gln Gly Glu Asn Asp Trp Asp Trp Cys Cys Glu Leu Cys Cys Asn
Pro 35 40 45 Ala Cys Phe Gly Cys 50 1816PRTYersinia kristensenii
18Ser Asp Trp Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Ala Gly Cys 1
5 10 15 1917PRTVibrio cholerae 19Ile Asp Cys Cys Glu Ile Cys Cys
Asn Pro Ala Cys Phe Gly Cys Leu 1 5 10 15 Asn 2017PRTVibrio mimicus
20Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Phe Gly Cys Leu 1
5 10 15 Asn 2118PRTEscherichia coli 21Asn Thr Phe Tyr Cys Cys Glu
Leu Cys Cys Asn Pro Ala Cys Ala Pro 1 5 10 15 Cys Tyr 2213PRTVibrio
cholerae 22Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Phe 1 5
10 2314PRTVibrio cholerae 23Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro
Ala Cys Phe Gly 1 5 10 2417PRTVibrio mimicus 24Ile Asp Arg Cys Glu
Ile Cys Cys Asn Pro Ala Cys Phe Gly Cys Leu 1 5 10 15 Asn
2516PRTYersinia enterocolitica 25Asp Trp Asp Cys Cys Asp Val Cys
Cys Asn Pro Ala Cys Ala Gly Cys 1 5 10 15 2616PRTYersinia
enterocolitica 26Asp Trp Asp Cys Cys Asp Val Cys Cys Asn Pro Ala
Cys Ala Gly Cys 1 5 10 15 2717PRTYersinia enterocolitica 27Asn Asp
Asp Trp Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Ala Gly 1 5 10 15
Cys 2816PRTYersinia enterocolitica 28Trp Asp Trp Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Phe Gly Cys 1 5 10 15 2930PRTYersinia
enterocolitica 29Gln Ala Cys Asp Pro Pro Ser Pro Pro Ala Glu Val
Ser Ser Asp Trp 1 5 10 15 Asp Cys Cys Asp Val Cys Cys Asp Pro Ala
Cys Ala Gly Cys 20 25 30 3031PRTYersinia enterocolitica 30Gln Glu
Thr Ala Ser Gly Gln Val Gly Asp Val Ser Ser Ser Thr Ile 1 5 10 15
Ala Thr Glu Val Ser Glu Ala Glu Cys Gly Thr Gln Ser Ala Thr 20 25
30 3122PRTYersinia enterocolitica 31Thr Gln Gly Glu Asn Asp Trp Asp
Trp Cys Cys Glu Leu Cys Cys Asn 1 5 10 15 Pro Ala Cys Phe Gly Cys
20 3227PRTEscherichia coli 32Met Lys Lys Leu Met Leu Ala Ile Phe
Ile Ser Val Leu Ser Phe Pro 1 5 10 15 Ser Phe Ser Gln Ser Thr Glu
Ser Leu Asp Ser 20 25 3325PRTEscherichia coli 33Ser Lys Glu Lys Ile
Thr Leu Glu Thr Lys Lys Cys Asp Val Val Lys 1 5 10 15 Asn Asn Ser
Glu Lys Lys Ser Glu Asn 20 25 3420PRTEscherichia coli 34Met Asn Asn
Thr Phe Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys 1 5 10 15 Ala
Gly Cys Tyr 20 3527PRTEscherichia coli 35Met Lys Lys Ser Ile Leu
Phe Ile Phe Leu Ser Val Leu Ser Phe Ser 1 5 10 15 Pro Phe Ala Gln
Asp Ala Lys Pro Val Glu Ser 20 25 3626PRTEscherichia coli 36Ser Lys
Glu Lys Ile Thr Leu Glu Ser Lys Lys Cys Asn Ile Ala Lys 1 5 10 15
Lys Ser Asn Lys Ser Gly Pro Glu Ser Met 20 25 3719PRTEscherichia
coli 37Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys
Thr 1 5 10 15 Gly Cys Tyr 3825PRTYersinia enterocolitica 38Met Lys
Lys Ile Val Phe Val Leu Val Leu Met Leu Ser Ser Phe Gly 1 5 10 15
Ala Phe Gly Gln Glu Thr Val Ser Gly 20 25 3926PRTYersinia
enterocolitica 39Gln Phe Ser Asp Ala Leu Ser Thr Pro Ile Thr Ala
Glu Val Tyr Lys 1 5 10 15 Gln Ala Cys Asp Pro Pro Leu Pro Pro Ala
20 25 4020PRTYersinia enterocolitica 40Glu Val Ser Ser Asp Trp Asp
Cys Cys Asp Val Cys Cys Asn Pro Ala 1 5 10 15 Cys Ala Gly Cys 20
4172PRTEscherichia coli 41Met Lys Lys Leu Met Leu Ala Ile Phe Ile
Ser Val Leu Ser Phe Pro 1 5 10 15 Ser Phe Ser Gln Ser Thr Glu Ser
Leu Asp Ser Ser Lys Glu Lys Ile 20 25 30 Thr Leu Glu Thr Lys Lys
Cys Asp Val Val Lys Asn Asn Ser Glu Lys 35 40 45 Lys Ser Glu Asn
Met Asn Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys 50 55 60 Asn Pro
Ala Cys Ala Gly Cys Tyr 65 70 4272PRTEscherichia coli 42Met Lys Lys
Ser Ile Leu Phe Ile Phe Leu Ser Val Leu Ser Phe Ser 1 5 10 15 Pro
Phe Ala Gln Asp Ala Lys Pro Val Glu Ser Ser Lys Glu Lys Ile 20 25
30 Thr Leu Glu Ser Lys Lys Cys Asn Ile Ala Lys Lys Ser Asn Lys Ser
35 40 45 Gly Pro Glu Ser Met Asn Ser Ser Asn Tyr Cys Cys Glu Leu
Cys Cys 50 55 60 Asn Pro Ala Cys Thr Gly Cys Tyr 65 70
4371PRTYersinia enterocolitica 43Met Lys Lys Ile Val Phe Val Leu
Tyr Leu Met Leu Ser Ser Phe Gly 1 5 10 15 Ala Phe Gly Gln Glu Thr
Val Ser Gly Gln Phe Ser Asp Ala Leu Ser 20 25 30 Thr Pro Ile Thr
Ala Glu Val Tyr Lys Gln Ala Cys Asp Pro Pro Leu 35 40 45 Pro Pro
Ala Glu Val Ser Ser Asp Trp Asp Cys Cys Asp Val Cys Cys 50 55 60
Asn Pro Ala Cys Ala Gly Cys 65 70 446PRTArtificial SequenceCarboxy
terminus fragments of peptide 44Lys Lys Lys Lys Lys Lys 1 5
457PRTArtificial SequenceCarboxy terminus fragments of peptide
45Asp Lys Lys Lys Lys Lys Lys 1 5 4621PRTArtificial SequenceGC-C
agonist peptide (bacterial STanalog) 46Xaa Xaa Xaa Xaa Xaa Cys Cys
Xaa Xaa Cys Cys Xaa Xaa Xaa Cys Xaa 1 5 10 15 Xaa Cys Xaa Xaa Xaa
20 4721PRTArtificial SequenceGC-C agonist peptide 47Xaa Xaa Xaa Xaa
Xaa Cys Cys Xaa Xaa Cys Cys Asn Pro Ala Cys Xaa 1 5 10 15 Gly Cys
Xaa Xaa Xaa 20 4821PRTArtificial sequenceGC-C agonist peptide 48Xaa
Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Cys Cys Asn Pro Ala Cys Xaa 1 5 10
15 Gly Cys Xaa Xaa Xaa 20 4921PRTArtificial SequenceGC-C agonist
peptide 49Xaa Xaa Xaa Xaa Xaa Cys Cys Glu Xaa Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Xaa Xaa Xaa 20 5021PRTArtificial
SequenceGC-C agonist peptide 50Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa
Cys Cys Xaa Xaa Xaa Cys Xaa 1 5 10 15 Xaa Cys Xaa Xaa Xaa 20
5119PRTArtificial SequenceGC-C agonist peptide 51Gln Ser Ser Asn
Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys
Tyr 5219PRTArtificial SequenceGC-C agonist peptide 52Asn Leu Ser
Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 5319PRTArtificial SequenceGC-C agonist peptide 53Asn Ser
Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10 15
Gly Cys Tyr 5419PRTArtificial SequenceGC-C agonist peptide 54Gln
Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 5519PRTArtificial SequenceGC-C agonist peptide 55Asn
Ser Ser Asn Tyr Cys Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 5619PRTArtificial SequenceGC-C agonist peptide 56Asn
Ser Ser Asn Tyr Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 5719PRTArtificial SequenceGC-C agonist peptide 57Asn
Ser Ser Asn Tyr Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 5819PRTArtificial SequenceGC-C agonist peptide 58Asn
Ser Ser Asn Tyr Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 5919PRTArtificial SequenceGC-C agonist peptide 59Asn
Ser Ser Asn Tyr Cys Cys Glu His Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 6019PRTArtificial SequenceGC-C agonist peptide 60Asn
Ser Ser Asn Tyr Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 6119PRTArtificial SequenceGC-C agonist peptide 61Asn
Ser Ser Asn Tyr Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 6219PRTArtificial SequenceGC-C agonist peptide 62Asn
Ser Ser Asn Tyr Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 6319PRTArtificial SequenceGC-C agonist peptide 63Asn
Ser Ser Asn Tyr Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr 1 5 10
15 Gly Cys Tyr 6414PRTArtificial SequenceGC-C agonist peptide 64Cys
Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
6514PRTArtificial SequenceGC-C agonist peptide 65Cys Cys Glu Asn
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 6614PRTArtificial
SequenceGC-C agonist peptide 66Cys Cys Glu Cys Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 6714PRTArtificial SequenceGC-C agonist
peptide 67Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1
5 10 6814PRTArtificial SequenceGC-C agonist peptide 68Cys Cys Glu
His Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
6914PRTArtificial SequenceGC-C agonist peptide 69Cys Cys Glu Lys
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 7014PRTArtificial
SequenceGC-C agonist peptide 70Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 7114PRTArtificial SequenceGC-C agonist
peptide 71Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1
5 10 7214PRTArtificial SequenceGC-C agonist peptide 72Cys Cys Glu
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
7313PRTArtificial SequenceGC-C agonist peptide 73Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 7413PRTArtificial
SequenceGC-C agonist peptide 74Cys Cys Glu Arg Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 7513PRTArtificial SequenceGC-C agonist
peptide 75Cys Cys Glu Asp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 7613PRTArtificial SequenceGC-C agonist peptide 76Cys Cys Glu Gln
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 7713PRTArtificial
SequenceGC-C agonist peptide 77Cys Cys Glu Gly Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 7813PRTArtificial SequenceGC-C agonist
peptide 78Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 7913PRTArtificial SequenceGC-C agonist peptide 79Cys Cys Glu Met
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 8013PRTArtificial
SequenceGC-C agonist peptide 80Cys Cys Glu Pro Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 8113PRTArtificial SequenceGC-C agonist
peptide 81Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 8213PRTArtificial SequenceGC-C agonist peptide 82Cys Cys Glu Val
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 8319PRTArtificial
SequenceGC-C agonist peptide 83Asn Thr Ser Asn Tyr Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 8419PRTArtificial
SequenceGC-C agonist peptide 84Asn Ile Ser Asn Tyr Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 8518PRTArtificial
SequenceGC-C agonist peptide 85Ser Ser Asn Tyr Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly 1 5 10 15 Cys Tyr 8618PRTArtificial
SequenceGC-C agonist peptide 86Ser Ser Gln Tyr Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly 1 5 10 15 Cys Tyr 8719PRTArtificial
SequenceGC-C agonist peptide 87Asn Ser Ser Asn Tyr Cys Cys Glu Arg
Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 8819PRTArtificial
SequenceGC-C agonist peptide 88Asn Ser Ser Asn Tyr Cys Cys Glu Asp
Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 8919PRTArtificial
SequenceGC-C agonist peptide 89Asn Ser Ser Asn Tyr Cys Cys Glu Gln
Cys Cys Asn Pro Ala Cys Thr 1 5
10 15 Gly Cys Tyr 9019PRTArtificial SequenceGC-C agonist peptide
90Asn Ser Ser Asn Tyr Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr 1
5 10 15 Gly Cys Tyr 9119PRTArtificial SequenceGC-C agonist peptide
91Asn Ser Ser Asn Tyr Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Thr 1
5 10 15 Gly Cys Tyr 9219PRTArtificial SequenceGC-C agonist peptide
92Asn Ser Ser Asn Tyr Cys Cys Glu Met Cys Cys Asn Pro Ala Cys Thr 1
5 10 15 Gly Cys Tyr 9319PRTArtificial SequenceGC-C agonist peptide
93Asn Ser Ser Asn Tyr Cys Cys Glu Pro Cys Cys Asn Pro Ala Cys Thr 1
5 10 15 Gly Cys Tyr 9419PRTArtificial SequenceGC-C agonist peptide
94Asn Ser Ser Asn Tyr Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr 1
5 10 15 Gly Cys Tyr 9519PRTArtificial SequenceGC-C agonist peptide
95Asn Ser Ser Asn Tyr Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Thr 1
5 10 15 Gly Cys Tyr 9614PRTArtificial SequenceGC-C agonist peptide
96Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
9714PRTArtificial SequenceGC-C agonist peptide 97Cys Cys Glu Asp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 9814PRTArtificial
SequenceGC-C agonist peptide 98Cys Cys Glu Gln Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 9914PRTArtificial SequenceGC-C agonist
peptide 99Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1
5 10 10014PRTArtificial SequenceGC-C agonist peptide 100Cys Cys Glu
Ile Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
10114PRTArtificial SequenceGC-C agonist peptide 101Cys Cys Glu Met
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 10214PRTArtificial
SequenceGC-C agonist peptide 102Cys Cys Glu Pro Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 10314PRTArtificial SequenceGC-C agonist
peptide 103Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 10414PRTArtificial SequenceGC-C agonist peptide 104Cys Cys
Glu Val Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
10513PRTArtificial SequenceGC-C agonist peptide 105Cys Cys Glu Ala
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 10613PRTArtificial
SequenceGC-C agonist peptide 106Cys Cys Glu Asn Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 10713PRTArtificial SequenceGC-C agonist
peptide 107Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 10813PRTArtificial SequenceGC-C agonist peptide 108Cys Cys Glu
Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 10913PRTArtificial
SequenceGC-C agonist peptide 109Cys Cys Gln His Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 11013PRTArtificial SequenceGC-C agonist
peptide 110Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 11113PRTArtificial SequenceGC-C agonist peptide 111Cys Cys Glu
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 11213PRTArtificial
SequenceGC-C agonist peptide 112Cys Cys Glu Ser Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 11313PRTArtificial SequenceGC-C agonist
peptide 113Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 11414PRTArtificial SequenceGC-C agonist peptide 114Cys Cys Glu
Leu Cys Cys Ala Pro Ala Cys Thr Gly Cys Tyr 1 5 10
11514PRTArtificial SequenceGC-C agonist peptide 115Cys Cys Glu Leu
Cys Cys Leu Pro Ala Cys Thr Gly Cys Tyr 1 5 10 11614PRTArtificial
SequenceGC-C agonist peptide 116Cys Cys Glu Leu Cys Cys Pro Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 11714PRTArtificial SequenceGC-C agonist
peptide 117Cys Cys Glu Leu Cys Cys Phe Pro Ala Cys Thr Gly Cys Tyr
1 5 10 11814PRTArtificial SequenceGC-C agonist peptide 118Cys Cys
Glu Leu Cys Cys Gly Pro Ala Cys Thr Gly Cys Tyr 1 5 10
11914PRTArtificial SequenceGC-C agonist peptide 119Cys Cys Glu Leu
Cys Cys Thr Pro Ala Cys Thr Gly Cys Tyr 1 5 10 12014PRTArtificial
SequenceGC-C agonist peptide 120Cys Cys Glu Leu Cys Cys Gln Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 12114PRTArtificial SequenceGC-C agonist
peptide 121Cys Cys Glu Leu Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr
1 5 10 12214PRTArtificial SequenceGC-C agonist peptide 122Cys Cys
Glu Leu Cys Cys Lys Pro Ala Cys Thr Gly Cys Tyr 1 5 10
12314PRTArtificial SequenceGC-C agonist peptide 123Cys Cys Glu Leu
Cys Cys His Pro Ala Cys Thr Gly Cys Tyr 1 5 10 12414PRTArtificial
SequenceGC-C agonist peptide 124Cys Cys Glu Tyr Cys Cys Val Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 12514PRTArtificial SequenceGC-C agonist
peptide 125Cys Cys Glu Tyr Cys Cys Ile Pro Ala Cys Thr Gly Cys Tyr
1 5 10 12614PRTArtificial SequenceGC-C agonist peptide 126Cys Cys
Glu Tyr Cys Cys Met Pro Ala Cys Thr Gly Cys Tyr 1 5 10
12714PRTArtificial SequenceGC-C agonist peptide 127Cys Cys Glu Tyr
Cys Cys Trp Pro Ala Cys Thr Gly Cys Tyr 1 5 10 12814PRTArtificial
SequenceGC-C agonist peptide 128Cys Cys Glu Tyr Cys Cys Ser Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 12914PRTArtificial SequenceGC-C agonist
peptide 129Cys Cys Glu Tyr Cys Cys Cys Pro Ala Cys Thr Gly Cys Tyr
1 5 10 13014PRTArtificial SequenceGC-C agonist peptide 130Cys Cys
Glu Tyr Cys Cys Tyr Pro Ala Cys Thr Gly Cys Tyr 1 5 10
13114PRTArtificial SequenceGC-C agonist peptide 131Cys Cys Glu Tyr
Cys Cys Glu Pro Ala Cys Thr Gly Cys Tyr 1 5 10 13214PRTArtificial
SequenceGC-C agonist peptide 132Cys Cys Glu Tyr Cys Cys Arg Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 13313PRTArtificial SequenceGC-C agonist
peptide 133Cys Cys Glu Leu Cys Cys Ala Pro Ala Cys Thr Gly Cys 1 5
10 13413PRTArtificial SequenceGC-C agonist peptide 134Cys Cys Glu
Leu Cys Cys Leu Pro Ala Cys Thr Gly Cys 1 5 10 13513PRTArtificial
SequenceGC-C agonist peptide 135Cys Cys Glu Leu Cys Cys Pro Pro Ala
Cys Thr Gly Cys 1 5 10 13613PRTArtificial SequenceGC-C agonist
peptide 136Cys Cys Glu Leu Cys Cys Phe Pro Ala Cys Thr Gly Cys 1 5
10 13713PRTArtificial SequenceGC-C agonist peptide 137Cys Cys Glu
Leu Cys Cys Gly Pro Ala Cys Thr Gly Cys 1 5 10 13813PRTArtificial
SequenceGC-C agonist peptide 138Cys Cys Glu Leu Cys Cys Thr Pro Ala
Cys Thr Gly Cys 1 5 10 13913PRTArtificial SequenceGC-C agonist
peptide 139Cys Cys Glu Leu Cys Cys Gln Pro Ala Cys Thr Gly Cys 1 5
10 14013PRTArtificial SequenceGC-C agonist peptide 140Cys Cys Glu
Leu Cys Cys Asp Pro Ala Cys Thr Gly Cys 1 5 10 14113PRTArtificial
SequenceGC-C agonist peptide 141Cys Cys Glu Leu Cys Cys Lys Pro Ala
Cys Thr Gly Cys 1 5 10 14213PRTArtificial SequenceGC-C agonist
peptide 142Cys Cys Glu Leu Cys Cys His Pro Ala Cys Thr Gly Cys 1 5
10 14313PRTArtificial SequenceGC-C agonist peptide 143Cys Cys Glu
Tyr Cys Cys Val Pro Ala Cys Thr Gly Cys 1 5 10 14413PRTArtificial
SequenceGC-C agonist peptide 144Cys Cys Glu Tyr Cys Cys Ile Pro Ala
Cys Thr Gly Cys 1 5 10 14513PRTArtificial SequenceGC-C agonist
peptide 145Cys Cys Glu Tyr Cys Cys Met Pro Ala Cys Thr Gly Cys 1 5
10 14613PRTArtificial SequenceGC-C agonist peptide 146Cys Cys Glu
Tyr Cys Cys Trp Pro Ala Cys Thr Gly Cys 1 5 10 14713PRTArtificial
SequenceGC-C agonist peptide 147Cys Cys Glu Tyr Cys Cys Ser Pro Ala
Cys Thr Gly Cys 1 5 10 14813PRTArtificial SequenceGC-C agonist
peptide 148Cys Cys Glu Tyr Cys Cys Cys Pro Ala Cys Thr Gly Cys 1 5
10 14913PRTArtificial SequenceGC-C agonist peptide 149Cys Cys Glu
Tyr Cys Cys Tyr Pro Ala Cys Thr Gly Cys 1 5 10 15013PRTArtificial
SequenceGC-C agonist peptide 150Cys Cys Glu Tyr Cys Cys Glu Pro Ala
Cys Thr Gly Cys 1 5 10 15113PRTArtificial SequenceGC-C agonist
peptide 151Cys Cys Glu Tyr Cys Cys Arg Pro Ala Cys Thr Gly Cys 1 5
10 15214PRTArtificial SequenceGC-C agonist peptide 152Cys Cys Glu
Leu Cys Cys Asn Pro Thr Cys Thr Gly Cys Tyr 1 5 10
15313PRTArtificial SequenceGC-C agonist peptide 153Cys Cys Glu Leu
Cys Cys Asn Pro Thr Cys Thr Gly Cys 1 5 10 15414PRTArtificial
SequenceGC-C agonist peptide 154Cys Cys Glu Phe Cys Cys Asn Pro Thr
Cys Thr Gly Cys Tyr 1 5 10 15514PRTArtificial SequenceGC-C agonist
peptide 155Cys Cys Glu Trp Cys Cys Asn Pro Thr Cys Thr Gly Cys Tyr
1 5 10 15614PRTArtificial SequenceGC-C agonist peptide 156Cys Cys
Glu Leu Cys Cys Asn Gly Ala Cys Thr Gly Cys Tyr 1 5 10
15713PRTArtificial SequenceGC-C agonist peptide 157Cys Cys Glu Leu
Cys Cys Asn Gly Ala Cys Thr Gly Cys 1 5 10 15814PRTArtificial
SequenceGC-C agonist peptide 158Cys Cys Glu Phe Cys Cys Asn Gly Ala
Cys Thr Gly Cys Tyr 1 5 10 15914PRTArtificial SequenceGC-C agonist
peptide 159Cys Cys Glu Trp Cys Cys Asn Gly Ala Cys Thr Gly Cys Tyr
1 5 10 16014PRTArtificial SequenceGC-C agonist peptide 160Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Val Gly Cys Tyr 1 5 10
16113PRTArtificial SequenceGC-C agonist peptide 161Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Val Gly Cys 1 5 10 16214PRTArtificial
SequenceGC-C agonist peptide 162Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Val Gly Cys Tyr 1 5 10 16314PRTArtificial SequenceGC-C agonist
peptide 163Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Val Gly Cys Tyr
1 5 10 16414PRTArtificial SequenceGC-C agonist peptide 164Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Gly Gly Cys Tyr 1 5 10
16513PRTArtificial SequenceGC-C agonist peptide 165Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Gly Gly Cys 1 5 10 16614PRTArtificial
SequenceGC-C agonist peptide 166Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Gly Gly Cys Tyr 1 5 10 16714PRTArtificial SequenceGC-C agonist
peptide 167Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Gly Gly Cys Tyr
1 5 10 16814PRTArtificial SequenceGC-C agonist peptide 168Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Ala Cys Tyr 1 5 10
16913PRTArtificial SequenceGC-C agonist peptide 169Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Ala Cys 1 5 10 17014PRTArtificial
SequenceGC-C agonist peptide 170Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Thr Ala Cys Tyr 1 5 10 17114PRTArtificial SequenceGC-C agonist
peptide 171Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Ala Cys Tyr
1 5 10 17214PRTArtificial SequenceGC-C agonist peptide 172Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala 1 5 10
17314PRTArtificial SequenceGC-C agonist peptide 173Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu 1 5 10 17414PRTArtificial
SequenceGC-C agonist peptide 174Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Pro 1 5 10 17514PRTArtificial SequenceGC-C agonist
peptide 175Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe
1 5 10 17614PRTArtificial SequenceGC-C agonist peptide 176Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Gly 1 5 10
17714PRTArtificial SequenceGC-C agonist peptide 177Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Thr 1 5 10 17814PRTArtificial
SequenceGC-C agonist peptide 178Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Asn 1 5 10 17914PRTArtificial SequenceGC-C agonist
peptide 179Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Asp
1 5 10 18014PRTArtificial SequenceGC-C agonist peptide 180Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys 1 5 10
18114PRTArtificial SequenceGC-C agonist peptide 181Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys His 1 5 10 18214PRTArtificial
SequenceGC-C agonist peptide 182Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Val 1 5 10 18314PRTArtificial SequenceGC-C agonist
peptide 183Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Ile
1 5 10 18414PRTArtificial SequenceGC-C agonist peptide 184Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Met 1 5 10
18514PRTArtificial SequenceGC-C agonist peptide 185Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Trp 1 5 10 18614PRTArtificial
SequenceGC-C agonist peptide 186Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Ser 1 5 10 18714PRTArtificial SequenceGC-C agonist
peptide 187Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Cys
1 5 10 18814PRTArtificial SequenceGC-C agonist peptide 188Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Gln 1 5 10
18914PRTArtificial SequenceGC-C agonist peptide 189Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Glu 1 5 10 19014PRTArtificial
SequenceGC-C agonist peptide 190Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Arg 1 5 10 19114PRTArtificial SequenceGC-C agonist
peptide 191Cys Cys Ala Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 19214PRTArtificial SequenceGC-C agonist peptide 192Cys Cys
Leu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
19314PRTArtificial SequenceGC-C agonist peptide 193Cys Cys Met Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 19414PRTArtificial
SequenceGC-C agonist peptide 194Cys Cys Trp Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 19514PRTArtificial SequenceGC-C agonist
peptide 195Cys Cys Ser Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 19614PRTArtificial SequenceGC-C agonist peptide 196Cys Cys
Cys Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
19714PRTArtificial SequenceGC-C agonist peptide 197Cys Cys Gln Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 19814PRTArtificial
SequenceGC-C agonist peptide 198Cys Cys Asp Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 19914PRTArtificial SequenceGC-C agonist
peptide 199Cys Cys Arg Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5
10 20013PRTArtificial SequenceGC-C agonist peptide 200Cys Cys Ala
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 20113PRTArtificial
SequenceGC-C agonist peptide 201Cys Cys Leu Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 20213PRTArtificial SequenceGC-C agonist
peptide 202Cys Cys Met Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 20313PRTArtificial SequenceGC-C agonist peptide 203Cys Cys Trp
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 20413PRTArtificial
SequenceGC-C agonist peptide 204Cys Cys Ser Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 20513PRTArtificial SequenceGC-C agonist
peptide 205Cys Cys Cys Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 20613PRTArtificial SequenceGC-C agonist peptide 206Cys Cys Gln
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 20713PRTArtificial
SequenceGC-C agonist peptide 207Cys Cys Asp Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 20813PRTArtificial SequenceGC-C agonist
peptide 208Cys Cys Arg Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 20914PRTArtificial SequenceGC-C agonist peptide 209Cys Cys Ala
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
21014PRTArtificial SequenceGC-C agonist peptide 210Cys Cys Leu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 21114PRTArtificial
SequenceGC-C agonist peptide 211Cys Cys Met Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 21214PRTArtificial SequenceGC-C agonist
peptide 212Cys Cys Trp Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 21314PRTArtificial SequenceGC-C agonist peptide 213Cys Cys
Ser Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
21414PRTArtificial SequenceGC-C agonist peptide 214Cys Cys Cys Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 21514PRTArtificial
SequenceGC-C agonist peptide 215Cys Cys Gln Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 21614PRTArtificial SequenceGC-C agonist
peptide 216Cys Cys Asp Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 21714PRTArtificial SequenceGC-C agonist peptide 217Cys Cys
Arg Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
21813PRTArtificial SequenceGC-C agonist peptide 218Cys Cys Ala Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 21913PRTArtificial
SequenceGC-C agonist peptide 219Cys Cys Leu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 22013PRTArtificial SequenceGC-C agonist
peptide 220Cys Cys Met Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 22113PRTArtificial SequenceGC-C agonist peptide 221Cys Cys Trp
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 22213PRTArtificial
SequenceGC-C agonist peptide 222Cys Cys Ser Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 22313PRTArtificial SequenceGC-C agonist
peptide 223Cys Cys Cys Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 22413PRTArtificial SequenceGC-C agonist peptide 224Cys Cys Gln
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 22513PRTArtificial
SequenceGC-C agonist peptide 225Cys Cys Asp Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 22613PRTArtificial SequenceGC-C agonist
peptide 226Cys Cys Arg Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 22714PRTArtificial SequenceGC-C agonist peptide 227Cys Cys Glu
Phe Cys Cys Ala Pro Ala Cys Thr Gly Cys Tyr 1 5 10
22814PRTArtificial SequenceGC-C agonist peptide 228Cys Cys Glu Phe
Cys Cys Leu Pro Ala Cys Thr Gly Cys Tyr 1 5 10 22914PRTArtificial
SequenceGC-C agonist peptide 229Cys Cys Glu Phe Cys Cys Pro Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 23014PRTArtificial SequenceGC-C agonist
peptide 230Cys Cys Glu Phe Cys Cys Phe Pro Ala Cys Thr Gly Cys Tyr
1 5 10 23114PRTArtificial SequenceGC-C agonist peptide 231Cys Cys
Glu Phe Cys Cys Gly Pro Ala Cys Thr Gly Cys Tyr 1 5 10
23214PRTArtificial SequenceGC-C agonist peptide 232Cys Cys Glu Phe
Cys Cys Thr Pro Ala Cys Thr Gly Cys Tyr 1 5 10 23314PRTArtificial
SequenceGC-C agonist peptide 233Cys Cys Glu Phe Cys Cys Gln Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 23414PRTArtificial SequenceGC-C agonist
peptide 234Cys Cys Glu Phe Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr
1 5 10 23514PRTArtificial SequenceGC-C agonist peptide 235Cys Cys
Glu Phe Cys Cys Lys Pro Ala Cys Thr Gly Cys Tyr 1 5 10
23614PRTArtificial SequenceGC-C agonist peptide 236Cys Cys Glu Phe
Cys Cys His Pro Ala Cys Thr Gly Cys Tyr 1 5 10 23713PRTArtificial
SequenceGC-C agonist peptide 237Cys Cys Glu Phe Cys Cys Val Pro Ala
Cys Thr Gly Cys 1 5 10 23813PRTArtificial SequenceGC-C agonist
peptide 238Cys Cys Glu Phe Cys Cys Ile Pro Ala Cys Thr Gly Cys 1 5
10 23913PRTArtificial SequenceGC-C agonist peptide 239Cys Cys Glu
Phe Cys Cys Met Pro Ala Cys Thr Gly Cys 1 5 10 24013PRTArtificial
SequenceGC-C agonist peptide 240Cys Cys Glu Phe Cys Cys Trp Pro Ala
Cys Thr Gly Cys 1 5 10 24113PRTArtificial SequenceGC-C agonist
peptide 241Cys Cys Glu Phe Cys Cys Ser Pro Ala Cys Thr Gly Cys 1 5
10 24213PRTArtificial SequenceGC-C agonist peptide 242Cys Cys Glu
Phe Cys Cys Cys Pro Ala Cys Thr Gly Cys 1 5 10 24313PRTArtificial
SequenceGC-C agonist peptide 243Cys Cys Glu Phe Cys Cys Tyr Pro Ala
Cys Thr Gly Cys 1 5 10 24413PRTArtificial SequenceGC-C agonist
peptide 244Cys Cys Glu Phe Cys Cys Glu Pro Ala Cys Thr Gly Cys 1 5
10 24513PRTArtificial SequenceGC-C agonist peptide 245Cys Cys Glu
Phe Cys Cys Arg Pro Ala Cys Thr Gly Cys 1 5 10 24614PRTArtificial
SequenceGC-C agonist peptide 246Cys Cys Glu Trp Cys Cys Ala Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 24714PRTArtificial SequenceGC-C agonist
peptide 247Cys Cys Glu Trp Cys Cys Leu Pro Ala Cys Thr Gly Cys Tyr
1 5 10 24814PRTArtificial SequenceGC-C agonist peptide 248Cys Cys
Glu Trp Cys Cys Pro Pro Ala Cys Thr Gly Cys Tyr 1 5 10
24914PRTArtificial SequenceGC-C agonist peptide 249Cys Cys Glu Trp
Cys Cys Phe Pro Ala Cys Thr Gly Cys Tyr 1 5 10 25014PRTArtificial
SequenceGC-C agonist peptide 250Cys Cys Glu Trp Cys Cys Gly Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 25114PRTArtificial SequenceGC-C agonist
peptide 251Cys Cys Glu Trp Cys Cys Thr Pro Ala Cys Thr Gly Cys Tyr
1 5 10 25214PRTArtificial SequenceGC-C agonist peptide 252Cys Cys
Glu Trp Cys Cys Gln Pro Ala Cys Thr Gly Cys Tyr 1 5 10
25314PRTArtificial SequenceGC-C agonist peptide 253Cys Cys Glu Trp
Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr 1 5 10 25414PRTArtificial
SequenceGC-C agonist peptide 254Cys Cys Glu Trp Cys Cys Lys Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 25514PRTArtificial SequenceGC-C agonist
peptide 255Cys Cys Glu Trp Cys Cys His Pro Ala Cys Thr Gly Cys Tyr
1 5 10 25613PRTArtificial SequenceGC-C agonist peptide 256Cys Cys
Glu Trp Cys Cys Val Pro Ala Cys Thr Gly Cys 1 5 10
25713PRTArtificial SequenceGC-C agonist peptide 257Cys Cys Glu Trp
Cys Cys Ile Pro Ala Cys Thr Gly Cys 1 5 10 25813PRTArtificial
SequenceGC-C agonist peptide 258Cys Cys Glu Trp Cys Cys Met Pro Ala
Cys Thr Gly Cys 1 5 10 25913PRTArtificial SequenceGC-C agonist
peptide 259Cys Cys Glu Trp Cys Cys Trp Pro Ala Cys Thr Gly Cys 1 5
10 26013PRTArtificial SequenceGC-C agonist peptide 260Cys Cys Glu
Trp Cys Cys Ser Pro Ala Cys Thr Gly Cys 1 5 10 26113PRTArtificial
SequenceGC-C agonist peptide 261Cys Cys Glu Trp Cys Cys Cys Pro Ala
Cys Thr Gly Cys 1 5 10 26213PRTArtificial SequenceGC-C agonist
peptide 262Cys Cys Glu Trp Cys Cys Tyr Pro Ala Cys Thr Gly Cys 1 5
10 26313PRTArtificial SequenceGC-C agonist peptide 263Cys Cys Glu
Trp Cys Cys Glu Pro Ala Cys Thr Gly Cys 1 5 10 26413PRTArtificial
SequenceGC-C agonist peptide 264Cys Cys Glu Trp Cys Cys Arg Pro Ala
Cys Thr Gly Cys 1 5 10 26514PRTArtificial SequenceGC-C agonist
peptide 265Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala
1 5 10 26614PRTArtificial SequenceGC-C agonist peptide 266Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu 1 5 10
26714PRTArtificial SequenceGC-C agonist peptide 267Cys Cys Glu Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Pro 1 5 10 26814PRTArtificial
SequenceGC-C agonist peptide 268Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Phe 1 5 10 26914PRTArtificial SequenceGC-C agonist
peptide 269Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Gly
1 5 10 27014PRTArtificial SequenceGC-C agonist peptide 270Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Thr 1 5 10
27114PRTArtificial SequenceGC-C agonist peptide 271Cys Cys Glu Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Asn 1 5 10 27214PRTArtificial
SequenceGC-C agonist peptide 272Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Asp 1 5 10 27314PRTArtificial SequenceGC-C agonist
peptide 273Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys
1 5 10 27414PRTArtificial SequenceGC-C agonist peptide 274Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys His 1 5 10
27514PRTArtificial SequenceGC-C agonist peptide 275Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Val 1 5 10 27614PRTArtificial
SequenceGC-C agonist peptide 276Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Ile 1 5 10 27714PRTArtificial SequenceGC-C agonist
peptide 277Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Met
1 5 10 27814PRTArtificial SequenceGC-C agonist peptide 278Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Trp 1 5 10
27914PRTArtificial SequenceGC-C agonist peptide 279Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Ser 1 5 10 28014PRTArtificial
SequenceGC-C agonist peptide 280Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Cys 1 5 10 28114PRTArtificial SequenceGC-C agonist
peptide 281Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Gln
1 5 10 28214PRTArtificial SequenceGC-C agonist peptide 282Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Glu 1 5 10
28314PRTArtificial SequenceGC-C agonist peptide 283Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Arg 1 5 10 28414PRTArtificial
SequenceGC-C agonist peptide 284Cys Cys Ala Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 28514PRTArtificial SequenceGC-C agonist
peptide 285Cys Cys Leu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 28614PRTArtificial SequenceGC-C agonist peptide 286Cys Cys
Met Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
28714PRTArtificial SequenceGC-C agonist peptide 287Cys Cys Trp Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 28814PRTArtificial
SequenceGC-C agonist peptide 288Cys Cys Ser Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 28914PRTArtificial SequenceGC-C agonist
peptide 289Cys Cys Cys Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 29014PRTArtificial SequenceGC-C agonist peptide 290Cys Cys
Gln Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
29114PRTArtificial SequenceGC-C agonist peptide 291Cys Cys Asp Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 29214PRTArtificial
SequenceGC-C agonist peptide 292Cys Cys Arg Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 29313PRTArtificial SequenceGC-C agonist
peptide 293Cys Cys Ala Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 29413PRTArtificial SequenceGC-C agonist peptide 294Cys Cys Leu
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 29513PRTArtificial
SequenceGC-C agonist peptide 295Cys Cys Met Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 29613PRTArtificial SequenceGC-C agonist
peptide 296Cys Cys Trp Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 29713PRTArtificial SequenceGC-C agonist peptide 297Cys Cys Ser
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 29813PRTArtificial
SequenceGC-C agonist peptide 298Cys Cys Cys Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 29913PRTArtificial SequenceGC-C agonist
peptide 299Cys Cys Gln Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 30013PRTArtificial SequenceGC-C agonist peptide 300Cys Cys Asp
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 30113PRTArtificial
SequenceGC-C agonist peptide 301Cys Cys Arg Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 30214PRTArtificial SequenceGC-C agonist
peptide 302Cys Cys Ala Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 30314PRTArtificial SequenceGC-C agonist peptide 303Cys Cys
Leu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
30414PRTArtificial SequenceGC-C agonist peptide 304Cys Cys Met Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 30514PRTArtificial
SequenceGC-C agonist peptide 305Cys Cys Trp Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 30614PRTArtificial SequenceGC-C agonist
peptide 306Cys Cys Ser Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 30714PRTArtificial SequenceGC-C agonist peptide 307Cys Cys
Cys Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
30814PRTArtificial SequenceGC-C agonist peptide 308Cys Cys Gln Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 30914PRTArtificial
SequenceGC-C agonist peptide 309Cys Cys Asp Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 31014PRTArtificial SequenceGC-C agonist
peptide 310Cys Cys Arg Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 31113PRTArtificial SequenceGC-C
agonist peptide 311Cys Cys Ala Trp Cys Cys Asn Pro Ala Cys Thr Gly
Cys 1 5 10 31213PRTArtificial SequenceGC-C agonist peptide 312Cys
Cys Leu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10
31313PRTArtificial SequenceGC-C agonist peptide 313Cys Cys Met Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 31413PRTArtificial
SequenceGC-C agonist peptide 314Cys Cys Trp Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 31513PRTArtificial SequenceGC-C agonist
peptide 315Cys Cys Ser Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 31613PRTArtificial SequenceGC-C agonist peptide 316Cys Cys Cys
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 31713PRTArtificial
SequenceGC-C agonist peptide 317Cys Cys Gln Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 31813PRTArtificial SequenceGC-C agonist
peptide 318Cys Cys Asp Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 31913PRTArtificial SequenceGC-C agonist peptide 319Cys Cys Arg
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 32014PRTArtificial
SequenceGC-C agonist peptide 320Cys Cys Glu Leu Cys Cys Val Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 32114PRTArtificial SequenceGC-C agonist
peptide 321Cys Cys Glu Leu Cys Cys Ile Pro Ala Cys Thr Gly Cys Tyr
1 5 10 32214PRTArtificial SequenceGC-C agonist peptide 322Cys Cys
Glu Leu Cys Cys Met Pro Ala Cys Thr Gly Cys Tyr 1 5 10
32314PRTArtificial SequenceGC-C agonist peptide 323Cys Cys Glu Leu
Cys Cys Trp Pro Ala Cys Thr Gly Cys Tyr 1 5 10 32414PRTArtificial
SequenceGC-C agonist peptide 324Cys Cys Glu Leu Cys Cys Ser Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 32514PRTArtificial SequenceGC-C agonist
peptide 325Cys Cys Glu Leu Cys Cys Cys Pro Ala Cys Thr Gly Cys Tyr
1 5 10 32614PRTArtificial SequenceGC-C agonist peptide 326Cys Cys
Glu Leu Cys Cys Tyr Pro Ala Cys Thr Gly Cys Tyr 1 5 10
32714PRTArtificial SequenceGC-C agonist peptide 327Cys Cys Glu Leu
Cys Cys Glu Pro Ala Cys Thr Gly Cys Tyr 1 5 10 32814PRTArtificial
SequenceGC-C agonist peptide 328Cys Cys Glu Leu Cys Cys Arg Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 32914PRTArtificial SequenceGC-C agonist
peptide 329Cys Cys Glu Tyr Cys Cys Ala Pro Ala Cys Thr Gly Cys Tyr
1 5 10 33014PRTArtificial SequenceGC-C agonist peptide 330Cys Cys
Glu Tyr Cys Cys Leu Pro Ala Cys Thr Gly Cys Tyr 1 5 10
33114PRTArtificial SequenceGC-C agonist peptide 331Cys Cys Glu Tyr
Cys Cys Pro Pro Ala Cys Thr Gly Cys Tyr 1 5 10 33214PRTArtificial
SequenceGC-C agonist peptide 332Cys Cys Glu Tyr Cys Cys Phe Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 33314PRTArtificial SequenceGC-C agonist
peptide 333Cys Cys Glu Tyr Cys Cys Gly Pro Ala Cys Thr Gly Cys Tyr
1 5 10 33414PRTArtificial SequenceGC-C agonist peptide 334Cys Cys
Glu Tyr Cys Cys Thr Pro Ala Cys Thr Gly Cys Tyr 1 5 10
33514PRTArtificial SequenceGC-C agonist peptide 335Cys Cys Glu Tyr
Cys Cys Gln Pro Ala Cys Thr Gly Cys Tyr 1 5 10 33614PRTArtificial
SequenceGC-C agonist peptide 336Cys Cys Glu Tyr Cys Cys Asp Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 33714PRTArtificial SequenceGC-C agonist
peptide 337Cys Cys Glu Tyr Cys Cys Lys Pro Ala Cys Thr Gly Cys Tyr
1 5 10 33814PRTArtificial SequenceGC-C agonist peptide 338Cys Cys
Glu Tyr Cys Cys His Pro Ala Cys Thr Gly Cys Tyr 1 5 10
33913PRTArtificial SequenceGC-C agonist peptide 339Cys Cys Glu Leu
Cys Cys Val Pro Ala Cys Thr Gly Cys 1 5 10 34013PRTArtificial
SequenceGC-C agonist peptide 340Cys Cys Glu Leu Cys Cys Ile Pro Ala
Cys Thr Gly Cys 1 5 10 34113PRTArtificial SequenceGC-C agonist
peptide 341Cys Cys Glu Leu Cys Cys Met Pro Ala Cys Thr Gly Cys 1 5
10 34213PRTArtificial SequenceGC-C agonist peptide 342Cys Cys Glu
Leu Cys Cys Trp Pro Ala Cys Thr Gly Cys 1 5 10 34313PRTArtificial
SequenceGC-C agonist peptide 343Cys Cys Glu Leu Cys Cys Ser Pro Ala
Cys Thr Gly Cys 1 5 10 34413PRTArtificial SequenceGC-C agonist
peptide 344Cys Cys Glu Leu Cys Cys Cys Pro Ala Cys Thr Gly Cys 1 5
10 34513PRTArtificial SequenceGC-C agonist peptide 345Cys Cys Glu
Leu Cys Cys Tyr Pro Ala Cys Thr Gly Cys 1 5 10 34613PRTArtificial
SequenceGC-C agonist peptide 346Cys Cys Glu Leu Cys Cys Glu Pro Ala
Cys Thr Gly Cys 1 5 10 34713PRTArtificial SequenceGC-C agonist
peptide 347Cys Cys Glu Leu Cys Cys Arg Pro Ala Cys Thr Gly Cys 1 5
10 34813PRTArtificial SequenceGC-C agonist peptide 348Cys Cys Glu
Tyr Cys Cys Ala Pro Ala Cys Thr Gly Cys 1 5 10 34913PRTArtificial
SequenceGC-C agonist peptide 349Cys Cys Glu Tyr Cys Cys Leu Pro Ala
Cys Thr Gly Cys 1 5 10 35013PRTArtificial SequenceGC-C agonist
peptide 350Cys Cys Glu Tyr Cys Cys Pro Pro Ala Cys Thr Gly Cys 1 5
10 35113PRTArtificial SequenceGC-C agonist peptide 351Cys Cys Glu
Tyr Cys Cys Phe Pro Ala Cys Thr Gly Cys 1 5 10 35213PRTArtificial
SequenceGC-C agonist peptide 352Cys Cys Glu Tyr Cys Cys Gly Pro Ala
Cys Thr Gly Cys 1 5 10 35313PRTArtificial SequenceGC-C agonist
peptide 353Cys Cys Glu Tyr Cys Cys Thr Pro Ala Cys Thr Gly Cys 1 5
10 35413PRTArtificial SequenceGC-C agonist peptide 354Cys Cys Glu
Tyr Cys Cys Gln Pro Ala Cys Thr Gly Cys 1 5 10 35513PRTArtificial
SequenceGC-C agonist peptide 355Cys Cys Glu Tyr Cys Cys Asp Pro Ala
Cys Thr Gly Cys 1 5 10 35613PRTArtificial SequenceGC-C agonist
peptide 356Cys Cys Glu Tyr Cys Cys Lys Pro Ala Cys Thr Gly Cys 1 5
10 35713PRTArtificial SequenceGC-C agonist peptide 357Cys Cys Glu
Tyr Cys Cys His Pro Ala Cys Thr Gly Cys 1 5 10 35814PRTArtificial
SequenceGC-C agonist peptide 358Cys Cys Glu Tyr Cys Cys Asn Pro Thr
Cys Thr Gly Cys Tyr 1 5 10 35913PRTArtificial SequenceGC-C agonist
peptide 359Cys Cys Glu Tyr Cys Cys Asn Pro Thr Cys Thr Gly Cys 1 5
10 36013PRTArtificial SequenceGC-C agonist peptide 360Cys Cys Glu
Phe Cys Cys Asn Pro Thr Cys Thr Gly Cys 1 5 10 36113PRTArtificial
SequenceGC-C agonist peptide 361Cys Cys Glu Trp Cys Cys Asn Pro Thr
Cys Thr Gly Cys 1 5 10 36214PRTArtificial SequenceGC-C agonist
peptide 362Cys Cys Glu Tyr Cys Cys Asn Gly Ala Cys Thr Gly Cys Tyr
1 5 10 36313PRTArtificial SequenceGC-C agonist peptide 363Cys Cys
Glu Tyr Cys Cys Asn Gly Ala Cys Thr Gly Cys 1 5 10
36413PRTArtificial SequenceGC-C agonist peptide 364Cys Cys Glu Phe
Cys Cys Asn Gly Ala Cys Thr Gly Cys 1 5 10 36513PRTArtificial
SequenceGC-C agonist peptide 365Cys Cys Glu Trp Cys Cys Asn Gly Ala
Cys Thr Gly Cys 1 5 10 36614PRTArtificial SequenceGC-C agonist
peptide 366Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Val Gly Cys Tyr
1 5 10 36713PRTArtificial SequenceGC-C agonist peptide 367Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Val Gly Cys 1 5 10
36813PRTArtificial SequenceGC-C agonist peptide 368Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Val Gly Cys 1 5 10 36913PRTArtificial
SequenceGC-C agonist peptide 369Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Val Gly Cys 1 5 10 37014PRTArtificial SequenceGC-C agonist
peptide 370Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Gly Gly Cys Tyr
1 5 10 37113PRTArtificial SequenceGC-C agonist peptide 371Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Gly Gly Cys 1 5 10
37213PRTArtificial SequenceGC-C agonist peptide 372Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Gly Gly Cys 1 5 10 37313PRTArtificial
SequenceGC-C agonist peptide 373Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Gly Gly Cys 1 5 10 37414PRTArtificial SequenceGC-C agonist
peptide 374Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Ala Cys Tyr
1 5 10 37513PRTArtificial SequenceGC-C agonist peptide 375Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Ala Cys 1 5 10
37613PRTArtificial SequenceGC-C agonist peptide 376Cys Cys Glu Trp
Cys Cys Asn Pro Ala Cys Thr Ala Cys 1 5 10 37713PRTArtificial
SequenceGC-C agonist peptide 377Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Ala Cys 1 5 10 37814PRTArtificial SequenceGC-C agonist
peptide 378Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Val
1 5 10 37914PRTArtificial SequenceGC-C agonist peptide 379Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Ile 1 5 10
38014PRTArtificial SequenceGC-C agonist peptide 380Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Met 1 5 10 38114PRTArtificial
SequenceGC-C agonist peptide 381Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Trp 1 5 10 38214PRTArtificial SequenceGC-C agonist
peptide 382Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Ser
1 5 10 38314PRTArtificial SequenceGC-C agonist peptide 383Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Cys 1 5 10
38414PRTArtificial SequenceGC-C agonist peptide 384Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Gln 1 5 10 38514PRTArtificial
SequenceGC-C agonist peptide 385Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Glu 1 5 10 38614PRTArtificial SequenceGC-C agonist
peptide 386Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Arg
1 5 10 38714PRTArtificial SequenceGC-C agonist peptide 387Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala 1 5 10
38814PRTArtificial SequenceGC-C agonist peptide 388Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu 1 5 10 38914PRTArtificial
SequenceGC-C agonist peptide 389Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Pro 1 5 10 39014PRTArtificial SequenceGC-C agonist
peptide 390Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe
1 5 10 39114PRTArtificial SequenceGC-C agonist peptide 391Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Gly 1 5 10
39214PRTArtificial SequenceGC-C agonist peptide 392Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Thr 1 5 10 39314PRTArtificial
SequenceGC-C agonist peptide 393Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Asn 1 5 10 39414PRTArtificial SequenceGC-C agonist
peptide 394Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Asp
1 5 10 39514PRTArtificial SequenceGC-C agonist peptide 395Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys 1 5 10
39614PRTArtificial SequenceGC-C agonist peptide 396Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys His 1 5 10 39714PRTArtificial
SequenceGC-C agonist peptide 397Cys Cys Val Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 39814PRTArtificial SequenceGC-C agonist
peptide 398Cys Cys Ile Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 39914PRTArtificial SequenceGC-C agonist peptide 399Cys Cys
Phe Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
40014PRTArtificial SequenceGC-C agonist peptide 400Cys Cys Gly Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 40114PRTArtificial
SequenceGC-C agonist peptide 401Cys Cys Thr Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 40214PRTArtificial SequenceGC-C agonist
peptide 402Cys Cys Asn Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 40314PRTArtificial SequenceGC-C agonist peptide 403Cys Cys
Tyr Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
40414PRTArtificial SequenceGC-C agonist peptide 404Cys Cys Lys Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 40514PRTArtificial
SequenceGC-C agonist peptide 405Cys Cys His Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 40613PRTArtificial SequenceGC-C agonist
peptide 406Cys Cys Val Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 40713PRTArtificial SequenceGC-C agonist peptide 407Cys Cys Ile
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 40813PRTArtificial
SequenceGC-C agonist peptide 408Cys Cys Phe Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 40913PRTArtificial SequenceGC-C agonist
peptide 409Cys Cys Gly Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 41013PRTArtificial SequenceGC-C agonist peptide 410Cys Cys Thr
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 41113PRTArtificial
SequenceGC-C agonist peptide 411Cys Cys Asn Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 41213PRTArtificial SequenceGC-C agonist
peptide 412Cys Cys Tyr Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 41313PRTArtificial SequenceGC-C agonist peptide 413Cys Cys Lys
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 41413PRTArtificial
SequenceGC-C agonist peptide 414Cys Cys His Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 41514PRTArtificial SequenceGC-C agonist
peptide 415Cys Cys Val Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 41614PRTArtificial SequenceGC-C agonist peptide 416Cys Cys
Ile Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
41714PRTArtificial SequenceGC-C agonist peptide 417Cys Cys Phe Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 41814PRTArtificial
SequenceGC-C agonist peptide 418Cys Cys Gly Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 41914PRTArtificial SequenceGC-C agonist
peptide 419Cys Cys Thr Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 42014PRTArtificial SequenceGC-C agonist peptide 420Cys Cys
Asn Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
42114PRTArtificial SequenceGC-C agonist peptide 421Cys Cys Tyr Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 42214PRTArtificial
SequenceGC-C agonist peptide 422Cys Cys Lys Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 42314PRTArtificial SequenceGC-C
agonist peptide 423Cys Cys His Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr 1 5 10 42413PRTArtificial SequenceGC-C agonist peptide
424Cys Cys Val Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10
42513PRTArtificial SequenceGC-C agonist peptide 425Cys Cys Ile Tyr
Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 42613PRTArtificial
SequenceGC-C agonist peptide 426Cys Cys Phe Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 42713PRTArtificial SequenceGC-C agonist
peptide 427Cys Cys Gly Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 42813PRTArtificial SequenceGC-C agonist peptide 428Cys Cys Thr
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 42913PRTArtificial
SequenceGC-C agonist peptide 429Cys Cys Asn Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 43013PRTArtificial SequenceGC-C agonist
peptide 430Cys Cys Tyr Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 43113PRTArtificial SequenceGC-C agonist peptide 431Cys Cys Lys
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 43213PRTArtificial
SequenceGC-C agonist peptide 432Cys Cys His Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 43314PRTArtificial SequenceGC-C agonist
peptide 433Cys Cys Glu Phe Cys Cys Val Pro Ala Cys Thr Gly Cys Tyr
1 5 10 43414PRTArtificial SequenceGC-C agonist peptide 434Cys Cys
Glu Phe Cys Cys Ile Pro Ala Cys Thr Gly Cys Tyr 1 5 10
43514PRTArtificial SequenceGC-C agonist peptide 435Cys Cys Glu Phe
Cys Cys Met Pro Ala Cys Thr Gly Cys Tyr 1 5 10 43614PRTArtificial
SequenceGC-C agonist peptide 436Cys Cys Glu Phe Cys Cys Trp Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 43714PRTArtificial SequenceGC-C agonist
peptide 437Cys Cys Glu Phe Cys Cys Ser Pro Ala Cys Thr Gly Cys Tyr
1 5 10 43814PRTArtificial SequenceGC-C agonist peptide 438Cys Cys
Glu Phe Cys Cys Cys Pro Ala Cys Thr Gly Cys Tyr 1 5 10
43914PRTArtificial SequenceGC-C agonist peptide 439Cys Cys Glu Phe
Cys Cys Tyr Pro Ala Cys Thr Gly Cys Tyr 1 5 10 44014PRTArtificial
SequenceGC-C agonist peptide 440Cys Cys Glu Phe Cys Cys Glu Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 44114PRTArtificial SequenceGC-C agonist
peptide 441Cys Cys Glu Phe Cys Cys Arg Pro Ala Cys Thr Gly Cys Tyr
1 5 10 44213PRTArtificial SequenceGC-C agonist peptide 442Cys Cys
Glu Phe Cys Cys Ala Pro Ala Cys Thr Gly Cys 1 5 10
44313PRTArtificial SequenceGC-C agonist peptide 443Cys Cys Glu Phe
Cys Cys Leu Pro Ala Cys Thr Gly Cys 1 5 10 44413PRTArtificial
SequenceGC-C agonist peptide 444Cys Cys Glu Phe Cys Cys Pro Pro Ala
Cys Thr Gly Cys 1 5 10 44513PRTArtificial SequenceGC-C agonist
peptide 445Cys Cys Glu Phe Cys Cys Phe Pro Ala Cys Thr Gly Cys 1 5
10 44613PRTArtificial SequenceGC-C agonist peptide 446Cys Cys Glu
Phe Cys Cys Gly Pro Ala Cys Thr Gly Cys 1 5 10 44713PRTArtificial
SequenceGC-C agonist peptide 447Cys Cys Glu Phe Cys Cys Thr Pro Ala
Cys Thr Gly Cys 1 5 10 44813PRTArtificial SequenceGC-C agonist
peptide 448Cys Cys Glu Phe Cys Cys Gln Pro Ala Cys Thr Gly Cys 1 5
10 44913PRTArtificial SequenceGC-C agonist peptide 449Cys Cys Glu
Phe Cys Cys Asp Pro Ala Cys Thr Gly Cys 1 5 10 45013PRTArtificial
SequenceGC-C agonist peptide 450Cys Cys Glu Phe Cys Cys Lys Pro Ala
Cys Thr Gly Cys 1 5 10 45113PRTArtificial SequenceGC-C agonist
peptide 451Cys Cys Glu Phe Cys Cys His Pro Ala Cys Thr Gly Cys 1 5
10 45214PRTArtificial SequenceGC-C agonist peptide 452Cys Cys Glu
Trp Cys Cys Val Pro Ala Cys Thr Gly Cys Tyr 1 5 10
45314PRTArtificial SequenceGC-C agonist peptide 453Cys Cys Glu Trp
Cys Cys Ile Pro Ala Cys Thr Gly Cys Tyr 1 5 10 45414PRTArtificial
SequenceGC-C agonist peptide 454Cys Cys Glu Trp Cys Cys Met Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 45514PRTArtificial SequenceGC-C agonist
peptide 455Cys Cys Glu Trp Cys Cys Trp Pro Ala Cys Thr Gly Cys Tyr
1 5 10 45614PRTArtificial SequenceGC-C agonist peptide 456Cys Cys
Glu Trp Cys Cys Ser Pro Ala Cys Thr Gly Cys Tyr 1 5 10
45714PRTArtificial SequenceGC-C agonist peptide 457Cys Cys Glu Trp
Cys Cys Cys Pro Ala Cys Thr Gly Cys Tyr 1 5 10 45814PRTArtificial
SequenceGC-C agonist peptide 458Cys Cys Glu Trp Cys Cys Tyr Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 45914PRTArtificial SequenceGC-C agonist
peptide 459Cys Cys Glu Trp Cys Cys Glu Pro Ala Cys Thr Gly Cys Tyr
1 5 10 46014PRTArtificial SequenceGC-C agonist peptide 460Cys Cys
Glu Trp Cys Cys Arg Pro Ala Cys Thr Gly Cys Tyr 1 5 10
46113PRTArtificial SequenceGC-C agonist peptide 461Cys Cys Glu Trp
Cys Cys Ala Pro Ala Cys Thr Gly Cys 1 5 10 46213PRTArtificial
SequenceGC-C agonist peptide 462Cys Cys Glu Trp Cys Cys Leu Pro Ala
Cys Thr Gly Cys 1 5 10 46313PRTArtificial SequenceGC-C agonist
peptide 463Cys Cys Glu Trp Cys Cys Pro Pro Ala Cys Thr Gly Cys 1 5
10 46413PRTArtificial SequenceGC-C agonist peptide 464Cys Cys Glu
Trp Cys Cys Phe Pro Ala Cys Thr Gly Cys 1 5 10 46513PRTArtificial
SequenceGC-C agonist peptide 465Cys Cys Glu Trp Cys Cys Gly Pro Ala
Cys Thr Gly Cys 1 5 10 46613PRTArtificial SequenceGC-C agonist
peptide 466Cys Cys Glu Trp Cys Cys Thr Pro Ala Cys Thr Gly Cys 1 5
10 46713PRTArtificial SequenceGC-C agonist peptide 467Cys Cys Glu
Trp Cys Cys Gln Pro Ala Cys Thr Gly Cys 1 5 10 46813PRTArtificial
SequenceGC-C agonist peptide 468Cys Cys Glu Trp Cys Cys Asp Pro Ala
Cys Thr Gly Cys 1 5 10 46913PRTArtificial SequenceGC-C agonist
peptide 469Cys Cys Glu Trp Cys Cys Lys Pro Ala Cys Thr Gly Cys 1 5
10 47013PRTArtificial SequenceGC-C agonist peptide 470Cys Cys Glu
Trp Cys Cys His Pro Ala Cys Thr Gly Cys 1 5 10 47114PRTArtificial
SequenceGC-C agonist peptide 471Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Val 1 5 10 47214PRTArtificial SequenceGC-C agonist
peptide 472Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Ile
1 5 10 47314PRTArtificial SequenceGC-C agonist peptide 473Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Met 1 5 10
47414PRTArtificial SequenceGC-C agonist peptide 474Cys Cys Glu Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Trp 1 5 10 47514PRTArtificial
SequenceGC-C agonist peptide 475Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Ser 1 5 10 47614PRTArtificial SequenceGC-C agonist
peptide 476Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Cys
1 5 10 47714PRTArtificial SequenceGC-C agonist peptide 477Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Gln 1 5 10
47814PRTArtificial SequenceGC-C agonist peptide 478Cys Cys Glu Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Glu 1 5 10 47914PRTArtificial
SequenceGC-C agonist peptide 479Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Arg 1 5 10 48014PRTArtificial SequenceGC-C agonist
peptide 480Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Ala
1 5 10 48114PRTArtificial SequenceGC-C agonist peptide 481Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Leu 1 5 10
48214PRTArtificial SequenceGC-C agonist peptide 482Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Pro 1 5 10 48314PRTArtificial
SequenceGC-C agonist peptide 483Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Phe 1 5 10 48414PRTArtificial SequenceGC-C agonist
peptide 484Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Gly
1 5 10 48514PRTArtificial SequenceGC-C agonist peptide 485Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Thr 1 5 10
48614PRTArtificial SequenceGC-C agonist peptide 486Cys Cys Glu Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Asn 1 5 10 48714PRTArtificial
SequenceGC-C agonist peptide 487Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Asp 1 5 10 48814PRTArtificial SequenceGC-C agonist
peptide 488Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Lys
1 5 10 48914PRTArtificial SequenceGC-C agonist peptide 489Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys His 1 5 10
49014PRTArtificial SequenceGC-C agonist peptide 490Cys Cys Val Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 49114PRTArtificial
SequenceGC-C agonist peptide 491Cys Cys Ile Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 49214PRTArtificial SequenceGC-C agonist
peptide 492Cys Cys Phe Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 49314PRTArtificial SequenceGC-C agonist peptide 493Cys Cys
Gly Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
49414PRTArtificial SequenceGC-C agonist peptide 494Cys Cys Thr Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 49514PRTArtificial
SequenceGC-C agonist peptide 495Cys Cys Asn Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 49614PRTArtificial SequenceGC-C agonist
peptide 496Cys Cys Tyr Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 49714PRTArtificial SequenceGC-C agonist peptide 497Cys Cys
Lys Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
49814PRTArtificial SequenceGC-C agonist peptide 498Cys Cys His Phe
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 49913PRTArtificial
SequenceGC-C agonist peptide 499Cys Cys Val Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 50013PRTArtificial SequenceGC-C agonist
peptide 500Cys Cys Ile Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 50113PRTArtificial SequenceGC-C agonist peptide 501Cys Cys Phe
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 50213PRTArtificial
SequenceGC-C agonist peptide 502Cys Cys Gly Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 50313PRTArtificial SequenceGC-C agonist
peptide 503Cys Cys Thr Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 50413PRTArtificial SequenceGC-C agonist peptide 504Cys Cys Asn
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 50513PRTArtificial
SequenceGC-C agonist peptide 505Cys Cys Tyr Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 50613PRTArtificial SequenceGC-C agonist
peptide 506Cys Cys Lys Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 50713PRTArtificial SequenceGC-C agonist peptide 507Cys Cys His
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 50814PRTArtificial
SequenceGC-C agonist peptide 508Cys Cys Val Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 50914PRTArtificial SequenceGC-C agonist
peptide 509Cys Cys Ile Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 51014PRTArtificial SequenceGC-C agonist peptide 510Cys Cys
Phe Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
51114PRTArtificial SequenceGC-C agonist peptide 511Cys Cys Gly Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 51214PRTArtificial
SequenceGC-C agonist peptide 512Cys Cys Thr Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 51314PRTArtificial SequenceGC-C agonist
peptide 513Cys Cys Asn Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 51414PRTArtificial SequenceGC-C agonist peptide 514Cys Cys
Tyr Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
51514PRTArtificial SequenceGC-C agonist peptide 515Cys Cys Lys Trp
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 51614PRTArtificial
SequenceGC-C agonist peptide 516Cys Cys His Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 51713PRTArtificial SequenceGC-C agonist
peptide 517Cys Cys Val Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 51813PRTArtificial SequenceGC-C agonist peptide 518Cys Cys Ile
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 51913PRTArtificial
SequenceGC-C agonist peptide 519Cys Cys Phe Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 52013PRTArtificial SequenceGC-C agonist
peptide 520Cys Cys Gly Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 52113PRTArtificial SequenceGC-C agonist peptide 521Cys Cys Thr
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 52213PRTArtificial
SequenceGC-C agonist peptide 522Cys Cys Asn Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 52313PRTArtificial SequenceGC-C agonist
peptide 523Cys Cys Tyr Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5
10 52413PRTArtificial SequenceGC-C agonist peptide 524Cys Cys Lys
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 52513PRTArtificial
SequenceGC-C agonist peptide 525Cys Cys His Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys 1 5 10 52613PRTArtificial SequenceGC-C agonist
peptide 526Cys Cys Xaa Xaa Cys Cys Xaa Xaa Xaa Cys Xaa Xaa Cys 1 5
10 52770PRTArtificial SequenceGC-C agonist peptide 527Cys Xaa Xaa
Xaa Xaa Cys Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Tyr 1 5 10 15 Xaa
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Asn Xaa 20 25
30 Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Cys Xaa Xaa
35 40 45 Xaa Xaa Thr Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Cys Xaa
Xaa Xaa 50 55 60 Xaa Tyr Xaa Xaa Xaa Xaa 65 70 52814PRTArtificial
SequenceGC-C agonist peptide 528Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 52919PRTArtificial SequenceGC-C agonist
peptide 529Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Tyr 53019PRTArtificial SequenceGC-C
agonist peptide 530Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn
Pro Ala Cys Trp 1 5 10 15 Gly Cys Tyr 53119PRTArtificial
SequenceGC-C agonist peptide 531Asn Ser Ser Asn Tyr Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr
53214PRTArtificial SequenceGC-C agonist peptide 532Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr 1 5 10 53314PRTArtificial
SequenceGC-C agonist peptide 533Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr 1 5 10 53415PRTArtificial SequenceGC-C agonist
peptide 534Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr 1 5 10 15 53515PRTArtificial SequenceGC-C agonist peptide
535Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr 1 5
10 15 53615PRTArtificial SequenceGC-C agonist peptide 536Asn Cys
Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15
53715PRTArtificial SequenceGC-C agonist peptide 537Asn Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15
53815PRTArtificial SequenceGC-C agonist peptide 538Asn Cys Cys Glu
Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15
53915PRTArtificial SequenceGC-C agonist peptide 539Asn Cys Cys Glu
Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15
54015PRTArtificial SequenceGC-C agonist peptide 540Asn Cys Cys Glu
Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15
54121PRTArtificial SequenceGC-C agonist peptide 541Asn Ser Ser Asn
Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys
Tyr Asp Phe 20 54221PRTArtificial SequenceGC-C agonist peptide
542Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp
1 5 10 15 Gly Cys Tyr Asp Phe 20 54321PRTArtificial SequenceGC-C
agonist peptide 543Asn Ser Ser Asn Tyr Cys Cys Glu Phe Cys Cys Asn
Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr Asp Phe 20 54421PRTArtificial
SequenceGC-C agonist peptide 544Asn Ser Ser Asn Tyr Cys Cys Glu Tyr
Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr Asp Phe 20
54521PRTArtificial SequenceGC-C agonist peptide 545Asn Ser Ser Asn
Tyr Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys
Tyr Asp Phe 20 54621PRTArtificial SequenceGC-C agonist peptide
546Asn Ser Ser Asn Tyr Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr
1 5 10 15 Gly Cys Tyr Asp Phe 20 54721PRTArtificial SequenceGC-C
agonist peptide 547Asn Ser Ser Asn Tyr Cys Cys Glu Lys Cys Cys Asn
Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr Asp Phe 20 54816PRTArtificial
SequenceGC-C agonist peptide 548Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 54916PRTArtificial
SequenceGC-C agonist peptide 549Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Trp Gly Cys Tyr Asp Phe 1 5 10 15 55016PRTArtificial
SequenceGC-C agonist peptide 550Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 55116PRTArtificial
SequenceGC-C agonist peptide 551Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 55216PRTArtificial
SequenceGC-C agonist peptide 552Cys Cys Glu Trp Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 55316PRTArtificial
SequenceGC-C agonist peptide 553Cys Cys Glu Arg Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 55416PRTArtificial
SequenceGC-C agonist peptide 554Cys Cys Glu Lys Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 55517PRTArtificial
SequenceGC-C agonist peptide 555Asn Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 55617PRTArtificial
SequenceGC-C agonist peptide 556Asn Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Trp Gly Cys Tyr Asp 1 5 10 15 Phe 55717PRTArtificial
SequenceGC-C agonist peptide 557Asn Cys Cys Glu Phe Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 55817PRTArtificial
SequenceGC-C agonist peptide 558Asn Cys Cys Glu Tyr Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 55917PRTArtificial
SequenceGC-C agonist peptide 559Asn Cys Cys Glu Trp Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 56017PRTArtificial
SequenceGC-C agonist peptide 560Asn Cys Cys Glu Arg Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 56117PRTArtificial
SequenceGC-C agonist peptide 561Asn Cys Cys Glu Lys Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 56215PRTHomo sapiens
562Pro Gly Thr Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Gly Cys 1 5
10 15 56316PRTArtificial SequenceGC-agonist peptide - human
guanylin analog 563Pro Gly Thr Cys Glu Gly Ile Cys Ala Tyr Ala Ala
Cys Thr Gly Cys 1 5 10 15 56416PRTArtificial SequenceGC-agonist
peptide - human guanylin analog 564Pro Gly Thr Cys Glu Ile Gly Cys
Ala Tyr Ala Ala Cys Thr Gly Cys 1 5 10 15 56517PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 565Pro Gly Thr
Cys Glu Ile Gly Cys Gly Ala Tyr Ala Ala Cys Thr Gly 1 5 10 15 Cys
56617PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 566Pro Gly Thr Cys Glu Ile Gly Cys Ala Gly Tyr Ala Ala Cys
Thr Gly 1 5 10 15 Cys 56717PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 567Pro Gly Thr Cys Glu Ile Gly Cys Ala Tyr
Gly Ala Ala Cys Thr Gly 1 5 10 15 Cys 56817PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 568Pro Gly Thr
Cys Glu Ile Gly Cys Ala Tyr Ala Gly Ala Cys Thr Gly 1 5 10 15 Cys
56917PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 569Pro Gly Thr Cys Glu Ile Gly Cys Ala Tyr Ala Ala Gly Cys
Thr Gly 1 5 10 15 Cys 57017PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 570Pro Gly Thr Cys Glu Ile Gly Cys Ala Tyr
Ala Ala Cys Gly Thr Gly 1 5 10 15 Cys 57117PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 571Pro Gly Thr
Cys Glu Ile Gly Cys Ala Tyr Ala Ala Cys Thr Gly Gly 1 5 10 15 Cys
57216PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 572Pro Gly Thr Cys Ala Glu Ile Cys Ala Tyr Ala Ala Cys Thr
Gly Cys 1 5 10 15 57316PRTArtificial SequenceGC-agonist peptide -
human guanylin analog 573Pro Gly Thr Cys Glu Ala Ile Cys Ala Tyr
Ala Ala Cys Thr Gly Cys 1 5 10 15 57416PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 574Pro Gly Thr
Cys Glu Ile Ala Cys Ala Tyr Ala Ala Cys Thr Gly Cys 1 5 10 15
57517PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 575Pro Gly Thr Cys Glu Ile Gly Cys Ala Ala Tyr Ala Ala Cys
Thr Gly 1 5 10 15 Cys 57617PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 576Pro Gly Thr Cys Glu Ile Gly Cys Ala Tyr
Ala Ala Ala Cys Thr Gly 1 5 10 15 Cys 57717PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 577Pro Gly Thr
Cys Glu Ile Gly Cys Ala Tyr Ala Ala Cys Ala Thr Gly 1 5 10 15 Cys
57817PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 578Pro Gly Thr Cys Glu Ile Gly Cys Ala Tyr Ala Ala Cys Thr
Ala Gly 1 5 10 15 Cys 57917PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 579Pro Gly Thr Cys Glu Ile Gly Cys Ala Tyr
Ala Ala Cys Thr Gly Ala 1 5 10 15 Cys 58017PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 580Pro Gly Thr
Cys Ala Glu Ile Cys Ala Ala Tyr Ala Ala Cys Thr Gly 1 5 10 15 Cys
58117PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 581Pro Gly Thr Cys Glu Ala Ile Cys Ala Ala Tyr Ala Ala Cys
Thr Gly 1 5 10 15 Cys 58217PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 582Pro Gly Thr Cys Glu Ile Ala Cys Ala Ala
Tyr Ala Ala Cys Thr Gly 1 5 10 15 Cys 58315PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 583Ser His Thr
Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys 1 5 10 15
58415PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 584Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly
Cys 1 5 10 15 58515PRTArtificial SequenceGC-agonist peptide - human
guanylin analog 585Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys
Ala Gly Cys 1 5 10 15 58615PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 586Ser His Thr Cys Glu Tyr Cys Ala Asn Ala
Ala Cys Ala Gly Cys 1 5 10 15 58715PRTArtificial SequenceGC-agonist
peptide - human guanylin analog 587Ser His Thr Cys Glu Ile Cys Ala
Asn Ala Ala Cys Ala Gly Cys 1 5 10 15 58815PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 588Ser His Thr
Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys 1 5 10 15
58915PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 589Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly
Cys 1 5 10 15 59015PRTArtificial SequenceGC-agonist peptide - human
guanylin analog 590Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys
Ala Gly Cys 1 5 10 15 59115PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 591Ser His Thr Cys Glu Ile Cys Ala Asn Ala
Ala Cys Ala Gly Cys 1 5 10 15 59215PRTArtificial SequenceGC-agonist
peptide - human guanylin analog 592Ser His Thr Cys Glu Leu Cys Ala
Asn Ala Ala Cys Ala Gly Cys 1 5 10 15 59315PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 593Ser His Thr
Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys 1 5 10 15
59415PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 594Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly
Cys 1 5 10 15 59515PRTArtificial SequenceGC-agonist peptide - human
guanylin analog 595Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys
Ala Gly Cys 1 5 10 15 59615PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 596Ser His Thr Cys Glu Leu Cys Ala Asn Ala
Ala Cys Ala Gly Cys 1 5 10 15 59715PRTArtificial SequenceGC-agonist
peptide - human guanylin analog 597Ser His Thr Cys Glu Val Cys Ala
Asn Ala Ala Cys Ala Gly Cys 1 5 10 15 59815PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 598Ser His Thr
Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys 1 5 10 15
59915PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 599Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly
Cys 1 5 10 15 60015PRTArtificial SequenceGC-agonist peptide - human
guanylin analog 600Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys
Ala Gly Cys 1 5 10 15 60115PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 601Asn Asp Glu Cys Glu Val Cys Ala Asn Ala
Ala Cys Ala Gly Cys 1 5 10 15 60215PRTArtificial SequenceGC-agonist
peptide - human guanylin analog 602Asn Asp Glu Cys Glu Tyr Cys Ala
Asn Ala Ala Cys Ala Gly Cys 1 5 10 15 60315PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 603Asn Asp Glu
Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys 1 5 10 15
60415PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 604Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly
Cys 1 5 10 15 60515PRTArtificial SequenceGC-agonist peptide - human
guanylin analog 605Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys
Ala Gly Cys 1 5 10 15 60615PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 606Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala
Ala Cys Ala Gly Cys 1 5 10 15 60715PRTArtificial SequenceGC-agonist
peptide - human guanylin analog 607Asn Asp Glu Cys Glu Ile Cys Ala
Asn Ala Ala Cys Ala Gly Cys 1 5 10 15 60815PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 608Asn Asp Glu
Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys 1 5 10 15
60915PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 609Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly
Cys 1 5 10 15 61015PRTArtificial SequenceGC-agonist peptide - human
guanylin analog 610Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys
Ala Gly Cys 1 5 10 15 61115PRTArtificial SequenceGC-agonist peptide
- human guanylin analog 611Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala
Ala Cys Ala Gly Cys 1 5 10 15 61215PRTArtificial SequenceGC-agonist
peptide - human guanylin analog 612Asn Asp Glu Cys Glu Leu Cys Ala
Asn Ala Ala Cys Ala Gly Cys 1 5 10 15 61315PRTArtificial
SequenceGC-agonist peptide - human guanylin analog 613Asn Asp Glu
Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys 1 5 10 15
61415PRTArtificial SequenceGC-agonist peptide - human guanylin
analog 614Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly
Cys 1 5 10 15 61515PRTHomo sapiens 615Gln Glu Glu Cys Glu Leu Cys
Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15 61615PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 616Gln Glu
Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15
61715PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 617Gln Asp Glu Cys Glu Thr Cys Ile Asn Met
Ala Cys Thr Gly Tyr 1 5 10 15 61815PRTArtificial SequenceGC-agonist
peptide - human lymphoguanylin analog 618Gln Asp Asp Cys Glu Thr
Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15 61915PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 619Gln Glu
Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15
62015PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 620Gln Glu Glu Cys Glu Glu Cys Ile Asn Met
Ala Cys Thr Gly Tyr 1 5 10 15 62115PRTArtificial SequenceGC-agonist
peptide - human lymphoguanylin analog 621Gln Asp Glu Cys Glu Glu
Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15 62215PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 622Gln Asp
Asp Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15
62315PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 623Gln Glu Asp Cys Glu Glu Cys Ile Asn Met
Ala Cys Thr Gly Tyr 1 5 10 15 62415PRTArtificial SequenceGC-agonist
peptide - human lymphoguanylin
analog 624Gln Glu Glu Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly
Tyr 1 5 10 15 62515PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 625Gln Asp Glu Cys Glu Tyr Cys Ile Asn Met
Ala Cys Thr Gly Tyr 1 5 10 15 62615PRTArtificial SequenceGC-agonist
peptide - human lymphoguanylin analog 626Gln Asp Asp Cys Glu Tyr
Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15 62715PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 627Gln Glu
Asp Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15
62815PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 628Gln Glu Glu Cys Glu Ile Cys Ile Asn Met
Ala Cys Thr Gly Tyr 1 5 10 15 62915PRTArtificial SequenceGC-agonist
peptide - human lymphoguanylin analog 629Gln Asp Glu Cys Glu Ile
Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15 63015PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 630Gln Asp
Asp Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Tyr 1 5 10 15
63115PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 631Gln Glu Asp Cys Glu Ile Cys Ile Asn Met
Ala Cys Thr Gly Tyr 1 5 10 15 63216PRTArtificial SequenceGC-agonist
peptide - human lymphoguanylin analog 632Gln Glu Glu Cys Glu Thr
Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
63316PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 633Gln Asp Glu Cys Glu Thr Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 63416PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 634Gln Asp
Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
63516PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 635Gln Glu Asp Cys Glu Thr Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 63616PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 636Gln Glu
Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
63716PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 637Gln Asp Glu Cys Glu Glu Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 63816PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 638Gln Asp
Asp Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
63916PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 639Gln Glu Asp Cys Glu Glu Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 64016PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 640Gln Glu
Glu Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
64116PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 641Gln Asp Glu Cys Glu Tyr Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 64216PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 642Gln Asp
Asp Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
64316PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 643Gln Glu Asp Cys Glu Tyr Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 64416PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 644Gln Glu
Glu Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
64516PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 645Gln Asp Glu Cys Glu Ile Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 64616PRTArtificial
SequenceGC-agonist peptide - human lymphoguanylin analog 646Gln Asp
Asp Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Cys Ser 1 5 10 15
64716PRTArtificial SequenceGC-agonist peptide - human
lymphoguanylin analog 647Gln Glu Asp Cys Glu Ile Cys Ile Asn Met
Ala Cys Thr Gly Cys Ser 1 5 10 15 64816PRTHomo sapiens 648Asn Asp
Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu 1 5 10 15
64915PRTArtificial SequenceGC-agonist peptide - human uroguanylin
analog 649Gln Asp Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly
Tyr 1 5 10 15 65016PRTArtificial SequenceHuman uroguanylin peptide
analog 650Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
Xaa Xaa 1 5 10 15 6517PRTArtificial SequenceFragment insert into
human uroguanylin peptide analog 651Ile Ala Glu Asp Ser His Thr 1 5
6527PRTArtificial SequenceFragment insert into human uroguanylin
peptide analog 652Ile Ala Gln Asp Pro Ser Thr 1 5 6534PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
653Asp Pro Asn Thr 1 6547PRTArtificial SequenceFragment insert into
human uroguanylin peptide analog 654Ile Ala Gln Asp Pro Asn Thr 1 5
6554PRTArtificial SequenceFragment insert into human uroguanylin
peptide analog 655Lys Pro Asn Thr 1 6564PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
656Asp Pro Gly Thr 1 6575PRTArtificial SequenceFragment insert into
human uroguanylin peptide analog 657Glu Asp Pro Gly Thr 1 5
6587PRTArtificial SequenceFragment insert into human uroguanylin
peptide analog 658Val Ala Ala Arg Ala Asp Leu 1 5 6597PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
659Arg Thr Ile Ala Asn Asp Asp 1 5 6606PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
660Thr Ile Ala Asn Asp Asp 1 5 6617PRTArtificial SequenceFragment
insert into human uroguanylin peptide analog 661Arg Thr Met Asp Asn
Asp Glu 1 5 6627PRTArtificial SequenceFragment insert into human
uroguanylin peptide analog 662Arg Thr Ile Ala Gly Asp Asp 1 5
6636PRTArtificial SequenceFragment insert into human uroguanylin
peptide analog 663Arg Thr Ile Ala Asn Asp 1 5 6647PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
664Arg Ser Ile Ser Gln Glu Asp 1 5 6657PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
665Arg Thr Ile Ala Thr Asp Glu 1 5 6667PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
666Ile Ile Thr Pro Pro Asp Pro 1 5 6677PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
667Arg Tyr Ile Asn Gln Glu Glu 1 5 6686PRTArtificial
SequenceFragment insert into human uroguanylin peptide analog
668Ala Ser Ser Tyr Ala Ser 1 5 6696PRTArtificial SequenceFragment
insert into human uroguanylin peptide analog 669Thr Ser Ser Tyr Ala
Ser 1 5 67016PRTArtificial SequenceHuman uroguanylin peptide analog
670Asn Xaa Xaa Xaa Glu Leu Xaa Val Asn Xaa Xaa Xaa Thr Xaa Xaa Leu
1 5 10 15 67116PRTArtificial Sequencehuman uroguanylin analog
671Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67216PRTArtificial Sequencehuman uroguanylin analog
672Glu Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67316PRTArtificial Sequencehuman uroguanylin analog
673Glu Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67416PRTArtificial Sequencehuman uroguanylin analog
674Glu Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67516PRTArtificial Sequencehuman uroguanylin analog
675Glu Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67616PRTArtificial Sequencehuman uroguanylin analog
676Asp Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67716PRTArtificial Sequencehuman uroguanylin analog
677Asp Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67816PRTArtificial Sequencehuman uroguanylin analog
678Asp Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 67916PRTArtificial Sequencehuman uroguanylin analog
679Asp Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68016PRTArtificial Sequencehuman uroguanylin analog
680Gln Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68116PRTArtificial Sequencehuman uroguanylin analog
681Gln Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68216PRTArtificial Sequencehuman uroguanylin analog
682Gln Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68316PRTArtificial Sequencehuman uroguanylin analog
683Gln Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68416PRTArtificial Sequencehuman uroguanylin analog
684Lys Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68516PRTArtificial Sequencehuman uroguanylin analog
685Lys Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68616PRTArtificial Sequencehuman uroguanylin analog
686Lys Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68716PRTArtificial Sequencehuman uroguanylin analog
687Lys Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 68816PRTArtificial Sequencehuman uroguanylin analog
688Glu Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 68916PRTArtificial Sequencehuman uroguanylin analog
689Glu Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69016PRTArtificial Sequencehuman uroguanylin analog
690Glu Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69116PRTArtificial Sequencehuman uroguanylin analog
691Glu Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69216PRTArtificial Sequencehuman uroguanylin analog
692Asp Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69316PRTArtificial Sequencehuman uroguanylin analog
693Asp Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69416PRTArtificial Sequencehuman uroguanylin analog
694Asp Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69516PRTArtificial Sequencehuman uroguanylin analog
695Asp Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69616PRTArtificial Sequencehuman uroguanylin analog
696Gln Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69716PRTArtificial Sequencehuman uroguanylin analog
697Gln Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69816PRTArtificial Sequencehuman uroguanylin analog
698Gln Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 69916PRTArtificial Sequencehuman uroguanylin analog
699Gln Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 70016PRTArtificial Sequencehuman uroguanylin analog
700Lys Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 70116PRTArtificial Sequencehuman uroguanylin analog
701Lys Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 70216PRTArtificial Sequencehuman uroguanylin analog
702Lys Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 70316PRTArtificial Sequencehuman uroguanylin analog
703Lys Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15 70416PRTArtificial Sequencehuman uroguanylin analog
704Glu Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 70516PRTArtificial Sequencehuman uroguanylin analog
705Glu Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 70616PRTArtificial Sequencehuman uroguanylin analog
706Glu Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 70716PRTArtificial Sequencehuman uroguanylin analog
707Glu Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 70816PRTArtificial Sequencehuman uroguanylin analog
708Asp Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 70916PRTArtificial Sequencehuman uroguanylin analog
709Asp Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71016PRTArtificial Sequencehuman uroguanylin analog
710Asp Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71116PRTArtificial Sequencehuman uroguanylin analog
711Asp Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71216PRTArtificial Sequencehuman uroguanylin analog
712Gln Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71316PRTArtificial Sequencehuman uroguanylin analog
713Gln Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71416PRTArtificial Sequencehuman uroguanylin analog
714Gln Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71516PRTArtificial Sequencehuman uroguanylin analog
715Gln Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71616PRTArtificial Sequencehuman uroguanylin analog
716Lys Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71716PRTArtificial Sequencehuman uroguanylin analog
717Lys Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71816PRTArtificial Sequencehuman uroguanylin analog
718Lys Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 71916PRTArtificial Sequencehuman uroguanylin analog
719Lys Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15 72016PRTArtificial Sequencehuman uroguanylin analog
720Glu Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15 72116PRTArtificial Sequencehuman uroguanylin analog
721Glu Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15 72216PRTArtificial Sequencehuman uroguanylin analog
722Glu Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15 72316PRTArtificial Sequencehuman uroguanylin analog
723Glu Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15 72416PRTArtificial Sequencehuman
uroguanylin analog 724Asp Asp Asp Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 72516PRTArtificial Sequencehuman
uroguanylin analog 725Asp Asp Glu Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 72616PRTArtificial Sequencehuman
uroguanylin analog 726Asp Glu Asp Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 72716PRTArtificial Sequencehuman
uroguanylin analog 727Asp Glu Glu Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 72816PRTArtificial Sequencehuman
uroguanylin analog 728Gln Asp Asp Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 72916PRTArtificial Sequencehuman
uroguanylin analog 729Gln Asp Glu Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 73016PRTArtificial Sequencehuman
uroguanylin analog 730Gln Glu Asp Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 73116PRTArtificial Sequencehuman
uroguanylin analog 731Gln Glu Glu Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 73216PRTArtificial Sequencehuman
uroguanylin analog 732Lys Asp Asp Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 73316PRTArtificial Sequencehuman
uroguanylin analog 733Lys Asp Glu Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 73416PRTArtificial Sequencehuman
uroguanylin analog 734Lys Glu Asp Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 73516PRTArtificial Sequencehuman
uroguanylin analog 735Lys Glu Glu Cys Glu Leu Cys Ile Asn Met Ala
Cys Thr Gly Cys Ser 1 5 10 15 73615PRTArtificial Sequencehuman
uroguanylin analog 736Asn Glu Cys Glu Leu Cys Val Asn Val Ala Cys
Thr Gly Cys Leu 1 5 10 15 73714PRTArtificial Sequencehuman
uroguanylin analog 737Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys
Thr Gly Cys 1 5 10 73814PRTArtificial Sequencehuman uroguanylin
analog 738Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu 1
5 10 73913PRTArtificial Sequencehuman uroguanylin analog 739Glu Cys
Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys 1 5 10
74013PRTArtificial Sequencehuman uroguanylin analog 740Cys Glu Leu
Cys Val Asn Val Ala Cys Thr Gly Cys Leu 1 5 10 74112PRTArtificial
Sequencehuman uroguanylin analog 741Cys Glu Leu Cys Val Asn Val Ala
Cys Thr Gly Cys 1 5 10 74215PRTArtificial Sequencehuman uroguanylin
analog 742Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly
Cys 1 5 10 15 74316PRTArtificial Sequencehuman uroguanylin analog
743Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15 74416PRTArtificial Sequencehuman uroguanylin analog
744Asn Asp Glu Cys Glu Leu Cys Xaa Asn Xaa Ala Cys Thr Gly Cys Leu
1 5 10 15 74516PRTArtificial Sequencehuman uroguanylin analog
745Asn Asp Glu Cys Glu Leu Asp Val Asn Val Ala Cys Thr Gly Xaa Leu
1 5 10 15 74616PRTArtificial Sequencehuman uroguanylin analog
746Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15 74716PRTArtificial Sequenehuman uroguanylin analog 747Asn
Asp Glu Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Leu 1 5 10
15 74816PRTArtificial Sequenehuman uroguanylin analog 748Asn Asp
Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser 1 5 10 15
74916PRTArtificial Sequencehuman uroguanylin analog 749Asn Asp Glu
Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Tyr 1 5 10 15
75016PRTArtificial Sequencehuman uroguanylin analog 750Xaa Asp Glu
Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu 1 5 10 15
75114PRTArtificial Sequencehuman uroguanylin analog 751Cys Cys Glu
Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
75214PRTArtificial Sequencehuman uroguanylin analog 752Cys Cys Glu
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10
75313PRTArtificial Sequencehuman uroguanylin analog 753Cys Cys Glu
Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys 1 5 10 75413PRTArtificial
Sequencehuman uroguanylin analog 754Cys Cys Glu Phe Cys Cys Asn Pro
Ala Cys Thr Gly Cys 1 5 10 75514PRTArtificial Sequencehuman
uroguanylin analog 755Xaa Xaa Glu Tyr Xaa Xaa Asn Pro Ala Xaa Thr
Gly Xaa Tyr 1 5 10 75613PRTArtificial Sequencehuman uroguanylin
analog 756Xaa Xaa Glu Tyr Xaa Xaa Asn Pro Ala Xaa Thr Gly Xaa 1 5
10
* * * * *